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Summary 
Essential hypertension is a highly hereditable trait of complex aetiology, where 
multiple environmental and life style factors contribute to blood pressure 
variation. Family health studies of blood pressure suggest that heritability 
accounts for 30 – 50 % of variation. Consequently the study of genetic 
architecture has proven useful to detect a small number of genes, loci, and 
single nucleotide polymorphisms (SNPs) that have appreciable effects on blood 
pressure. Genetic linkage and association methods have long provided the 
foundation of gene identification in humans. Although linkage studies have 
proven to be highly successful in identifying genes of monogenic (or Mendelian) 
disorders, this analysis has minimal or limited power to detect gene of complex 
traits and disease. Furthermore, candidate gene approaches have not yet 
reported any reproducible associations with hypertension. Accordingly, gene 
identification efforts have become increasingly reliant on association 
approaches.  
A recent genome wide association study (GWAS) identified a locus upstream of 
the Uromodulin (UMOD) gene transcriptional start site, which was associated 
with hypertension. This group used an extreme case - control design in a 
discovery sample of 1,621 hypertension cases and 1,699 hypercontrols, 
representing the top 2% and bottom 20% of the BP distribution. The minor G 
allele of rs13333226 when adjusted for estimated glomerular filtration rate 
(eGFR) was associated with a 7 % lower risk of developing hypertension. UMOD 
encodes the protein uromodulin which is interchangeably known as Tamm 
Horsfall protein (THP). It is a kidney specific protein and is exclusively 
synthesised at the level of the thick ascending limb of the loop of Henle (TAL) 
and is the most abundant protein in human urine. The biological role of 
uromodulin still remains unclear; however other UMOD variants have been 
associated with chronic kidney disease. Due to UMODs exclusive expression at 
the kidney it may have a role in regulating blood pressure via sodium 
homeostasis mechanisms.  As hypertension is characterised by a disturbance of 
renal function that subsequently leads to an augmented Na+ reabsorption, the 
present study aimed to follow up the GWAS signal to assess whether altered 
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UMOD expression and/or function impacts on sodium homeostasis and influence 
blood pressure phenotypes.  
Promoter activity assays here demonstrate that the index SNP (rs13333226) is 
not a functional variant causing altered transcription, however the minor G 
allele of rs13333226 is associated with reduced promoter activity. These findings 
are consistent with the original GWAS study that this allele is associated with 
lower risk of hypertension. In this study we reported a SNP in LD with rs13333226 
within the 2 Kb promoter region (rs4997081) that may be a causal variant 
altering transcriptional activity of UMOD. Furthermore, with computational and 
experimental evidence we show that binding of rs4997081 to TFAP2A in a 
genotype dependent manner leads to transcriptional changes of UMOD which 
were associated with altered sodium reabsorption via downstream signalling of 
Tumor necrosis factor alpha (TNF-α).  
 
Cardiovascular characterisation of UMOD knockout mice (KO) revealed 
significantly lower systolic blood pressure (SBP) in comparison to the wild type 
(WT) counterparts. The reported novel blood pressure phenotypes in the KO 
mice were not sensitive to change by salt loading (2% NaCl) over a six week 
period. KO mice displayed increased concentrations of sodium in the urine upon 
salt loading, to greater levels than the WT mice (± 2% NaCl). Urinary electrolyte 
analysis corrected to creatinine levels revealed augmented sodium loss in the KO 
mice during the high salt diet. Chronic renal function curves demonstrate that 
the reduced SBP is attained by increased natriuresis via augmented GFR in the 
KO mice. Histological examination illustrated cellular swelling and papillary 
oedema in the KO mice before and after salt loading which may be triggered by 
the pro-inflammatory cytokines TNF-α and Interleukin 1 (IL-1) according to 
metabolomic analysis. These inflammatory signals may affect Na+ homeostasis at 
the TAL in the KO mice by reducing NKCC2 expression. Expression analysis 
studied in outer medulla tissue illustrated down regulation of the major NaCl 
transporters in the absence of UMOD which were further attenuated upon salt 
loading conditions possibly by increased levels of TNF-α at the TAL. KO mice 
displayed increased levels of urinary TNF-α in addition to augmented mRNA 
abundance in the outer medulla tissue. In addition, immunohistochemical 
analysis revealed reduced NKCC2 staining with increased TNF-α staining in renal 
tissue of the KO mice during normal and high salt diets. These results were 
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confirmed in vitro and suggest UMOD acts as a negative regulator of TNF-α 
production by the TAL to maintain NaCl/volume homeostasis.  
We have confirmed with a small pilot study using human renal tissue samples 
from normotensive and hypertensive individuals, that in times of altered UMOD 
expression there are changes in NKCC2 and NHE3 expression levels, but not TNF-
α. More interestingly we have demonstrated that UMOD, NKCC2, and NHE3 
expression levels are altered in a genotype dependant manner, in that the minor 
G allele of rs13333226 appears to be associated with blood pressure via altered 
sodium homeostasis. 
 
In summary we are the first to functionally follow up a hypertension signal from 
a GWAS. Our post GWAS follow up demonstrates novel biological evidence that 
UMOD plays a functional regulatory role in blood pressure regulation by means of 
fluid volume control and sodium homeostasis.  
 
 
 
 
1 Introduction 
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1.1 Cardiovascular disease 
Cardiovascular disease (CVD) is a common complex disease of major public 
health importance with high prevalence throughout the world. CVD refers to 
disorders of the heart and circulatory system, and includes hypertension, 
coronary heart disease, angina, myocardial infarctions, stroke, metabolic 
syndromes, and renal disease. According to the World Health Organisation 
(WHO), an estimated 17.5 million, or approximately 30% of total global deaths 
resulted from CVD, and hypertension is the leading cause of mortality globally 
(www.WHO.int, 2012). The 2012 WHO statistical report revealed that one in 
three adults worldwide have raised blood pressure which causes around half of 
all deaths from stroke or heart disease and end stage organ damage 
(www.WHO.int, 2012). Consequently the identification and characterisation of 
molecular mechanisms contributing to the pathogenesis of hypertension is 
fundamental for future treatment and prevention of the disease.  
 
1.2 Human essential hypertension 
Hypertension is a chronic medical condition of elevated BP, defined as clinically 
significant when systolic blood pressure (SBP) ≥ 140 mmHg and diastolic blood 
pressure (DBP) ≥ 90 mmHg. This cut off is used for patient diagnosis and 
treatment, however these reference cut offs are somewhat arbitrary, and it has 
long been debated the best way to define hypertension. In the 1940’s and 1950’s 
Sir Robert Platt and Sir George Pickering debated whether hypertension was a 
qualitative Mendelian trait that follows a bimodal distribution, with one peak at 
the level of normotension and another at hypertension where curves would likely 
overlap as blood pressure is affected by environmental factors. Whereas, 
Pickering believed that essential hypertension is a quantitative non-Mendelian 
trait with unimodal distribution. According to this concept hypertension 
represents the extreme far end of the overall blood pressure distribution, and 
does not exist separately (Platt, 1959, Oldham et al., 1960). 
Hypertension is known as either essential (primary) or secondary hypertension. 
In approximately 5 – 10 % of hypertensive individuals, increased blood pressure is 
secondary to renal disease, constrictive vessel disease, or monogenic disease, 
the remaining 90 - 95 % have essential hypertension (Carretero and Oparil, 
2000b). Human essential hypertension affects at least 10 million people in the 
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UK and is a major contributor to death from stroke, myocardial infarction, end 
stage renal disease, and congestive heart failure (Carretero and Oparil, 2000b).  
The condition is characterised by a disturbance of renal function that 
subsequently leads to an increase in Na+ reabsorption (Coleman et al., 1977, 
Cowley, 1992, Guyton, 1991). Thus, there is an accumulation of Na+ in the body, 
promoting a marked expansion of extracellular volume and therefore cardiac 
output. As cardiac output increases, it raises blood flow to virtually all body 
tissues. In response, an autoregulatory mechanism for local control of blood flow 
causes an immediate adjustment in the blood vessel diameter, re-establishing 
adequate tissue perfusion. Inadequate autoregulation therefore increases 
peripheral vascular resistance and blood pressure. The price for this biological 
adaptation is hypertension.  
 
1.3 Blood pressure control – An overview 
Blood pressure (BP) refers to the pressure exerted by circulating blood on the 
walls of blood vessels, and is chiefly determined by cardiac output and total 
peripheral resistance. It is a quantitative trait that is highly variable between 
and within individuals (Wright et al., 2003). Cardiac output and total peripheral 
resistance are controlled by a complex network of interacting physiological 
pathways involving vascular, neural, endocrine, and renal mechanisms to 
maintain continuous BP control. Through these networks, BP is maintained by a 
number of homeostatic systems that work together to interact and feedback in 
response to changes in BP caused by diet, activity, stress, and environmental 
factors, the main regulatory systems are outline in Figure 1-1.  
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Figure 1-1 Physiological systems controlling blood pressure 
Blood pressure control
Renin Angiotensin system
A renal body fluid regulatory system where 
hormones that regulates long term blood 
pressure via water and salt homeostasis 
Baroreceptor
reflexes
Negative feedback loop where increased BP 
stimulates baroreceptors in the aortic arch 
and carotid sinus; inhibiting the 
vasoconstrictor center, exciting the vagal 
centre in the brain, causing vasodilatation, 
decreased HR, and reducing force of 
contraction. Converse response to reduced 
BP
Carotid and aortic 
Chemoreceptors
Detect low O2 levels and 
increase CO2  and H2 to 
excite the vasomotor centre 
to increase HR causing 
vasoconstriction 
Endothelium derived 
vasoactive substances
Nitric oxide (vasodilatory) and endothelin
(vasoconstrictive) to alter vascular tone
Natriuretic peptides 
Released in response to increased BP 
resulting in cardiac and vascular 
vasodilatation. Acts to inhibit vascular 
and renal effects of Ang II
Capillary 
fluid shift
Exchange of fluid across the capillary membranes 
between blood and interstitial fluid. Reduced capillary 
pressure increase osmosis, increasing blood volume and 
BP, reduced capillary pressure has the opposite effect 
Kidney Kinin
Kallikrein
system
Controls renal blood flow. 
Stimulates increase Na+ and 
water excretion in times of 
increased BP to reduced ECF
Renin Angiotensin system –
Vasoconstriction (short term 
effect) of Ang II causing increased 
peripheral resistance and BP. Ang 
II can stimulate aldosterone 
production from the adrenal cortex 
resulting in increased tubule Na+ 
and water reabsorption ,increasing 
blood volume and BP 
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1.4 The kidney and blood pressure control 
The kidney is the principle organ responsible for long term BP management by 
regulating body fluid volume and osmolality via regulation of electrolyte 
balance. The main mechanism of the kidney to control blood pressure is by the 
renin angiotensin aldosterone system (RAAS). However, long term regulation of 
blood pressure relies on the synchronised regulation of Na+ (sodium), K+ 
(potassium), and Cl- (chloride) movement in the kidney to maintain blood volume 
and water balance.  
1.4.1 Renin Angiotensin Aldosterone System (RAAS) 
The classical RAAS pathway is activated upon times of low extracellular fluid 
volume, low renal perfusion, and high sodium (Na+) content in the distal tubules. 
The first response is the release of renin from the juxtaglomerular apparatus in 
the kidney into the circulation. Once in the blood, renin catalyses the liver 
derived angiotensinogen to form Angiotensin I (Ang I), which is physiologically 
inactive. Ang I is rapidly converted into active Ang II by hydrolysis in the lungs by 
angiotensin converting enzyme (ACE). This peptide plays important roles in blood 
pressure homeostasis via effects on the kidneys to conserve Na+ and stimulate 
aldosterone release. Ang II is a potent vasoconstrictor and causes rises in blood 
pressure by activating the sympathetic nervous system to initiate increased 
heart rate and blood vessel constriction. In addition Ang II stimulates 
aldosterone secretion from the adrenal gland, leading to kidney tubular Na+ and 
Cl- reabsorption and water retention, resulting in further increases in blood 
pressure. Finally, Ang II also stimulates the pituitary gland to secrete anti-
diurectic hormone (ADH), resulting in increased water reabsorption in the kidney 
collecting ducts. A negative feedback loop exists whereby increased 
juxtaglomerular perfusion caused by the above effects reduces renin release, 
thus regulating volume homeostasis via Na+ balance (Clarke et al., 2013, Ng and 
Vane, 1967) (Cushman et al., 1971, Bruneval et al., 1986, Mehta and Griendling, 
2007).  
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1.4.2 Sodium transport in the kidney  
Na+ is the predominant extra cellular cation and is of critical importance to 
maintain extra cellular fluid volume (ECF) and hence BP. The ability of the 
kidneys to absorb large quantities of Na+ relies on sequential actions at various 
segments along the nephron, each with highly specialised transport capacities. A 
schematic of the nephron segments is outlined in Figure 1-2 (adapted from 
www.biomedsearch.com).  
The nephron consists of a renal corpuscle, a proximal tubule, a loop of Henle, a 
distal tubule, and a collecting duct system. The renal corpuscle consists of 
glomerular capillaries and Bowman’s capsule. The proximal tubule initially forms 
several coils followed by a straight segment that descends into the medulla. The 
next segment is the loop of Henle, which consists of a straight section of the 
proximal tubule, the descending thin limb (which ends in a hair pin turn), the 
thin ascending limb, and the thick ascending limb. Near the end of the thick 
ascending limb, the nephron passes between its afferent and efferent arterioles. 
The short segment of the thick ascending limb is called the macula densa. The 
distal tubule begins a short distance beyond the macula densa and extends to 
the point in the cortex where two or more nephrons join to form the cortical 
collecting duct. The collecting ducts enter the medulla and become the outer 
medulla collecting ducts, and then the inner medullary collecting ducts.  
Proximal tubule cells have an extensively amplified apical membrane (urine side 
of the cell) called the brush border. The basolateral membrane (blood side of 
the cell) of the proximal tubule is highly invaginated and these invaginations 
contain mitochondria. In contrast, the cells of the descending thin limb and 
ascending thin limb of the loop of Henle have poorly developed apical and 
basolateral surfaces. The cells of the thick ascending limb and the distal tubule 
have highly developed apical and basolateral membranes with extensive folding 
of the basolateral surfaces.  
The collecting duct is composed of two cell types; the principle cell and the 
intercalated cell. Principle cells have a moderate basolateral membrane, 
whereas, intercalated cells have a high density of mitochondria thus a developed 
basolateral membrane. The final segment of the nephron is the inner medullary 
Chapter 1  26 
 
collecting duct, where apical and basolateral surfaces are poorly developed. In 
terms of ion transport the proximal tubule is responsible for 60 – 70 % of the 
filtered Na+, whereas 15 – 25 % is absorbed by the loop of Henle. The distal 
tubule reabsorbs 5 – 10 % and the collecting ducts only 1 -2 % (Sahay et al., 
2007).  
 
 
Figure 1-2 Schematic of a nephron segment (adapted from www.biomedsearch.com)  
 
 
 
 
 
Cortex
Medulla
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A variety of ion channels, pumps, and transporters are found along the nephron 
to accomplish the fundamental functions of the kidney in regulating Na+ 
homeostasis. The following transporters comprise the main proteins involved in 
renal Na+ handling: NHE (Sodium Hydrogen exchanger), NKCC2 (Sodium potassium 
chloride co-transporter), ROMK (renal outer medulla potassium channel) and 
ENaC (epithelial sodium channel), and the Na+ pump (Na+- K+ /ATPase).  Figure 
1-3.  
Tubules are lined with epithelial cells that contain Na+- K+ /ATPase in their 
basolateral cell membrane. Cells routinely expel Na+ ions via the Na+- K+ /ATPase 
pump to create and maintain a lower concentration of Na+ in the cytosol than in 
the surrounding ECF, which generates the electrochemical gradient that drives 
most Na+ coupled transport processes (Fujimoto et al., 1980).  
The Na+ /H+ exchangers (NHEs) are typical Na+ coupled transporters that mediate 
the counter transport of one extracellular Na+ for one cytolsolic proton (H+) at 
the luminal apical membrane in the proximal convoluted tubule and the TAL. 
NHE3 is confined mainly to the apical membrane of renal cells (Amemiya et al., 
1995), and functions by direct reabsorption of filtered Na+ along with indirect 
reabsorption of bicarbonate and chloride and secretion of ammonium. The 
transporter is responsible for 10 - 20 % of total Na+ reabsorption. NHE3 actions 
are outlined in (Figure 1-4).  
NKCC2 is localised at the apical membrane of the TAL. The function of this co-
transporter is to reabsorb Na+ without reabsorbing water. Na+, K+, and Cl- are 
transported into the cell over the apical membrane at a stoichiometry of 1:1:2 
via the electrochemical gradient of the sodium pump. Na+ and Cl- are transported 
into the peritubular fluid while K+ re-cycles back into the tubular lumen via 
ROMK (Ares et al., 2011). NKCC2 mediates approximately 90-100 % of Cl- 
reabsorption, and 30- 50 % of all Na+ transport, furthermore its function is linked 
with paracellular Na+, Ca+, and Mg+ flux (Hebert and Andreoli, 1986). Inhibition 
of NKCC2 results in decreased K+ exit through ROMK halting NaCl reabsorption 
and paracellular transport of Ca+ and Mg+ (Hebert and Andreoli, 1984, Herrera et 
al., 2009). Additionally, Na+ and Cl- reabsorption by the TAL maintains high 
interstitial osmolality, necessary for countercurrent multiplication and water 
reabsorption by the collecting duct system. Thus NKCC2 activity is essential for 
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salt conservation and for acute and chronic regulation of water. ROMK channels 
supply a sufficient amount of K+ to the NKCC2 co-transporter to maintain 
reabsorptive transport of NaCl. As Na+ transport of NKCC2 is rate limited by the 
availability of luminal K+ in the TAL, changes in activity of ROMK has detrimental 
effects of NaCl reabsorption (Fang et al., 2010). Figure 1-5 outlines the actions 
of NKCC2 and ROMK.   
The collecting duct is responsible for the final adjustment in urine 
concentration, K+ homeostasis, acid base balance, and Na+ reabsorption which is 
accomplished by ENaC. This channel is a heteromultimeric channel consisting of 
three subunits; α, β, and ƴ and is found at the apical membrane, where the α-
subunit is necessary for proper channel function and insertion onto the apical 
membrane (Loffing et al., 2000). When active, this channel accounts for 
electrogenic Na+ reabsorption by active transport powered by the sodium pump. 
While mediating electrogenic Na+ absorption, transepithelial Cl- absorption is 
thought to be both paracellular (via tight junctions) and transcellular (across 
intercalated cells) (Pech et al., 2013). ENaC mediates Na+ absorption across the 
apical membrane of principal cells, which provides the driving force for K+ 
secretion through K+ channels and plays a role in H+ or HCO3
- secretion (Garty and 
Palmer, 1997). The lumen-negative potential generated by ENaC also provides a 
driving force for Cl- absorption across tight junctions and lateral intercellular 
spaces (Warden et al., 1988). ENaC inhibitors, such as amiloride or benzamil, 
eliminate the lumen-negative transepithelial voltage, which is thought to reduce 
Cl- absorption by eliminating the driving force for paracellular Cl- absorption 
(Sansom et al., 1984). Figure 1-6 outlines the actions of ENaC.  
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Figure 1-3 Indication of transporter position in the nephron. 
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Figure 1-3 Na+ transport actions of NHE3 
The NHE3 anti-porters are positioned at the luminal apical membrane in the proximal 
convoluted tubule and the thick ascending limb (TAL) of the loop of Henle. NHE3 
transports Na+ into the cell in exchange for H+ into the tubular lumen by the 
electrochemical gradient produced by Na+ -K+ /ATPase. The secreted H+ combines with 
HCO3- to form H2O and CO2 and the latter diffuses into cells. Carbonic anhydrase (CA) 
allows rapid conversion of H2CO3 into H2O and CO2. Secreted H+ generates OH- inside the 
cell which is then converted into HCO3- by combining with CO2. The HCO3- leaves the cell 
via the basolateral Na+ -3HCO3- co-transporter (adapted from (Sahay et al., 2007)). 
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Figure 1-4 Na+ transport actions of NKCC2 and ROMK 
NKCC2 and ROMK symporters are co-localised at the position of the luminal apical 
membrane at the TAL. NKCC2 transports 1 Na+, 1 K+, and 2 Cl- into the cell via 
electrochemical gradient produced by Na+ - K+ /ATPase. Na+ and Cl- are transported to 
the peritubular fluid whilst K+ is re-cycled back to the tubular lumen via ROMK. For each 
Na+ ion transported into the cell by NKCC2, 1 Na+ ion is absorbed via paracellular 
pathways. The absorption of Na+ and Cl- by NKCC2 is an example of secondary active 
transport (adapted from (Sahay et al., 2007)). 
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Figure 1-5 Na+ transport actions of ENaC 
ENaC sodium transporters are positioned on the apical membranes of the distal 
convoluted tubule and predominantly along the collecting duct. ENaC at the collecting 
duct is responsible for the electrogenic Na+ reabsorption by the Na+ -K+ /ATPase pump 
across the apical membrane of principal cells. Providing the driving force for K+ secretion 
through K+ channels and plays a role in H+ or HCO3- secretion. The lumen-negative 
potential generated by ENaC also provides a driving force for Cl- absorption across tight 
junctions and lateral intercellular spaces (adapted from (Sahay et al., 2007)).  
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1.4.3 Pressure diuresis and natriuresis 
A central component of the feedback system for long-term control of arterial 
pressure is the pressure-diuresis/natriuresis mechanism, whereby increases in 
renal perfusion pressure lead to decreases in sodium reabsorption with increases 
in urine output and sodium excretion. Guyton and colleagues were the first to 
demonstrate these mechanisms were capable of determining and maintaining 
long term arterial pressure (Guyton, 1967, Guyton et al., 1964, Guyton et al., 
1980). The concept posed that when arterial pressure rises (regardless of 
stimulus or cause); the kidneys excrete excess quantities of salt and water, thus 
decreasing blood volume. The contraction of blood flow reduces as does BP. 
Conversely, when arterial pressure falls below normal levels, the incoming fluid 
is greater than the excreted fluid causing increased BP. They reported that if 
daily water intake and salt intake remained constant, then arterial pressure 
would be normal i.e. the rate of fluid loss is equal to the rate of fluid gained. 
The theory implicated that in times of increased peripheral resistance would 
result in increased urine output (with increased Na+ and water excretion) to 
reduce ECF and blood volume. This kidney fluid system constituting a pressure 
feedback control mechanism was defined as “infinite gain” (Cowley, 1992). 
When a control system corrects a perturbation minimally, its feedback gain is 
near zero. When it corrects it completely, its gain is infinite, and the infinite 
gain function ultimately dominates. 
The use of renal function curves demonstrates the normal effect of differing 
arterial pressures on fluid excretion by the kidneys (Guyton, 1991), in that 
arterial pressures below 40 to 60 mmHg in normal kidneys results in no urine 
output. However above this basal level, kidney excretion increases rapidly with 
pressure. Therefore, intake and excretion must be equal and to calculate 
pressure natriuresis and this is known as “equilibrium pressure”. The kidney fluid 
system does not act rapidly as effects on pressure may not be apparent until 2 – 
4 days pass before the pressure is within 1 mmHg of the equilibrium level 
(Guyton et al., 1980). The pressure diuresis/natriuresis mechanism is the only 
known control system of these capabilities. Hypertension provides the error 
signal for re-establishing extracellular fluid volume by turning on pressure 
natriuresis. 
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1.4.4 Glomerular filtration rate 
Glomerular filtration rate (GFR) describes the flow rate of filtered fluid through 
the kidney, and is the accepted standard method to assess kidney function. 
Normal values in humans, related to age, sex, and body mass, are approximately 
130 ml / m / 1.73 m2 in healthy males and 120 ml / m / 1.73 m2 in healthy 
females (Stevens et al., 2006). GFR is measured as urinary and plasma creatinine 
level as an estimated filtration maker. Creatinine is freely filtered by the 
glomerulus and studies support the similarity of creatinine clearance (CrCl) to 
GFR and its reciprocal relationship with serum creatinine levels (Stevens and 
Levey, 2005, Levey, 1990). An estimated GFR below 60 ml / m / 1.73 m2 is 
associated with decreased kidney function and risk of essential hypertension as 
CVD is between 5 and 30 times higher in patients undergoing dialysis than in 
subjects of the same age, race, and gender from the general population (Sarnak 
et al., 2003, Go et al., 2004). This reflects a high prevalence, incidence, and 
fatality of CVD in subjects with compromised kidney function measured as GFR. 
Manjunath et al compared the risk relationship between GFR and CVD among 
middle aged and elderly subjects. Both cohorts displayed increased risk of CVD 
with lower GFR however the absolute risk was higher in the older cohort 
(Manjunath et al., 2003a, Manjunath et al., 2003b). Additionally, McQuarrie and 
colleagues reported that patients with essential hypertension and chronic kidney 
disease had a lower mean eGFR (38.6 ml / m / 1.73 m2) in comparison to the 
control group of hypertensive subjects (90.4 ml / m / 1.73 m2). These findings 
support the importance of GFR as a predictor or renal function and risk for 
hypertension.  
1.5 Salt sensitivity in Hypertension 
In a subset of the human population, BP rises as a result of habitual increased 
salt consumption (Weinberger, 1996); individuals who manifest this trait are salt 
sensitive. If the kidney fluid system for pressure control and the RAAS function 
normally, humans can consume extremely small or extremely high levels of salt 
without major alterations in arterial pressure (salt resistance) (Guyton, 1991). 
What distinguishes salt sensitive from salt resistance subjects is that in the face 
of high salt intake salt sensitive subjects raise their BP and can only maintain 
sodium balance by resorting to pressure natriuresis. An association between salt 
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sensitivity and a greater propensity to develop essential hypertension and renal 
failure has been described in some populations such as elderly people and black 
people (Luft et al., 1991, Aviv et al., 2004b). In elderly patients with 
hypertension, Shimamoto and colleagues demonstrated that the hemodynamic 
response to NaCl load changed with time. Initially the increased BP was 
sustained by increased cardiac output; however, after two weeks hypertension 
was sustained by peripheral resistance (Shimamoto and Shimamoto, 1990). 
Another study investigated effects of low and high NaCl diet on cardiac output 
and peripheral vascular resistance in salt sensitive and non salt sensitive 
subjects and found increments of cardiac output in the high and low NaCl diets 
in the salt sensitive subjects, whereas peripheral resistance did not differ 
between the groups on either diet (Fujita et al., 1980). Hemodynamic responses 
to high NaCl is easier to determine in rodent models in salt sensitive stains. 
During high NaCl intake cardiac output was similar between the strains but 
peripheral resistance reduced in Dahl resistant rats but increased in Dahl 
sensitive rats. Simchon et al confirmed that 4 weeks of 8% NaCl caused sustained 
hypertension in Dahl sensitive rats due to increased blood volume and cardiac 
output (Simchon et al., 1991). These studies are consistent with Guyton’s 
hypothesis.  
Other groups have described a model of salt sensitivity in differing ethnicities, 
and reported in comparison to white people; black people have lower plasma 
renin activity (PRA) (Kilcoyne et al., 1974, Berenson et al., 1979, Channick et 
al., 1969, El-Gharbawy et al., 2001, Lasker et al., 1985). With high sodium 
intake, black people have a higher GFR and a lower renal plasma flow (RPF) 
(Campese et al., 1991). With low sodium intake, the GFR/RPF ratio is not 
different between black people and white people (Price et al., 2002), however, 
interestingly, ACE inhibition is more effective than antihypertensive agents in 
attenuating the progression of decline in kidney function of black people who 
manifest kidney disease with essential hypertension (Sica and Douglas, 2001, 
Wright et al., 2002). It has been suggested that the lower PRA and sodium 
sensitivity in black people could arise from either; a primary increase in 
proximal tubule sodium reabsorption resulting in expansion of the ECF volume or 
a primary reduction in sodium reabsorption by the proximal tubules leading to 
tubular hyperfusion of the macula densa and suppression of the RAAS (reviewed 
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in (Aviv et al., 2004a)). Urinary excretion of K+ is lower in black populations than 
white populations, Luft et al reported that black people consistently excreted 
less urinary K+ than white people when maintained on a 80 mmol/d K+ diet with 
differing regimes of NaCl, reaching as high as 1500 mmol/d. At the end of the 
study white subjects had a net K+ deficit of -334 mmol, whereas black subjects 
had a net deficit of only -45 mmol (Luft et al., 1979b). Potassium transport is 
highly linked to sodium reabsorption; therefore sodium transport mechanisms 
described in section 1.4.2 may explain salt sensitivity in black people. Studies 
have suggested that NKCC2 activity is higher in black people as furosemide 
treatment increased urinary K+ excretion in this demographic, thus increasing 
Na+ reabsorption and ECF volume, reducing PRA, and urinary K+ excretion (Luft et 
al., 1979a). In addition to the clinical evidence, animal models have illustrated 
that an increase of NKCC2 is associated with salt sensitive hypertension. In Dahl 
salt sensitive and Milan hypertensive rats NKCC2 Na+ transport was elevated 
(Alvarez-Guerra and Garay, 2002, Ferrandi et al., 1990).  
Although physiological examination of BP control has helped dissect the basic 
relationships between rapid, intermediate, and long term control systems of 
arterial pressure the causation of essential hypertension remains an important 
factor for investigation. 
1.6 Causation and Epidemiology of essential 
Hypertension 
The etiology of elevated blood pressure has not been determined in the vast 
majority of individuals with essential hypertension as there is no known singular 
cause of the complex heterogeneous and multifactoral disorder. Studies have 
focused on the dissection of environmental and genetic causality of essential 
hypertension in the search of understanding the molecular pathogenesis of the 
condition.  
1.6.1 Environmental factors 
There is growing evidence that complex interactions among multiple 
environmental factors play an important role in determining an individual’s risk 
of various common diseases including hypertension (KUNEŠ J, 2006). This 
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evidence supports that gene-gene interactions and gene-environmental 
interactions must be ubiquitous given the complexities of intermolecular 
interactions that are necessary to regulate gene expression and the hierarchical 
complexity of quantitative traits. A number of environmental factors increase BP 
these include; obesity, high dietary sodium intake, excess alcohol consumption, 
smoking, stress, aging, sedentary life style, low K+ intake, and low calcium 
intake (1988, Sever and Poulter, 1989). It has been documented that 50 -70 % of 
the variance in SBP is attributed to environmental factors (Cui et al., 2002, 
Annest et al., 1979), for example; populations who have inherited optimal BP 
will have SBP ≤120 and DBP ≤80 mmHg, whereas if one or more environmental 
factors were added to this population SBP would increase to the range of ≤135 
mmHg and DBP ≤85 mmHg. If subjects who have inherited BP in the normal 
range (≤130 / ≤85 mmHg) were to have one or more environmental risk factors 
BP would increase to the high normal range (139/85 mmHg) or stage one of the 
hypertensive category (140 - 159/85 - 89 mmHg). If one or more environmental 
factors were added to populations of inherited hypertension (≥140/90 mmHg) 
these subjects would display severe high BP (Campese, 1994). 
 
Therefore, it can be said that environmental factors also have an important link 
with genetic components. The relationship between the two can influence 
intermediary phenotypes such as sympathetic nerve activity, the Renin 
Angiotensin Aldosterone System (RAAS), the renal kallikrein system, vascular 
reactivity, Na+ excretion, and cardiac contractility contributing to blood pressure 
phenotypes. Increased sodium intake is most relevant to studies of this thesis as 
this is linked with augmented extracellular fluid volume and BP.  
The International Study of Salt and Blood Pressure (INTERSALT) project was a 
large, prospective epidemiological study involving 52 centres from 32 countries. 
Results from 10,079 individuals identified a strong link between sodium 
excretion and systolic blood pressure that was independent of any other risk 
factors for hypertension (Elliott et al., 1989). Additional intervention studies 
reduced salt intake in either normotensive or hypertensive individuals and 
showed that blood pressure levels were reduced on low sodium diets. This was 
the case for both acute (less than 4 weeks) and prolonged salt restricted diets, 
which reduced salt intake from 10 g/day to 5g/day (MacGregor et al., 1982, 
Meneton et al., 2005). Moreover, a recent meta analysis of 19 separate cohorts 
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demonstrated that high sodium intake (average increase in salt intake of 5 
g/day) increased the risk of total incidence of CVD (Strazzullo et al., 2009). 
 
1.6.2 Genetic factors 
Epidemiology and family aggregation studies have established multiple lines of 
evidence demonstrating that genetic factors contribute 30-50 % of blood 
pressure variation (Levy et al., 2000). Individuals who have one or two parents 
with hypertension are approximately twice as likely to develop increased blood 
pressure phenotypes, furthermore, blood pressure is increasingly correlated in 
identical twins (monozygotic) than non identical twins (dizygotic) (Luft, 2001). 
The Victorian family Heart study investigated the correlation between SBP with 
family member pairs, reporting a decreased correlation of SBP with decreasing 
genetic similarity (Harrap et al., 2000). Adoption studies show correlations in 
blood pressure are more significant between biological parent and child than 
parent and adopted child (Biron et al., 1976, Mongeau et al., 1986). Similar to 
other complex diseases, the identification of genetic mechanisms in prevalent 
hypertension is difficult due to lack of identifying specific genes involved, and 
the extent to which particular genes contributes to the phenotypes, populations 
and environments. However, the study of genetic variation implicates common 
and rare mutations that are involved in the genetic architecture of essential 
hypertension.  
1.6.2.1 Monogenic forms  
Monogenic (single gene mutation) or Mendelian disorders have identified rare 
variants responsible for large effects on blood pressure. Work primarily 
performed by Lifton and colleagues (Lifton et al., 2001) identified rare 
mutations affecting at least 10 genes that altered BP predominantly through 
changed renal salt homeostasis and water handling, reinforcing the importance 
of renal involvement in long term blood pressure control. The Mendelian 
mutations can be characterised into groups that contribute to a common 
mechanism of altered tubular reabsorption of sodium, potassium, and chloride, 
volume expansion, hypertension, or hypotension. Each are discussed in turn 
below. 
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1.6.2.2 Glucorticoid Remediable Aldosteronism (GRA) 
This is an autosomal dominant form of monogenic hypertension where 
aldosterone secretion is regulated by adrenocorticotrophic hormone. There are 
variable associated findings of the condition including: normal or elevated 
aldosterone levels despite lower or suppressed renin activity (Sutherland et al., 
1966), low serum potassium levels (Hypokalemia), and metabolic alkalosis 
caused by elevated blood pH (Rich et al., 1992). The genetic mutation arises due 
to a chimeric gene fusing nucleotide sequence between two closely related 
aldosterone steroid biosynthesis genes. These genes encode aldosterone 
synthase and steroid 11β- hydroxylase. The chimeric gene results from a 
mismatch crossing over to produce a gene containing the promoter region of 
11β- hydroxylase with the structural portion of aldosterone synthase (Lifton et 
al., 1992a, Lifton et al., 1992b). This encodes a protein with aldosterone 
synthase enzymatic activity whose expression is regulated by 
adrenocorticotrophic hormone (ACTH). As a consequence, aldosterone secretion 
becomes linked to cortisol secretion leading to increased volume expansion, 
metabolic alkalosis with hypokalemia, low plasma renin, high aldosterone, and 
hypertension. 
1.6.2.3 Apparent Mineralocorticoid excess (AME) 
AME is an autosomal recessive form of monogenic juvenile hypertension with 
hypokalemia, and metabolic alkalosis with suppressed plasma renin activity due 
to a virtual absence of aldosterone ((Carretero and Oparil, 2000b). The mutation 
is found in the renal specific isoform of 11β- hydroxysteriod dehydrogenase 
(Mune et al., 1995). The normal functions of this enzyme converts cortisol into 
the inactive metabolite cortisone, which is of importance as cortisol and 
aldosterone have similar capacity to bind to the mineralocorticoid receptor 
(MR). This enzymatic discrepancy allows MR in the nephron to be occupied and 
activated by cortisol resulting in Na+ and water retention, volume expansion, low 
renin, low aldosterone, and salt sensitive hypertension mediated by increased 
ENaC activity (Mune et al., 1995).  
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1.6.2.4 Liddle’s syndrome 
This syndrome is a dominant form of monogenic hypertension resulting from 
mutations of ENaC β or γ subunits. The condition results in the deletion or 
missense mutations of the cytoplasmic C terminal, PPXY (proline, proline, 
proline, any amino acid, tyrosine) of the ENaC subunits. The PPXY domain of the 
ENaC subunits interacts with Nedd4-1 and Nedd4-2 proteins as a first step in the 
ubiquitination and clearance of ENaC (Staub et al., 1996, Kamynina et al., 2001). 
Disruption of the PPPXY domain therefore causes reduced clearance of ENaC 
from the tubule membrane, resulting in increased ENaC numbers and activity, 
leading to salt retention and hypertension. This condition is associated with 
early onset of hypertension, hypokalemia alkalosis, suppressed plasma renin 
activity, and low plasma aldosterone levels (reviewed in (Lifton et al., 2001). 
The severity of the hypertension and hypokalemia vary between individuals 
raising the possibility that some sufferers have salt sensitive hypertension and 
some have Liddle’s syndrome (Hansson et al., 1995).  
 
1.6.2.5 Pseudohyoaldosteronism type I (PHA I) 
This condition features severe neonatal hypotension with salt wasting despite 
marked elevations in aldosterone levels. There are two forms, autosomal 
recessive and autosomal dominant (Huang et al., 1995). Patients with the 
dominant form arise from a heterozygous loss of function mutation of the MR. 
This partial loss of function impairs salt reabsorption as ENaCs action to establish 
the electrical driving force for K+ and H+ secretion in the distal tubule is 
abolished accounting for the hyperkalemia and metabolic acidosis (Geller et al., 
1998), indicating that two normal copies of MR are required for normal salt 
reabsorption. The autosomal recessive form arises from loss of function mutation 
in any of the ENaC subunits (Chang et al., 1996). Akin to the dominant form of 
PHA I, the recessive form features salt wasting and hypotension in neonates. 
Unlike the dominant form these sufferers do not improve with age. Expression 
studies have confirmed this mutation impairs ENaC function in the same way as 
dominant PHA I, however in addition to these affects on renal sodium handling 
these sufferers can display respiratory failure due to impaired clearance of 
water in the lung (Barker et al., 1998, Hummler et al., 1996).  
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1.6.2.6 Pseudohypoaldosteronism type II (PHA II) 
Pseudohypoaldosteronism type II (PHAII), is also referred to as Gordon’s 
Syndrome, with sufferers displaying hypertension, hyperkalemia, 
hyperchloraemia, and metabolic acidosis rather than volume depletion. It is an 
autosomal dominant condition caused by mutations in serine-threonine kinase 
genes, WNK1 and WNK4 (Mansfield et al., 1997, Wilson et al., 2001). WNK stands 
for “With No Kinase” and are named so as they lack lysine in the ATP-binding 
cassette of the catalytic region. Patients with WNK1 mutations have intronic 
mutations that increase the abundance of WNK1 and patients with WNK4 
mutations have missense mutations that localise at the short region in a highly 
conserved WNK residue. PHA II mutant WNK4 mutations decrease cell surface 
expression of ROMK, inhibiting K+ and Cl- transport (Kahle et al., 2003). PHA II 
patients have increased distal chloride reabsorption resulting in reduced 
electronegativity of the lumen, thereby decreasing the electrochemical gradient 
for K+ excretion. Yang et al developed a mouse model to replicate human PHA II; 
mice were generated with one normal copy of WNK4 and one mutant WKN4 
(D561A) (Yang et al., 2003). The rodent model confirmed phenotypes of the 
human disease; hypertension and hyperkalemia. There are no in vivo studies so 
far dissecting the role of WNK1 mutations and ion transport, however in vitro 
assays have shown WNK1 mutations inhibits ROMK activity by stimulating 
endocytosis of ROMK (Wade et al., 2006). Serum and glucocorticoid regulated 
kinase 1 (SGK1) is induced and activates ENaC and ROMK by phosphorylation of 
effector molecules such as Nedd 4-2. The serine residues S1169 of SGK1 
phosphorylate WNK4. Once phosphorylated at this site, WNK4 is no longer able 
to inhibit ENaC and ROMK (Ring et al., 2007).  
1.6.2.7 Brachydactyly  
Brachydactyly is an inherited condition which is defined by shortened fingers and 
toes due to unusually short bones.  Hypertension and Brachydactyly are always 
inherited together (100 % co-segregation) (Luft, 1998) and map to the short arm 
of chromosome 12. In this monogenic condition, BP is not affected by volume 
expansion as the responses to renin, aldosterone, and norepinephrine appear to 
be normal, and individuals with the condition do not display salt sensitivity 
(Schuster et al., 1996). Studies on the autonomic nervous system have revealed 
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decreased baroreflex sensitivity with significantly impaired blood pressure 
buffering, which suggests that hypertension in the patients may be related to an 
abnormality in the baroreceptor reflex function (Jordan et al., 2000).Thus 
identification of the gene responsible may provide useful in the dissection of 
genetic alterations in essential hypertension.  
 
1.6.2.8 Bartter and Gitelman syndromes 
Gitelman syndrome presents as a form of hypotension and renal sodium wasting 
caused by monogenic mutations. This condition is genetically homogeneous and 
is caused by loss of function mutations of the NCC transporter (Na-Cl co-
transporter in the distal convoluted tubule (DCT)) (Simon et al., 1996b). Patients 
usually present in adulthood with lower BP than the general population and 
display neuromuscular symptoms. These individuals have low serum magnesium 
(Mg+) and low urinary calcium (Ca+) (Bettinelli et al., 1992). The sodium wasting 
at the DCT activates the RAAS, however in this condition activation of the MR is 
able to augment ENaC activity, protecting sodium homeostasis at the expense of 
increased H+ and K+ secretion.  
Bartter syndrome is distinguished from Gitelman syndrome by hypercalciuria 
(increased urinary calcium) with normal or only mildly reduced Mg+ levels. 
Neonates usually present with life threatening hypotension where the mutation 
occurs from three genes that are necessary for normal sodium reabsorption in 
the TAL. Mutations result from loss of function of NKCC2 impairing sodium 
reabsorption across the apical membrane (refer to Figure 1-5), resulting in salt 
wasting phenotypes with consequent activation of the RAAS. ROMK and CLCNKB 
gene mutations cause similar phenotypes of low BP, sodium wasting and 
hypokalemia. ROMK usually directs K+ across the apical membrane of the TAL 
(refer to Figure 1-5). The mutations results in salt wasting as: fluid entering the 
TAL has increased concentrations of Na+ and Cl- with low K+ thus the 
stochiometric flux of Na+ and K+ via NKCC2 rapidly depletes K+ in the luminal 
fluid which prevents efficient reabsorption of Na+ and Cl- (Simon et al., 1996a). 
This chain of events can be avoided by K+ entering back into the luminal fluid, 
implicating ROMK as the necessary channel for the recycling of K+ to maintain 
Na+ and Cl- reabsorption. Bartter’s syndrome type 3 is caused by mutations of 
the Cl- channel CLCNKB (Simon et al., 1997). NaCl entering the cell via NKCC2 at 
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the apical membrane must exit the cell via the Na+ -K+ /ATPase at the 
basolateral membrane; however this mutation prevents normal Cl- exit due to 
inhibition of membrane localisation. Demonstrating the importance of 
synchronised actions of these channels in blood pressure regulation.  
1.7 Antihypertensive Treatment 
The goal of antihypertensive treatment is to reduce CVD risk and its morbidity 
and mortality rates. Life style modifications such as: weight reduction, increased 
physical activity, moderation of alcohol intake, dietary modification, sodium 
intake reductions, potassium repletion, calcium repletion, macronutrient 
alteration, and smoking cessation will benefit BP management (Carretero and 
Oparil, 2000a). In spite of this, pharmacological intervention is the required 
treatment to control BP in most cases. Table 1-1 outlines the antihypertensive 
treatments for patients with comorbid conditions. Patients are commonly 
treated with one or more of the following antihypertensive therapies, 
angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor 
antagonists, calcium channel blockers, diuretics and beta-blockers. ACE 
inhibitors reduce the formation of angiotensin II and aldosterone, which leads to 
reduced vascular tone and extracellular fluid volume and thus reduce BP. 
Angiotensin II receptor antagonists and calcium-channel blockers act as 
vasodilators to widen resistance arteries, reducing peripheral resistance. 
Diuretics increase water and salt excretion, thereby reducing extracellular fluid, 
blood volume and BP. Beta-blockers reduce cardiac output and hence reduce BP. 
The National Institute for Health and Care Excellence (NICE) quality standard 
guidelines defined in March 2013 (http://guidance.nice.org.uk/QS28), 
recommend the management and treatment of primary hypertension in adults 
should be followed by clinicians as per Figure 1-6 and Figure 1-7.  
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Condition Drug Therapy (hypertension) 
 
Heart Failure ACE inhibitors, Diuretics, or Β-blockers 
Diabetes mellitus (type 1)  ACE inhibitors 
Isolated systolic hypertension Diuretics or calcium channel blockers 
Myocardial Infarction  Β-blockers or ACE inhibitors 
Angina Β-blockers or calcium channel blockers 
Atrial tachycardia and fibrillation  Β-blockers or calcium channel blockers  
Cyclosporine induced hypertension Calcium channel blocker  
Diabetes Mellitus (type 1 and 2) ACE inhibitors or calcium channel 
blockers 
Dyslipidemia Β-blocker (nonintrinsic 
sympathomimetic activity), diuretics, 
or α-blockers 
Hyperthyroidism Β-blocker 
Renal insufficiency (excluding renal 
hypertension) 
ACE inhibitor 
Peripheral vascular disease  Β-Blocker 
Pre-eclampsia ACE inhibitor or angiotensin II receptor 
blockers 
Renovascular disease ACE inhibitor or angiotensin II receptor 
blockers 
Table 1-1 Antihypertensive drug therapy for patients with comorbid conditions (adapted 
from (Carretero and Oparil, 2000a) 
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Figure 1-6  NICE guidelines to clinicians for management of hypertension. 
Adapted from (http://pathways.nice.org.uk/pathways/hypertension/management-of-
hypertension). 
All people with 
Hypertension 
Life style 
Intervention 
Exercise (increase)
Diet (monitor salt, fats, and sugar consumption)
Alcohol consumption (reduce)
Smoking status (cessation)
Antihypertensive 
treatment
Review Annually 
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Figure 1-7 NICE guidelines to clinicians for antihypertensive treatment  
Adapted from (http://pathways.nice.org.uk/pathways/hypertension/antihypertensive-
drug-treatment). 
 
 
 
Starting antihypertensive drug 
treatment
General  treatment 
principles 
● Prescribe non-propietary drugs if appropriate 
● People with isolated systolic hypertension ≥160      
mmHg  should be treated the same as people with 
raised SBP and DBP
● Do  not combine ACE inhibitors with 
Angiotensin II receptor blocker 
● Take into account any co-morbidities
Blood pressure targets: Daytime average of 
ambulatory blood pressure or home blood 
pressure monitoring 
● Age ≤ 80 years BP should 
be ≤ 135/85 mmHg
● Age ≥ 80 years BP 
should be  ≤ 145/85 
mmHg
Treatment
≤ 55 years ≥ 55 years or Black (African or 
Caribbean origin of any age) 
Step 1: ACE inhibitor 
or Ang II blocker Step 1: Calcium 
channel blocker 
Step 2: Combine treatment of ACE 
inhibitor or Ang II blocker with Calcium 
channel blocker 
Step 3: Combine step 2 with 
Thiazide like diuretic 
Step 4: Resistant hypertension, follow step 3 
and consider the addition of other diuretics 
and α and/or β blockers 
Monitor treatment and review 
annually 
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1.7.1 Hypertensive treatment with Diuretics  
As the kidney is the principle organ responsible for long term blood pressure 
control via mechanisms regulating Na+ homeostasis, fluid volume balance, and 
acid base balance defects in ion transport or regulators of ion transport can lead 
to the development of essential hypertension. In essential hypertension, 
pharmacological intervention targets kidney ion transporters. Diuretics are used 
as a common treatment (in combination with other pharmacological 
intervention) to produce natriuresis and diuresis by acting upon and blocking the 
activities of various Na+ transporters along the nephron. There are many types of 
diuretics that fall into the following categories: high ceiling loop diuretics, 
Thiazides, carbonic anhydrase inhibitors, potassium and calcium sparing 
diuretics, osmotic diuretics, and low ceiling diuretics.  
Carbonic anhydrase inhibitors act on the proximal tubule to inhibit, as the name 
implies, carbonic anhydrase and NHE3 function in hypertension. These are mild 
diuretics that promote natriuresis. However, these drugs can cause metabolic 
acidosis and hypokalemia. Loop diuretics are the most potent class of diuretic 
therapeutics, and they are effective even if GFR is compromised (Sahay et al., 
2007). They reach the tubular lumen by secretion in the proximal tubule at the 
prime site of action; the thick ascending limb of the loop of Henle. This class of 
loop diuretics acts to block NKCC2 actions in hypertension, but can cause 
increased acid excretion and metabolic alkalosis (Reeves and Molony, 1988), akin 
to Barrter syndrome which share homology to the actions of loop diuretics. 
Thiazides are a type of diuretics that target the distal convoluted tubule, where 
they block 40 % of coupled reabsorption of Na+ and Cl-. The action of thiazides 
mimics the characteristics of Gitleman syndrome (Hoover et al., 2003). 
Potassium sparing diuretics comprise of two different classes; 
amiloride/triamterene and spironolactone. The former are epithelial Na+ 
channel blockers and the latter are competitive aldosterone antagonists. Distal 
K+ sparing agents act on the principle cells in the late distal convoluted tubule, 
initial connecting tubule, and cortical collecting duct where they inhibit luminal 
sodium entry. These drugs only allow short term natriuresis. One caveat of these 
drugs is the progressive diuretic tolerance in patients, this is due to diuretics 
blocking Na+ reabsorption in one segment of the nephron which leads to 
hypertrophy of other nephron segments and consequent increase Na+ 
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reabsorption in these segments. Thus combining different classes of diuretics 
acting on differing segments of the nephron may minimise these effects. These 
diuretics and their actions are outlined in Table 1-2.  
Drug name Site of action Mechanism 
Acetazolamide Proximal tubule NHE3 
Frusemide Loop of Henle NKCC2 
Bumetanide Loop of Henle NKCC2 / Na+ -K+ /ATPase 
Thiazides Early distal convoluted 
tubule 
NCC 
Amiloride Late distal convoluted 
tubule and collecting 
duct 
ENaC 
Spironolactone Late distal convoluted 
tubule and collecting 
duct 
Mineralocorticoid 
antagonist 
Table 1-2 Common diuretics and their site of action (adapted from (Sahay et al., 2007)) 
 
1.8 The study of Genetic architecture to identify genes of 
essential hypertension  
The most common type of human genetic variation is the single nucleotide 
polymorphism (SNP), a position at which two alternative bases occur at 
appreciable frequency (> 1 %) in the human population. These heritable 
variations lead to susceptibility to hypertension. Furthermore, detailed studies 
of genes involved in renal salt handling have identified rare variants (minor 
allele frequency < 0.1%) that influence blood pressure (Lifton et al., 2001, Ji et 
al., 2008). Low frequency variants may have substantial effects without 
demonstrating Mendelian segregation and could contribute to missing heritability 
(McCarthy et al., 2008). Strategies to identify variants involved in complex traits 
of essential hypertension can be divided in two broad categories; linkage and 
association studies. These can be further subdivided into candidate gene analysis 
and genome wide scans. Candidate gene analysis is where the study of 
physiologically relevant genes are tested for co-inheritance with phenotype (i.e. 
hypertension), while genome-wide scans, no assumptions are made and markers 
throughout the genome are analysed. In recent years, genetic markers studied in 
linkage and association studies have advanced in the cataloguing of SNPs 
throughout the genome improving high throughput genetic screening.  
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1.8.1 Candidate gene studies of hypertension 
Candidate gene studies examine polymorphisms in a subset of genes based on 
prior biological evidence (i.e. test known physiological pathways that affect the 
phenotype of interest). This type of analysis allows detection of small effects 
using moderate sample size by limiting the number of SNPs tested allowing 
favourable multiple correction analysis. However, the use of moderate sample 
size precludes the study of rare variants as very few participants in the sample 
have rare genotypes. Furthermore, in candidate gene studies the number of 
genotyped polymorphisms limit the investigation of possible epistasis and 
discount variants that lack an obvious phenotype/physiological relationship to 
complex disease (Charchar et al., 2008). Candidate gene studies of over 15 
Mendelian hypertensive or hypotensive syndromes have identified genes involved 
in renal sodium handling ion channels (SLC12A3, SLC12A1, KCNJ1, SCNN1A, 
SCNN1B, SCNN1G, CLCNKB), aldosterone signalling (REN, AGT, ACE, AGTR1), and 
ion channel regulation (WNK1, WNK4, SGK1). The implicated variants explain 
less than 1% of the observed population variance in BP and these studies are 
mainly assimilating physiological assumptions that reduce the significance 
threshold by an order of magnitude.  
As these types of studies often ignore epistasis, gene environment interaction, 
and rare variants there are often inconsistencies between studies in essential 
hypertension (Pascoe et al., 1992, Wang et al., 2006, Williams et al., 2004, Ji et 
al., 2008). To date there are no reproducible candidate gene studies of essential 
hypertension (Padmanabhan et al., 2008), this is potentially due to some of the 
drawbacks of this type of assessment; the wrong genes may have been initially 
identified, causative genes may lie upstream or downstream of the investigated 
gene, and as candidate gene studies rely on previously reported disease 
mechanisms, limits the discovery of genetic variants in novel pathways. 
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1.8.2 Linkage analysis studies of hypertension 
Linkage studies test the co-segregation of genomic loci and traits in related 
individuals (Bailey-Wilson and Wilson, 2011) to identify low frequency, rare 
variants with large effects. This type of analysis is performed in family cohorts 
where affected and unaffected family members are phenotyped and genotyped. 
The genetic relationship between family members are statistically analysed to 
find genetic markers in linkage disequilibrium (when two loci (genetic markers) 
are inherited together from parent to child more often than expected as a 
consequence of independent inheritance, they are considered to be linked) with 
the loci being responsible for the phenotype. When two loci are close together 
on the same chromosome they segregate more often, and are less likely to be 
separated by a recombination event at meiosis. Most linkage studies analyse 
affected sibling pairs, since siblings have on average 50% genetic identity, they 
should share markers near loci responsible for hypertension more often than 
would be expected by chance. The number of phenotypes studied, the family 
structure, the number of families, the number of genetic markers and the 
linkage between the markers and the loci all dictate the statistical power of 
linkage analysis.  
Linkage analysis has identified BP loci on every chromosome (Binder, 2007). Only 
approximately half of these studies reported a genome wide significant QTL 
(quantitative trait loci), and these studies lacked replication. However, the MRC 
British Genetics of Hypertension (BRIGHT) study was successful in identifying 
susceptibility loci that modestly increase risk of hypertension by non-parametric 
linkage (Caulfield et al., 2003). This study initially recruited 2010 affected 
sibling pairs from 1599 families with severe hypertension (top 5% of blood 
pressure distribution) and included 3599 individuals in the genome-wide scan; it 
is the largest homogenous linkage study in hypertension genetics. The study 
identified a locus on chromosome 6q that achieved genome-wide significance, 
and three further loci with suggestive significance on chromosomes 2q, 5q and 
9q (Caulfield et al., 2003). It has been reported that variants located near the 
telomere of the chromosome should be viewed with caution (Harrap, 2003) as 
linkage evidence can be difficult to interpret, as was the case of the locus at 6q 
in the BRIGHT study. Therefore, a follow-up study included additional 
polymorphic markers in the regions of interest, and increased the study cohort 
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to 2142 affected sibling pairs was performed (Munroe et al., 2006). Support for 
the loci at 2q, 6q and 9q were weakened with this analysis, however, there was 
increased support for linkage to the locus at 5q. A further two regions at 1q and 
11q achieved suggestive significance. A second linkage study was performed 
using a cohort of families comprising an affected individual, and either two 
parents or siblings and single parent. The results confirmed the locus at 5q 
(Munroe et al., 2006).  
Although useful, linkage studies have low power for variants with modest effects 
and fail to produce robust validated loci for hypertension. The field of complex 
disease genetics has recently progressed from linkage to association study design 
as association analysis has far greater power to detect variants of modest effect 
and of lower frequency. Therefore, association studies involving genotype and 
phenotype of unrelated individuals who are effected and unaffected by 
phenotype are studied to find disease causing variants. Table 1-3 outlines the 
wide spread clustering of hypertension quantitative trait loci (QTLs). 
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Study 
 
Phenotype Subject (n) Chromosome Population 
(Caulfield et al., 
2003) 
 
Hypertension 3599 2,5,6,9 White 
 
(Munroe et al., 
2006) 
 
Hypertension 3863 5 White 
 
(Rao et al., 
2003) 
 
Hypertension 1300 2 African 
American  
 
(Chang et al., 
2007) 
Hypertension 1726 1 African 
American &  
European 
American 
(Perola et al., 
2000) 
Hypertension 
(DBP) 
 
113 1,2,3,22 White  
(Hunt et al., 
2002) 
 
Hypertension 
(SBP) 
2959 1,7,12,15,6 
 
White 
(James et al., 
2003) 
 
SBP 1671 1,3,8,17 White 
(Puppala et al., 
2011) 
 
SBP 1089 6 Mexican-
American 
(Rice et al., 
2002) 
 
SBP 519 3,11 White 
(Hamet et al., 
2005) 
DBP, Mean BP 500 DBP: 1,3,16.  
Mean BP: 16 
 
French 
Canadian 
(Atwood et al., 
2001) 
 
SBP 495 2,8,18,21 Mexican 
(Kristjansson et 
al., 2002) 
 
Hypertension 490 2,11,17,18 White 
(Benjafield et 
al., 2005) 
 
SBP 427 2,5,6,9,15,16,1
8,20,21 
White 
(Zhu et al., 
2001) 
 
Hypertension 393 2,3,8,15 Chinese 
(Ciullo et al., 
2006) 
 
Hypertension 173 1,4,8 White 
 
(Gong et al., 
2003) 
Hypertension 158 12 Chinese 
Table 1-3 Linkage analysis studies  
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Study 
 
Phenotype Subject (n) Chromosome Population 
(Yang et al., 
2009) 
 
Hypertension 1008 20 Chinese 
 
(Simino et al., 
2011) 
Hypertension 4266,2154, 
4299,2435 
6,8,20,21 African 
American, 
Asian, White, 
Mexican 
American 
 
(Bell et al., 
2006) 
 
Hypertension 3863 5,9,11,15,16,19 White  
(Levy et al., 
2000) 
 
SBP 1585 17,18 White 
(Xu et al., 
1999) 
 
BP 1450 3,11,15,16,17 Chinese 
(Cooper et al., 
2002) 
 
DBP 792 2,3,5,7,10,19 Nigerian 
(Rice et al., 
2000) 
 
SBP 679 1,2,5,7,8,19 White 
(Pankow et 
al., 2000) 
 
SBP 636 6,18 White 
(Pausova et 
al., 2005) 
 
Hypertension 389 1,8,11,13 White 
(Allayee et 
al., 2001) 
 
SBP 388 4,6,8,19 White 
 
(Hamet et al., 
2005) 
DBP, Mean BP 500 DBP: 1,3,16.  
Mean BP: 16 
 
French 
Canadian 
(Krushkal et 
al., 1999) 
 
SBP 427 2,5,6,9,15,16,1
8,20,21 
White 
(Angius et al., 
2002) 
 
Hypertension 77 1,2,13,15,17,19 White 
(Barbalic et 
al., 2009) 
 
SBP 1389 20 White 
Table 1-3  
Continued 
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1.8.3 Genome wide association studies of hypertension  
The lack of convincing evidence from linkage studies has shifted attention to 
association studies to identify causative variants in hypertension. Genome wide 
association studies (GWAS) can uncover common variants with small effect sizes 
that are often not identified via candidate gene and linkage analysis studies 
(Ehret, 2010), they are hypothesis generating tests with the aim of identifying 
common variants not previously implicated in the disease process. There are no 
assumptions made regarding the location or function of the causal SNP, 
presuming that common diseases are attributed in part to allelic variants present 
in 1 – 5 % of the population (Reich and Lander, 2001). Typically, association 
studies are carried out in unrelated populations and the same allele(s) 
associated with the trait are assessed throughout the tested population. 
Differing from linkage studies where traits are associated with differing alleles in 
differing families. When considering qualitative traits of BP, association analysis 
measures statistical associations between hypertension (phenotype) and genetic 
marker (genotype) directly by comparing allele frequencies between cases and 
controls to establish if a particular allele(s) occurs more frequently in cases vs. 
controls and vice versa. Whereas, quantitative traits e.g. blood pressure values 
are assessed for association by means of linear regression. The tested association 
of both qualitative and quantitative traits operate over shorter genomic 
distances than that of linkage analysis, but requires more markers. Most 
association studies rely on large scale, indirect association, to detect causal 
variants (Palmer and Cardon, 2005). Indirect association measures the 
relationship between a phenotype and a genetic marker i.e. SNPs, which are 
correlated with the true causal allele due to linkage disequilibrium (LD). In 
general SNPs in LD with causal variants are more likely to be inherited together 
because they are physically close to one another on the genome. However, 
sometimes this is not the case; studies have shown that levels of local LD vary, 
with some adjacent SNPs being independent despite their proximity and others 
of ≥ 100 Kb apart being in useful LD (Weiss and Clark, 2002). 
 
Technological advances now permit the genotyping of hundreds of thousands to 
more than one million SNPs on a single microarray at a reasonable cost (Fan et 
al., 2000, Oliphant et al., 2002), allowing investigation of a large proportion of 
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the variants in the genome. Association study of SNPs against hypertension and 
BP traits allows unbiased investigation of genetic causes of the traits, which can 
be considered one of the first direct applications of the Human Genome Project 
(Lander et al., 2001) and the HapMap project (Frazer et al., 2007).  
To date there have been few GWAS studies on hypertension, that have had 
success in identifying genetic variants that are associated with increased BP, 
SBP, or DBP (Sabatti et al., 2009, Wang et al., 2009, Kato et al., 2008, Levy et 
al., 2007). The Wellcome Trust Case Control Consortium (WTCCC) was the first 
published GWAS in hypertension (2007). This study failed to identify significant 
variants of hypertension due to poor tagging by genotyping chips, 
misclassification bias in control groups, confounding by age, and insufficient 
power. Quantitative phenotypes (SBP and DBP) assessed by GWAS also failed to 
produce any significant genome wide hits, and implicated genes only an effect 
size of 2 mmHg for SBP and 1 mmHg for DBP (Levy et al., 2007). An intronic SNP 
to Cadherin 13 protein (CDH13) was suggestively associated with dichotomous 
hypertension is a GWAS meta-analysis in three European cohorts (Org et al., 
2009). Consequent analysis revealed that even with large sample sizes, power 
was limited to < 1 % for the replicated variants (Altshuler and Daly, 2007).  
Two influential GWAS were examined in two large meta-analyses of subjects of 
European descent, CHARGE (n = 29, 136) and GlobalBPgen (n = 34,433) (Newton-
Cheh et al., 2009, Levy et al., 2009). Fourteen BP loci were discovered in or 
near genes encoding six enzymes, two ion channels, two transcription factors, a 
structural protein, and a hypothetical gene (Ehret, 2010). To date GWAS 
investigation has implicated more than 50 genes in essential hypertension and BP 
regulation (reviewed in (Simino et al., 2012)). These variants generally only have 
small effects on BP (< 1 mmHg) and collectively only explain approximately 2.5 % 
of BP variation within populations. The vast majority (> 80 %) of associated 
variants fall outside of the coding regions, emphasising the importance of 
including coding and non coding regions of the genome in search for disease 
associated variants (Hindorff et al., 2009).  
SNPs in the promoter region of UMOD have been linked with kidney disease, the 
minor T allele at position -3,653 (rs12917707) was associated with a 20 % 
reduction in chronic kidney disease incidence (Kottgen et al., 2009). The minor C 
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allele at position -1,550 (rs4293393) was associated with enhanced renal 
function in both controls and subjects with chronic kidney disease (Kottgen et 
al., 2010), whereas the dominant T allele at this site was associated with 
increased risk of chronic kidney disease (Gudbjartsson et al., 2010). 
One particular GWAS identified a promoter region variant (rs13333226) in the 
Uromodulin (UMOD) gene was associated with BP (Padmanabhan et al., 2010). 
Padmanabhan and colleagues carried out a GWAS in 1,621 hypertensive cases 
and 1,699 controls with follow up validation analysis in 19,845 cases and 16,541 
controls using an extreme case control design. They identified a locus on 
chromosome 16 in the 5’ region of UMOD. It was reported that the minor G allele 
was associated with a lower risk of developing hypertension, reduced urinary 
uromodulin excretion, improved renal function; and each copy of the G allele 
was associated with a 7.7% reduction in risk of CVD events after adjusting for 
age, sex, BMI, and smoking status. Suggesting that the expression of uromodulin 
in the TAL may play a putative role of this variant in hypertension via altered 
sodium homeostasis. 
1.9 Discovery of Uromodulin 
Tamm Horsfall Protein was discovered in 1950 by Igor Tamm and Frank Horsfall 
(Tamm and Horsfall, 1950). They used a salt precipitation procedure to isolate a 
potent inhibitor of viral hemoagglutination from urine. Subsequently, the group 
went on to characterise the mucoprotein by investigating its putative enzymatic 
inhibitory properties, and reported neuraminidase treatment abolished the 
inhibitory effects in hemoagglutination (Tamm and Horsfall, 1952). In 1964, 
Bayer et al confirmed by electron microscopy the binding of influenza to the 
urinary mucoprotien (Bayer, 1964). Urinary THP was visualised as a network of 
filaments made up of a collection of smaller fibrils (4 – 24 nm in diameter), 
however the length could not the detected due to the tendency of end to end 
aggregates forming. Albert Neuberger and co workers in the 1970’s 
demonstrated that THP: migrates in SDS polyacrylamide gels at an apparent 
weight of 80 – 90 kDa, 20 – 30 % of which is derived from high sialic acid content 
and N-linked glycans; is the most abundant protein in the urine, excreted at 
approximately 50 mg/d; and is present in most mammalian urine (Fletcher et 
al., 1970a, Fletcher et al., 1970b).  
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Muchmore and Decker in 1985, used lectin based affinity chromatography to 
isolate a glycoprotein with in vitro immunosuppressive properties from urine of 
pregnant women, and called the protein uromodulin (Muchmore and Decker, 
1985). In 1987, Pennica et al confirmed by complementary DNA (cDNA) analysis, 
that Uromodulin (UMOD) and THP were identical proteins (Pennica et al., 1987).  
1.9.1 Protein Structure 
Based on the cDNA sequence, the UMOD precursor is composed of 640 amino acid 
residues and motifs include signal sequence residues 1 – 24, 1 epidermal growth 
factor like and 2 calcium binding epidermal growth factor like domains (residues 
31 – 64, 65 – 107, and 108 – 149), 1 zona pellucid domain at residues 334 - 585 
(this is essential for polymerisation), 8 potential N-glycosylation sites, and 1 
stretch of hydrophobic amino acids similar that acquire 
glycosylphosphatidylinositol (GPI) attachment site (residue 614). There are 48 
cysteine residues involved in disulphide bond formation (Hamlin and Fish, 1977). 
It was proposed an additional epidermal growth factor like domain spanning 
residues 281 – 336 was present in the region between the 2nd calcium binding 
epidermal growth factor domain and zona pellucida domain. However, a new 
domain D8C (residues 199-287), common to families of proteins including liver 
specific zona pellucida, glycoprotein 2, UMOD and several other uncharacterised 
proteins was described by Yang et al (Yang et al., 2004).  
UMOD is GPI anchored to the apical plasma membrane, thus its biosynthesis and 
intracellular trafficking must proceed through a secretory pathway. During 
biosynthesis, the UMOD precursor is translocated to the ER (endoplasmic 
reticulum). The signal peptide is then cleaved and the protein glycosylated on 7 
of the 8 potential N-glycosylation sites. Disulphide bridges are formed and 
glypiation on its C terminus occurs, the Golgi apparatus further modifies the N-
glycan moieties. The mature glycan moieties and the GPI modifications act to 
route the protein to the apical membrane of epithelial cells in the TAL, this is 
when UMOD is finally GPI anchored and facing the tubular lumen, here it is said 
to form supramolecular structures to ensure its proposed physiological properties 
are performed (Hoyer et al., 1979). The protein is released for the lumen side of 
the membrane by specific but currently unidentified protease(s). Proteolytic 
cleavage was originally thought to occur after residue F548 (Fukuoka and 
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Kobayashi, 2001), but later thought F587 (Santambrogio et al., 2008). 
Proteolytic cleavage of the GPI anchor still remains to be determined. The 
structure and suggested maturation of UMOD is outlined in Figure 1-8 below. 
 
Figure 1-8 Structure and Maturation of Uromodulin 
The top panel represents the structure of Uromodulin containing a “leader peptide” (where 
it is predicted to be cleaved at residue 23), 3 EGF-like binging domains, the unknown 
central domain of 8 conserved cysteine residues (D8C), a ZP domain, and the GPI 
anchoring site (predicted at position 614). The 7 N-glycosylation sites are indicated and 
the high mannose chain on residue Asn 274 is highlighted in red. The bottom panel 
represents the predicted model of Uromodulin maturation, excretion, and polymerisation. 
The site of the TAL is where Uromodulin is exclusively synthesised, and is co-
translationally inserted in the ER where the GPI anchoring, formation of intramolecular 
disulphide bonds and N-glycosylation occurs. At the golgi, glycans chains are modified 
with the exception of the one at Asn 274, which retains high mannose moiety. Uromodulin 
then reaches the apical membrane in a polymerisation incompetent conformation 
established by the interaction of two hydrophobic motifs, one within the ZP domain, and 
one localised between the ZP domain and the GPI anchor. The protease that cleaves the 
hydrophobic components of Uromodulin into a polymerisation competent monomer from 
the membrane is yet to be defined. This image was reproduced with permission from 
(Rampoldi et al., 2011). 
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1.9.2 Gene 
UMOD is located on the reverse strand of chromosome 16 (16p12.3) at the 
position between 20,344,374 – 20,364,037 bp. The gene is encoded on the 
reverse strand into 15 splice variants differing in their 5’ untranslated region. 
According to Ensembl databases, 4 of the 15 transcripts have an alternative 
upstream exon, however further analysis is needed to verify the function of this 
additional exon in terms of gene expression. In spite of this, many studies have 
shown that UMOD is exclusively transcribed in the kidney, RNA isolated from 150 
different tissues were hybridized using a probe for human THP revealed only RNA 
from human kidney gave positive signals (Pennica et al., 1987). Further 
immunofluorescence and immunochemical analysis indicated that UMOD resides 
in the kidney cells exclusively at the TAL (Sikri et al., 1981). Bachmann et al 
utilised protein gold immunocytochemistry to report that rat UMOD was localised 
in vesicles of Golgi cisternae, fused to the apical membrane of TAL cells 
(Bachmann et al., 1985). Recombinant UMOD in HeLa cells shows that UMOD 
accumulates intracellulary as a precursor of approximately 86 kDa, which is 
converted into a mature molecule of 97 kDa (Rindler et al., 1990) 
The transcription specificity of UMOD in the kidney is determined by the cis-
acting promoter sequence. It has been shown that 3, 3.9, and 1.5 Kb of mouse, 
bovine, and goat genomic sequences, respectively, locate upstream of the first 
UMOD exon (Zhu et al., 2002, Kim et al., 2003, Huang et al., 2005). The same 
was shown for the 5.6 Kb of the human genomic sequence, consisting of 3.7 Kb 
promoter, exon 1, intron 1, and the untranslated part of exon 2 (Zbikowska et 
al., 2002). Deletions in the Bovine UMOD promoter revealed cis elements critical 
for transcription specificity are located within the first 600 bp adjacent to the 
transcript start site (Kim et al., 2003). Zhu et al reported that the first 589 bp of 
the UMOD promoter as highly conserved across species (human, rat, mouse, and 
cow) and that the 3 Kb promoter region drives kidney specific function of the 
gene (Zhu et al., 2002).  
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1.10 Physiological and pathological roles of UMOD 
Due to UMODs structure it has one peculiar feature; it has a tendency to 
aggregate with gel like properties in solution when NaCl concentrations are close 
to 100 mmol/l or CaCl (calcium chloride) is 1 mmol/l (Brown and Rose, 1992, 
Benting et al., 1999) which may be responsible for the binding properties of the 
protein. This along with the GPI anchoring and multidomain structure on the 
luminal side of the apical membrane, in conjunction with rich and highly 
variable post translational protein modification, and a large presence of 
polymerised protein in the urine suggests that UMOD may play multiple roles 
with site specific physiological functions. However, over 60 years of research has 
not elucidated the biological role of UMOD, the following sections below 
recapitulate some of the proposed functions. 
1.10.1.1  Role of UMOD at the apical membrane 
Sorting of the apical membrane proteins requires GPI anchors, N-glycosylation, 
and polymerisation, with the large turnover of UMOD and its half life of 16 hours 
it is assumed that the biosynthesis plays either a direct or indirect role in the 
formation of the apical membrane targeted cargo vesicles and vesicle 
trafficking. GPI anchored proteins associate with lipid raft domains that play a 
role in organising the apical membrane and signalling transduction pathways 
(Rajendran and Simons, 2005). When the apical membrane is highly ordered it 
allows for close packing of GPI anchored proteins on the surface of cell 
membranes, in the case of UMOD this may promote formation of the complex gel 
like structures providing a water barrier at the luminal membrane of the TAL 
cells, serving as a physical barrier to water permeability. Such a barrier may 
play a role in ion transport to maintain countercurrent gradients in the 
interstitium (Hoyer and Seiler, 1979). 
1.10.1.2 Urolithiasis and bacterial infections 
In the absence of UMOD there is susceptibility to calcium oxalate stones due to 
the lack of gel like properties of the protein, thus altered salt concentration at 
the apical membrane is apparent (Stevenson et al., 1971). Mo et al showed that 
UMOD knockout mice spontaneously formed intra-renal crystals predominantly in 
the interstitial space and in the collecting duct of the deep medulla and papilla 
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(Mo et al., 2004). They reported that the stones were consisted primarily of 
calcium phosphate in the form of hydroxyapatite and strongly resemble the 
stones found in humans caused by idiopathic calcium oxalate stones. The 
inhibitory affect of UMOD in stone aggregation had been described in cases of 
calcium oxalate (Bates et al., 2004, Diamond and Paolino, 1973). There is 
consensus that inhibition of stone formation in normal urine is caused mainly by 
urinary macromolecules rather than low molecular weight components, and this 
property has been associated with polyanionic structures (Fellstrom et al., 
1986). UMOD is said to be a polyanionic macromolecule due to the large extent 
of sialylation and presence of sulphate groups bound to the N-linked glycans thus 
playing a crucial role in regulating stone formation (van Rooijen et al., 1998).  
Urinary tract infections (UTI’s) are mainly caused by E Coli, and critically 
depends on filamentous appendages on the bacterial surface called fimbriae 
(Bates et al., 2004). Colonization is mediated by binding of lectin like adhesins 
present on E coli fimbriae to carbohydrate structures carried by glycoprotiens 
exposed at the cell surface. E coli fimbriae are classified according to their 
sugar specificity: type 1, type P, and type S, Pak et al illustrated that UMOD 
binds with type 1 E coli fimbriae in vitro, and Raffi et al described UMOD as a 
general host defence mechanism against urinary tract infections (Pak et al., 
2001, Raffi et al., 2005) in vivo with a UMOD knockout mouse model, supporting 
the notion that urinary UMOD represents a protective mechanism against UTI’s. 
1.10.1.3 Urinary excretion 
In adults, there appears to be considerable variation in daytime excretion 
values, but does correlate with urinary volumes brought about with diuresis in 
those drinking in response to thirst (Lynn et al., 1982). A positive correlation 
between urinary UMOD and dietry salt intake revealed that in subjects with high 
salt sensitivity i.e. exaggerated BP response to high salt intake, there is a 
greater excretion of UMOD in the urine compared low salt intake (Torffvit et al., 
2004). UMOD excretion seems to increase gradually from birth to adulthood, 
where it remains stable until a decline after the sixth decade of life (Ollier-
Hartmann et al., 1984, Sobel and Kaye, 1985), with urinary UMOD/creatinine 
ratio also remains stable from the age of 4 until the age of 70. Reduced urinary 
excretion of UMOD has also been correlated with GFR and corresponds to 
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declining kidney function in virtually all chronic kidney diseases (Prajczer et al., 
2010). In an attempt to elucidate why urinary UMOD excretion is altered in 
disease Ma et al studied potential mechanisms using human UMOD mutations in 
polarised Madin Darby canine kidney cells (MDCK). They found that a cysteine 
altering mutation in the evolutionary conserved cysteine rich domain had more 
sever deficits in ER exit and surface translocation, triggering increased apoptosis 
than a cysteine altering mutation outside of the domain. Both mutants were able 
to specifically bind and trap UMOD preventing it from exiting the ER and 
translocating to the cell surface, explaining partly in some diseases the marked 
reductions in urinary UMOD (Ma et al., 2012).  
1.10.1.4  Inflammation 
Identification of GPI anchored enriched endocytic compartments have lead to 
the hypothesis that UMOD exerts its immunosuppressive affects by binding with 
high affinity to tumour necrosis factor alpha (TNF-α) and interleukin one (IL-1) 
(Sabharanjak et al., 2002, Kirkham et al., 2005). Although the exact ligands 
responsible are yet to be defined, this gives rise to the hypothesis that UMOD 
may play a role in modulating cell surface events, receptor engagement, and 
signal transduction at the TAL. Older studies reported that UMOD induced pro-
inflammatory effects, one group demonstrated that specific glycans of UMOD 
isolated from healthy adults interacts with IL-1β, and glycans contain either N-
acetylgalactosamine or sulphate residues for inhibition of lymphocyte 
proliferation (Tandai-Hiruma et al., 1999). Consequently, several reports have 
shown that urinary UMOD binds to and activates leukocytes, including 
neutrophils, lymphocytes, and monocytes (Toma et al., 1994, Horton et al., 
1990). According to Yu et al, UMOD from pregnant women increases the 
phagocytic activity of neutrophils by prostaglandin E2 release, suggesting that 
UMOD has specific interactions with the membranes of neutrophils (Yu et al., 
1992). Similarly, blood mononuclear cells were activated by UMOD in pregnant 
women, in this case increased levels of IL-1, IL-6, and TNF-α were released from 
monocytes leading to the proliferation of both B and T lymphocytes (Yu et al., 
1993). Another group observed that in non pregnant women UMOD induced 
secretion of TNF-α from monocytes but several fold lower than that of pregnant 
women (Su and Yeh, 1999). Human monocytes isolated form peripheral blood, 
deprived of lymphocytes are able to phagocytise a particle form of UMOD and 
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generate reactive oxygen metabolites as well as other lysosomal enzymes 
(Thomas et al., 1993).  
Conversely, a more recent study has shown that UMOD binds with high affinity to 
human TNF-α and IL-8, and low affinity to IL-6 and INF-γ and UMOD is 
enzymatically digested by carbohydrate specific degrading enzymes reducing 
protein binding to pro-inflammatory cytokines, mononuclear cell proliferation, 
and neutrophil phagocytosis enhancing activities (Wu et al., 2008). Advances 
from the previous study have shown that in UMOD knockout mice there is a 
marked elevation of circulating TNF-α and IL-1 and enlarged spleens with 
prominent white pulp macrophage infiltration. They reported that 
lipopolysaccharide (LPS) exasperated the increase of circulating cytokines 
without an increase in urinary excretion in UMOD knockout mice. This along with 
a reduced CrCl suggests that diminished kidney function may contribute to 
reduced cytokine clearance in the UMOD knockout mice (Wu et al., 2008). In 
2008 it was reported that UMOD protects the kidney from ischemic injury by 
decreasing inflammation and altering Toll like receptor 4 (TLR4). This group 
performed renal perfusion injury in UMOD wild type and knockout mice 
demonstrating that in the presence of UMOD there was less injury and increased 
expression of UMOD, whereas knockout mice displayed renal damage, tubular 
fibrosis, and increased inflammation. Furthermore, the outer medulla of the 
knockout mice had associated necrosis with significant interstitium neutrophil 
infiltration and basolateral location of TLR4 allowing greater affinity for pro-
inflammatory cytokines (El-Achkar et al., 2008). Collectively, this suggests UMOD 
may have dual immunomodulating effects through regulating pro-inflammatory 
and anti-inflammatory cytokines. 
The physiological role of UMOD remains to be fully determined; however there is 
mounting evidence and research reporting the consequences associated with 
changes in UMOD primary structure, transcription, expression, post translational 
modification, localisation, and urinary excretion have identified a number of 
pathological conditions that implicate potential biological roles of UMOD as a 
regulatory protein in health and disease.  
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1.10.1.5 Uromodulin and kidney disease 
Renal cystic diseases are a major group of inherited renal conditions, 
representing the leading cause of end stage renal disease. Cystic kidney disease 
(CKD), in both the dominant and recessive variants, accounts for the clinical 
conditions. Hart et al and Rampoldi et al discovered autosomal dominant 
mutations in UMOD lead to medullary cystic kidney disease type 2 (MCKD2), 
familial juvenile hyperuricemic nephropathy (FJHN), and glomerular cystic 
kidney disease (GCKD) (Hart et al., 2002, Rampoldi et al., 2003). These 
conditions are characterised by urinary concentration deficits, urinary salt 
wasting, hyperuricemia, gout, medullary cysts, interstitial nephritis, glomerular 
cysts, hypertension, and end stage renal failure. MCKD2 is autosomal dominant 
disorder is mainly characterised by hypertension and end stage renal failure, in 
the fourth decade of life, with a triad of renal complications; tubular membrane 
disintegration, tubular atrophy, with cyst development at the corticomedullary 
border and interstitial cell infiltration associated with fibrosis. The condition 
share clinical and morphological similarities with the autosomal dominant FJHN. 
GCKD is characterised by a cystic dilatation of Bowmen’s capsule and collapse of 
the glomerulus (Zaucke et al., 2010). All three disorders have significant clinical 
overlap and arise from UMOD mutations and are often referred to as Uromodulin 
associated kidney diseases (UAKD) and are said to cause the so called 
“uromodulin storage disease” (Vylet'al et al., 2006, Wolf et al., 2007). 
To date there have been more than 58 UMOD mutations reported, that mainly 
localise to exon 3 and 4 of the UMOD gene, with the majority being missense 
mutations or small inframe deletions (Lhotta, 2010). Early genome wide linkage 
mapping in Italian, Czech, and Belgian families revealed loci for MCKD and FJHN 
on chromosome 16 in the regions of 16p11.2 and 16p12 (Dahan et al., 2001, 
Stiburkova et al., 2000) in close proximity to the UMOD gene. These conditions 
are associated with mutations that lead to amino acid changes at cysteine sites 
causing defective protein folding and immature UMOD being retained at the ER 
and not released at the apical membrane and remains intracellular (Bernascone 
et al., 2006, Rampoldi et al., 2003). Accumulation of misfolded UMOD in the ER 
causes ER stress causing ER degradation by increased synthesis of chaperones 
and foldases in order to activate elimination of the misfolded protein (Kitamura, 
2008). This unfolded protein response may trigger apoptosis and autophagy or 
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alternatively lead to cell activation via MAP kinases and NF-kB leading to the 
eventual progressive renal failure seen in MCKD2, FJHN, and GCKD (Lhotta et al., 
1998).  
It is known that the transcription factor hepatic nuclear factor 1-β (HNFIβ) 
positively regulates UMOD expression and binds to the promoter elements of the 
gene. Inactivation of HNFIβ in vivo is associated with decreased UMOD 
transcription (Liu et al., 2012). Interestingly mutations of HNFIβ are associated 
with features of MCKD2, FJHN, and GCKD (Smagula et al., 1990). This 
transcription factor is also known to regulate nephrocystins which prompted 
work by Zaucke et al in 2010 to investigate if UMOD is linked to cillary 
cystogenesis (Zaucke et al., 2010). They reported 7 novel UMOD mutations 
(missense or deletion mutations) between exon 4 - 5 and that UMOD is expressed 
in primary cilia of renal tubules and the number of UMOD positive tubules 
declines in UAKD. The mutations caused localisation of UMOD in the mitotic 
spindle poles co-localised with nephrocystin-1, suggesting a novel cause of cystic 
kidney disease pathologies of MCKD2, FJHN, and GCKD.  
1.10.1.6 Deficits in urine concentration in UMOD associated kidney   
disease 
The TAL are nephron segments characterised by high electrolyte and water 
impermeability and it was proposed that UMOD plays a role in salt transports and 
acts as a water barrier at this level, a process crucial for urine concentration. 
Bleyer et al reported low urine osmolality was consistent in subjects with UMOD 
mutations (Bleyer et al., 2003). A transgenic mouse model for UAKD confirmed 
urinary concentrating deficit (Bernascone et al., 2006). Water reabsorption by 
the tubule is regulated by transmembrane systems of aquaporin and ion channels 
(Agre and Kozono, 2003), Bachmann and colleagues studied the renal effects of 
UMOD deficiency in UMOD knockout mice and reported the inability of these 
mice to concentrate urine possibly due to a decrease in cyclooxygenase-2 (COX-
2) expression (Bachmann et al., 2005). COX-2 inhibition prevents regulation of 
key renal water and sodium transport proteins including aquaporin 2 (AQP2), 
NHE3, and NKCC2 (Norregaard et al., 2005). Confirming the role of UMOD in 
urine osmolality.  
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1.11 Uromodulin and blood pressure 
This far, it is clear that UMOD variants play a role in the pathogenesis of renal 
disease and plays an important role in the regulation of sodium homeostasis. 
Padmanabhan and colleagues successfully identified and verified the 
polymorphism rs13333226 with lower risk of hypertension (p= 1.14 x 10-7) using 
an extreme case - control strategy. This group reported that each copy of the G 
allele was associated with a 0.49mmHg lower SBP and 0.30mmHg lower DBP in 
the Global BPGen cohort. The association plot of the genomic region around 
rs13333226 in the initial discovery sample is outlined in Figure 1-9 
(Padmanabhan et al., 2010).  
 
Figure 1-9 The association plot of the genomic region around rs13333226 
Observed (-logP) is the –log10 transformed P values for association with hypertension 
status in the discovery sample. Recombination rate, is represented by the blue line. The 
level of LD between rs13333226 and the surrounding SNPs, measured by r2, is indicated 
with red demonstrating high LD. GP2 = glycoprotein 2 (zymogen granule membrane). 
UMOD = uromodulin. PDILT = protein disulfide isomerase-like, testis expressed. 
FLJ20581 = acyl-CoA synthetase medium-chain family member 5. LOC123876 = acyl-
CoA synthetase medium-chain family member 2A. Image reproduced from 
(Padmanabhan et al., 2010). 
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The genome wide association study further reported that the minor G allele of 
rs13333226 was associated with lower urinary UMOD excretion, and the 
association was independent of kidney function as the hypertensive subjects 
displayed a higher eGFR in association with the G allele. Whereas, in the 
normotensive participants this association did not reach statisitcal significance. 
Ultimatley suggesting that UMODs association with hypertension is independent 
of renal function. In order to further examine the relationship of the G allele 
and changes in renal function, levels of urinary excretion were examined in 
hypertensive and normotensive individuals. The minor G allele at rs13333226 was 
shown to be associated with lower urinary uromodulin levels in both groups of 
participants. The hypertensive subjects who carried the GG genotype had lower 
urinary uromodulin levels as well as lower fractional urinary sodium excretion, 
therefore suggesting higher sodium reabsorption at the TAL. However, this was 
not replicated in the normotensive participants who appeared to have increased 
sodium excretion with increased uromodulin excretion. This relationship of lower 
uromodulin excretion and increased sodium reabsorption in the GG carriers, yet 
a lower risk of hypertension seem contradictory. Although lower sodium 
excretion could be the results of increased sodium reabsorption as a result of 
increased sodium load possibly corresponding to a decreased distal reabsorption. 
The dietary information for hypertensive and normotensive cohorts was not 
available therefore it cannot be proven that lower sodium excretion was simply 
attributed to low sodium levels in the diet (Padmanabhan et al., 2010).  
In support of this hypothesis, analysis with the Hypertension Evaluation by 
Remler and CalciUria Level (HERCULES) study participants reported an inverse 
relationship between urinary UMOD levels and proximal tubule sodium 
reabsorption (Bochud et al., 2009). Additionally, G allele subjects from the 
Groningen Renal Hemodynamic Cohort Study Group (GRECO) study (Visser et al., 
2008) show a larger increase in GFR in response to an increased sodium intake, 
whereas the fractional excretion of sodium was less (Figure 1-10). Suggesting 
that subjects carrying the G allele restore sodium excretion by a rise in filtered 
load i.e. at a level that matches higher intake than in non carriers. This is 
associated with a larger rise in ECF volume in response to high salt, that maybe 
responsible for the larger rise in GFR. These data make a link between genetic 
variants in the UMOD gene and blood pressure through interactions, fluid volume 
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control, and sodium reabsorption. This is a critical point as rs13333226 is located 
in close proximity to the UMOD gene start site, and as already introduced UMOD 
mutations are associated with chronic renal failure and autosomal dominant 
renal diseases that lead to altered sodium transport and blood pressure 
phenotypes (Turner et al., 2003, Rampoldi et al., 2003, Hart et al., 2002). 
 
 
Figure 1-10 Genotype dependant urinary Uromodulin and sodium excretion  
Padmanabhan and colleagues (Padmanabhan et al., 2010) measured urinary Uromodulin 
and sodium excretion in healthy 64 male individuals from the GRECO study (Groningen 
Renal Hemodynamic Cohort Study Group) (Visser et al., 2008) who took part in a 7 day 
low sodium diet (50 mmol Na+/day) followed by a 7 day high sodium diet (200 mmol 
Na+/day). Urine was collected over a 24 hour period and commercial ELISAs were used 
to assess urinary UMOD levels. The minor G allele was associated with reduced urinary 
UMOD levels and sodium exaction.  Image produced by (Padmanabhan et al., 2010).  
 
As a clinical follow up, the association of rs13333226 with lower risk of 
hypertension was evaluated by examining subjects from the Malma diet and 
cancer study, a ten year follow up cohort (Berglund et al., 1993). The G allele 
was examined in this cohort to assess if it prevents the occurrence of 
cardiovascular disease over long-term, revealing a 7% reduction in the risk of 
CVD. Although these studies did not reveal a definitive functional explanation 
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for the effect of UMOD on blood pressure the finding of an association between 
hypertension and the genetic UMOD variant rs13333226 is biologically plausible.  
The original GWAS performed by Padmanabhan et al reported that a high salt 
diet in healthy individuals, the minor G allele was associated with a larger 
increase in measured GFR and hence filtered sodium load with smaller increases 
in tubular sodium excretion. Taken together with reported findings from the 
literature suggests that UMOD variants may alter gene expression and contribute 
to qualitative traits of blood pressure via regulation of sodium homeostasis, 
providing a new window of opportunity to study the physiological role of UMOD 
as a regulator of blood pressure. We hypothesis that altered UMOD expression 
and/or function impacts on sodium homeostasis and influence blood pressure 
phenotypes.  
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1.12 Aims 
The specific aims of this thesis are:  
 
• To investigate human UMOD promoter sequences to identify the potential 
functional promoter polymorphisms that maybe a causal SNPs in blood 
pressure regulation 
 
• To investigate the physiological role of UMOD in blood pressure regulation 
and sodium homeostasis utilising a UMOD knockout rodent model 
 
• To investigate expression levels of ion transporters at the thick ascending 
limb of the loop of Henle by UMOD 
 
• To perform a small pilot study in human kidney samples from 
normotensive and hypertensive cohorts to translate the findings from in 
vivo and in vitro studies  of this thesis 
 
 
 
 
2 General Methods 
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This chapter outlines laboratory practices and laboratory methods common to 
more than one chapter. Each subsequent results chapter has specific Materials 
and Methods section. 
2.1 General laboratory practice  
Laboratory equipment and reagents were of the highest commercially available 
grades. Hazardous reagents were handled as described in the Control of 
Substances Hazardous to Health regulations. A laboratory coat and non-latex 
powder-free gloves were worn during all procedures. 
Laboratory glassware was cleaned in Decon 75 detergent (Decon Laboratories 
Ltd, East Sussex, UK), rinsed with distilled water and dried at 37°C. Otherwise, 
sterile disposable plastic ware were used, including 0.5 ml, 1.5 ml and 2 ml 
microcentrifuge tubes (Greiner Bio-one, Stonehouse, UK), 15 ml and 50 ml 
centrifuge tubes (Corning, Birmingham, UK), and also 5 ml and 20 ml 'Universal' 
containers (Sterilin, Newport, UK). Laboratory-ware and liquids requiring 
sterilisation were autoclaved in a Priorclave Tactrol 2. 
Reagents were weighed using an Ohaus Portable Advanced balance (sensitive to 
0.01 g), or a Mettler HK160 balance (sensitive to 0.0001 g). Solutions were pH'd 
using a Mettler Toledo digital pH meter calibrated with pH 4.0, 7.0 and 10.0 
prepared from buffer tablets (Sigma, Dorset, UK). Volumes from 0.1 µl to 1,000 
µl were dispensed with Gilson Medical Instruments pipettes. Volumes from 1 ml 
to 25 ml were measured with sterile disposable pipettes (Corning, Birmingham, 
UK) and a Gilson battery-powered pippetting aid (Gilson Medical Instruments). 
Autoclaved distilled water (dH2O) was used to prepare aqueous solutions unless 
otherwise indicated, and a Jenway 1000 hotplate/stirrer was used to aid 
dissolving and mixing.  
Vortexing was carried out using an FSA Laboratory Supplies WhirliMixer. 
Centrifugation for samples up to 2 ml was performed at 4-20°C in a table top 
Eppendorf 4515 microcentrifuge, while larger sample volumes were centrifuged 
in a Sigma 4K15, compatible with 15 ml and 50 ml centrifuge tubes, 20 ml 
'Universal' tubes and with carriers for standard reaction plates. A Julabo TW8 
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water bath was used for experiments requiring incubations from 37°C to 90°C, 
and a Grant SBB14 boiling water bath was used for temperatures up to 100°C. 
Experiments involving ribonucleic acid (RNA), certified nuclease-free reagents 
and plastic ware used, including RNase-free microcentrifuge tubes, RAININ 
nuclease-free filtered pipette tips and Ambion nuclease-free H2O. Pipettes and 
benches were wiped with Ambion RNaseZap reagent before all RNA experiments. 
2.2 General Techniques  
2.2.1 Nucleic acid extraction 
Total genomic DNA was extracted from animal tissues and cell lysates using the 
DNeasy Blood and Tissue kit (QIAGEN, Manchester, UK) following manufacturer’s 
instructions for the spin-column protocol. In brief, appropriate volumes of ATL 
buffer and proteinase K were added to animal tissue samples or cell lysate 
suspension and vortexed to begin the lysis process. Samples were then incubated 
at 56oC until completely lysed. Appropriate volumes of AL buffer were added to 
each sample and mixed thoroughly by vortexing. Buffer AL contain chaotrophic 
salts which allows nucleic acid to be absorbed onto the silica gel membrane of 
the Spin Columns by removing water from the hydrated molecules in solution. 
Polysaccharides and proteins are not absorbed and are removed. 100% ethanol 
was added to the sample, mixed, and transferred on to the Spin Column. 
Samples were centrifuged at 6000 x g for 1 minute at room temperature to allow 
DNA to bind to the silica gel membrane of the Spin Column. The Spin Column 
was then washed with buffer AW1 and centrifuged at 6000 x g for 1 minute, 
followed by a second wash step with AW2 buffer and centrifuged at 16000 x g for 
3 minutes at room temperature. Finally, the DNA was eluted with 50µl nuclease 
free water by centrifugation at 6000 x g for 1 minute.  
2.2.2 Polymerase Chain Reaction (PCR) 
All thermal cycling for standard PCRs was performed on an MJ Research PTC 
Gradient Cycler in 96-well plates (Thermo Fischer Scientific, Loughborough, UK). 
PCR primers were designed using the Ensembl online resource database and 
purchased from MWG Biotech. KOD HotStart (Novagen, Darmstadt, Germany) a 
commercial 'Hotstart' Taq polymerase PCR system, was used for standard PCRs in 
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this project. For amplifying from genomic DNA templates, 100 ng of genomic 
DNA was used, while 5-10 ng of template was used for amplifying plasmid 
templates. All primers sequences are listed in specific results chapters. The 
standard reaction mixes and temperature cycling parameters follow: 
KOD HotStart: 
 
Reaction mix 
 
Volume (µl) Final concentration 
10X Buffer 5 1X 
25mM MgS04
a 3 1.5mM 
dNTPs (2mM) each  5 0.2mM each 
Sense (5’) Primer (10µM) 1.5 0.3µM 
Anti-Sense (3’) Primer (10µM) 1.5 0.3µM 
Template X 100ng 
PCR  Grade Water  up to 25µl  
KOD Hot Start DNA 
Polymerase 
 
1 0.02U/µl 
Total reaction volume 50  
 
Temperature cycling: 
 
KOD Hot Start was used in this project to ensure absolute fidelity of DNA 
replication, as it employs proofreading capability. This is of benefit as other 
commercially available Taq polymerases can incorporate incorrect nucleotides. 
KOD DNA polymerase is derived from Thermococcus kodakaraensis thermophilic 
bacteria and possesses 3'-5' exonuclease activity that excises mis-incorporated 
bases during PCR.  
2.2.3 Agarose Gel Electrophoresis 
Throughout, 0.8-1.5% agarose (Eurogentec, London, UK) gels were used, 
dissolved and electrophoresed in 1 X Tris-Borate EDTA (TBE) buffer (Fisher 
Bioreagents, Loughborough, UK). Gels were electrophoresed at 6 V per cm of 
gel. BIO-RAD Power Pac 300 and BIO-RAD electrophoresis tanks were used, 1 ng / 
Heat cycling Time
95oC 2  min
95oC 20 sec
58oC – 64oC 10 sec
70oC 10 – 20 sec/kb
x35 
cycles
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100 ml ethidium bromide (Sigma, Dorset, UK) was added to molten agarose 
before pouring gels. Gels were visualised by UV transillumination on a BIO-RAD 
Fluor-S MultiImager. Promega 1kb and 100bp DNA ladders were used for sizing 
products. Samples were loaded with 6 X loading dye (50% glycerol, 0.05% 
bromophenol blue). 
2.2.4 Agarose DNA extraction and purification 
Unless stated otherwise agarose gel extraction of PCR products or restriction-
digested DNA was performed with the Qiagen QIAquick Gel Extraction kit 
following the manufacturer's instructions, using a bench microcentrifuge at full 
speed. Bands in agarose gels were visualised on a UV transiluminator (UVP) and 
carefully excised with a scalpel blade. The bands were weighed and 300 µl of 
buffer QG was added per 100 µg of agarose before heating the agarose/buffer 
QG mixture to 50°C for 10 minutes. After centrifugation to absorb the DNA to 
the membrane, the membrane was washed with 500 µl of buffer QG followed by 
750 µl buffer PE (which contains 70% ethanol) with centrifugation. All traces of 
ethanol were removed by a final centrifugation for 1 minute; DNA was eluted in 
nuclease-free water. Fragments were then ready for cloning in preparation for 
promoter activity assays in Vitro. 
2.2.5 Plasmid purification 
2.2.5.1 Transformation of competent bacteria (PCR vector) 
StrataClone PCR-Script vectors containing PCR “inserts” were transformed in 
JM109 competent Escherichia coli (E.coli) bacteria (Promega, Southampton, UK) 
as hosts for eukaryotic expression vectors. For transformation, competent cells 
were thawed on ice and separated into 50µl aliquots in chilled 1.5ml centrifuge 
tubes. For transformation of an intact plasmid, 2ng plasmid DNA was added to 
the bacteria, for transformation of ligated plasmid/insert mixes 2-5µl of the 
ligation reaction was added to JM109s. Tubes were flicked gently to mix and 
returned to ice for 10 minutes, then 'heat shocked' at 42°C for 45 seconds before 
returning to ice for a further 2 minutes. Chilled SOC medium (Sigma, Dorset, UK) 
(900 µl) was added to the cells and they were placed in a shaking incubator (New 
Brunswick Scientific Inova 44) at 37°C, 225 rates per minute, for one hour. 
Unless otherwise stated all plasmids used in this project encoded ampicillin 
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resistance for selection of transformed cells. Transformation mixtures were 
spread onto 90 mm culture plates (Sterilin, Newport, UK) of Luria agar (Sigma) 
containing 100 µg/ml ampicillin (Sigma). For transformations of intact plasmids 
100 µl of neat, 1 in 10 and 1 in 100 dilutions in SOC media were spread, for 
transformations of ligation reactions; the entire transformation culture was 
spread onto 5 plates. Culture plates were inverted and placed in a 37°C 
incubator (Heraeus) overnight. Plates were checked for bacterial colonies the 
next morning and if necessary screened for positive clones as detailed in section 
2.3.3. 
2.2.5.2 Small scale DNA purification 
The QIAprep Spin Miniprep Kit (QIAGEN, Manchester, UK) was used to purify 
plasmid DNA from overnight starter cultures. One ml of the incubation was 
transferred into a 1.5 ml tube, and centrifuged at 10,000 x g for 10 minutes to 
pellet the cells. The supernatant was discarded and the cell pellet lysed by 
resuspending them in 250 µl of Buffer P1. The DNA was denatured by adding 250 
µl Buffer P2 and inverted to mix thoroughly. The reaction was then neutralised 
by adding 350 µl of Buffer N3 and immediately mixed by inversion. Samples were 
then centrifuged for 10 minutes at 13, 000 x g in a table top centrifuge. The 
supernatants were transferred into a QIAprep spin column, which was 
centrifuged at 13,000 x g for 1 minute to bind DNA on to the silica membrane. 
The flow through was discarded and the column washed with 500 µl of Buffer PB. 
The sample was then centrifuging at 13,000 x g for 1 minute. Another wash with 
750 µl of Buffer PE was performed, after which the column was centrifuged at 
top speed for 1 minute to ensure there was no residual buffer remaining. The 
column was transferred to a new 1.5 ml tube and the DNA eluted by adding 50 µl 
of nuclease-free water, standing at room temperature for 1 minute then 
centrifuging at 13, 000 x g for 1 minute. Plasmid DNA was quantified by 
Nanodrop (2.3.11) and stored at -20°C until required. 
 
2.2.5.3 Large scale DNA purification 
Large scale plasmid DNA was extracted from bacteria using the filter column 
based Qiagen Plasmid Maxi kit (QIAGEN, Manchester, UK). Bacterial cultures 
were streaked and grown overnight at 37°C on ampicillin Luria agar plates. 
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Single colonies were picked and used as a 'starter' culture grown over a 12 hour 
period in 5 ml Luria broth (Sigma, Dorset, UK) containing 100 µg/ml ampicillin in 
a shaking incubator at 37°C. One ml of this culture was used to inoculate 100-
500 ml 100 µg/ml ampicillin Luria broth to produce an overnight culture from 
which the plasmid was extracted (100 ml was sufficient for most plasmids, 
however when low yields were obtained, the extraction was repeated with 500 
ml culture). Bacteria were harvested by centrifugation at 6,000 g for 15 minutes 
at 4°C in a Beckman Coulter Avanti J-26XP. Culture media was removed and the 
bacteria were resuspended in 10 ml buffer P1 (50mM 2-amino-2-hydroxymethyl-
1,3-propanediol, pH8; 10 mM EDTA, 100 µg/ml RNase A). Ten ml of buffer P2 
(200 mM NaOH; 1% sodium dodecyl sulphate (SDS)) was added and the solutions 
were kept on ice for exactly five minutes. Ten ml of chilled buffer P3 (3 M 
potassium acetate at pH5.5) was added to neutralise the lysate. The 
precipitated lysates were centrifuged at 20000 x g at 4°C for 30 minutes, the 
supernatant was retained. Columns were equilibrated with 10ml of buffer QBT 
(750 mM NaCl; 50 mM 3-morpholinopropanesulfonic acid pH7 (MOPS); 15% 
isopropanol; 0.15% Triton-X 100). The supernatant was then applied and the 
columns were allowed to empty by gravity flow, the columns were washed twice 
with 30 ml buffer QC (1 M NaCl; 50 mM MOPS pH7; 15% isopropanol), and the 
plasmid DNA was eluted with 15 ml buffer QF (1.25 M NaCl; 50 mM Tris pH8.5; 
15% isopropanol) into polypropylene centrifuge tubes. Plasmid DNA was 
precipitated with 10.5 ml isopropanol and centrifuged at 15000 x g for 30 
minutes at 4°C. The supernatant was carefully removed. The DNA pellets were 
washed with 5 ml 70% ethanol, and aliquoted into five 1.5 ml microfuge tubes. 
The samples were centrifuged at maximum speed for 10 minutes at 4°C on a 
table top centrifuge. The ethanol was carefully pipetted off and the pellets were 
thoroughly air-dried (10-20 minutes) before resuspending the DNA in 50 µl H2O 
per tube. Finally, the contents of the five tubes were pooled together and DNA 
yields measured. 
2.2.6 Glycerol stocks 
Successfully transformed bacteria were preserved for long-term storage by 
preparing glycerol stocks. One ml of overnight broth cultures was mixed with 1 
ml sterile 40% glycerol solution and frozen at -80°C. Bacteria were recovered 
from glycerol stocks by streaking for single colonies on selective agar. 
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2.3 UMOD Promoter Sequence cloning  
2.3.1 Promoter Sequence PCR 
To amplify the 2kb UMOD promoter region, primers were designed and PCR run 
using KOD polymerase as per section 2.2.2. Table 2-1 below outlines the primer 
sequences used to amplify the 1 and 2Kb UMOD promoter regions from genomic 
DNA from each cell type. Each primer pair contained SacI and Hind III restriction 
sites at the 5’ end of the forward or reverse primers respectively and preceded 
by 3xC residues: 
 
 
Primer 
 
Sequence (5’-3’) 
 
Human UMOD Pr 2000 FWD 
 
CCCGAGCTCGGTGATTACACTTATGAATAGATTC 
Human UMOD Pr 1000 FWD CCCGAGCTCTTTCCTGCTCAGCCCAAGTTCACAC 
Human UMOD Pr REV ATAAGTATGAGGCACATCATGACCAAGCTTCCC 
Table 2-1 Amplification of the 1 and 2 Kb UMOD promoter region. 
Primers used to amplify the 1 and 2Kb UMOD promoter sequences from genomic DNA 
were designed to contain the sequences for incorporating restriction endonucleases 
(marked in blue) in preparation for cloning and sub-cloning.  
 
2.3.2 DNA blunt cloning of the 2Kb UMOD promoter region into 
PCR vectors   
PCR products were 'blunt cloned' into PCR amplification vectors (Stratagene PCR-
Script Amp SK(+) (PCR-Script)) using the Stratagene blunt PCR cloning kit 
following the manufacturer's instructions (Agilent Technologies, California, USA). 
The PCR-Script plasmid is supplied linearised by digestion with SrfI restriction 
enzyme. This cloning platform also allowed blue/white selection based on lacZ 
gene disruption; IPTG (isopropyl-beta-D-thiogalactopyranoside) (20 mM) and X-
gal (8 µg/ml) were added to ampicillin (100 µg/ml) selective LB agar, white 
colonies were screened for the insert. All cloning in this chapter utilised 
plasmids expressing the ampicillin resistance gene, selective Luria agar and 
broth were used with 100 µg/ml ampicilin (Sigma, Dorset, UK). 
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In this project, promoter sequence PCR reactions were electrophoresed as 
described in section 2.2.3, bands were excised from the agarose gel and purified 
as per section 2.2.4. PCR products (5 µl) were used in ligation reactions with 10 
ng Staratgene PCR vector, the precise molar ratio of plasmid:insert was not 
calculated but the insert was vastly in excess, as is necessary in PCR-cloning. 
The ligation reactions constituted of:  
Reaction Mix Volume (µl) 
PCR vector (10 ng/µl) 1  
10 X Stratagene PCR buffer 
rATP (10 mM) 
1 
0.5 
PCR product 5 
Srfl (5 U/µl)  1 
T4 DNA ligase 
Nuclease free water 
  
Total Reaction Volume  
1 
0.5 
 
10 
 
Ligation reactions were incubated at room temperature for an hour, and then 
de-activated by heating to 65°C for 5 minutes.  
Forty µl of XL-10 Gold cells were thawed on ice and 1.6 µl β-mercaptoethanol 
was added. Cells were incubated on ice for 10 minutes, 4 µl of ligation reaction 
was added and cells were incubated on ice for 30 minutes, then heat-shocked at 
42°C for 30 seconds before returning to ice for 2 minutes. SOC media was heated 
to 42°C and 450 µl was added and transformation cultures were incubated in a 
shaking incubator at 37°C for an hour. Transformation cultures were spread over 
IPTG/X-Gal/ampicillin (IPTG (isopropyl-beta-D-thiogalactopyranoside) (20 mM) 
and X-gal (5-bromo-4-chloro-3-indolyl b-D-galactopyranoside) (8 µg/ml) selective 
LB agar plates, where white colonies were selected and screened for the insert 
by PCR.  
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2.3.3 Selecting positive clones 
Individual colonies were picked with a sterile pipette tip, streaked onto a 
numbered 0.8 cm grid on a selective agar plate. The pipette tips were then 
washed in a numbered well of a 96-well plate containing 10 µl H2O. KOD 
HotStart polymerase PCR reaction master mixes were added to each well to 
make a 20 µl PCR reaction. Following PCR, products were electrophoresed to 
screen the for the expected size. Positive PCR results were later confirmed by 
DNA sequencing. Positive white colonies were screened by PCR across the 
cloning site in the PCR-Script cloning vectors with T7 (5’ 
TAATACGACTCACTATAGGG3’) and T3 (5’ ATTAACCCTCACTAAAGGGA 3’) primers. 
PCR products were then sequenced using 8 overlapping primer pairs (1R+1F, 
2R+2F, 3R+3F, 4R+4F, 5R+5F, 6F+6R, 7F+7R, 8F+8R) to confirm the UMOD 
promoter. The primer sequences and region covered are listed in Table 2-2. 
Single positive colonies identified in the StrataClone PCR-Script vectors, were 
picked and used as a 'starter' culture grown over a 12 hour period in 5 ml Luria 
broth (Sigma, Dorset, UK) containing 100 µg/ml ampicillin in a shaking incubator 
at 37°C. This culture was then used for DNA purification (section 2.2.5). The PCR 
product was then digested out in preparation for sub-cloning into luciferase 
vectors to investigate promoter activity. 
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Primer 
 
Sequence 
 
Coverage (bp) 
 
 
Position 
 
UMOD 1F 
 
GACACCCATAATAAGGTTTAGACA 
 
  
20366046- 
20366022 
UMOD 1R CCACTGGCACTGGTGTTGTCATCT 
 
357 20365712- 
20365688 
UMOD 2F CCACTTATCCTTTTGGCAAAGATG 
 
 20365899- 
20365875 
UMOD 2R ATTCCACGGTGTATATGTGCCACA 
 
350 20365573- 
20365549 
UMOD 3F GTCCATCAATGATAGACTGGATTA 
 
 20365603- 
20365579 
UMOD 3R TCGAGGTTTGTTACATATGTATAC 
 
358 20365152- 
20365128 
UMOD 4R GAATTGAACAATGAGAGCACTTG 
 
 20364977- 
20364953 
UMOD 4F 
 
CAGACCCAGTTCAACATACATGA 
 
349 20365303- 
20365278 
UMOD 5F 
 
TGATATTTTCCTGCTCAGCCCAA  20365066- 
20365043 
UMOD 5R TCACTGGACCTGACCCACTCTGTA 
 
470 20364620- 
20364596 
UMOD 6F 
 
CATGAATATAATCATTACTATATGA  20364878- 
20364854 
UMOD 6R TGAAACACCCATTCTCATGAGATC 
 
362 20364518- 
20364494 
UMOD 7F 
 
AAGGTTAAGAAATGAGCCCACTG  20364759- 
20364735 
UMOD 7R 
 
CCAGGCAGAAGCCAGTATCTGAA 364 20364417- 
20364394 
UMOD 8F 
 
GAATATCCCTTTTGTCCTTATGCA  20364448-
20364424 
UMOD 8R 
 
GGTCATGATGTGCCTCATACTTAT 412 20364147- 
20364123 
Table 2-2 Colony screening by PCR and sequencing.  
Primer pairs used to confirm the 1Kb (denoted in red) and 2 Kb (denoted in black) UMOD 
promoter regions by PCR and sequencing reactions. 
 
2.3.4 Restriction endonuclease digest 
To enable the targeted ligation of the UMOD promoter sequences into plasmid 
backbones, appropriate restriction enzymes were used to digest inserts from PCR 
plasmids to generate compatible ends for ligation. Restriction endonucleases 
were purchased from New England Biolabs (Herts, UK) and used for digestions 
according to the manufacturer's protocols. Restriction endonucleases and 
reaction mixes used in this project are: 
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Reaction Mix 
 
Volume (µl) 
Template DNA X (1-2 µg)  
10 X Restriction buffer 
Bovine serum albumin (BSA) 
2.5 
0.25 
Restriction enzymes 1 
Nuclease free water  X 
 
Total Reaction Volume  
 
25 
 
One unit of restriction enzyme is defined as the amount required to digest 1 µg 
of template in one hour. Reaction mixtures were mixed gently and briefly pulsed 
in a bench microcentrifuge, then incubated at 37°C for between 1 and 4 hours. 
Cloning in this project was performed using 'double digests', wherein the insert 
and backbone were digested with two restriction enzymes, resulting in different 
overhanging ends, allowing directional cloning and minimising the likelihood of 
self-ligation of the plasmid backbone. The restriction enzymes used throughout 
this project are listed as follows: 
 
Restriction digested PCR reactions were then electrophoresed as described in 
section 2.2.3, and bands excised from the agarose gel (2.2.4). 
2.3.5 DNA sub-cloning  
Promoter sequences were digested out of the PCR-Script vectors with SacI and 
Hind III restriction enzymes prior to sub-cloning into similarly double-digested 
pGL4.70 Basic luciferase plasmids. Digested Stratagene PCR plasmids, pGL4.70 
Basic vectors, and “dropped” promoter sequences (inserts) were 
electrophoresed and gel purified. Prior to ligation of the insert into the pGL4.70 
luciferase vector, the backbone was de-phosphorylated using New England Bio 
Enzyme Sequence Buffer 
Sac I Buffer 2 
Hind III Buffer 2 
5’ ...G A G C T C ... 3’
3’ ...C T C G A G ... 5’
5’ ...A A G C T T ... 3’
3’ ...T T C G A A ... 5’
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labs Antarctic Phosphatase (Herts, UK). The reaction catalyzes the removal of 
the 5’ phosphate of DNA, thus the phosphatase treated fragment cannot self 
ligate due to the lack of the 5´ phosphoryl termini required by ligases. The 
reaction protocol is listed below: 
 
Reaction Mix 
 
 
Volume (µl) 
Template DNA X (1-5 µg)  
10 X Antarctic phosphatase buffer 1 
Phosphatase enzyme 1 
Nuclease free water  X 
 
Total Reaction Volume  
 
10 
 
The reaction mix was incubated at 37oC for 1 hour, then heat inactivated for 5 
minutes at 65oC. Unless stated otherwise, digested plasmid fragments or 
digested PCR products were ligated into digested plasmid backbones using the 
New England Biolabs Quick Ligation Kit. The kit includes a 2X reaction buffer 
(1332mM Tris pH7.6; 20mM MgCl2; 2mM dithiothreitol; 2mM ATP; 15% 
polyethylene glycol) and 'Quick' T4 DNA ligase (supplied in 50 mM KCl, 10 mM Tris 
(pH7.4), 0.1 mM EDTA, 1 mM dithiothreitol, 200 µg/ml BSA and 50% glycerol). 
Ligation reactions constituted are as follows: 
 
Reaction Mix 
 
 
Volume (µl) 
pGL4.70 backbone 
Insert (1 or 2Kb UMOD promoter) 
X (50–100 ng)  
X (molar ratio of 3:1) 
2 X quick ligation buffer buffer 10 
T4 DNA ligase 1 
Nuclease free water  X  
 
Total Reaction Volume  
 
20 
 
Reactions were mixed by gentle pipetting, pulsed in a microcentrifuge and 
incubated at room temperature for five minutes, and then put on ice. Ligations 
were transformed immediately or stored at -20°C before transformation. The 
amount of insert DNA to add to the ligation reaction for a given Insert:backbone 
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ratio and given amount of backbone DNA was calculated according to the 
following formula: 
 
2.3.6 Transformation of competent bacteria (Luciferase vector) 
One Shot® TOP10 competent Escherichia coli (E.coli) bacteria (Invitrogen, 
Paisley, UK) were used as hosts for luciferase expression vectors. Transformation 
protocols were carried out according to the manufacturer’s instructions. In 
brief, competent cells were thawed on ice and separated into 50µl aliquots per 
reaction, 2ng plasmid DNA was added to the bacteria, and mixed gently. Tubes 
were returned to ice for 10 minutes, then 'heat shocked' at 42°C for 45 seconds 
before returning to ice for a further 2 minutes to cool. Chilled SOC medium (900 
µl) (Sigma, Dorset. UK) was added to the cells and they were placed in a shaking 
incubator (New Brunswick Scientific Inova 44) at 37°C, 225 rates per minute 
(RPM), for one hour. Unless otherwise stated, all plasmids used in this project 
encoded ampicillin resistance for selection of transformed cells. Transformation 
mixtures (approximately 200µl) were spread onto 90 mm culture plates (Sterilin, 
Newport, UK) of Luria agar (Sigma, Dorset, UK) containing 100 µg/ml ampicillin 
(Sigma). Culture plates were inverted and placed in a 37°C incubator (Heraeus) 
overnight. Plates were checked for bacterial colonies the next morning and 
screened for positive clones as detailed in section 2.3.3 with the addition of 
pGL4.70 vector primers that anneal either side of the pGL4.70 Basic multiple 
cloning site (MCS), pGL4.70 forward primer 5’ CTAGCAAAATAGGCTGTCC 3’ and 
pGL4.70 reverse primer 5’ GTCTTCGAGTGGGTAGAATGG 3’. Positive clones were 
definitively confirmed by DNA sequencing and Maxi-preps were prepared for 
each pGL4.70 Basic plasmid. The six pGL4.70 Basic plasmids were named 
according to the promoter sequences they encoded: ACHN 1KB, 786-0 1Kb, TK10 
1Kb, ACHN 2Kb, 786-0 2Kb, and TK10 2Kb. 
Molar ratio insert:backbone) x (ng backbone) x (insert length,bp)
ng insert DNA = 
(backbone length, bp)
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2.3.7 Reporter construct transient transfection 
Prior to promoter activity assays, transfection efficiency protocols were 
conducted with GFP plasmid with >90% transfection efficiency in HeLa, NRK, 
HEK293 and HK-2 cells. Invitrogen Lipofectamine® 2000 lipofection reagent was 
used for all experiments involving transfection of cultured cells (Invitrogen, 
Paisley, UK). Lipofectamine® 2000 is a proprietary mix of lipids in 80% ethanol; it 
binds to and packages plasmid DNA into a lipid complex that allows the plasmids 
to cross cell membranes. Transfection protocols were optimised individually for 
each cell type used in experiments following suggested methods in the product 
literature. This involved ascertaining the optimal ratio of Lipofectamine® 
2000:DNA for maximal gene expression and minimal cytotoxicity. Ratios of 1:1, 
2:1 and 3:1 Lipofectamine® 2000:DNA (µl:µg) were used, with a total amount of 
DNA per well of 200 ng, 500 ng and 1 µg. Transfections were optimised and 
performed in 24-well culture plates. Regardless of the final conditions used, the 
same transfection protocol was followed: Cells were seeded the day before to be 
at 70-80% confluence at transfection. Lipofectamine® 2000/DNA mixtures were 
made in additive-free media in 5 ml universal tubes, Lipofectamine® 2000 was 
added to the media and mixed gently, plasmid DNA was added after five 
minutes, mixed, and once more then left for 30 minutes to allow Lipofectamine® 
2000/DNA complex formation. Transfection mixtures were then applied to cells, 
and assayed 24 hours later. 
2.3.8 RNA extraction  
Total RNA was extracted from animal tissue and cell lysates using Qiagen column 
based miRNeasy Mini kits (QIAGEN, Manchester, UK). Whole tissues or cells were 
homogenised in buffer RLT lysis solution, containing 0.01% (v/v) β-
mercaptoethanol or Qiazol homogenisation reagent included in the kit. Cultured 
cells were pelleted, supernatant removed, and rinsed with PBS and homogenised 
by pipetting. Unless otherwise stated tissues were homogenised with a Polytron 
2100 rotor homogeniser at full speed, then centrifuged at 5000 g to collect 
lysates. An equal volume of 70% ethanol was added to the sample lysates before 
being applied to the RNeasy columns, followed by centrifugation (15 seconds at 
8000 g) to wash cellular debris through the column. The flow through was 
discarded and 700µl of buffer RW1 was added to the Spin Columns, samples were 
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spun as before and the flow though discarded. An optional on column DNA digest 
was carried out (refer to section 2.3.10). Spin Columns were then transfe
fresh collection tubes and 500µl of buffer RPE added, and centrifugations 
repeated as before. The flow through was discarded prior to another 500µl of 
buffer RPE. The Spin Column was then centrifuged for 2 minutes, at 8000 x g, at 
room temperature 
50 µl RNase-free H
and room temperature. RNA samples were stored at 
2.3.9 RNA Validation (Agilent tested)
Total RNA isolated was quality tested for degradation prior to c
electrophoresis on the Agilent Bioanalyser 2100 and a Eukaryote Total RNA Nano 
Series II chip. The analysis was run at the Molecular Biology Support Unit at the 
University of Glasgow. Electrograms produced indicate defined bands for 18S and 
28S ribosomal RNA (rRNA) speci
Figure 2-1 Agilent Bioanalyser 2100 assessment of mRNA quality
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2.3.10 DNase treatment of extracted RNA 
In order to remove any contaminating DNA, extracted total RNA was treated 
with DNase using the reagents provide in the QIAGEN miRNeasy mini kit (QIAGEN, 
UK) and according to the manufacturer’s instructions. The on column digestion 
of DNA during the RNA purification is as follows; 350µl of buffer RWT was added 
to the spin column and centrifuged for 15 seconds at 8000 x g, 10µl of DNase I 
stock was solution was added to 70µl of buffer RDD, this was then added to the 
spin column and left to incubate for 15 minutes at room temperature, finally 
350µl of buffer RWT was added to the column and centrifuged for 15 seconds. All 
flow through was discarded and spin column carried over for completion of RNA 
purification (2.3.8). 
 
2.3.11 Measuring Nucleic acid concentration 
A Nanodrop® ND-1000 spectrophotometer (Thermo Scientific, Loughborough, 
UK), was used to measure DNA and RNA concentrations. This method is sensitive 
at measuring concentrations between 2-37000 ng/µl of double-stranded DNA. 
Absorbance ratios (260 nm/280 nm) of approximately 1.8 for DNA and 2.0 for 
RNA indicated that the nucleic acid preparations were sufficiently free from 
protein contamination for downstream experiments. Additionally, the ratio of 
absorption at 260 nm and 230 nm was used as an indicator of RNA purity; pure 
RNA has a ratio of 2.0 - 2.2, (a common contaminant is phenol, which absorbs at 
230 nm and is used in Total RNA extraction). The concentration of the sample is 
calculated using the Beer-Lambert Law of absorption; 
 
Concentration of DNA (µg/ml) = (A260 reading – A320 reading) x 50 
Concentration of RNA (µg/ml) = (A260 reading – A320 reading) x 40 
 
2.4 Quantitative Real-Time PCR 
An Applied Biosystems 7900HT Sequence Detection System (Taqman®) was used 
for all quantitative real-time PCR in this project. The system encompasses a 
heating block for thermal cycling and detectors to measure fluorescence in each 
well of a 384-well optical plate. Fluorescence is measured after every 
amplification cycle to quantify the accumulation of PCR product; during the 
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exponential phase of PCR cycling the rate of product accumulation is 
proportional to template concentration, relative template abundance can 
therefore be quantified by monitoring increasing fluorescence in each well 
during temperature cycling. This is explained in more detail in subsequent 
sections below with specific protocols for cDNA template preparation and 
reaction set up. 
2.4.1 Preparation of cDNA 
cDNA preparations for quantitative real-time PCR (qRT-PCR) were prepared by 
reverse transcription from RNA templates. Applied Biosystems 'TaqMan Reverse 
Transcription Reagents' were used for cDNA synthesis using random hexamer or 
oligo dT primers. 1 µg of RNA template was used unless RNA concentrations were 
low; the same amount of RNA template was always used in all reactions in the 
same experiment, dictated by the lowest RNA concentration. Reverse 
transcription reactions were performed in 96-well plates to allow multichannel 
pipettes to be used for PCR reaction set up, the reaction constituents and 
temperature programs follow: 
 
Applied Biosystems TaqMan Reverse Transcription Reagents: 
 
RNA Up to 1µg 
H2O Adjust to 7.7µl 
Then add the following to each tube from a master mix: 
 
Vol.(µl) 
10X Reaction Buffer    2.0 
MgCl2 (25mM)     4.4 
dNTPs (2.5mM ea.)     4.0 
Primers (50µM)     1.0 
RNase Inhibitor (20U/µl)    0.4 
MultiScribe RT (50U/µl)    0.5 
 
Heat to 25°C for 10 minutes, 48°C for 30 minutes then 95°C for 5 minutes. 
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2.4.2 Taqman® qRT-PCR  
Applied Biosystems Gene Expression Assays were used for all qRT-PCRs in this 
project. The assays consisted of a 20 X reaction mix containing template-specific 
forward and reverse primers (18 mM each) and a probe that anneals between the 
two primers (5 mM). The probe DNA is fluorescently tagged at its 3' end, but 
fluorescence from intact probes is prevented by a quencher molecule that is 
bound to its 5' end. During PCR amplification, the 5'-3' nucleolytic activity of the 
DNA polymerase cleaves the quencher from the probe, resulting in fluorescence 
levels proportional to the amount of PCR product present. All Gene Expression 
Assays used in this project were designed to anneal across two exons in cDNA, 
guaranteeing that non-specific amplification did not occur from residual genomic 
DNA. Expression of the gene of interest was always measured relative to the 
housekeeping control gene (β-actin). The gene of interest and β-actin were 
amplified in duplex PCR reactions, probes for the gene of interest were tagged 
to 'FAM' labelled fluorescent dyes, while β-actin probes were labelled with 'VIC' 
dye, they fluoresce at different wavelengths, allowing them to be measured in 
the same reaction. All reactions were performed in 5 µl volumes in 384-well 
plates. The pre-designed RT-PCR gene expression assays are listed in specific 
results chapters.  The reaction constituents and temperature cycling parameters 
follows: 
Reaction mix 
 
Volume (µl) 
2X PCR Master Mix 2.5 
20X Gene Expression Assay 0.25 
20X β-actin Expression Assay 0.25 
cDNA 2.0 
Nuclease-free H2O - 
Total Volume 
 
5 µl 
 
Temperature cycling: 
 
Heat Cycle Time 
50oC 2 min 
95oC 10 min 
95oC 15 sec  
60oC 1 min 
 
x35 
cyclescyc
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All samples were amplified in technical replicates of duplicate or triplicate, with 
at least three biological replicates. Fluorescence of FAM and VIC dyes were 
measured for all reactions during temperature cycling, data was analysed using a 
combination of Applied Biosystems SDS (Sequence Detection Software) and 
Microsoft Excel (2007) software.  
2.4.3 Analysis of qRT-PCR 
SDS plotted the amplification curves as cycle number vs. fluorescence for both 
dyes in every well. FAM and VIC fluorescence were analysed as separate data 
sets, a fluorescence threshold was identified for each data set where 
amplification curves were in their exponential phase. The extension phase of 
PCR releases fluorescence from the respective qRT-PCR probe, and a threshold 
of fluorescence is set during the exponential phase of amplification. The cycle 
number at which the threshold crosses this set threshold is termed the cycle 
threshold (Ct). qRT-PCR results in this project were analysed using the relative 
quantification method of comparative Ct. The 'cycle threshold value' (Ct value) 
for each amplification curve was interpolated by finding the precise fractional 
cycle number (to 5 decimal places) at which the curve crossed the fluorescence 
threshold. Ct values for FAM and VIC data were exported from SDS as text files 
and converted to Excel documents for data analysis. This method assumes that 
assay efficiencies are equal. Efficiencies were calculated using serial dilutions of 
cDNA product and the following equation: 
Efficiency (%) = (10-1/slope) x 100 
The housekeeper (β-actin) acts as a normalising control for RNA concentrations 
and small pipetting discrepancies. This house keeper was tested for consistent 
expression and reproducibility in appropriate samples. Housekeeping gene 
expression was used to calculate the dCt for the given gene of interested and 
the equation to calculate dCt is as follows: 
dCt = Ct(sample) – Ct(Housekeeper) 
All experiments were compared to a reference control to calculate the ddCt as 
follows:  
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ddCt = dCt(sample) – dCt(reference) 
Fold change (Relative quantification) was calculated as follows: 
Relative Quantification (RQ) = 2-ddCt  
This method calculates gene expression normalised to the endogenous control 
relative to a calibrator from within the experiment (i.e. a sample or sample 
group designated to have relative gene expression level of 1.0), it is 
advantageous because it does not require the inclusion of a standard curve from 
a serial dilution of template in each experiment.  
2.5 DNA Sequencing  
DNA sequencing was performed by purifying end point PCR products, to remove 
un-incorporated dNTPs, primers and salts, followed by dideoxy sequencing 
reactions, and a second purification step before capillary electrophoresis to 
separate sequencing products by size. The steps of DNA sequencing are outlined 
below: 
2.5.1 PCR Clean up 
PCR products were purified for sequencing using the Agencourt AMPure kit. This 
relies on binding of DNA products over 100bp in length to magnetic beads in the 
kit solution. Ninety µl of AMPure was added to each 50µl PCR reaction, the 
plates were sealed, briefly vortexed, and centrifuged to 1000 rpm for 1 second. 
They were left to stand for 5 minutes and then placed onto a SPRIPlate (solid 
phase reversible immobilisation plate) magnetic plate holder (Agencourt) for 10 
minutes allowing the separation of beads/PCR products from the liquid phase. 
Keeping the PCR plate on the SPRIPlate, the PCR reaction constituents were 
removed by inverting the plates upside-down. The beads were then washed with 
200µl of freshly prepared 70% ethanol for 30 seconds before inverting the plate 
(still on the magnet) and centrifuging upside-down to 600rpm for 1 second to 
remove as much ethanol as possible. PCR Plates were removed from the 
SPRIPlate and left to air-dry for 20 minutes. 
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The PCR product was eluted from the beads by the addition of 40 µl of nuclease 
free water. The PCR plates were sealed and vortexed to resuspend the AMPure 
beads, then returned to SPRIPlates plates, 10µl was carefully pipetted out per 
sequencing reaction. This cleaned PCR product was either stored at -20oC or 
taken forward to the next step. 
2.5.2 Dideoxy Sequencing 
Applied Biosystems BigDye Terminator v3.1 Cycle Sequencing kits were used for 
all sequencing reactions in this project, reactions were performed in 96-well 
plates as follows:  
Reaction mix 
 
Volume (µl) 
5X Sequencing Buffer 3.5  
Ready Reaction Mix 0.5  
Template 10 (variable for plasmid DNA) 
Primer (1pmol/µl) 3.2 
Nuclease Free water  2.8 (variable for plasmid DNA) 
 
Total Reaction Volume  
 
20 µl 
 
Temperature cycling: 
 
Heat Cycle  Time 
 
96°C 45 sec 
50°C 25 sec 
60°C 4 min 
 
 
2.5.3 Sequencing Reaction Purification 
Sequencing reactions were purified to remove reaction constituents and 
unincorporated nucleotides and primers prior to electrophoresis using Agencourt 
CleanSEQ reagent. 10µl of CleanSEQ reagent was added to each sequencing 
reaction, followed by 62µl of freshly prepared 85% ethanol. Plates were briefly 
vortexed and centrifuged to 1000 rpm for 1 second to collect the liquid to the 
bottom of the wells, then placed on a SPRIPlate for 3 minutes. Wells were 
emptied by inverting the plates upside-down, the CleanSEQ beads were washed 
twice with 100 µl 85% ethanol for 30 seconds each, emptying the wells between 
washes. Plates were inverted and centrifugation at 600 rpm for one second. 
Plates were removed from the SPRIPlates and air dried for 20 minutes, 40 µl of 
X25 
cycles 
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H2O was added to each well and CleanSEQ beads were resuspended by vortexing. 
Plates were briefly centrifuged to 1000 rpm for 1 second and returned to 
SPRIPlates. 20 µl of sequencing products were loaded into optically clear 
barcoded 96 well plates ready for capillary electrophoresis. 
2.5.4 Capillary Electrophoresis  
Sequencing capillary electrophoresis was performed on a 48-capillary Applied 
Biosystems 3730 Genetic Analyser with 36 cm capillaries. Electrophoresis was 
preceded by filling the capillaries with fresh POP-7 polymer (Applied Biosystems) 
and warming the capillaries to 60°C. Sequencing products were separated by 
size by electrophoresis at 8500 volts for 50 minutes. 
2.5.5 Sequencing Analysis 
Sequencing was analysed offline using CLC genomics workbench 5. Experimental 
sequences were aligned with known sequences derived from the bioinformatic 
database ENSEMBL genome browser. 
2.6 Cell culture 
Eukaryotic cell lines were handled under sterile conditions using class II 
biological safety cabinets (Holten Safe 2010). Cells were grown in a monolayer 
and maintained in tissue culture flasks with vented caps (Corning, Birmingham, 
UK) in inCusafe 37°C, 5% carbon dioxide (CO2) incubators.  
HeLa cells (an immortalised human cell line derived from cervical cancer), 
NRK52E cells (an immortalised rat kidney epithelial cell line), and HEK293 cells 
(an immortalised cell line derived from human embryonic kidney cells) were 
obtained from The European Collection of Animal Cell Cultures (ECACC). HeLa 
cells were maintained in Dulbecco’s modified Eagles medium supplemented with 
10% (v/v) fetal calf serum (FCS), 2mM L-Glutamine, and 100 U/ml Penicillin, and 
100 µg/ml streptomycin (Invitrogen, Paisley, UK). NRK52E and HEK293 cells were 
maintained in Dulbecco's Modified Eagle Medium containing 4.5g/L D-glucose; 
10% (v/v) FCS; 2mM GlutaMAX; 1mM sodium pyruvate; 100 U/ml Penicillin; 100 
µg/ml streptomycin (Invitrogen, Paisley,  UK). HK-2 cells (an immortalised 
Human proximal tubule cell line derived from human kidney) obtained from 
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Lonza, UK. The cells were maintained with Keratinocyte serum free media (K-
SFM, Gibco, Invitrogen, Paisley, UK) supplemented with epidermal growth factor 
(5ng/ml) and bovine pituitary extract (40µg/ml).  
2.6.1 Cell Passage (sub culturing) and Cryopreservation  
Cell were passaged regularly and when approximately 80-90% confluence to 
prevent overcrowding in culture flasks. All experiments were performed with 
cells of lowest possible passage number and experiments were completed in as 
few passages as possible. Fresh cell culture stocks were recovered from storage 
in liquid nitrogen after approximately 25 passages. 
Passaging was performed by removing culture media and rinsing cells gently with  
sterile phosphate buffered saline (PBS), (Lonza, Slough, UK) before detaching 
them from the flask with 2ml 1X TE (0.05% trypsin; 0.2% ethylenediamine 
tetraacetic acid (EDTA). Cells were collected in 10 ml foetal bovine-serum (FBS)-
containing medium, which inactivates the trypsin, and centrifuged at 1500 rpm 
for 5 minutes. As HK-2 cells are maintained in serum free media, soyabean 
trypsin inhibitor (Sigma, Dorset, UK) was used to neutralise and inactivate the 
trypsin. Following centrifugation, the media/TE mix was poured off and the cell 
pellets were resuspended in cell culture media for sub culturing at ratios 1 in 3. 
For cyrostorage cells, were resuspended in growth media with 10% (v/v) 
dimethylsulfoxide (DMSO) to prevent ice particle forming during the freezing 
process then aliquotted into cryopreservation viles. The cryoviles were placed in 
an isopropanol freezing container (Nalgene) in a -80°C freezer overnight, 
ensuring freezing no faster than 1°C per minute.  
2.6.2 Cell Revival 
To revive cells from cryopreservation they were quickly defrosted at 37oC and 
the cell suspension immediately transferred into a 10ml universal containing 
5mls of complete growth media. The suspension was then centrifuged at 1500 
rpm for 5 minutes. The supernatant was poured off leaving the cell pellet 
behind, this removes the DMSO. The cell pellet was then resuspended in 
complete growth media and seeded accordingly. 
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2.6.3 Cell counting  
Cells were counted with a Bright Line Haemocytometer (Sigma, Dorset, UK). 10 
µl of a cell suspension was pipetted under a cover slip onto the grid, using a light 
microscope; the number of viable cells in each 1 mm corner square was counted 
and averaged. Cells crossing the bottom or right-hand edge of any square were 
not counted. The average number of cells in each 1 mm square was derived, and 
then multiplied by 104 to give the number of cells per ml in the suspension. The 
subsequent concentration of cells per ml can be determined using the following 
calculation: 
Cell number / ml = average cell count per square x 104 x original volume 
The calculated cell concentration (cells/ml) was then used at seeding cells at 
the desired density.  
2.7 Extraction and Quantification of Protein  
Protein was routinely extracted from animal tissues and cell cultures in this 
project via the following methods detailed below. 
2.7.1 Extraction from tissues and cells 
Protein samples were prepared from cultured cells by rinsing with PBS and 
scraping with a pipette tip in 1X RIPA buffer (50mM Tris HCl, pH8, 150mM NaCl, 
1% Triton X-100, 0.5% Sodium deoxycholate, 0.1% Sodium dodecyl sulphate (SDS), 
and 100Mm Ethylenediaminetetraacetic acid (EDTA), final pH 7.4. Protease 
(complete, mini EDTA free) (Roche, Hertfordshire, UK) and phosphatase 
inhibitors (x100 stock solution) (Sigma) were added on the day of use as they do 
not remain stable in H2O. Samples were thawed to -80°C and passed through a 
hypodermic needle 10 times, then wheeled at 4oC for 30 minutes, before briefly 
centrifuging to remove cell debris. The protein rich supernatant was collected 
and concentration determined (2.7.2). Animal tissues were homogenised with a 
Polytron 2100 rotor homogeniser at full speed in 1X RIPA buffer containing 
protease and phosphatase inhibitors as above, then centrifuged at 5000 g at 4oC 
for 5 minutes. The protein rich supernatants were transferred to fresh tubes and 
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protein concentration determined (2.7.2). All protein samples were stored at -
80oC. 
2.7.2 Determination of protein concentration 
Protein concentrations were determined using a Pierce BCA (bicinchoninic acid) 
Protein Assay Kit (Thermo Scientific, Loughborough, UK) according to the 
manufacturer’s instructions. Assays were performed in flat bottom 96 well plates 
and dilutions of an albumin protein standard (provided) ranging from 25ng/µl - 2 
µg/µl were reconstituted in PBS and used to generate a standard curve for each 
assay. Reagents A and B included in the kit were mixed at a ratio of 50:1 
respectively, before being added to either protein samples or standards at a 
ratio of 8:1 (25 µl of sample:200 µl BCA reagent mixture). Plates were protected 
from light and incubated at 37oC for 30 minutes. Absorbance at 560nm was 
determined for all wells using a Wallac Victor2 plate reader. Both standards and 
samples were measured in duplicate and the average calculated. The 
concentration of the protein was then interpolated from the standard curve by 
Work Out software.  
2.8 Western Blotting 
Western blotting was used in this project to determine expression levels of 
proteins in animal tissues and cell lysates. Each results chapter details specific 
antibodies used to investigate expression levels of varying proteins. Each step of 
the Western blotting protocol used in this study follows: 
2.8.1 SDS polyacrylamide electrophoresis 
Protein samples were prepared in a total volume of 20 µl at a concentration of 
20 µg, incorporating the appropriate volume of 6 X Laemmli reducing loading dye 
(constituting 50% glycerol; 9% SDS; 0.375 M Tris pH6.8; 10% β-mercaptoethanol; 
0.05% bromophenol blue dye). Samples were denatured for 10 minutes at a 
temperature greater than 90oC to ensure proteins were denatured before adding 
to resolving gels. Proteins were then resolved using sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS/PAGE). 12% polyacrylamide gels 
(containing 40% (v/v) polyacrylamide (30%), 11.25 mM Tris pH 8.8, 0.1% (v/v) 
SDS, 300 µl ammonium persulphate (APS) and 30 µl TEMED) were used. A 5% 
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stacking gel (13.3% (v/v) polyacrylamide (30%), 3.75 mM Tris pH 6.8, 0.1% SDS, 
300 µl APS and 30 µl TEMED) was used with each gel. 
Also added was 15 µl of Amersham 'Rainbow markers' a protein molecular weight 
marker (full range 10 kDa - 250 kDa) linked to coloured dyes for easy 
identification on the blotting membrane. Empty wells were loaded with 20µl 6X 
Laemmli loading dye to help provide a constant resistance across the gel.  
The mix for each resolving gel constituted: 
 
Reagent 
 
Volume  
30% acrylamide 12 ml 
1.5 M Tris (pH8.8) 7.5 ml 
10% SDS 300 µl 
 H2O 10.2 ml 
TEMED 30 µl 
10% APS 300 µl 
  
Stacking gel consisted of: 
Reagent 
 
Volume  
30% acrylamide 2 ml 
0.5 M Tris (pH6.8) 3.75 ml 
10% SDS 159 µl 
 H2O 9.1 ml 
TEMED 15 µl 
10% APS 150 µl 
  
 
2.8.2 Protein blotting 
Following electrophoresis the stacking gel was removed and lanes not including 
protein were cut from the resolving gel. Six pieces of Whatman 3 mm 
chromatography blotting paper and a piece of Amersham Hybond-P membrane 
were cut to the same size of the gel. Filter paper and transfer sponges were 
equilibrated in transfer buffer and membranes were activated with methanol. 
Transfer buffer consisted of 0.025 M Tris pH10.5; 0.2 M Glycine; 0.1% SDS; 20% 
methanol. Transfer apparatus was prepared as follows (cathode to anode): 2 X 
transfer sponge, 3 x Whatman sheets, gel, membrane, 3 x Whatman sheets, and 
2 x transfer sponge. Blots were transferred overnight at 88 mAmps, 7 volts 
overnight in a Hoefer TE 50X transfer tank. 
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2.8.3 Antibody probing and washing 
Once the membranes had been transferred the membrane was blocked overnight 
at 4oC in Tris-buffered saline Tween buffer (TBST) (0.025 M Tris pH7.4; 0.14 M 
NaCl; 0.0027 M KCl; 0.1% Tween (Sigma, Dorset, UK)), 5% (w/v, g/ml) dried 
skimmed milk (Marvel) or 5% Bovine Albumin Serum (BSA) (Sigma, Dorset, UK) 
depending on the antibody specifications. All blocking was carried out on a lab 
shaker (Luckham R100) at 50 oscillations per minute with the membranes heat 
sealed into plastic bags using a Russell Hobbs heat sealer with minimal airspace 
to enhance contact of the antibody preparations with the membrane. Primary 
antibody exposure was performed in a total volume of 10-20 ml TBST, 1% milk or 
BSA. Membranes were again heat-sealed. The bags were taped to a lab shaker 
and left overnight at 4°C at 180 oscillations per minute. Primary antibody 
dilutions are detailed in specific methods sections.  
The membranes were washed with 100ml TBST in 5 x 10 minute washes. Horse-
radish peroxidase (HRP) conjugated secondary antibodies targeting the species in 
which the primary antibody was raised (DAKO, Norfolk, UK). Membranes were 
incubated in a total volume of 50 ml with 5% milk or BSA. Membranes were 
incubated for one hour at room temperature; details of specific antibodies used 
and dilutions are given in relevant chapters. Membranes were then washed for 5 
further 10 minutes washes with 100 ml TBST. 
2.8.4 Enhanced chemiluminescence and detection 
Proteins were visualised using Amersham enhanced chemiluminescence (ECL) 
Western blotting detection reagents per the manufacturer’s instructions. ECL 
detects binding of the HRP-conjugated secondary antibodies. Kodak general 
purpose blue medical X-ray film was used to develop the membrane to visualise 
present proteins. Films were exposed for varying lengths of time ranging from 1 
second to 15 minutes. A Kodak X-Omat 1000 was used to develop the X-ray films. 
The developed film, with sufficient protein banding, was placed on top of the 
membrane to mark on the rainbow size markers, allowing accurate sizing of 
protein bands. 
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2.8.5 Membrane stripping and re-probing 
The level of a particular protein in a sample was always measured relative to the 
level of a 'housekeeping' protein, such as glyceraldehyde-3-phosphate 
dehydrogenase (GAPdh) or beta-actin (β-actin). Membranes were stripped to 
remove conjugated antibodies and re-probed with antibodies specific to the 
housekeeper. The membrane were stripped in 100ml of a mild stripping buffer 
(0.2M Glycine, 1%SDS, and 1%Tween20®, pH 2.2) for 30 minutes at room 
temperature on a shaker at 50 oscillations per minute, then washed 3 X for 5 
minutes in TBST. Membranes were then re-blocked overnight at 4oC in TBST, 5% 
milk or BSA and probed, washed and analysed for the housekeeping protein 
exactly as described above. 
2.8.6 Densitometry 
Immuno-detected protein bands on photographic films were measured to 
compare protein levels between samples using the BIORAD Fluor-S MultiImager 
and 'Quantity One' software (BIORAD). This allows the scanning of X-ray films to 
generate a digital image. Individual bands were labelled and demarked by boxes 
using a drawing tool in the Quantity One software. The intensity of the bands 
was then measured by the software and expressed in units of optical density per 
mm2 (ODU/mm2). The intensity of the protein band of interest was divided by 
the intensity of the band for the housekeeping gene to find the relative level of 
the protein of interest in each sample. 
Two methods of background subtraction were used for densitometry analysis. A 
'global' background subtraction method was used for blots with clean and 
constant background intensities, this involved drawing a box in an area of the 
image that represented the background, the software then calculated the 
average intensity of all pixels in this box and subtracted it from all pixels in 
boxes containing bands. Alternatively, 'local' background subtraction was used 
for blots where the background intensity level was variable or high across the 
blot; the software calculated average background intensity for each box by 
measuring the average intensity of all pixels in a one-pixel border around each 
box and subtracted this from each pixel in the box to find the band intensity. 
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The applicable densitometry method used for individual western blots is 
described in each results chapter. 
2.9 Experimental animals 
A UMOD KO (UMOD-/-) mouse model that was generated by Bates et al 
(Oklahoma University, USA) along with the WT (UMOD+/+) strain (129/sv), have 
been utilised in this project (Bates et al., 2004). All experiments in this thesis 
have been performed using litter mates of KO or WT mice, unless stated 
otherwise. Generation of the KO mice follows; in brief, human cDNA UMOD 
probes were used to isolate mouse cDNA UMOD which was then used to probe a 
mouse 129/sv liver λ Fix II genomic library to obtain full length mouse UMOD. 
Restriction analysis, sequencing, and comparison with human and rat gene 
restriction maps were used to characterise the UMOD gene. The KO mice were 
generated with an omega type replacement targeting vector incorporating a 2kb 
segment 5’ of the cap site of the UMOD gene and the first four exons plus the 
intervening introns. The linearised vector was introduced to the embryonic stem 
cells of a 129/sv strain mouse via electroporation. Successfully transfected 
embryonic stem cells were then injected into developing blastocysts of C57Bl/6 
mice, thus producing chimeric pups. The chimeric pups were then bred with 
black Swiss female mice to obtain hetergozygous mice for UMOD deficiency. 
These mice were then inbred for 10 generations to produce WT mice and KO. 
The genotype of the WT and KO mice was verified using end point PCR of tail 
genomic DNA with specific primers (forward: 5’ AGGGCTTTACAGGGGATGGTTG-
3’ and reverse: 5’ GATTGCACTCAGGGGGCTCTGT 3’) Figure 2-2. Throughout this 
thesis UMOD-/- mice will be referred to as KO and UMOD+/+ mice will be 
referred to as WT. 
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Figure 2-2 Confirmation of the 
End point PCR verified the 
at exon three of the UMOD
2.10 Hemodynamic parameters
2.10.1 Tail cuff 
Blood pressure was assessed indirectly in conscious mice using the
mouse tail cuff plethysmography pressure equipment (Panlab Harvard apparatus, 
Edenbridge, UK). 
recording (VPR) technology and operates by placing a tail cuff over the mouse 
tail and occluding 
deflation the tail blood volume is measured as a change in pressure. Precise 
details of the procedure and animals used are outlined in specific results 
chapters. 
 
2.10.2 Radiotelemetry
Hemodynamic parameters were then measured directly using the Radio
Telemetry Monitoring of Blood Pressure and Heart Rate Dataquest IV Telemetry 
System (Data Sciences International, 
provides scheduled sampling every 5 minu
pressure, heart rate, pulse pressure, and activity levels throughout 24 hour 
periods as previously described 
implantation of the transmitter (radio frequency 
was performed to verify accuracy to within 3 mmHg. 
The mouse carotid artery 
procedure was as follows: 
 
UMOD knockout strain.  
UMOD-/- (KO) strain with the absence of a PCR product band 
 gene. 
 
plethysmography 
The plethysmography equipment utilizes volume pressure 
the tail blood flow by an internal pressure transducer. Upon 
 
New Brighton, 
tes of systolic, diastolic, mean arterial 
(Huetteman and Bogie, 2009)
transducer PA
 
cannulation with subcutaneous device placement 
mice of 12 week old were anesthetized with Isoflurane 
101 
 
 Harvard 
-
USA). Radiotelemetry 
. Before the 
-C10), calibration 
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(inhalant) and monitored throughout the surgical procedure. Hair was removed 
from the upper back and the neck area by shaving and the incision areas were 
cleaned with ethanol. The first incision was made on the back between the right 
shoulder blade and the mid scapula, where a small subcutaneous pocket was 
formed by blunt dissection for the telemetry probe to nest in (PA-C10, Data 
Sciences International, Virginia, USA). The mouse was then placed in a supine 
position to expose the neck. A vertical 1.5 cm midline incision through the skin 
overlaying the trachea was made and a Luer-Lock needle (Henleys Medical 
supplies Ltd, London, UK) was used to tunnel the catheter of the telemetry 
probe through to the open incision. The mandibular glands were carefully 
separated and the common carotid artery was isolated with blunt dissection. The 
cleaned up vessel was then ligated permanently with a suture (4-0 silk, Ethicon, 
Edinburgh, UK) at the site of bifurcation of internal and external branches of the 
carotid artery. The suture was then secured and retracted towards the head of 
the mouse. Another suture was placed approximately 8-10mm below the first 
suture, and retracted towards the tail of the mouse, to prevent blood flow 
through the artery. A third and final suture was placed in the middle of the two 
retracted sutures and tied loosely, this suture acts as an anchor to hold in place 
the telemetry pressure sensing catheter during advancement on cannulation. A 
26 gauge hypodermic needle (BD Biosciences, New Jersey, USA) was bent to 90 
degrees (bevel side up) and used to puncture the carotid lumen. Right angled 
forceps (Fine Science Tools, Heidelberg, Germany) were used to open the 
puncture site to allow entry and advancement of the telemetry catheter. The 
catheter was advanced until reaching the retracted occlusion suture towards the 
tail end. The middle suture was then tied with one knot to secure the catheter 
whilst the occlusion suture was released; this allows further advancement of the 
catheter without it being forced out by the consequent blood flow back into the 
vessel.  Once in place, the sutures were secured and all retracted suture were 
released. The open incision at the neck was sutured with 4-0 vicryl silk (Ethicon, 
Edinburgh, UK). The back pocket containing the telemetry probe was sutured 
securely (4-0 Vicryl silk). Mice where then allowed to recover in a hot box 
(32oC). Following surgery intraperitoneal injection of carprofen analgesia was 
administered. Once the mice had regained consciousness, they were returned to 
their cages and allowed one week recovery period before initiation of recording 
and/or cardiovascular stimulation.  At the end of the recording period mice of 
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18 weeks of age were placed in metabolic cages for a 24 hour period (described 
below) then sacrificed by exsanguination.  
 
2.11 Renal function 
2.11.1 Metabolic cage measurements 
Mice were placed in the metabolic cages (Techniplast, model number 3700M022, 
Buguggiate, Italy) at week 6 of the ± 2% NaCl for a 24 hour period. Urine output 
and fluid intake was monitored and recorded at the end of the 24 hours. Urine 
samples collected within the 24 hour period were used for further analysis.  
2.11.2 Creatinine clearance 
Estimated glomerular filtration rate (eGFR) was measured indirectly by 
quantitative determination of creatinine clearance (CrCl) by measuring 
creatinine, glucose, and urea in WT and KO mice (± 2% NaCl) plasma and urine 
samples. CrCl was measured using Roche/Hitachi cobas c systems kits (Roche 
Diagnostics, Burgess Hill, UK). The following kits were used; CREP2 (for 
creatinine measurements), GLUC3 (for glucose measurements), and UREAL (for 
urea measurements). The protocol included in the kits was a standardised 
method using 150 µl of sample (urine or plasma). Urine was collected as per 
section 2.11.1 and blood was collected by cardiac puncture into heparinised 
tubes. Whole blood was spun down by centrifugation at 1000 g for 15 minutes at 
4oC. Plasma was carefully removed and stored at -80 oC until required.  
The test principle to measure creatinine is an enzymatic method based on the 
conversion of creatinine with the creatininases, creatinase, and sarcosine 
oxidase to glycine, formaldehyde, and hydrogen peroxide. Catalyzed by 
peroxidase, the released hydrogen peroxide reacts with 4-aminophenazone and 
HTIB to form a quinone imine chromogen. This chromogen formation causes a 
colour change of the solution and the intensity of the colour change is directly 
proportional to the creatinine concentration of the sample and is measured 
photometrically at 700/540 nm. Creatinine of the sample is destroyed by 
creatinase, SOD, and catalase during incubation with TAPS buffer (N-
Chapter 2  104 
 
Tris(hydroxymethyl)methyl-3-aminopropanessulfionic acid), 30 mmol/l, pH8.1)). 
The enzymatic processes are as follows:  
Glucose was also measured using an enzymatic reference method with 
hexokinase which catalyzes the phosphorylation of glucose to glucose-6-
phosphate by ATP. Glucose-6-phosphate dehydrogenase oxidises glucose-6-
phosphate in the presence of NADP (Nicotinamide adenine dinucleotide) to 
gluconate-6-phosphate. The rate of NADPH (Nicotinamide adenine dinucleotide 
phosphate) formation during the reaction is directly proportional to the glucose 
concentration and is measured photometrically.  
Finally Urea was measured as a kinetic test with urease and glutamate 
dehydrogenase (GLDH). Urea is hydrolyzed by urease to form ammonium and 
carbonate. In the second phase of the reaction 2-oxoglutarate reacts with 
ammonium in the presence of GLDH and the coenzyme NADH to produce L-
glutamate. In this reaction 2 moles of NADH are oxidised to NAD+ for each mole 
of urea hydrolyzed. The rate of decrease in the NADH concentration was directly 
proportional to the urea concentration of the sample, and is measured 
photometrically at 700/340 nm.  
The assays were ran on a clinically validated automated analyser (c311, Roche 
diagnostics, Burgess Hill, UK), using the manufacturers calibrators and quality 
controls. Values were then normalised to kidney weight and urine flow per 
minute.  The following calucaltions was used to dervie CrCl (ml/min): 
Urinary creatinine concentration x urine rate flow  
plasma creatinine concentration  
The values were then corrected to kidney weight (ml/min/mg). 
Creatinine + H2O
Creatine + H2O
Sarcosine + O2 + H2O
H2O2 + 4-aminophenazone + HTIB
Creatine
Sacrosine + Urea
Gylcine + HCHO + H2O2
Quinone imine chromagen + H2O + HI
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2.11.3 Electrolyte analysis 
Urine samples collected from the 24 hour metabolic cage study were taken 
forward to investigate electrolyte analysis. The measurements were carried out 
by Dr James Harvie at the University of Glasgow Veterinary Medicine School. The 
assays were run on the Olympus AU640 clinical chemistry analyzer (Beckman 
Coulter Ltd, London, UK) using the indirect ISE (ion selective electrode) method 
known as potentiometry. The ISE coverts the activity of a specific ion dissolved 
in a solution into an electrical potential which is then measured as voltage. The 
voltage sensing electrode is an ion specific membrane and works alongside a 
reference electrode of a stable and known electric potential (acting as the assay 
control). The concentration of Na+, K+, and Cl- were measured in the 150 µl 
mouse urine samples as µmol/l and normalised to the voltage reading from the 
stable electrode. Values were then normalised to kidney weight.  
2.12 Histology 
2.12.1 Ex vivo analysis 
Mice were sacrificed by cervical dislocation, upon termination tissues were 
removed, cleaned of any connective tissue, and prepared for histological 
analysis. Body weight, kidney weight, and tibia length were recorded. All tissue 
weights were normalised to tibia length.  
 
2.12.2 Fixation and sectioning 
Left and right kidneys from WT and KO mice (± 2% NaCl) were dissected, cleaned 
of any connective tissue, and fixed in 10 % (v/v) neutral buffered formalin (10 % 
formalin: 90 % H2O, 33 mM NaH2PO4, 45 mM Na2HPO4) overnight. Tissues were 
processed through a gradient of alcohol solutions to Histoclear (a xylene 
substitute, Thermo Scientific, Loughborough, UK), with the terminal step into 
paraffin wax. The fixation of tissue was performed in a Citadel 1000 processor 
(Thermo Scientific, Loughborough, UK) in the following sequence: 
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Solution 
 
Length of incubation (min) 
70 % ethanol 15 
85 % ethanol 15 
90 % ethanol 25 
95 % ethanol 25 
100 % ethanol 15 
100 % ethanol 15 
100 % ethanol 15 
Histoclear 30 
Histoclear 30 
Paraffin wax 30 
Paraffin wax 30 
 
Glass histology slides were coated with aminoalkylsilanes by placing in 2% 3-
aminopropyltriethoxysaline (APES) and acetone for 30 seconds. Sections were 
washed twice with acetone for 10 seconds followed by two washed with dH2O for 
5 minutes each. Slides were then dried at 37oC overnight. Kidney tissues were 
cut transversely along the corticopapillary axis and embedded in this orientation 
in paraffin wax in preparation for sectioning using a Shandon Histocentre 3 
embedding centre (Fisher Scientific, Loughborough, UK). Paraffin blocks were 
sectioned at 3 µm slices to expose the transverse section of embedded kidney 
tissue using a Leica Finese 325 Microtome (Fisher Scientific. Loughborough, UK). 
Tissue sections were mounted onto the prepared slides and baked for 3 hours at 
65oC and then at 40oC overnight. Paraffin was removed from the tissue sample 
by 2 x 7 minute washes in Histoclear. Samples were then rehydrated by passing 
through a decreasing ethanol concentration gradient of 100 %, 90 %, and 75 % 
ethanol for 7 minutes each, followed by a final wash in dH2O for 7 minutes.  
2.12.3 Haematoxylin and eosin staining (H & E) 
Haematoxylin and eosin (H & E) stain is a standard method used to stain the 
nucleus and cytoplasm respectively. H & E was used in this project to investigate 
the morphology of kidney tissue from WT and KO before and after 2% NaCl 
stimulation. Deparaffinised sections were stained in haematoxylin for 4 minutes 
and washed in dH2O for 10 minutes, followed by one 30 second wash in acid 
alcohol (1 % (v/v) HCI in ethanol) to remove the excess haematoxylin. Nuclei 
were counter stained in eosin for 2 minutes followed by a further 5 minute wash 
in dH2O. Sections were dehydrated through increasing concentrations of ethanol 
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(75 %, 95 %, and 100 %) for 7 minutes each. Sections were then cleared by 2 ten 
minute washes in Histoclear and cover slips were fixed using DPX mounting 
medium (non-aqueous xylene based, Sigma, Dorset, UK). The nuclei appear 
blue/purple whereas cytoplasm appeared pink.  
2.12.4 Periodic acid-Schiff (PAS) 
This method was employed to localize total insoluble polysaccharides. Periodic 
acid is an oxidative reagent which acts upon the 1, 2 glycol linkage within the 
sugar molecule of carbohydrate, resulting into production of two free aldehyde 
groups. The produced aldehydes then react with leucobasic fuschin of Schiff’s 
reagent to produce visible magenta red colour. This method is commonly 
employed for polysaccharides as it does not breakdown polysaccharide chains 
and provides a clear basis for reaction which is specific to polysaccharides 
allowing investigation of tissue structures. 
WT and KO mice kidney sections (3 µm) ± 2% NaCl were stained as follows:  
Sections were deparaffinised and hydrated in an ethanol gradient (100 %, 95 %, 
and 70 % for 7 minutes each), and incubated in 0.5% Periodic acid (Sigma, 
Dorest, UK) for 15 minutes. Sections were rinsed for 5 minutes in running tap 
water followed by incubation in Schiff’s reagent (Sigma, Dorest, UK) for 15 
minutes. The sections were rinsed again in running tap water for 5 minutes prior 
to being counterstained with haematoxylin for 2 minutes. A final 5 minute wash 
step was performed in running tap water, followed by dehydration in ethanol (70 
%, 95 %, and 100 %) and cleared in Histoclear for 7 minutes each. The sections 
were then mounted using DPX mounting medium. The nuclei appear blue, whilst 
PAS positive structures appear magenta red. Sections were visualized using the 
EnVision detection system for mouse primary antibodies (K5007, DAKO, Glostrup, 
Denmark). All slides were imaged using an Aperio scanner XT at 20X 
magnification producing a resolution of 0.495 µm/pixel and investigated using 
the ImageScope software (Aperio v12.0.0.5039). 
Preparations of reagents are listed: 
 
Schiff’s reagent 
1gm of basic fuschin was dissolved in 0.15N HCl; agitated for three hours and 
then 1gm of sodium metabisulphate added and kept for overnight. Then 
decolorizing charcoal was added and kept shaking and filtered.  
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0.5% Periodic acid 
0.5gm of periodic acid was dissolved in 100ml distilled water.  
 
2.12.5 Immunohistochemistry 
Paraffin was removed from the cut kidney sections using Histoclear and then 
hydrated thorough an ethanol gradient of 100 %, 90 %, and 70 % for 7 minutes 
each and washed in dH2O for 7 minutes. Heat induced antigen retrieval was then 
performed with the sections incubated in 10 mM citric acid (pH 6.0) at 95 -100oC 
for 15 minutes and allowed to cool at room temperature. The slides were then 
washed twice in dH2O for 10 minutes. The endogenous peroxide was quenched 
from the tissue sections by incubating the slides for 15 minutes in 3 % hydrogen 
peroxide (H2O2) (v/v in methanol)), followed by 2 washes in dH2O. Sections were 
then incubated for 60 minutes with 2.5 % normal horse serum in a humidified 
chamber, to block all non specific binding. The kidney sections were then 
incubated overnight at room temperature with the primary antibody diluted in 1 
% (w/v) BSA in PBS (Sigma Aldrich, Poole, UK) in a humidified chamber. Each 
experiment included a blank and a negative control using 1 % BSA in PBS (no 
antibody and rabbit IgG antibody diluted in 1 % BSA in PBS respectively. The 
following day sections were washed 3 times in PBS for 5 minutes each. The 
sections were incubated for 30 minutes with Vectastain universal biotinylated 
secondary antibody (Vector Laboratories, ABC kit, Peterborough, UK), followed 
by two 5 minutes washed in PBS. DAB chromagen solution (3,3- diaminobenzidine 
and hydrogen peroxide solution) (Vector Laboratories, Peterborough, UK) was 
utilised for immunoperoxidase staining by incubating the sections for 5 minutes 
or until stain turns dark brown, at room temperature in a humidified chamber. 
The reaction was stopped by adding the sections to dH2O. Sections were then 
counterstained with Haematoxylin for 2 minutes, this enabled visualisation of 
the nuclei. Sections were washed in running tap water for 5 minutes then 
dehydrated in an ethanol gradient as follows; 70 % , 95 %, and 100 % for 7 
minutes each with a final incubation in Histoclear for 7 minutes also. Cover slips 
were then fixed using DPX. Antibodies, concentrations, and dilutions used are 
detailed in specific results chapters. 
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2.13 Enzyme Linked ImmunoSorbent Assay (ELISA) 
TNF-α levels were measured in urine from KO and WT mice (±2% NaCl) by 
enzyme linked immunosorbent assay (ELISA), using a commercially available 
mouse TNF-α ELISA kit (BD Sciences, Oxford, UK) following the manufacturer’s 
instructions.  
The assay was performed as follows; 96 well flat bottom plates were coated with 
anti TNF-α detection antibodies (monoclonal anti-mouse TNF-α phage antibody 
with fetal bovine serum (FBS)) overnight at 4oC. The following day, plates were 
washed with PBS containing 0.1% Tween 20 and blocked with 2% milk/PBS (w/v) 
for 2 hrs at room temperature. 50 µl of ELISA diluent (buffered protein base 
containing 0.09 % sodium azide) was added to each well followed by 50 µl of 
standard or sample. All samples and standard reactions were performed in 
triplicate. Standards were prepared by serial dilutions from a 2000 pg/ml stock 
solution (made from reconstituting a lyophilized Standard with standard/sample 
diluent solution (bovine serum containing 0.09 % sodium azide)) to produce the 
following standard concentrations; 1000 pg/ml, 500 pg/ml, 250 pg/ml, 125 
pg/ml, 62.5 pg/ml, and 31.3 pg/ml with the addition of a zero standard (0 
pg/ml) which was standard/sample diluent only. A subsequent 2 hour incubation 
period was performed at room temperature.  
Plates were then aspirated and washed with the provided wash buffer (300 µl 
per well), followed by decanting and aspirating until the wells were washed 4 
times. 100 µl per well of a horseradish peroxidise conjugated secondary antibody 
to bind to the captured TNF-α (provided in the kit) was added and incubated for 
30 minute at room temperature. Wash steps were repeated 5 times. TMB One-
Step Substrate Reagent (3,3',5,5'-tetramethylbenzidine) was added to each well 
(100 µl) and incubated for 30 minutes at room temperature whilst protected 
from the light, to initiate peroxidase catalyzed colour change. Following the 
incubation step 50 µl of Stop solution (provided in the kit) was added to stop the 
reaction by acidification. Absorbance readings were measured at 450 nm. The 
mean absorbance for was calculated for each set of triplicate samples and 
standards. The mean zero standard absorbance was then subtracted from each 
mean sample value. The standard curve was plotted with absorbance on the x-
axis and TNF-α concentration on the y-axis. Linear regression was used to apply 
the best fit line to the curve, applying a gradient. Each sample absorbance was 
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then normalised to the gradient. All samples were then corrected to urine 
volume.  
 
2.14 Metabolomic analysis  
Whole kidney tissue was extracted from WT and KO mice (± 2% NaCl) and 
prepared for metabolomic analysis as follows: 
Tissue was homogenised using 1 ml of extraction buffer (20 % H2O, 60 % 
methanol, and 20 % chloroform (v/v) using the Polytron 2100 method described 
in section 2.7.1. Tissue homogenates were then cold quenched to extract the 
metabolome. The extraction process involved rapidly cooling the tissue 
homogenate to 4 oC by submersion of the tube into a dry ice ethanol mix and 
incubating for 1 hour with agitation on a shaking platform. Debris was then 
pelleted by centrifugation at 13,000 g for 3 minutes and the supernatant 
retained for analysis by liquid chromatography tandem mass spectrometry (LC–
MS) analysis. Metabolite extracts were analysed using an UltiMate 1 LC system 
(Dionex, Camberley, UK) coupled to an Orbitrap Exactive (Thermo, Hemel 
Hempstead, UK). A 4.6 × 150 mm ZIC-HILIC column was used for separation. 
Buffers consisted of: A) 2% acetonitrile, 97.9% H2O, 0.1% formic acid and B) 
97.92% acetonitrile, 2% H2O, 0.08% formic acid. The gradient applied ran from 
80% B to 5% B over 30 min, followed by a 10 min wash at 5% B and equilibration 
for 6 min at 80% B. Metabolites were detected in a mass range from 70 to 1400 
amu, in both positive and negative ionisation modes at 50,000 resolution at m/z 
100. RAW data was converted to MzXML files using READw.exe and further split 
into positive and negative modes using MzMatch. Peaks were detected and 
metabolites were identified using MzMine 1.97 (Pluskal et al., 2010). Statistical 
analysis was performed using SigmaStat software (Cosmol, Östringen, Germany). 
t-tests were used to analyse the data, unless the assumptions of normal 
distribution or equal variance in the data were not met, in which case the Mann–
Whitney U test was used in its place as the alternative non-parametric test. 
Differentially expressed metabolites were uploaded and analysed with Ingenuity 
Pathway Analysis (IPA) software (386), where conical metabolic pathways of 
interest were investigated. 
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2.15 Renal Microarray mRNA expression analysis 
RNA amplification for array analysis was prepared using the Illumina® TotalPrep 
RNA Amplification Kit (AMIL1791) (Life Technologies, Paisley, UK). RNA from WT 
and KO mice ± 2% NaCl was extracted from whole kidney as per section 2.3.8, 
and the integrity of the sample analysed and validated to ensure it was free of 
protein, DNA, phenol ethanol, and salts (section 2.3.9). RNA samples were 
diluted to 45.45 ng / µl, and concentrations were confirmed by nanodropping 
each sample in triplicate (section 2.3.11) in preparation for first and second 
strand cDNA synthesis.    
2.15.1.1 First and second stand cDNA synthesis 
A reverse transcription master mix was comprised containing the following 
reagents; 
 
The reaction mix was incubated for 2 hours at 42oC, and then placed on ice to 
stop the reaction prior to the second strand cDNA synthesis. For second strand 
cDNA synthesis the following master mix was comprised; 
Reaction mix Volume (µl)
T7 Oligo(dT) primer 1
10 X First strand buffer 2
dNTP Mix 4
RNase Inhibitor 1
Arrayscript 1
Diluted RNA 11
Total Volume 20
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The reaction mix was added to the reverse transcription reaction and mixed 
fully; the combined mix was incubated at 16oC for 2 hours, and then placed on 
ice prior to the cDNA purification step. 250 µl of cDNA binding buffer (supplied in 
kit) was added to each sample and this mix was added to a cDNA filter cartridge 
(supplied with kit) and centrifuged at 10,000 g for 1 minute. The flow through 
was discarded and the filter cartridge was placed in a provided wash tube. A 
wash buffer was provided by the kit and was reconstituted with 100 % ethanol, 
once prepared 500 µl of the wash buffer was added to the cDNA filter cartridge 
and the previous centrifugation step repeated. The flow through was discarded 
and the cDNA filter cartridge was placed in a provided elution tube. Nuclease 
free water was heated to 55 oC, and 20 µl of it added to the cDNA filter 
cartridge and incubated at room temperature for 2 minutes, followed by 
centrifugation at 10,000 g for 1 minute. The elute was transferred to a 0.5 ml 
RNase free PCR tube in preparation for In Vitro Transcription (IVT) cRNA 
synthesis. 
The following master mix was comprised for the IVT step (for each cDNA 
sample); 
 
Reaction mix Volume (µl)
Nuclease free water 63
10 X Second strand buffer 10
dNTP mix 4
DNA Polymerase 2
RNase H 1
Total Volume 80
Reaction mix Volume (µl)
T7 10 X reaction buffer 2.5
T7 enzyme mix 2.5
Biotin-NTP mix 2.5
Total Volume 7.5
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Biotin-NTP biotinylates nucleic acid and binds with high affinity to Strepdavidin-
Cy3, allowing detection of downstream hybridisation of cRNA. The IVT master 
mix was added to each cDNA sample and incubated for 14 hours at 37 oC. The 
reaction was quenched by the addition of 75 µl of nuclease free water and being 
placed on ice. The cRNA purification step immediately followed; 350 µl of cRNA 
binding buffer (supplied with kit) and 250 µl of 100 % ethanol were added to 
each sample and this mix was applied to the cRNA filter cartridge supplied. The 
filter was centrifuged for 1 minute at 10,000 g and the flow through discarded. 
650 µl of provided wash buffer was added to the cRNA filter cartridge and the 
centrifugation step repeated. Nuclease free water was preheated to 55 oC and 
200 µl was added to the cRNA filter cartridge then centrifuged for 1.5 minutes at 
10,000 g. The cRNA samples were diluted to 150 ng / µl, and the concentration 
was confirmed by nanodropping the samples in triplicate.  
2.15.1.2 Hybridization to the BeadChip 
Hybridization buffer (HyB) and humidity control buffer (HCB) were prepared by 
heating to 58oC for 10 minutes to dissolve any salts, and cooled to room 
temperature before use. The BeadChip Hyb chamber apparatus was prepared by 
the addition of 200 µl of HyB and HCB to each well; the apparatus lid was 
applied and incubated at room temperature. The BeadChips were placed on the 
Hyb chamber insert. 5µl of the diluted cRNA was added to 10µl HYB buffer, and 
heated for 5 minutes at 65oC, vortexed, pulse centrifuged and allowed to cool to 
room temperature. The sample mixes were then applied to the inlet ports on the 
BeadChip.  
The BeadChip was loaded into the Hyb chamber, and incubated for 16 hours at 
58oC, on a rocking platform. A 1 X High-Temp wash buffer (provided with kit) 
was prepared, and placed in the hybex water bath insert within the hybex 
heating base, at 55oC overnight. The following day, BeadChips were removed 
from the Hyb chamber, and submerged face up in a pyrex beaker containing 
wash E1BC buffer (provided with kit). The cover seal was removed carefully, and 
placed in a slide rack in a wash chamber containing wash E1BC buffer. The slide 
rack was then placed in the hybex water bath, and the BeadChips were 
incubated for 10 minutes at 55oC. The slide rack was then placed in the wash 
chamber containing wash E1BC buffer used previously, and plunged in and out of 
the buffer 5 to 10 times, followed by agitation on an orbital shaker for 5 minutes 
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at room temperature. The rack was removed and placed in a staining chamber 
containing 250ml 100% ethanol and plunged in and out of the buffer 5 to 10 
times. The rack was agitated again on an orbital shaker for 10 minutes at room 
temperature and subsequently placed in a staining chamber containing 250ml of 
fresh wash E1BC buffer and plunged in and out of the buffer 5 to 10 times, 
followed by further agitation on an orbital shaker for 2 minutes at room 
temperature. 4ml of Block E1 buffer (provided with kit) was added to individual 
wash trays, and the BeadChip was placed in face up. The wash tray was placed 
on an orbital shaker for a final 10 minutes at room temperature. 
Streptavidin-Cy3 was diluted to 1:1000 with Block E1 buffer (provided with kit), 
and placed in a clean individual wash tray. Streptavidin-Cy3, acts as secondary 
agent to the biotinylated cRNA hybridized to the BeadChip, and is used to detect 
the intensity of this signal. The BeadChip was transferred to the wash tray and 
placed on an orbital shaker for 10 minutes at room temperature. The BeadChip 
was transferred to a slide rack and placed in a clean staining dish containing 
250ml fresh wash E1BC buffer, and plunged in and out of the buffer 5 times, 
followed by agitation on an orbital shaker for 5 minutes at room temperature. 
The BeadChip was then dried by placing the slide rack on clean paper towels, 
and centrifuging at 275 g for 4 minutes at room temperature. The dried 
BeadChips are then transferred to the Illumina® BeadArray Reader to scan, and 
the output data visualised using Beadstudio software.  
 
2.15.1.3 Microarray data analysis 
Illumina® Gene Expression Beadchips employ internal control features to monitor 
sample independent and sample dependent data quality. Control data results 
and microarray results were visualised with BeadStudio software. Quantile 
normalisation was performed without background subtraction; the BeadChip 
represents each probe (gene) with an average of 30 beads, where each bead has 
a given normalised expression value. The values were averaged per probe with 
unpaired 2 sample t-tests performed using Illumina® custom error model (386). 
Differentially expressed probes (genes) were identified using a difference score 
cut off +/- 13.0103 equating to a P value < 0.05. Ingenuity Pathway Analysis 
(IPA) software (386) was used to analyse differentially expressed probes.  
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2.15.1.4 Metabolomics and Microarray IPA anlysis 
Canonical pathways analysis identified link from the IPA library that were most 
significantly associated with the data set (differentially expressed 
gene/metabolites), and which from the data set that met the P value cut-off of 
5%. From here any genes/metabolites that were associated with a canonical 
pathway in the Ingenuity Pathways Knowledge Base (IPKB) were considered for 
the analysis. The significance of the association was measured firstly, by 
calculating a ratio of the number of genes with differentially expressed probes 
that mapped to the canonical pathway divided by the total number of genes 
with probes in the actual data set that mapped to the pathway displayed. 
Secondly, Fisher’s exact test was used to calculate a P value determining the 
probability that the association between the significant genes in the data set 
and the canonical pathway could be explained by chance alone. 
 
 
2.16 Statistical Analysis 
Values in this project are stated as Means ± standard error of the mean (SEM) 
unless otherwise indicated. The significance threshold (p value) for all analysis 
was set at 0.05. For comparisons of a continuous variable between 2 
experimental groups, paired and unpaired Student's t-tests were applied as 
appropriate. For statistical comparisons in data sets with more than two groups, 
analysis of variance (ANOVA) was applied, followed by the Dunnett's or Tukey’s 
post-tests, comparing all samples groups against a designated control group or 
for comparisons between the groups. Detailed statistical analyses for particular 
experiments are specified in the relevant results chapters.   
 
 
 
3 Human 2 Kb UMOD promoter studies 
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3.1 Introduction  
Genome-wide association studies of disease typically result in the identification 
of genomic susceptibility loci, in which several SNPs showing strong inter-marker 
linkage disequilibrium (LD) are equally associated with disease predisposition. To 
date, the search for rare and common variants affecting BP has identified 
thirteen loci from two large meta-analysis consortia, with each association 
revealing only a very small proportion of the total variation in systolic or 
diastolic blood pressure (Licht et al., 2009, Levy et al., 2009, Newton-Cheh et 
al., 2009). Moreover, the sum of rare and common genetic variants robustly 
identified so far through linkage and genome wide association studies explain 
only 1-2% of the population variation in BP and hypertension, suggesting the 
existence of more undiscovered blood pressure related variants. 
SNPs that are commonly linked with disease are frequently found in non-coding 
regions where they were thought to have no obvious function. However, the 
ENCODE (encyclopaedia of DNA elements funded by the National Human Genome 
Research Institute) revealed that up to 80% of the components of the human 
genome have at least one biochemical association with function, identifying 
regions of transcription, transcription factor association, chromatin structure, 
and histone modification in the human genome sequence 
(www.nature.com/encode/#/threads).  
Padmanabhan and colleagues identified and validated SNP rs13333226 at position 
-1,617 upstream of the UMOD transcriptional start site. When carried on the 
minor G allele rs13333226 was associated with a lower risk of hypertension 
(Padmanabhan et al., 2010). A previous candidate gene study of UMOD and 
hypertension revealed the minor allele of rs6497476 (located at -744 BP 
upstream of the transcriptional start site) was associated with lower risk of 
hypertension in a Japanese population, although did not reach significance (Iwai 
et al., 2006). Additional published GWAS have reported SNPs in the UMOD 
promoter region that help towards elucidating genetic risk of CVD – the minor T 
allele at position -3,653 (rs12917707) was associated with a 20% reduction in 
chronic kidney disease incidence (Kottgen et al., 2009), the minor C allele at 
position -1,550 (rs4293393) was associated with improved renal function in 
controls and sufferers of chronic kidney disease (Kottgen et al., 2010), whereas 
the major T allele at this site was associated with increased risk of chronic 
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kidney disease (Gudbjartsson et al., 2010). These genetic variations indicate 
that the UMOD locus is independently associated with hypertension as renal 
function was not compromised, thus, implicating UMOD functionally at altering 
blood pressure.  
It has been reported that not all implicated causal SNPs are directly associated 
with changes in phenotype (Collins et al., 1999), therefore it should be 
investigated whether the implicated SNPs are in fact functional variants or are 
SNPs in LD  leading to changes in BP. This association mapping relies on studying 
SNPs in LD with SNPs of interest to investigate multiple alleles in coding and 
non-coding regulatory regions to identify rare variants with large effect on 
phenotype and disease. Transcription is the initial step of gene expression 
requiring a multitude of actions involving transcription factors (TF), their 
corresponding cis-acting elements on DNA, additional co-factors, and chromatin 
structure. LD SNPs may alter expression of nearby genes via differential 
transcription factor (TF) binding. To date there are lacking examples of GWAS 
that have identified promoter SNPs linked with TF binding and altered 
transcription in essential hypertension. More recently, new strategies are being 
utilised to identify regulatory SNPs by combining computational and 
experimental approaches, for example in silico analysis with chromosomal 
immunoprecipitation (ChIP) technology (Kim et al., 2008, Ameur et al., 2009, 
Haring et al., 2007). Chromatin remodelling results in histone alterations which 
play a crucial role in post transcriptional modifications to gene expression.   
The experimental work in this chapter explores the 2 Kb UMOD promoter region 
to compare transcriptional activities of UMOD promoter SNPs derived from 
contrasting genotypes for rs13333226. The rational for investigating the 2 Kb 
promoter region was prompted by the findings from the GWAS implicating 
rs13333226 with lower risk of hypertension where SNPs up to the 2 Kb region 
have high levels of LD (>94%), with a reduced number of haplotypes. If a 
substantial decreased risk is caused by a single SNP, there is more likely to be an 
association between that risk and SNPs in LD with the implicated causal SNP 
(Weiss and Clark, 2002). Moreover, the discovery of a UMOD TAL specific gene 
promoter (Zhu et al., 2002) opens new avenues for studying molecular 
mechanisms behind UMOD gene regulation of blood pressure regulation and 
hypertension.  
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3.2 Aims 
• To identify human renal cell lines that are of contrasting genotype for SNP 
rs13333226 and sequence the 2Kb UMOD promoter. 
 
• To investigate the transcriptional effects of UMOD promoter 
polymorphisms with luciferase expression constructs to implicate 
causative SNP(s) that alter promoter activity. 
• To utilise the 'Transfac' transcription factor database to identify potential 
candidate transcription factor binding sites that may affect UMOD 
transcription. 
• To utilise Chromatin ImmunoPrecipitation (ChIP) assays to assess 
predicted transcriptional genotype-dependent binding to the 2kb UMOD 
promoter region. 
• To utilise small molecule transient transfection into cell cultures to 
validate transcription factor binding on UMOD promoter activity. 
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3.3 Methods 
3.3.1 Identifying renal cell lines with contrasting genotype for 
SNP rs13333226 
ACHN, 786-0 and TK10 are cell lines of the National Cancer Institutes’ collection 
of 60 human cancerous cells (NCI-60 collection). The cell types were chosen 
from the panel as they were of renal lineage. They were purchased from the 
American Type Culture Collection (ATCC) and used throughout this project. The 
cells were maintained in Dulbecco's Modified Eagle Medium containing 4.5g/L D-
glucose; 10% (v/v) FCS; 2mM GlutaMAX; 1mM sodium pyruvate; 100 U/ml 
Penicillin; 100 µg/ml streptomycin (Invitrogen, UK). Genomic DNA was extracted 
from the cell culture lysates as described in section 2.2.1 and genotyped for SNP 
rs13333226. Full experimental manipulations are detailed in the subsequent 
sections. 
 
3.3.2 Genotyping 
Before PCR amplification and sequencing of the 2Kb UMOD promoter region, the 
genomic DNA from ACHN, 786-0, and TK10 was genotyped for SNP rs13333226 
using Applied Biosystems genotyping assay (C_31122293_10, context sequence: 
GTCAAAGAGGTAGCACAGCTGTAGG[A/G]ATATTGACTCCTCTTCCCAAACAGC). The 
genotyping assay utilises double labelling to determine between alleles. The A 
allele being VIC labelled and G allele being FAM labelled. The genotyping assay 
was carried out in a 384 well format with at least four negative controls 
(containing no DNA) and two positive controls (where the allelic state was known) 
using the reaction mix and cycling conditions listed below. The assay reaction was 
completed on a GeneAmp PCR System 9700 (Applied Biosystems, Paisley, UK). 
 
Reaction Mix 
 
Volume (µl) 
2X Genotyping master mix 2.5  
20X working stock SNP 
genotyping assay 
0.5  
Template Xµl  for 20µg genomic DNA 
Nuclease Free water  0 (variable depending on DNA concentration) 
  
Total Reaction Volume  
 
5  
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3.3.3 UMOD Promoter Sequence cloning  
Following identification of human renal cell types of contrasting genotype for 
SNP rs13333226, PCR amplification of the 2Kb UMOD promoter region was 
performed followed by sequencing to confirm the promoter sequence and 
present polymorphisms in preparation for DNA cloning. All UMOD promoter 
construct cloning was performed as per sections 2.2 and 2.3 in the general 
methods. 
 
3.3.4 Promoter Activity Analysis 
Dual reporter Luciferase activity assays were performed to compare 
transcriptional activities of the 1 and 2 Kb UMOD promoters derived from all 
three renal cell lines of contrasting genotypes for SNP rs13333226. HeLa, NRK, 
HEK-293, and HK-2 cells were cultured as per section 2.6 for transient 
transfection experiments. Each pGL4.10 basic Luciferase expressing construct 
was transfected into triplicate wells of HeLa, NRK, HEK-293, and HK-2 cell 
cultures. Cells were seeded at 1x105 one day prior to transfection. When cells 
were approximately 80% confluent, the transfection reagent; 
Lipofectamine®2000 was used at a 3:1 ratio (Lipofectamine® 2000:plasmid DNA). 
A total of 1µg of plasmid DNA at a ratio of 1:50 (Renilla:plasmid DNA) was 
transfected. Optimem (Invitrogen, Paisley, UK), the necessary transfection 
media was used over the 24 hour transfection period. After transient 
transfection for 24 hours, the cells were harvested and the activity of the 
promoter constructs assayed using the Dual Luciferase Reporter Assay System 
(Promega, USA). Renilla and Firefly luciferase activity was measured in cell 
lysates, lysed in 1X passive lysis buffer, using the Dual Luciferase Reporter Assay 
System (Promega, Southampton, UK). All reagents were prepared following the 
Temperature cycling:
Heat Cycle Time
95oC 10min
92oC 15 sec
60oC 1min 
70oC
10oC
10 min
Hold
X40 cycles
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manufacturer’s instructions. Light emission measurements were carried out 
using the Lumat LB 9507 tube luminometer (Berthold Technologies, Harpenden, 
UK). The lumat 9507 was set to inject 50µl of LAR II reagent, pause for 2 seconds 
to measure the luciferase present in the lysates. Immediately followed by an 
injection of 50 µl of the Stop and Glo reagent, a further 2 second time pause 
occurs to allow measurement of the renilla over a ten second period. To 
determine the promoter activity, firefly luciferase expression levels (relative 
light units) were normalised against Renilla luciferase levels. Duplicate ratios 
were averaged to indicate luciferase activity within the sample. 
 
3.3.5 Site Directed Mutagenesis  
To investigate the effect of polymorphic variation on UMOD promoter activity, 
SNPs of interest were mutated to the alternative allele using the QuikChange 
Site-Directed Mutagenesis kit (Agilent Technologies, Wokingham, UK). The 
pGL4.10 luciferase plasmid containing the 2Kb UMOD promoter fragment from 
the 786-0 cell type was used in the site directed mutagenesis assays in this 
project. Mutagenic primers utilised to alter each SNP of interest were designed 
using the online Quikchange Primer Design Program 
(www.agilent.com/genomics/qcpd) and ordered from Eurofins MWG Operon 
(Manchester, UK); primer sequences are listed below: 
Oligo name 
 
Sequence (5’-3’) Allele change 
 
786-0 1F 
 
TTTGGCAAAGATGAAAGCAAATTACCAATGCTCAG
AACTGG 
 
G to A 
786-0 1R CCAGTTCTGAGCATTGGTAATTTGCTTTCATCTTT
GCCAAA 
 
786-0 2F GGTGGGATTGTAAACCAATTTATAATAATTCTCGG
GGTGCT 
T to A 
786-0 2R CAGCACCCCAGAGAATTATTATAAATTGGTTTACA
ATCCCA 
 
786-0 3F CTATTGTGGGATGCGGGGAGCGGGGAG G to C 
 
786-0 3R CTCCCCGCTCCCCGCATCCCACAATAG  
 
 
The Stratagene QuikChange Lightening Site Directed Mutagenesis assay allows 
mutagenesis at sites in a double stranded DNA plasmid, eliminating the need for 
subcloning. The principles of the assay can be outlined in three steps: step 1 
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uses an accelerated thermal cycling procedure to achieve multiple rounds of 
mutant strand synthesis. Components of the thermal cycling reaction include a 
supercoiled double stranded DNA template, two or more synthetic 
oligonucleotide primers containing the desired mutations, and the kit-provided 
enzyme blend featuring a Pfu Fusion DNA polymerase. First the mutagenic 
primers are annealed to denatured template DNA. The Pfu-based DNA 
polymerase then extends the mutagenic primers with high fidelity and without 
primer displacement, generating ds-DNA molecules with one strand bearing the 
mutations.  
In Step 2 of the procedure, the thermal cycling reaction products are treated 
with the restriction endonuclease Dpn I. The Dpn I endonuclease (target 
sequence: 5´-Gm6ATC-3´) is specific for methylated and hemimethylated DNA5 
and is used to digest the parental DNA template. DNA isolated from almost all 
Escherichia coli strains is dam methylated and therefore susceptible to 
digestion. 
In Step 3, the reaction mixture, which is highly enriched for multiple mutated 
single stranded DNA, is transformed into XL10-Gold ultracompetent cells. Double 
stranded plasmid DNA was then prepared from the transformants and analyzed 
by sequencing to identify clones bearing each of the desired mutations.  
Preparation of the mutant strand synthesis and control reactions with thermal 
cycling reactions was as follows: 
Reaction mixture 
 
Template DNA (≤5 Kb) Control template (4.5Kb) 
10 X QuikChange Multi 
reaction buffer 
  
5 µl 5 µl 
ds-DNA template X µl (50 ng) 5 µl (25 ng)   
 
Mutagenic primers (sense 
and anti-sense) 
1.25 µl (125 ng)  1.25 µl (125 ng) 
   
dNTP mix 1 µl 
 
1 µl 
 
QuikSolution reagent 
 
1.5 µl 1.5 µl 
Nuclease free water 
 
X µl final volume of 50 µl 34 µl 
QuikChange Lightening 
enzyme 
 
1 µl 1 µl 
Total reaction volume  50 µl 50 µl 
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Following the temperature cycling, reactions were placed on ice for 2 minutes to 
reduce the temperature to ≤37oC. Once the reactions had cooled 10 U of Dpn I 
restriction enzyme was added directly to each amplification reaction. Reactions 
were then mixed, centrifuged for 1 minute at full speed, and incubated at 37oC 
for 1 hour to digest the parental (non mutated) ds-DNA.  
The mutated DNA plasmid was then transformed as per section 2.2.5. Positive 
colonies were screened as per section 2.3.3. 
3.3.6 TESS analysis and Ingenuity pathway analysis 
Transfac Professional is a commercial transcription factor database curated by 
Biobase the bioinformatics company, it includes information on over 8,000 TFs 
and over 18,000 TF binding sequences found in vertebrate, bacteria, fungi, 
insect, nematode and plant genomic sequences (www.cbil.upenn.edu/tess). 
Biobase use experimental and bioinformatic evidence of TF binding to construct 
nucleotide positional weight matrices that can provide the relative likelihood 
that a TF binds to particular input sequences. Matrices are constructed by 
aligning multiple known TF binding sequences and recording the frequency that 
each nucleotide occurs at each position. This is collated into a consensus 
sequence for the matrix. The five most highly conserved consecutive bases are 
designated the 'core' binding sequence. Many matrices are constructed using the 
evidence of a single experimental study in a particular species, for example 
where libraries of random or mutated sequences were tested for TF binding. 
Thus a particular TF will have multiple matrices, relating to evidence from 
different studies and species. Other matrices are constructed by collating the 
evidence of several publications, often across several species. Here we 
examined potential putative transcription factor binding sites at position 
16:20365234.  
Temperature cycling:
Heat Cycle Time
95oC 2 min
95oC 20 sec
60oC 10 sec
68oC
68oC
30 sec/Kb of plasmid length 
5 min 
X 18 cycles
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The Ingenuity Pathway Knowledge Base (http://www.ingenuity.com) is 
currently the largest annotated database of knowledge on biological networks. 
This project exploited the database to define the presence of functional 
associations of TFAP2A with the UMOD gene and to draw simplified network 
connections among other genes.   
3.3.7 ChIP assay  
Functional Transcription factor binding sites can be identified in the genome by 
computational approaches or experimentally by Chromatin ImmunoPrecipitation 
(ChIP). In brief, ChIP relies on antibodies to selectively enrich chromatin 
fragments to identify the presence of specific histone modification at precise 
regions of the genome. The chromatin fragment bound to the antibodies are 
captured using protein A/G beads, where DNA and protein can then be isolated 
from the precipitate and analysed to determine the abundance of a region of 
interest. In this project X-ChIP was utilised to explore the potential binding of 
transcription factor TFAP2A to SNPs in the UMOD promoter region. The assay 
contains multiple steps which are outlined in Figure 3-1 and detailed as follows:  
 
Figure 3-1 Outline of the ChIP procedure.   
The flow chart outlines the ChIP experiment described in the subsequent sections. In this 
project samples were either used as Input (sonicated only), IgG treated, or 
immunoprecipitated for an antibody of interest (TFAP2A).  
Cell material
Immunoprecipitation
Isolate Nuclei
Sonicate
Chromatin
Reverse Crosslink
Isolate DNA or 
Protein 
QPCR or 
Western blot
Normalisation
Crosslinking
Input IgG IP
DNA isolation to 
reverse crosslink
Test efficiency of 
shearing and reverse 
crosslinking
Sample preparation
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3.3.7.1 Isolation of chromatin 
ACHN, 786-0 and TK10 cells were cultured and used for the extraction of total 
chromatin. Cells were seeded at 1 X 105 in 10cm cell culture dishes and were 
maintained as outlined in 2.6. Once cell cultures reached 80-90% confluence the 
culture media was removed and monolayers washed three times with ice cold 
PBS in preparation for crosslinking. 
3.3.7.2 Cross linking 
Cells were crosslinked with the addition of formaldehyde to a final concentration 
of 1% in culture media and incubated for 15 minutes at room temperature whilst 
shaking gently. Crosslinking the starting material with formaldehyde ensures that 
the chromatin structure is preserved during the isolation and ChIP procedure. 
Crosslinking was stopped by the addition of glycine to a final concentration of 
0.125 M for 5 minutes at room temperature gently shaking. Media was then 
discarded and dishes PBS washed 3 times. Cells were then collected with the 
addition of lysis buffer (1 X PBS supplemented with complete protease inhibitor 
cocktail, Roche, West Sussex, UK) and 1 X phosphatase inhibitors (100 X cocktail 
Sigma, Poole, UK) and PMSF (phenylmethanesulfonylfluoride) at a final 
concentration of 50 µg/ml). Cell lysates were centrifuged at 200 g for 5 minutes 
at 4oC. Cross linked cells were then re-suspended in a collection buffer 
constituted  of a 1:1 ratio of mNLB:IPDB buffers including the above mentioned 
inhibitors (mNLB: 50 mM Tris; 10mM EDTA, 5mM EGTA , 0.1%SDS, final pH8.0 and 
IPDB: 20 mM Tris, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.01% SDS, and 150 
mM NaCl, final pH8.0). Cell sediments were incubated on ice for 10 minutes, 
following sequential re-suspension in the mNLB:IPDB buffer mix. The crosslinked 
chromatin was taken forward for shearing by sonication. 
 
3.3.7.3 Sonication  
Chromatin was fragmented to an average size of 100-500 bp using a temperature 
controlled (≤10oC) bio- ruptor (Diagenode) water bath sonicator (hydrodynamic 
shearing) for 20 minutes (24 s on followed by 24 s off). The temperature must be 
maintained below 15oC to prevent the reversal of crosslinking by heat. Debris 
was then removed by centrifugation for 10 minutes at 15,000 g at 4oC and 
supernatants transferred to new tubes. To verify successful sonication 20 µl of 
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each sample was reverse crosslinked in elution buffer (10 mM Tris-HCl, 1 mM 
EDTA, and 1% SDS, final pH8.0) at 65oC overnight. Samples were diluted in equal 
volumes of TE (10 mM Tris and 1 mM EDTA, final pH 8.0), treated with 
proteinase K (10 mg/ml) for 2 hours at 55oC, and finally purified using Qiagen 
Qiaquick DNA extraction kit. Reverse crosslinked samples were electrophoresis 
on 1.2% agarose gels (2.2.3). All successfully sonicated samples were taken 
forward in the experiment. 
Chromatin DNA concentrations were determined using the Qubit® dsDNA HS kit 
(Invitrogen, Paisley, UK) and chromatin preps were adjusted to the same 
concentration (µg/ml) using mNLB:IPDB buffer plus inhibitors (1:1 ratio). In 
preparation for ChIP, IP buffer (plus inhibitors) was added to the chromatin to a 
final concentration of 0.1% SDS, 0.1 Triton X-100, 10 mM Tris-HCl, and 1 mM 
EDTA, final pH8.0.  
3.3.7.4 Chromatin immunoprecipitation  
Dynabeads® Magnetic beads (Invitrogen, Paisley, UK) coated with ChIP grade 
TFAP2A primary antibody (Rabbit monoclonal to TFAP2A, Abcam, Cambridge, 
UK) or IgG Control beads (rabbit anti mouse, Sigma, Dorset, UK) were used for 
all ChIP experiments in this project. Beads were prepared as follows:100 µl of 
beads (per 500 µl of chromatin) were placed in 1.5 ml tubes and spun down 
briefly by centrifugation then placed on a magnetic rack (DynaMagTM -2 Magnet, 
Invitrogen, Paisley, UK) for 5 minutes at room temperature. Beads were then 
washed twice with 0.5% BSA in PBS, following resuspension in 500 µl of 0.5% BSA 
in PBS and rotated for 1 hour at room tempareture to block non specific epitopes 
binding. Beads coated with ChIP grade TFAP2A and the IgG control beads were 
used at a 1:500 dilution for each chromatin sample. Beads were incubated with 
appropriate antibodies for 1 hour at room temperature whilst rotating. During 
the bead preparation phase chromatin samples were prepared for overnight 
incubation with the specific antibody coated beads. Samples were spun down by 
centrifugation at 2000 g for 5 minutes at 4oC. The chromatin rich supernatants 
were collected and the debris discarded. Protein concentrations of chromatin 
samples were measured and 500 µg used for each ChIP or input prep (untreated 
total chromatin from sonicated starting material). Beads were added to 
chromatin samples and incubated overnight at 4oC whilst rotating.  
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The next day ChIPs were washed twice with IPDB buffer, once with a high salt 
wash (20 mM Tris, 1 mM EDTA, 1% Triton X-100, 0.01% SDS, and 500 mM NaCl, 
final pH8.0, once with IPWB2 buffer (10 mM Tris, 1 mM EDTA, 1% Triton X-100, 
1% NP40, 1% Na-DOC, and 250 mM LiCi, final pH8.0, and finally two TE washes 
(10 mM Tris and 1 mM EDTA, final pH 8.0). The second TE wash was not 
aspirated off as each ChIP was then split in to two new tubes and treated for 
either DNA purification or protein purification.  
3.3.7.5 DNA purification (Chelex method) 
All ChIP samples, IgG samples and Input (total, 1%, and 10%) were DNA purified 
using the chelex method: samples were placed on the magnetic column and the 
TE was carefully aspirated off from the beads. 50 µl of 10% Chelex-100 (BioRad, 
Hemel Hempstead, UK), was added and the sample vortexed then heated to 97oC 
for 15 minutes. Chelex-100 acts as a chelating reagent to purify the DNA via ion 
exchange; it protects the DNA during heating by binding to Mg2+ in the extract 
to release it from the chromatin complex without degradation. 450 µl of 
nuclease free water was added to the bead/Chelex-100 mixture and vortexed 
once more, and the tube returned to the magnet. The supernatant was collected 
and ready for QPCR.  
3.3.7.6 Protein purification 
Protein purification was carried out on the other half of the sample for 
downstream analysis by western blot. This procedure required eluting the ChIP 
material from the beads and reversing crosslinked covalent bonds introduced by 
the formaldehyde treatment. Both aims were achieved by incubating the 
samples in 4 X SDS sample buffer to a 1 x final concentration: 40% glycerol, 240 
mM Tris pH6.8, 8% SDS, 0.045 bromophenol blue, and 5% beta-mercarptoethanol 
and heating to 97oC for 5 miuntes. The sample buffer is added to solubilise the 
protein and heated to denature the protein. Tubes were placed on the magnetic 
rack and the supernatant collected. 5 µl of 1 M DTT (Dithiothreitol) was added 
and samples incubated for a further 5 minutes at 97oC. The sample was then 
ready for SDS-PAGE and western blot.  
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3.3.7.7 Analysis by QPCR  
Quantitative PCR was carried out on ChIP-enriched DNA using Power SYBR® green 
master mix (Life Technologies, UK). The master mix contained: SYBR® green I 
DYE, AmpliTaq Gold® DNA polymerase, dNTPs, and ROX passive reference dye. 
The SYBR green dye binds to double stranded DNA providing a fluorescent signal 
that reflects the amount of double stranded DNA product generated during PCR 
in relationship to the internal reference dye ROX. Fluorescence was monitored 
on an Applied Biosystems 7900HT Sequence Detection System (Taqman®). The 
subsequent primer pairs were used for QPCR covering the region of interest; 5’ 
CACTTGGACACAGGAAGGG 3’ and 5’ CAAGTTAATGGGTGCAGC 3’ (TFAP2A sense 
and anti sense respectively). Reaction mixtures and cycling conditions are listed 
below: 
Reaction Mix Volume (µl) 
 
2X Power SYBR® Green PCR 
master mix 
 
25  
Forward primer 
Reverse primer 
Xµl (50 nM) 
Xµl (50 nM) 
Template Xµl (50 ng) 
Nuclease Free water  variable depending on DNA concentration 
  
Total Reaction Volume  
 
50 
 
 
Melting curves were performed to assess the dissociation of the double stranded 
DNA and to detect non-specific amplification of QPCR runs. ChIP enrichment was 
determined for IP samples, IgG samples, Input samples (total, 1%, and 10%), and 
non template controls for the region of interest in triplicate from three 
independent biological replicates.  
Temperature cycling:
Heat Cycle Time
95oC 10 min (Hold)
95oC 15 sec (denature)
60oC 1 min
X 40 cycles
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3.3.7.8 Analysis by Western blot  
To validate successful immunoprecipitation protein extracts from ChIP samples, 
IgG samples, and input (1%) where immunoblotted as per section 2.8 using the 
ChIP grade TFAP2A primary antibody (Rabbit monoclonal to TFAP2A, Abcam, 
Cambridge, UK). It was not necessary to quantify protein band density here as 
blotting was to determine pull down TFAP2A within the chromatin.    
3.3.7.9 Data normalisation 
The ChIP and QPCR procedure consists of many steps that may influence the 
final results, therefore, before the data obtained can be interpreted the 
variation must be considered. The QPCR data were normalised for differences in 
the amount of input chromatin, precipitation efficiency, and recovery of DNA 
after ChIP. Normalization only served to correct for technical variation and not 
biological variation. There is no consensus on how to normalise ChIP-QPCR in the 
literature and as a result there are multiple methods being used (Table 3-1).    
Table 3-1 Assay dependent ChIP normalisation strategies 
Normalisation strategy Normalisation method 
 
No normalisation 
 
ChIP data is not normalised, equal 
amount of input chromatin varies 
between experiment 
Background subtraction No-antibody signal is subtracted from 
ChIP signal 
Fold enrichment Normalised to background signal 
% of Input Normalised to the amount of input 
chromatin 
Relative to control genes Normalised to ChIP signal obtained at a 
control sequence 
Relative to nucleosome density  Normalised to the ChIP signal obtained 
with an antibody for modified histone 
protein 
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In this project, % of input method was used, where the QPCR signals derived 
from the ChIP are divided by the QPCR signals derived from 1% input taken after 
sonication during the ChIP assay. With this method, the input samples represent 
the amount of total chromatin used in the ChIP. Typically 1% input of starting 
chromatin is used as input. To calculate percent input the following calculations 
are used: 
Step 1: Adjust 1% input to 100%.  
Raw Ct (Ct Input – 6.644) 
The starting input fraction is 1%, which is a dilution factor of 100 which equates 
to 6.644 cycles. This is then subtracted from the Ct value of the diluted input. 
Step 2: Percent Input.  
Triplicate average Ct100*2^ (Adjusted input – Ct (IP)  
The above calculation was also used to determine IgG ChIp samples.   
3.3.8 Transient transfection of small molecules 
To assess the effect of transcription factor (TFAP2A) binding on SNP rs4997081 
and promoter activity, transient siRNAoligo-mediated gene silencing was 
performed in HeLa cells following transfection with the 2 Kb UMOD promoter 
constructs (ACHN, 786-0, and TK10). HeLa were cultured and transfected using 
Lipofectamine®2000 (Invitrogen, Paisley, UK) in 24 well plates, and all reactions 
were performed in triplicate. Cells were seeded at a density of 1 X 105 per well 
using normal growth media (2.6) and incubated at 37oC for 24 hours. The next 
day luciferase plasmids containing the contrasting genotype 2Kb UMOD promoter 
sequences were transfected into the HeLa cell cultures (2.3.7) and once again 
incubated at 37oC overnight. On day three siRNA was prepared for transfection 
by dilution in Optimem® (Invitrogen, Paisley, UK). Constituents of the 
transfection reaction per well on a 24 well plate are as follows: 500 µl 
Optimem®, 50 nM siRNA (TFAP2A siRNA, CyTM3 negative control, or GAPDH 
(Invitrogen, Paisley, UK)), and Lipofectamine®2000 at a 3:1 ratio 
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(Lipofectamine®2000: siRNA) and incubated over night at 37oC. Following the 24 
hour silencing period normal growth media replaced the transfection mix on cell 
cultures for 4 hours. Cell lysates were then collected and promoter activity 
assays performed (3.3.4). Additional plates were set up in parallel to the above 
experiment to collect cell lysates for RNA (2.3.8) isolation.  
The optimum conditions for transient delivery of TFAP2A siRNA into HeLa cells 
was assessed using siRNA that targeted GAPDH and CyTM3, as positive and 
negative controls respectively. Each siRNA were transfected separately into 
HeLa cell cultures as described above at the following concentrations: 5 nM, 10 
nM, 15 nM, 20 nM, 30 nM, 50 nM, and 100 nM. RNA was isolated and GAPDH and 
TFAP2A measured by qRT-PCR (2.4.1) with Applied biosystems Taqman assay 
probes (NM_002046.3, NM_002046.3, and X03205.1; GAPDH, TFAP2A, and 18s 
respectively).   
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3.4 Results 
3.4.1 Human UMOD promoter constructs 
Successful sub-cloning of the promoter fragments are demonstrated by 
endonuclease restriction digest shown in Figure 3-2 the “dropped” fragments 
represent the 1 and 2Kb promoter region fragments. The corresponding 1 Kb and 
2 Kb sequencing chromatograms are shown in Figure 3-3. Alignments of 
polymorphisms in the human UMOD promoter (1 and 2 kb) from Figures 3-2 and 
3-3 have been outlined in Table 3-2. A schematic outline of the SNPs contained 
in the 1 and 2 Kb human promoter constructs are shown in Figure 3-4 A. The 
polymorphisms in red represent the SNPs in linkage disequilibrium (LD) with 
rs13333226 and the polymorphisms in blue represent the SNPs not in LD with 
rs13333226 Figure 3-4 B.  
3.4.2 Transcriptional activity of the UMOD promoter  
The transcriptional activity of the 1 and 2 Kb human UMOD promoter SNPs were 
assessed as per 3.3.4. Relative promoter activity of the 1 Kb constructs of 
contrasting genotype for rs13333226 did not show any significant differences in 
transcriptional activity when measured in HeLa (Figure 3-5 A), NRK (B), Hek293 
(C), or HK-2 (D) cells. However, relative promoter activity was consistently and 
significantly increased in the TK10 2Kb promoter construct in all cell types 
(Figure 3-5) (4.5, 18, 17, and 6 fold change in; HeLa, NRK, Hek293, and HK-2 
cells respectively, ***p<0.0001). This indicates that the TK10 construct (of AA 
genotype for the index SNP rs13333226) harbours the risk allele associated with 
altered UMOD promoter activity and/or expression (Figure 3-6). One SNP is in LD 
with rs13333226, the C allele at position 20325634 (rs4997081). The other SNPs 
are the A alleles at position 20365697 (rs12708631) and 20365843 (rs18444928) 
which are not in LD with rs13333226.  
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Figure 3-2 1% Agarose gel image of UMOD promoter sub-cloning into pLG4.10 luciferase 
vector.  
Amplification of 1 Kb and 2 Kb promoter sequences from ACHN (GG), 786-0 (AA), and 
TK10 (AA) cell types, were double digested from the pGL4.10 basic luciferase plasmid 
with SacI and HindIII restriction enzymes. Undigested pGL4.10 basic luciferase plasmids 
are shown as uncut plasmid. The Control plasmid is pGL4.10 basic luciferase backbone 
containing an unrelated random 2 Kb insert. DNA was loaded at 1 µg per lane (plasmids 
were confirmed with sequencing). 
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Figure 3-3 Chromatogram display of 1 Kb and 2 Kb SNPs in the UMOD promoter (sense 
strand).  
Sequencing confirmed the presence of SNPs in the promoter region. The UMOD gene is 
present on the anti sense strand, thus the SNPs presented in this figure are designated 
from the reverse and complement strand. 
 
 
 
 
 
 
 
 
ACHN (GG) 1Kb and 2Kb 
G C
786-0 (AA) 1Kb and 2Kb 
A T
TK10 (AA) 1Kb and 2Kb   
A T
G               T             T G
G               T             T             G
A               A T             C
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Table 3-2 Promoter alignment and position of polymorphisms within the 1 and 2 Kb human 
UMOD promoter. 
 
Promoter 
region 
 
Polymorphism 
 
 
Position 
 
Ensembl 
ID 
 
Allele 
 
1Kb 
 
C/T 
 
16:20364588 
 
rs4293393 
 
G/A 
 
1Kb 
 
A/G 
 
16:20365012 
 
rs28362063 
 
T/C 
 
2Kb 
 
G/C 
 
16:20365234 
 
rs4997081 
 
G/C 
 
2Kb 
 
T/C 
 
16:20365654 
 
rs13333226 
 
A/G 
 
2Kb 
 
T/A 
 
16:20365697 
 
rs12708631 
 
T/A 
 
2Kb 
 
G/A 
 
16:20365843 
 
rs184444928 
 
T/A 
 
The exact location of the SNPs can be mapped to chromosome 16 upstream in the 
UMOD promoter using the Ensembl database. 
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Figure 3-4 Schematic summary of SNPs within the 1 and 2 Kb UMOD promoter region.  
(A) There are 6 currently known SNPs within the 2 Kb human UMOD promoter region. (B) 
Three human renal cell lines (786-0 (AA), TK-10 (AA), and ACHN (GG)) of contrasting 
genotype for the SNP of interest (rs13333226) were used in this project to represent the 
UMOD promoter regions for testing transcriptional activity of the incorporated SNPs. The 
UMOD gene is present on the anti sense strand, thus the SNPs presented in this figure 
are designated from the reverse and complement strand. 
 
 
11 10 9 8 7 6 5 4 3 2 1
Key Coding region (exon) 
Untranslated region
5’3’
20,364,122 bp - 20,366,122 bp
3’ 5’
rs184444928rs12708631rs1333226rs4997081
rs28362063rs4293393
2Kb UMOD promoter 
region
1Kb UMOD promoter 
region
A.
B.
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Figure 3-5 Transcriptional activity of the 1 and 2 Kb human UMOD promoter constructs. 
Transcriptional activity of contrasting genotype of SNP rs13333226, was assessed in (A) 
HeLa, (B) NRK, (C) Hek293, and (D) HK-2 cells, using luciferase activity assays 
(representative graphs). An increase in luciferase levels implicates altered promoter 
activity. Cells were seeded at 1x105 on day one. Transient transfection was performed on 
day two (1µg total plasmid (1:50 ratio; renilla:DNA)). Luciferase activity assays were 
performed on day three. Mean ratio ± SEM (normalised to Renilla), one way ANOVA 
followed by Tukey’s post hoc test, n=3 (independent technical replicates), ***p<0.0001. 
 
 
 
***
***
***
***
A. B.
C. D.
.
. .
.
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Figure 3-6 Three implicated functional SNPs in the 2 Kb UMOD promoter region.  
rs4997081, rs12708631, and rs184444928 are implicated as risk alleles associated with 
altered UMOD promoter activity predicted to increase/alter UMOD expression levels. The 
UMOD gene is present on the anti sense strand, thus the SNPs presented in this figure 
are designated from the reverse and complement strand. 
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3.4.3 Site directed mutagenesis of the 2Kb UMOD promoter 
region 
Site directed mutagenesis was performed (section 3.3.5) to assess transcriptional 
activity of each of the three implicated functional SNPs associated with 
enhanced UMOD promoter activity. The implicated SNPs from the promoter 
activity assays were introduced into pGL4.10 luciferase vectors by site directed 
mutagenesis creating three new novel promoter constructs (construct 1, 2, and 
3) outlined in Figure 3-7 (A and B). The 2Kb construct of AA genotype for SNP 
rs13333226 from the cell type 786-0 was used as the ‘wild type’ construct as this 
promoter region sequence did not have altered promoter activity during the 
luciferase assays between the 1 Kb and 2 Kb constructs. Luciferase promoter 
activities of the wild type (786-0), construct 1 (G to A allele change), construct 2 
(T to A allele change), and construct 3 (G to C allele change) were compared by 
transfection into HeLa, NRK, Hek293, and HK-2 cells (Figures 3-7 C-F). Relative 
promoter activities were measured 24 hours after transfection. The luciferase 
assays reveal that SNP rs4997081 results in significantly increased promoter 
activity in HeLa (7.5, 15, and 3 fold change; construct 3 vs. WT, construct 1, and 
construct 2 respectively ***p<0.0001), NRK (20, 4.5, and 3 fold change; construct 
3 vs. WT, construct 1, and construct 2 respectively, ***p<0.0001), Hek293 cells 
(10, 7.8, and 1.75 fold change; construct 3 vs. WT, construct 1, and construct 2 
respectively, ***p<0.0001), and in HK-2 cells (14.4, 4.6, and 4.4 fold change; 
construct 3 vs. WT, construct 1, and construct 2, ***p<0.0001). 
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Figure 3-7 Assessment of SNPs rs184444928, rs12708631, and rs4497081 in the 2Kb UMOD 
promoter region.  
(A) The schematic outline of the novel promoter constructs derived from site directed 
mutagenesis. (B) Corresponding chromatographs confirming successful site directed 
mutagenesis (construct 1, 2, and 3 respectively). Comparison of the three implicated 
SNPs in the 2 Kb promoter construct of TK-10 origin (AA genotype for SNP rs13333226) 
(C1) HeLa, (C2) NRK, (C3) Hek293, and (C4) HK-2 cells (representative graphs). Cells 
were seeded at 1x105 on day one. Transient transfection was performed on day two (1µg 
total plasmid (1:50 ratio; renilla:DNA)). Luciferase activity assays were performed on day 
three. Mean ratio ± SEM (normalised to Renilla), one way ANOVA followed by Tukey’s 
post hoc test, n=3 (independent technical replicates), ***p<0.0001, **p<0.001 (all 
comparisons against WT construct), ƚp<0.001 (construct 2 and 3 vs. construct 1) 
#p<0.001 (construct 3 vs. construct 2). The UMOD gene is present on the anti strand the 
SNPs presented in this figure are designated from the reverse and complement strand. 
G T T G A T
786-0
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Construct 2
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A T T G A T
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G T T C A T
A.
B.
C1. C2.
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ƚ
#
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#
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3.4.4 Transcriptional Element Search Software (TESS) analysis 
In Silico analysis of the 2 Kb promoter constructs with TESS software (section 
3.3.6), predicted 9 putative transcriptional binding sites for the G allele on the 2 
Kb ACHN and 786-0 constructs. Whereas, only 8 were identified for the 
contrasting C allele on the 2 Kb TK10 promoter construct. Moreover, all 8 
predicted transcriptional binding sites were identical for the C and G alleles with 
one exception, TFAP2A (Transcriptional factor also known as AP-2 alpha) 
suggesting this transcription factor may interact with a specific SNP genotype in 
the UMOD promoter (Table 3-3). To date there are no known transcription 
factor binding sites on UMOD promoter SNPs therefore Figure 3-8 outlines the 
predicted transcription factor binding sites of rs4997081 dependant on genotype. 
 
3.4.5 Ingenuity pathway analysis (IPA) of TFAP2A. 
We explored potential connections between UMOD and TFAP2A using IPA. The 
exploration for putative transcriptional factor binding elements harboured by 
the UMOD promoter polymorphism (rs4997081), revealed that TFAP2A may signal 
downstream of TNF-a altering UMOD expression (Figure 3-9). IPA therefore 
generated the hypothesis that in the absence of binding of rs4997081 at the C 
allele to TFAP2A may result in altered UMOD expression via downstream 
signalling to TNF-α. Figure 3-9 suggests a negative feedback loop that regulates 
UMOD expression levels that needs biological follow up.  
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Table 3-3 Differential putative transcriptional binding sites present in the UMOD promoter. 
C allele transcription binding sites 
(TK10) 
G allele transcription binding sites 
(ACHN/786-0) 
 AP2-alpha (TFAP2A) 
Sp1 Sp1 
MAZ MAZ 
T-Ag T-Ag 
CTCF CTCF 
GAL4 GAL4 
AML1c AML1c 
GCR1 GCR1 
GAGA GAGA 
TFAP2A is an additional transcription factor of the G allele of rs4997081 that is absent on 
the haplotype of contrasting genotype (C allele of rs4997081) 
 
 
Figure 3-8 Genotype dependant binding of rs4997081 to TFAP2A 
 
 
 
Sp1 MAZ CTCFT-Ag GAL4 AML1cAP2-α
(TFAP2A)
GCR1 GAGA
rs4997081 (G allele)
Sp1 MAZ CTCFT-Ag GAL4 AML1c GCR1 GAGA
rs4997081 (C allele)
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Figure 3-9 Connections of UMOD with TFAP2A  
A simplified signalling network pathway, obtained using IPA systems, represents a 
suggested molecular association between UMOD promoter variation and TFAP2A 
signalling. The signalling network pathway demonstrates a biologically plausible negative 
feedback loop that alters UMOD expression and potential molecular pathways to 
functionally follow up. The continuous orange line represents direct connections between 
UMOD and TNF-α known in the literature. The dashed orange line represents potential 
mechanisms demonstrated in the literature. Abbreviations and numbers under the 
continuous or dashed line represent the relevant publications associated with the 
pathway. 
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3.4.6 ChIP assay  
As TESS analysis predicted altered putative transcriptional binding to rs4997081 
dependant on genotype, potential TFAP2A binding to SNP rs4997081 was 
assessed by ChIP in HeLa cells (positive control), ACHN, 786-0, and TK10 cell 
lines, all of which endogenously express the transcription factor. The resolution 
obtained by the ChIP procedure is determined by fragment size of the chromatin 
sample used as input material. Sonication was optimised and achieved as per 
section 3.3.7.3. The differences between genomic DNA (from control cells 
(HeLa) and cell lines of interest (ACHN, 786-0, and TK10), with and without 
sonication is detailed in Figure 3-10.  
Following ChIP, no enrichment was observed at approximately 50 kDa in the pull 
down for TK10 cell types compared with HeLA, ACHN, and 786-0, confirming that 
the C allele on TK10 cell types is not a direct target for TFAP2A binding (Figure 
3-11).  
ChIP analysis by QPCR confirmed TFAP2A binding to SNP rs4998071 on the G 
allele on HeLa, ACHN, and 786-0 cell types, all of which exhibited significant 
enrichment compared to an IgG control (% input of enriched chromatin samples 
are as follows; HeLa; 0.16% vs. 1.52%, p<0.001, ACHN; 0.23% vs. 0.99%, p<0.001, 
and 768-0; 0.075 vs. 0.53%, p<0.01 (IgG vs. chromatin samples respectively). 
TK10 was not significantly different from the IgG control (0.29% vs. 0.39%, IgG 
vs. chromatin sample, p=0.5). All ChIP samples were significantly different from 
the experimental positive control (HeLa chromatin) (Figure 3-12).  
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Figure 3-10 Hydrodynamic shearing of Input. 
Electrophoresis demonstrates optimal fragmentation following sonication as the bulk of 
the chromatin has been sheared to a length between 500 and 250 bp (right hand panel, 
samples denoted as H; HeLa, A; ACHN, 7; 786-0, and T; TK10). To confirm optimum 
shearing conditions, some samples were not sonicated and whole chromatin 
electrophoresed (left hand panel), revealing larger chromatin fragment sizes.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Unsonicated
H A 7 T
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Figure 3-11 Chromatin ImmunoPrecipitation (ChIP) analysis for putative TFAP2A binding 
sites on the 2 Kb UMOD promoter SNP rs4997081.  
Pre-cleared chromatin from HeLa, ACHN, 786-0, and TK10 cells were immunoprecipitated 
with either non-specific IgGs or anti-TFAP2A. (A) Immunoprecipitated DNA or non-
immunoprecipitated chromatin samples (input) were tested for enrichment by western blot 
and (B) amplified by PCR using primers designed across the TFAP2A potential binding 
site at SNP rs4997081. Both methods confirm enrichment of TFAP2A in HeLa, ACHN, 
and 786-0 cell types. TK10 cells do not show enrichment for TFAP2A at position 
16:20365234. 
HeLa ACHN
786-0
TK10
HeLa
ACHN
786-0
TK10
A. 
B. 
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Figure 3-12 In vitro validation of TFAP2A as a potential regulator of UMOD promoter activity.  
Immunoprecipitation of chromatin from HeLa, ACHN, 786-0, and TK10 revealed 
enrichment of TFAP2A on the UMOD promoter only at position 16:20365234 on the G 
allele, the C haplotype does not display binding to the transcription factor (Data represent 
the mean of three biological replicates expressed as % input ± SEM). ChIP chromatin vs. 
IgG ***p<0.001, **p<0.001. HeLa chromatin vs. ACHN, 786-0, and TK10 chromatin 
‡p<0.05, ‡ ‡p<0.001.  
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3.4.7 Optimisation of siRNA Transfection in HeLa cells 
Prior to assessing TFAP2A binding on promoter activity, optimisation of 
endogenous knock down of the transcription factor with siRNA was performed as 
per section 3.3.8. Suitability of the transfection conditions for siRNA delivery to 
ACHN, 786-0, and TK10 cells was assessed using a positive control siRNA targeted 
against GAPDH and a negative control of Cy3TM labelled siRNA. Following 
transfection of the pGL4.10 luciferase plasmid and siRNA, RNA was isolated; and 
subsequent TFAP2A and GAPDH mRNA levels measured. Cy3TM labelled siRNA 
transfection at a range of 0-100 nM concentrations had no effect on TFAP2A 
mRNA expression levels in ACHN (7.4%), 786-0 (7.7%), or TK10 (5.3%) cell types 
(average % change over the range of concentration doses compared to non 
treated cells) (Figure 3-13). GAPDH-specific siRNA transfection at a final 
concentration of 100 nM resulted in efficient (>60 %) knock down of GAPDH in all 
cell types compared with non treated cells (ACHN; 62 %, 786-0; 64 %, and TK10; 
63.3 % knockdown) (Figure 3-14). Similarly, TFAP2A-specific siRNA transfection 
resulted in an efficient knock down of TFAP2A mRNA levels at a final 
concentration of 50 nM  in all cell types compared to the non treated cells 
(ACHN; 61 %, 786-0; 59 %, and TK10; 59 % knockdown) (Figure 3-15). 
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Figure 3-13 Cy3TM labelled transient transfection optimisation into HeLa cells containing 
human 2Kb UMOD promoter constructs.  
(A) HeLa cells containing the 2 Kb ACHN plasmid, (B) HeLa cells containing the 2 Kb 
786-0 plasmid, or (C) HeLa cells containing the 2 Kb TK10 plasmids were transfected with 
a scrambled negative control siRNA (Cy3TM labelled) (final concentration range of 0-100 
nM). TFAP2A mRNA was analysed 24 hours post transfection by qRT-PCR. Cycle 
threshold values were normalised to the cycle threshold of β-actin mRNA giving rise to the 
delta cycle threshold (dCt) where increasing dCt represents reduced expression. The 
mean of three independent biological experiments performed in triplicate, error bars 
represent SEM. Each condition of increasing concentration of siRNA was analysed 
against the non treated cells using a Student’s T-Test where p<0.05 was considered 
significant. 
 
 
 
 
 
 
 
 
(A) (B) 
(C) 
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Figure 3-14 GAPDH-specific siRNA transient transfection optimisation into HeLa cells 
containing human 2Kb UMOD promoter constructs. 
(A) HeLa cells containing the 2 Kb ACHN plasmid, (B) HeLa cells containing the 2 Kb 
786-0 plasmid, or (C) HeLa cells containing the 2 Kb TK10 plasmid were transfected with 
a GAPDH-specific siRNA positive control siRNA (final concentration range of 0-100 nM). 
TFAP2A mRNA was analysed 24 hours post transfection by qRT-PCR. Cycle threshold 
values were normalised to the cycle threshold of β-actin mRNA giving rise to the delta 
cycle threshold (dCt) where increasing dCt represents reduced expression. The mean of 
three independent biological experiments performed in triplicate, error bars represent 
SEM. *p<0.01, **p<0.001 compared to non treated cells using a Student’s T-Test where 
p<0.05 was considered significant. 
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Figure 3-15 Transient transfection of TFPA2A-specific siRNA into HeLa cells containing 
human 2Kb UMOD promoter constructs. 
(A) HeLa cells containing the 2 Kb ACHN plasmid, (B) HeLa cells containing the 2 Kb 
786-0 plasmid, or (C) HeLa cells containing the 2 Kb TK10 plasmid were transfected with 
a TFAP2A-specific siRNA (final concentration range of 0-100 nM). TFAP2A mRNA was 
analysed 24 hours post transfection by qRT-PCR. Cycle threshold values were 
normalised to the cycle threshold of β-actin mRNA giving rise to the delta cycle threshold 
(dCt) where increasing dCt represents reduced expression. Transfection with 100 nM 
concentrations of TFAP2A-specific siRNA resulted in undetermined ct values by QRT-
PCR. The mean of three independent biological experiments performed in triplicate, error 
bars represent SEM. *p<0.01, **p<0.001 compared to non treated cells using a Student’s 
T-Test where p<0.05 was considered significant. 
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3.5 UMOD Promoter activity following knockdown of 
TFAP2A 
Following transient TFAP2A silencing, functional validation of potential 
transcription factor binding to SNP rs4997081 was assessed. Transfection of 
Cy3TM labelled siRNA had no effect on the increased promoter activity of the 
TK10 construct (14 and 12 fold increased compared to ACHN and 786-0 
respectively, ***p<0.0001) (Figure 3-16). Conversely, the increased reporter 
activity of the TK10 construct was repressed by 12 fold in the absence of TFAP2A 
(Figure 3-16).  
 
 
 
 
Figure 3-16 Promoter activity following knockdown of TFAP2A 
Cy3 labelled transfection did not alter promoter activity of the 2 Kb TK10 construct 
(shaded bars). Silencing of TFAP2A in HeLa cells (transfection with the 2 Kb UMOD 
promoter sequences of contrasting genotype for rs13333226 (ACHN, 786-0, or TK10)), 
reduced reporter activity of the 2 Kb TK10 promoter construct, suggesting indirect effects 
of binding or inefficient binding to SNP rs4997081 on promoter activity. Three independent 
experiments were performed and the representative graphs are shown. Mean ratio ± SEM 
(normalised to Renilla), one way ANOVA followed by Tukey’s post hoc, n=3 (independent 
technical replicates), ***p<0.0001. 
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3.6 Discussion  
The experiments conducted in this chapter combined the use of experimental 
and computational analysis to determine causal variants within the 2 Kb 
promoter (cis-acting) region of the human UMOD gene. Sequencing the 2 Kb 
UMOD promoter confirmed 3 previously identified SNPs in LD with rs13333226 
(rs4293393, rs28362063, and rs4997081) and 2 SNPs not in LD (rs12708631 and 
rs184444928). SNPs rs4293393 and rs28362063 have formerly been examined in 
association with kidney disease and hypertension (Gudbjartsson et al., 2010, 
Kottgen et al., 2010), but to date the SNPs rs4997081, rs12708631, and 
rs184444928 have not been investigated in relation to hypertension, prompting 
the investigation in this study of rs13333226 associated UMOD haplotypes. 
Promoter studies herein demonstrate that the 2 Kb UMOD promoter locus around 
rs13333226 is associated with altered promoter activity. From the haplotypes 
studied, it is clear that rs13333226 is not a causative SNP directly affecting 
function and does not account for observed difference in promoter activity. 
Increased promoter activity was identified in the 2 Kb TK10 construct of AA 
genotype for rs13333226. The promoter activity assay results in this chapter 
demonstrate the minor G allele of rs13333226 is associated with reduced 
transcript activity, consistent with findings from the GWAS, BRIGHT and 
HERCULES cohorts where this haplotype is associated with lower UMOD excretion 
and lower risk of hypertension (Padmanabhan et al., 2010). It is not an unusual 
finding that functionally implicated SNPs are not the casual variants. Previous 
studies have re-sequenced candidate genes identified by GWAS to identify rare 
genetic variants of potentially stronger association with phenotype than trait-
associated variants (Palmer and Cardon, 2005) and found that the increased 
GWAS signal was accounted for by SNPs in LD with the original implicated 
variants (Kottgen et al., 2012). Accordingly, this study required to consider 
whether rs13333226 is directly functional (i.e. could lead to the observed 
biology) or is it indirectly associated with other DNA sequence variants (LD SNPs) 
in the UMOD promoter.  
Site directed mutagenesis was performed to test the hypothesis that SNPs in LD 
with rs13333226 may be the casual variants associated with changes in promoter 
activity. The results implicated the minor C allele of SNP rs4997081 as 
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responsible for increasing transcriptional activity since additional implicated 
SNPs not in LD with rs13333226 did not alter promoter activity. To investigate 
this finding further, Transfac matrices were generated to list potential TF 
binding sites lost, created or affected by the C allele polymorphism of 
rs4997081. The Transfac analysis protocol used here demonstrated that the C 
allele of rs4997081 (2 Kb TK10 construct) has one less predicted putative TF 
binding site to that of the contrasting G allele (2 Kb ACHN construct). Nine 
predicted TF sites were linked with the G allele whereas only 8 were predicted 
to bind with the C allele; furthermore, the predicted TF sites were identical 
between the genotypes with the exclusion of TFAP2A on the C allele.  
TFAP2A is a transcription factor that can positively or negatively regulate the 
promoter activity of many genes involved in physiological and pathological 
processes such as development, cell growth, differentiation, proliferation, 
tumorigenesis, and apoptosis but is predominantly associated with pro-
inflammatory genes (Hilger-Eversheim et al., 2000, Orso et al., 2010) and G 
protein coupled receptors (Salanga et al., 2009). In the kidney, inflammatory G 
protein coupled receptors such as prostaglandin E2 (PGE2) predominate in the 
TAL and are activated by cyclooxygenase (COX) causing reduced NaCl 
reabsorption, and promotes natriuresis and diuresis (Breyer and Breyer, 2001). 
Ferreri and colleagues (Battula et al., 2012) reported that the COX2 mediated 
PGE2 synthesis in the TAL is constitutively produced by increased TNF-α 
expression which consequentially inhibits NKCC2 activity and Na+ reabsorption. In 
vivo, TNF-α infusion causes decreased GFR with increased fractional excretion of 
sodium, supporting previous studies that suggest the pro-inflammatory cytokine 
has natriuretic and diuretic actions at the TAL (Shahid et al., 2008a). There is 
evidence in the literature to suggest TNF-α signals downstream of TFAP2A 
exerting inflammatory events. Immunohistochemical examination of invasive 
breast cancer tissue indicated that TFAP2A acted as a tumor suppressor gene by 
inhibiting TNF-α induced inflammation and apoptosis (Gee et al., 1999), whereas 
Nyormoi et al reported more recently that TNF-α downregulates TFAP2A post 
transcriptionally by cleavage degradation during TNF-α induced inflammation 
(Nyormoi et al., 2001). TFAP2A was also shown to be differentially expressed in 
blood samples from pregnant patients with pre-term delivery caused by 
mechanisms of COX2 and TNF-α signalling (Enquobahrie et al., 2009). Thus, 
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despite conflicting results from published work there is evidence of a functional 
link between TFAP2A and TNF-α in inflammatory pathways that may be linked with 
enhanced natriuresis. 
The functional relationship of TFAP2A and TNF-α was also predicted in the 
current study by the pathway analysis software, where IPA revealed a possible 
negative feedback loop regulated by UMOD expression levels. As introduced in 
section 1.10.1.1 identification of GPI anchored enriched endocytic 
compartments have lead to the discovery that UMOD exerts its 
immunosuppressive affects by binding with high affinity to TNF-α. It is 
recognised that cytokine excretion is predominantly via the kidney and 
augmented levels of TNF-α at the TAL decrease Na+ and Cl- reabsorption 
(Escalante et al., 1994), suggesting the interaction between UMOD and cytokines 
may be critical in promoting clearance of TNF-α to maintain sodium regulation. 
There have been no direct links between Na+ reabsorption and TFAP2A published 
to date, however, TFAP2A is found in kidney tissue acting as a tumour suppressor 
(Dalgin et al., 2008) where it could be hypothesised as having functional roles in 
ion regulation. This hypothesis suggests variants in the UMOD promoter may give 
rise to altered or inhibitory effects on inflammatory cytokines suggesting a 
feedback loop involving TFAP2A binding and TNF-α signalling, affecting sodium 
transport. To examine this hypothesis a number of future functional studies are 
required to be undertaken to investigate if in the absence of binding of TFAP2A 
to the C allele leads to loss of function of native UMOD; or does it lead to gain of 
harmful functions of UMOD ?  
 
In the meantime and in attempt to address the functional consequences of 
TFAP2A binding on genetic control of transcription was assessed. Results 
illustrated by ChIP confirmed the absence of TFAP2A binding to the C allele, as 
lack of enrichment was evident in western blot analysis. This absence was 
consolidated further by experimental validation and quantification using QPCR, 
where enrichment was approximately 3.4 fold higher on the G allele of 
rs4998071 in ACHN cell types. To examine the enrichment functionally, transient 
transfection of siRNA to knock down expression of TFAP2A was performed and 
promoter activity re-assessed. It was expected that in the absence of TFAP2A 
binding to the C allele of rs4997081 (2 Kb TK10 construct) the knock down of the 
TF would have no effect on promoter activity of this haplotype and the 
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contrasting G allele haplotype (2 Kb ACHN and 786-0 constructs) would display 
increased promoter activity. Conversely, results here demonstrated reduced 
promoter activity of the C allele with no effect on the contrasting G allele.  
There are a number of reasons that may explain this finding: TFAP2A may not in 
fact be causing transcriptional changes to UMOD gene expression resulting in 
altered promoter activity, there may be indirect binding or inefficient binding to 
rs4997081 at the C allele driving enhanced promoter activity. Furthermore, 
there are SNPs in LD with rs13333226 and rs4997081 that extend beyond the 2 Kb 
region of the UMOD promoter, as a result future work should focus on 
investigating additional variants in promoter region. In addition, the initial 
putative TF binding predictions were based on in silico methods, which have 
been known to result in false positives. Nonetheless, in this chapter the ChIP 
analysis was consistent with in silico analysis in that TFAP2A did not bind to the 
C allele of rs4997081. Future work should focus on the other putative predicted 
TF binding sites of rs4997081 starting with those implicated with TESS software, 
as should SNPs in LD with rs13333226 in the 3 Kb promoter region as this 
promoter region has been shown to drive kidney specific function of UMOD (Zhu 
et al., 2002).  
Taken together the data demonstrates that the index SNP (rs13333226) is not a 
functional variant causing altered transcription, however the minor G allele of 
rs13333226 is associated with reduced promoter activity, consistent with the 
original GWAS study that this allele is associated with lower risk of hypertension. 
The evidence suggests that the C allele of rs4997081 leads to increased 
transcriptional activity and is a causal variant to follow up. TFAP2A was 
predicted and confirmed to be a putative TF binding site for the G allele of 
rs4497081. The increased promoter activity on the C allele of rs4997081 cannot 
be explained by the absence of TFAP2A binding as knockdown of the TF reduced 
promoter activity of the C allele and not the G allele as would have first been 
expected. However, this does not mean that the absent binding of TFAP2A to 
the C allele of rs4997081 is not involved in altered gene transcription because 
transient knockdown did result in reduced promoter activity of the C allele 
suggesting indirect effects of binding at the G allele on transcriptional activity. 
The subsequent chapters now consider the physiological role of UMOD in BP 
regulation and sodium homeostasis to elucidate the mechanisms of altered 
UMOD expression.   
 
 
4 Cardiovascular Phenotype of the UMOD+/+ and 
UMOD-/- mice 
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4.1 Introduction 
The role of UMOD has remained elusive for many years, although recent studies 
are now reporting its intra and extra cellular functions. The former being related 
to urinary concentrating mechanisms which disturb transcellullar electrolyte 
transport (Bachmann et al., 2005, Malagolini et al., 1997) whereas; the latter 
have been linked with anti-inflammatory properties of the glycoprotein (Bates et 
al., 2004, Mo et al., 2004, Schroter et al., 1993, Dahan et al., 2003). Insight into 
the proposed physiological roles of UMOD has been evaluated using UMOD-/- 
(KO) mice models, established independently by two groups. Bates et al (Bates 
et al., 2004) obtained successful knockout of UMOD by deletion of the first four 
exons, intervening first intron, and the 3 Kb gene promoter region. Whereas, Mo 
et al (Mo et al., 2004) deleted the first four exons and the 650 bp of the 
promoter region, both KO methods resulted in ablation of the transcriptional 
activity of the gene. To date there are no reported phenotypic differences 
between the two independently generated UMOD KO strains. 
Reports from these groups detail that UMOD deficiency predisposes knockout 
mice to frequent urinary tract infections and bladder colonization by type-1 
fimbrated E coli, demonstrating that UMOD acts as a general host defence factor 
against infection (Raffi et al., 2005, Raffi et al., 2009). It has also been shown 
that the KO mice spontaneously formed calcium oxalate stones primarily in the 
collecting duct and papillary regions (Mo et al., 2004) and display kidney injury 
due to increased levels of the pro-inflammatory cytokine TNF-α. This injury was 
accompanied by altered tubular expression of Toll like receptor 4 (El-Achkar et 
al., 2008), reinforcing the findings of extracellular functions of UMOD.  
In terms of intracellular roles of UMOD, steady state electrolyte handling in the 
KO mice is similar to the WT counterparts, however in terms of renal function; 
creatinine clearance has been shown to be significantly reduced in KO mice with 
urine concentration ability being impaired under water deprivation (Bachmann 
et al., 2005). The TAL is responsible for reabsorbing approximately 25% of 
filtered NaCl and plays an essential role in the generation of the medullary 
interstitial hyperosmolality. It has been suggested that UMOD could participate 
in the water impermeability at the TAL (Serafini-Cessi et al., 2003), accordingly 
a failure of this feature in KO mice would reduce NaCl reabsorption, decrease 
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the interstitial osmolality, and impair the urine concentrating ability potentially 
explaining manifestation of monogenic diseases that cause changes in BP. 
Intracellular examination of UMOD deficient mice did indeed show impaired 
urinary concentrating ability; with increased expression of the thiazide sensitive 
NaCl channel (NCC) in the distal convoluted tubule, suggesting a compensatory 
adaptation for putatively insufficient NaCl reabsorption in the TAL (Bachmann et 
al., 2005, Abdallah et al., 2001, Wagner et al., 2008). Biochemical and 
histological analysis has been used to assess changes in biosynthesis of proteins 
related to NaCl transport along the nephron in UMOD KO mice. Bachmann et al 
revealed upregulation of major distal transporters (Na+/K+ -ATPase, NKCC2, 
NHE3, ROMK, and ENaC) and downregulation of juxtaglomerular apparatus 
components (Bachmann et al., 2005). Further studies by this group, reported 
that the augmented total NKCC2 expression was in fact as a result of increased 
intracellular expression of NKCC2, where it remained unphosphorylated and 
inactive in UMOD-/- mice (Mutig et al., 2011b). This group also reported that in 
the absence of UMOD the reduced NKCC2 activity results in impaired NaCl 
reabsorption at the TAL, implying the permissive role of UMOD in the modulation 
of Na+ transport.  
Data collected thus far from UMOD-/- mice conclusively document the absence 
of any of the morphological defects observed in humans with UMOD associated 
kidney disease (UAKD). It seems a reasonable hypothesis that the physiological 
consequences of UAKD outlined in section 1.10.1.5, are a direct result of an 
altered in UMOD function at the TAL (Dahan et al., 2003, Rampoldi et al., 2003). 
Reports from the KO mice so far support the idea that absent or altered UMOD 
expression and function may be the pathological cause of altered ion transport 
contributing to hypertension. However, lack of cardiovascular characterisation 
and evidence of Na+ handling and transport studies in the UMOD -/- mice, the 
functional role of UMOD in blood pressure control and sodium homeostasis still 
remains elusive. The potential impact UMOD has on the ability to reabsorb NaCl 
at the TAL and the important role of pressure natriuresis on blood pressure 
control is investigated in this chapter in WT and KO mice to follow up the 
hypertension signal identified in the GWAS study (Padmanabhan et al., 2010). It 
is hypothesised that cardiovascular characterisation studies in the UMOD KO 
mice will demonstrate an altered cardiovascular phenotype. 
Chapter 4  161 
 
4.2 Aims 
• To assess hemodynamic parameters in the WT and KO mice under basal 
conditions and following cardiovascular stimulation with 2% NaCl. 
• Assessment of sodium balance and ion regulation in the WT and KO mice 
under basal and 2% NaCl loading. 
• Assessment of renal function in the WT and KO mice under basal 
conditions and following stimulation with 2% NaCl. 
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4.3 Methods 
4.3.1 Experimental Animals 
Experimental animals used in this project were produced by Bates et al as per 
section 2.9 (Bates et al., 2004). The strains used here were WT and KO where 
the knock out was confirmed with end point PCR (section 2.9). Throughout this 
chapter male mice of 12 weeks of age of were used for all procedures with the 
exception of tail cuff plethysmography where animals of 11 weeks of age 
onwards were studied. All mice used for experimental procedure were housed in 
individual cages in a temperature controlled room (24 ± 1 oC) at a constant 
humidity of 60 % (± 5 %), with light cycles from 6 AM to 6 PM. All mice were 
allowed access ad libitum to standard rodent chow (rat and mouse No.1 
maintenance diet, Special Diet Services) and normal tap water (normal salt). All 
procedures were performed in accordance with Animals (Scientific procedures) 
Act, 1986 and under the project licences held by Dr Delyth Graham (University of 
Glasgow, UK) (project license number 60/4286).  
4.3.2 Salt Challenge 
Male mice of both strains (WT and KO) were utilised at 12 weeks of age for salt 
loading studies. Mice were housed and maintained as above. Each strain was 
then grouped into either normal salt or high salt, giving rise to the following 4 
groups: WT normal salt, WT +2% NaCl, KO normal salt, and KO +2% NaCl. Animals 
received (ad libitum) either normal tap water or 2% NaCl in the drinking water 
for a six week period. Normal tap water was used to prepare 2% NaCl (w/v). 
4.3.3 Hemodynamic parameters  
4.3.3.1 Tail cuff plethysmography  
Tail cuff plethysmography technology is outlined in section 2.10.1. Male mice of 
11 weeks were studied over a 7 week period, week zero was performed as a 
training period for the animals to become familiarised with the procedure. The 
training period was used to reduce stress limiting factors by familiarising the 
mice with handling and pre-warming for vasodilatation. Data obtained in this 
period was not used in any statistical analysis. During the training week animals 
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were exposed to the procedure on 5 consecutive days. At week one, the mice 
were 12 weeks of age and the pressure recordings from the plethysmography 
procedure were now included. Salt loading also began on week one. On the day 
of procedure mice were pre-warmed to 32-35oC and maintained at this 
temperature throughout with heat mats. Mice were wrapped in a muslin cloth to 
restrain them during pressure recordings. For each animal averages of 10 
inflation/deflation cycles were conducted to obtain mean SBP. The procedure 
was performed over three consecutive days which represented one week of data 
and repeated the same days every week and at the same time of the day, until 
the study was completed. 
4.3.3.2 Radiotelemetry 
Male mice of 12 weeks of age (both WT and KO) were implanted with 
radiotelemetry probes to monitor hemodynamic parameters directly; the 
surgical procedure is outlined in section 2.10.2. Following the surgical procedure 
and once mice had regained consciousness, they were returned to individual 
cages and allowed one week recovery period before initiation of recording. The 
first BP study was termed “baseline” where hemodynamic parameters were 
monitored in WT and KO mice under normal salt conditions (n=6 per group). The 
baseline measurements were recorded over a 21 day period with cycles of 
scheduled sampling every 5 minutes over a 24 hour period. Averages of daytime 
(7:00 am – 7:00 pm) and night time (7:00 pm - 7:00 am) BP were recorded and 
data points displayed as daytime/night time averages. The second BP study was 
performed over a six week period where WT and KO (n= 8 per group) were 
subjected to cardiovascular stimulation with 2% NaCl in the drinking water and 
was termed “salt loaded”. Data here were generated from three consecutive 
daytime and night time averages and data points were represented as weekly 
daytime and night time averages. As the battery life of the radiotelemetry 
probes do not extend beyond 26 days, it is not possible to carry out a 
longitudinal continuous (real time) study for six weeks; therefore, probes were 
switched on for 3 full 24 hour cycles then off for the remainder of the week. 
This is the accepted way of showing long- term data with mouse telemetry 
(Carlson and Wyss, 2000, Zhao et al., 2011). This method was consistent with the 
tail cuff studies as BP was measured in the mice on three consecutive days each 
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week. Statistical analysis of radiotelemetry was performed using repeated 
measures ANOVA. 
 
4.3.4 Renal Function 
Renal function was assessed in WT and KO mice ± 2% NaCl at the end of the 6 
week study by means of metabolic cage measurements, creatinine clearance, 
and electrolyte analysis as outlined in sections 2.11.1, 2.11.2, and 2.11.3. Mice 
were placed in the metabolic cages for a 24 hour period, where fluid intake was 
monitored and urine was collected. Mice were individually placed in the 
metabolic cages for the 24 hour period.  
4.3.5 Ex vivo analysis 
At the end of the 6 week study all mice were of 18 weeks of age. The procedure 
was terminated as per section 2.12.1. Tissues were removed, cleaned of any 
connective tissue, and prepared for analysis. Body weight, kidney weight, and 
tibia length were recorded. All tissue weights were normalised to tibia length.  
Ex vivo investigation including; histological investigation, metabolic analysis, and 
microarray mRNA expression analysis which are detailed in section 2.12.  
 
4.3.6 Generalised Estimation Equation regression analysis (GEE) 
Generalised estimating equations (GEE) were used in this project to analyse 
longitudinal correlated response data in WT and KO mice following six weeks ± 
2% NaCl loading. The variables used in this study were; the correlation of SBP 
(mmHg) with, fluid intake (µl/24h), urine output (µl/24h), and electrolyte 
analysis (Na+, K+, and Cl- µmol/24h) in both mouse strains (± 2% NaCl). The main 
function of GEE analysis is to estimate the population averaged mean effect and 
the estimation of inferences of the regression coefficients in the model. In GEE 
models, the estimated regression coefficient represents the effect of the 
explanatory variables (SBP, fluid intake, urine output) on the population average 
effect of the response variables (electrolyte excretion). GEE describes the 
change in population mean given the changes in covariates after accounting for 
correlation between observations. The GEE regression co-efficient (β co-
efficient) is interpreted as change in mean outcome for a unit change of the 
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exposure in the entire population derived from General Linear Model statistical 
analysis (GLM), where p<0.05 is considered significant.  
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4.4 Results  
4.4.1 Cardiovascular phenotype (baseline blood pressure) 
Hemodynamic parameters were firstly, investigated in WT (UMOD+/+) and KO 
(UMOD-/-) mice under basal conditions using radiotelemetry (as described in 
section 4.3.3.2). Baseline hemodynamic parameters were measured over a three 
week period as daytime and night time daily averages, in male mice of 12 weeks 
of age in WT and KO strains (Figure 4-1). KO mice have significantly lower daily 
averaged day and night time systolic blood pressure (SBP) than WT counterparts 
under normal salt conditions (116.6 ± 0.3 mmHg vs. 136.2 ± 0.4 mmHg; KO vs. 
WT respectively, n=6 per group, *** p<0.0001 (Figure 4-1 A). However, daily 
averaged day and night time diastolic blood pressure (DBP) were not significantly 
different between the two strains (115 ± 1.4 mmHg vs. 113.7 ± 1.6 mmHg) (WT 
vs. KO) n=6 per group, p=0.34 (Figure 4-1 B). KO mice had significantly lower 
daily averaged daytime and night time mean arterial pressure (MAP) compared 
to the WT counterpart (125.5 ± 5.2 mmHg vs. 115.1 ± 5.7 mmHg, KO vs. WT 
respectively), n=6 per group, **p<0.001 (Figure 4-1 C). Daily averaged daytime 
and night time pulse pressure (21.9 ± 0.5 vs. 9.4 ± 0.2) (WT vs. KO) and heart 
rate (553.2 ± 5.2 bpm vs. 485.8 ± 2.5 bpm) (WT vs. KO) were also significantly 
different between the strains; n=6 per group, ***p<0.0001 (Figure 4-1 D and E). 
Although, activity levels were not different between WT and KO mice (3.9 ± 0.2 
vs. 3.7 ± 0.6, WT vs. KO respectively) n=6 per group, p=0.49 (Figure 4-1 F). 
Week one is a recovery period from the surgical procedure and was not included 
in the statistical analysis. 
 
4.4.2 Cardiovascular stimulation with 2% NaCl (Indirect blood 
pressure monitoring) 
Hemodynamic parameters were then assessed in WT and KO mice that had 
undergone cardiovascular stimulation over a six week period with 2% NaCl in the 
drinking water. During the 6 week period with 2% NaCl, SBP was measured by tail 
cuff plethysmography (section 4.3.3.1) in both mouse strains following salt 
loading (Figure 4-2). Salt loading significantly elevated SBP in WT mice from the 
third week onwards compared to non salt loaded controls, this elevation was 
distinctly increased at week 6 of the salt loading period; 136.2 ± 1.4 mmHg vs. 
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173.3 ± 2.9 mmHg (WT control vs. WT +2% NaCl, *** p<0.0001, n=10 per group) 
(Figure 4-2 A). However, salt loading the KO strain, over a 6 week period, did 
not significantly affect SBP (119.4 ± 3.1 vs. 126.2 ± 3.1 mmHg; KO control vs. KO 
+2% NaCl; week 6, n=10 per group) (Figure 4-2 B). 
 
4.4.3 Cardiovascular stimulation with 2% NaCl (Direct blood 
pressure monitoring) 
The difference in hemodynamic response to salt between WT and KO mice was 
confirmed by radiotelemetry (Figure 4-3). Salt loading significantly increased 
weekly daytime and night time average SBP WT mice compared to the KO strain 
(WT: 144.4 ± 6.3 mmHg vs. KO: 122.2 ± 7.0 mmHg), **p<0.001, n=8 per group, 
Figure 4-3 A. Weekly averaged daytime and night time PP was also significantly 
different between WT mice and the KO mice; n=8 per group, ***p<0.0001, Figure 
4-3 D. However, all other parameters measured including weekly averaged 
daytime and night time; DBP (p=0.88) (Figure 4-3 B), MAP (p=0.10) (Figure 4-3 
C), HR (p=0.06) (Figure 4-3 E), and Activity (p=0.25) (Figure 4-3 F), were not 
significantly different between the strains under 2% NaCl loading, n=8 per group.  
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Figure 4-1 Summary of WT (UMOD+/+) and KO (UMOD-/-) baseline hemodynamic parameters 
using radiotelemetry. 
Radiotelemetry probes were implanted in male WT and KO mice of 12 weeks of age to 
record baseline hemodynamic parameters over a three week period. Baseline 
hemodynamic parameters were measured as daytime and night time daily averages. (A) 
SBP, (B) DBP (C) MAP, (D) PP, (E) HR, and (F) activity recordings in WT and KO mice 
(***p<0.0001, **p<0.001), n=6 per group. Displayed as daily averaged daytime and night 
time Mean ± SEM. Week one was a recovery period following surgery and was not 
included in the analysis. Analysed with repeat measure ANOVA. 
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Figure 4-2 Summary of SBP from WT (UMOD+/+) and KO (UMOD-/-) mice by Tail cuff 
plethysmography. 
Non invasive tail cuff plethysmography was utilised to asses SBP in male WT and KO 
mice (±2% NaCl). Week zero represents the training period where data obtained was not 
used in any statistical analysis. At week one, the mice were 12 weeks of age and the 
pressure recordings were included in the analysis. Salt loading also began on week one. 
For each animal averages of 10 inflation/deflation cycles were conducted to obtain mean 
SBP. The procedure was performed over three consecutive days which represented one 
week of data and repeated the same days every week and at the same time of the day, 
until the study was completed. (A) Comparison of SBP in WT mice and (B) KO mice, 
control (non salt loaded mice) vs. 2% NaCl loaded. WT mice have increased SBP upon 
stimulation with 2% NaCl from week three onwards, whereas SBP in the KO mice is not 
affected by NaCl loading. Results displayed as weekly Mean ± SEM, n=10 per group, 
***p<0.0001. Analysed with Student’s T test. 
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Figure 4-3 Summary of hemodynamic parameters following administration of 2% NaCl in WT 
and KO mice measured by radiotelemetry. 
Radiotelemetry probes were implanted in male WT and KO mice of 12 weeks of age to 
record hemodynamic parameters in response to NaCl stimulation (2% NaCl in the drinking 
water). Hemodynamic parameters were measured over a six week period as daytime and 
night time weekly averages. (A and D) SBP and PP were significantly different between 
WT and KO mice (***p<0.0001, **p<0.001. (C- F) DBP, MAP, HR, and activity were not 
significantly different between the strains.  Displayed as weekly Mean ± SEM weekly 
daytime and night time averages, n= 8 per group. Hemodynamic parameters were 
recorded over a 6 week period where week one was a recovery period following surgery 
and was not included in the analysis. Analysed with repeated measure ANOVA. 
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4.4.4 Sodium Excretion 
Detailed analysis of fluid intake, urine output, body weight and urine 
electrolytes were performed at week 6 of the ± 2% NaCl to assess sodium 
excretion between WT and KO mice. (Figure 4-4). Fluid intake was increased in 
WT mice at week one and six of the salt loading period (week one; 5.3 ± 0.6 ml 
vs. 7.8 ± 1.1 ml; and week six; 6.4 ± 0.7 ml vs. 9.1 ± 0.9 ml; normal NaCl vs. 2% 
NaCl respectively, *p=0.02, n=10 per group). The KO mice showed increased fluid 
intake at weeks one, three, and five when treated with 2% NaCl (week one; 5.0 
± 0.8 ml vs. 8.1 ± 1.1 ml; week three; 5.4 ± 0.7 ml vs. 8.1 ± 0.4 ml and week 
five; 5.8 ± 0.6 ml vs. 9.3 ± 0.9 ml; normal NaCl vs. 2% NaCl respectively, 
*p=0.03, **p=0.005 and **p=0.009, n=10 per group) (Figure 4-4 A). Body weight 
was unchanged in WT mice on salt loading whereas KO mice + 2% NaCl had a 
lower body weight at weeks one (21.2 ± 0.5 g vs. 19.4 ± 0.2 g), two (21.6 ± 0.6 g 
vs. 19.3 ± 0.2 g), four (22.4 ± 0.9 g vs. 19.9 ± 0.3 g), five (22.0 ± 0.6 g vs. 20.1 ± 
0.3 g) and six (23.3 ± 0.8 g vs. 20.7 ± 0.4 g) (*p<0.05, **p<0.01, KO normal salt 
vs. KO +2% NaCl respectively, n=10 per group) (Figure 4-4 B).  
Sodium homeostasis was assessed further at week six of the salt loading period, 
by measuring urine output and urinary sodium excretion (Figure 4-5). Twenty 
four hour urine output was significantly increased in KO mice before and after 
salt loading compared to the WT counterparts, (45.7 ± 4.1 µl/g vs. 25.1 ± 6.7; 
KO vs. WT normal salt and 59.8 ± 5.8 µl/g vs. 36.4 ± 7.1 µl/g; KO vs. WT 
following six weeks of salt loading, *p<0.05, n=5 per group) (Figure 4-5 A). 
Urinary Na+ excretion was increased in KO mice following six weeks of salt 
loading compared to the non salt loaded controls (3.2 ± 0.6 µmol/24h/g vs. 27.7 
± 4.8 µmol/24h/g, ***p<0.0001, n=5 per group). WT mice also had significantly 
increased urinary sodium compared to the non salt loaded controls (2.4 ± 0.8 
µmol/24h/g vs. 10.1 ± 1.0 µmol/24h/g, **p<0.001, n=5 per group) however, KO 
salt loaded mice had a 2.7 fold increased Na+ in the urine compared to the salt 
loaded WT mice (Ɨp<0.0001, n=5 per group) (Figure 4-5 B). These findings 
remained when urinary Na+ (µmol/g) was corrected to urinary creatinine 
(µmol/g) (KO vs. all groups *p=0.01, n=5 per group and WT normal NaCl vs. WT 
+2% NaCl *p=0.02, n=5 per group) (Figure 4-5 C). All data was normalised to 
urine volume collected over a 24 hour period and kidney weight upon animal 
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sacrifice. Displayed as Mean ± SEM analysed with one way ANOVA followed by 
Tukey’s post hoc test. 
When adjusted for the salt affect using GEE analysis (section 4.3.6), urinary Na+ 
concentrations in the KO mice were consistently increased (516.8 µmol/d (95% CI 
256.6; 776.9 ***p<0.0001)) when salt loaded (2% NaCl) over a 6 week period 
compared to the WT mice, n=5 per group) (Table 4-2). In the GEE model, after 
adjusting for the salt effect, KO mice had an increased fluid intake of 1.1 ml/24 
h compared to WT animals (Table 4-3). The GEE analyses for urine volume and 
electrolytes at 6 weeks were adjusted for both salt and fluid volume intake to 
dissect strain specific effects. KO mice had significantly greater urine volume 
(548.3 ± 123.1 µl/24 h, **p<0.001, n=10 per group), as well as urine sodium, 
potassium and chloride excretion compared to WT mice (Table 4-2). The urinary 
Na+/K+ ratio was similar in both strains. However, in week 6, after adjusting for 
salt-intake, the average 24 hour urinary sodium excretion in KO mice was 
appreciably greater than observed for the WT strain (**p<0.001).  
The chronic renal function curves showed a left ward shift in SBP, MAP, and DBP 
KO mice compared to the WT strain (Figure 4-6). A left-ward shift in the renal 
function curve demonstrates that sodium is being excreted at a lower arterial 
pressure in the KO mouse. 
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Figure 4-4 Water balance in WT and KO mice ± 2% NaCl. 
Male WT and KO mice were housed in individual cages over a six week period where fluid 
intake and body weight was monitored on a daily basis. (A) Fluid intake was significantly 
increased at week 1 and 6 in WT mice when salt-loaded compared to the control WT 
animals (*p=0.02, n=10 per group). The salt loaded KO mice displayed increased fluid 
intake at weeks 1, 3 and 5 compared to the non salt-loaded control animals (*p=0.03, 
**p=0.005, and **p=0.009, n=10 per group). In addition to monitoring fluid intake, male WT 
and KO mice were weighed daily (B) Body weights were significantly reduced in KO mice 
at weeks 1, 2, 4, 5 and 6 of the salt loading period compared to the non salt loaded control 
(*p<0.05, **p<0.01). Body weights were unchanged in WT mice following salt loading. 
Results displayed as weekly Mean ± SEM analysed with unpaired Student’s T test. 
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Figure 4-5 Micturition and natriuresis in WT and KO mice under salt loading conditions.  
Male WT and KO mice were placed in metabolic cages at week six of the ±2% NaCl 
loading study for a 24 hour period. Urine was collected and measured. (A) Urine output 
was significantly increased in KO mice before and after salt loading compared to the WT 
mice (*p<0.05, n=5 per group). All data was normalised to body weight. Urine collected 
from the metabolic cages was then assessed for Na+ content (µmol/24h/g) using the 
indirect ion selective electrode method; potentionmetry. (B) Urinary Na+ was increased in 
WT and KO mice following six weeks of salt loading with 2% NaCl (** p<0.001 
***p<0.0001, n=5 per group) however the KO mice displayed a 2.7 fold increased 
natriuresis compared to the WT salt loaded mice (Ɨ p<0.0001, n=5 per group). Urinary Na+ 
concentrations were normalised to urinary creatinine concentrations (µmol/g). (C) 
Na+/creatinine ratio was significantly increased in WT mice upon salt loading (*p=0.02, 
n=5 per group). KO mice also displayed an increase Na+/creatinine ratio which was 
significantly higher than all other groups (*p=0.01, n=5 per group). All data was 
normalised to urine volume collected over a 24 hour period and kidney weight upon 
animal sacrifice. Both data sets are displayed as Mean ± SEM analysed with one way 
ANOVA followed by Tukey’s post hoc test. 
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Figure 4-6 Chronic renal function curves in WT and KO mice ± 2% NaCl.  
Chronic renal function curves for (A) SBP, (B) MAP, and (C) DBP. Curves were shifted to 
the left in KO mice compared to the WT strain. A leftward shift demonstrates an increased 
Na+ excretion in the salt loaded KO animals with no change in arterial pressure. Data 
residuals are plotted as Mean SBP, MAP, or DBP (mmHg) against 24 hour urinary Na+ 
excretion normalised to urine volume and kidney weight.  Each data point represents one 
animal n=8 per group. No statistical analysis was performed.  
 
 
A. B.
C.
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Table 4-1 Cardiovascular parameters measured by radiotelemetry in WT and KO mice during the 6th week of 2% NaCl loading. 
 
  
UMOD+/+ UMOD-/- GEE/GLM 
Period Variables Normal Salt High Salt Normal Salt High Salt Beta P 
Week 6 SBP (mmHg) 133.5(3.1) 153.5 (17.3) 116.7(2.6) 116 (8.5) -27.2 (3.9)* <0.001 
       
 
Water intake 
(µl/24h) 6412.7(1516) 9174.6 (2149.7) 5904.8 (1191) 7476.2 (944.9) -1103.2 (487.6)
*
 0.024 
Urine Vol (µl/24h) 555.6 (316.7) 777.8 (370.1) 1044.4 (342.3) 1388.9 (422.6) 548.3 (123.1)# <0.001 
Urine Na+ 
(µmol/24h) 54.9 (35.7) 457.4 (314.2) 217 (85.1) 1258 (372.1) 460.9 (176.8)
 #
 0.009 
Urine K+ 
(µmol/24h) 64.4 (37.4) 177.5 (106.2) 310.7 (192.4) 425.1 (87.4) 195.8 (62.5)
 #
 0.002 
Urine Cl- 
(µmol/24h) 88.2 (50.7) 532.4 (358.7) 408.3 (217.2) 1407.4 (364.1) 540.7 (181.9)
 #
 0.003 
Urine Na+/K+ Ratio 1.2 (0.91) 2.51 (0.27) 1.05 (0.76) 2.94 (0.55) 0.222 (0.37) # 0.545 
 GEE GLM beta co-efficients are presented as KO effect with respect to WT after adjustment for covariates. 
Covariates for GEE GLM - *=strain, salt intake  # =strain, salt intake, water intake (n=8 per group) 
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4.4.5 Renal function 
Having shown that KO mice had increased sodium excretion renal function was 
assessed (Figure 4-7). At baseline, KO mice had significantly decreased 
glomerular filtration rate, estimated by measurement of creatinine clearance 
(CrCl), compared to WT (15.6 ± 0.4 ml/min/g vs. 20.4 ± 0.1 ml/min/g; KO vs. 
WT respectively,**p<0.001, n=7 per group) (Figure 4-7 A). Although, salt loading 
resulted in increased glomerular filtration rate in KO mice only, compared to all 
other groups (**p<0.001, n=7 per group). There was no difference in CrCl after 
treatment with 2% NaCl in the WT mice (p=0.07). Renal mass index (RMI) was 
similar between strains ±2% NaCl (p>0.5, n=10 per group) (Figure 4-7 B). 
Furthermore, histological evaluation showed normal cortical and outer medullary 
structure without arterial lesions, glomerulosclerosis, adhesions, tubular atrophy 
or interstitial fibrosis, with no signs of necrosis or apoptosis. However, diffuse 
oedema with cellular and interstitial swelling was observed in the papillary 
tissue of KO animals, both before and after salt loading (Figure 4-7 C). 
4.4.6 Systems approach using Metabolomics and Microarray 
analysis to investigate WT and KO mouse kidney profiles 
To further dissect the phenotypic differences in SBP and sodium handling 
between WT and KO mice, a systems approach was utilised for additional 
characterisation studies to provide insight into potential biological pathways to 
functionally follow up with mechanistic studies. Metabolic profiling in WT and 
KO mouse kidney (± 2% NaCl) identified 13 unique significant metabolite changes 
between KO and WT (normal salt), with 1 metabolite  a common change in both 
strain comparisons (Figure 4-8 A). When comparing metabolic profiles between 
KO and WT following 6 weeks of salt loading with 2% NaCl, there were 8 unique 
metabolic changes identified and only one being common between the two 
strains (Figure 4-8 A).  Salt loading the KO strain resulted in 14 significant 
unique metabolite changes, whereas there were 27 changes in the WT mice 
under salt loading conditions (Figure 4-8 A). Using IPA software, a canonical 
pathway was created illustrating the changes in metabolites that were directly 
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associated with Na+ and UMOD, demonstrating the metabolic changes may be 
directly associated with UMOD via TNF-α (Figure 4-8 B). 
The Illumina microarray and IPA analysis performed on kidney tissue from WT 
and KO mice (±2% NaCl) to identify and gain biological insights of genes 
differentially expressed between the strains and the effects of 2% NaCl. The 
data for each strain was filtered into the venn diagram illustrated in Figure 4-9 
A. The area of intersect displays genes in common between the two strains (± 2% 
NaCl) equating 51 genes. There were 67 differentially expressed genes in the WT 
mice between the normal NaCl group and the 2% NaCl group, whereas the KO 
mice displayed 210 differentially expressed genes between normal NaCl and 2% 
NaCl groups B (Figure 4-9 A). To narrow down the gene list IPA was used to 
analyse genes only associated with Na+ transport, demonstrating 3 differentially 
expressed genes in the KO strain (± 2% NaCl) compared to the WT mice (± 2% 
NaCl) (Figure4-9 B). The 3 identified genes were NKCC2 (SLC12a1), Sodium 
dependant neutral amino acid transporters (SLC38ac, also known as SNAT), and 
Peroxisome proliferator activated receptor gamma (PPARG). SLC12a1 was shown 
to be down regulated by 1.4 fold change, whereas SLC38ac and PPARG were up 
regulated by 1.4 fold change in KO mice upon salt loading (Table 4-3).  All 
differentially expressed genes, including those not related to sodium transport, 
identified via microarray technology are list in the appendix (Table A1 and A2).  
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Figure 4-7 Creatinine clearance in WT and KO mice ± 2% NaCl.  
Indirect creatinine clearance and renal mass index were assessed in male WT and KO 
mice (±2% NaCl). (A) Under basal conditions, KO mice had significantly reduced CrCl 
than WT mice, **p<0.001, n=7 per group. Salt loading (2%NaCl), resulted in a significant 
increase in renal function in KO mice compared to all other groups, (†p<0.001, n=7 per 
group) with significant, increased CrCl in KO mice following salt loading (***p<0.0001, n=7 
per group). There was no increase in glomerular filtration rate in WT mice upon salt 
loading, p=0.07, n=7 per group. (B) There were no differences in renal mass index 
between strains under either condition. All values were displayed as Mean ± SEM. All 
data was normalised to urine volume collected over a 24 h period and kidney weight 
(renal mass index normalised to tibia length), analysed with one way ANOVA followed by 
Tukey’s post hoc test. Periodic acid-Schiff assays were performed on sectioned (3µm) 
paraffin embedded whole kidney tissue from male WT and KO mice (±2%NaCl)  (C) PAS 
in WT and KO mice ±2% NaCl show glomeruli and arcuate arteries with normal structure. 
Tubular structure was normal in the cortex, and the outer and inner stripe of the outer 
medulla in both strains. However, the papilla showed diffuse oedema with widened 
interstitium and cellular swelling in KO but not WT mice. Scale bar represents 100 µm. 
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Figure 4-8 Metabolic analysis of kidney tissue from WT and KO mice (normal NaCl). 
Pathway analysis demonstrates UMOD is linked to the identified metabolite changes via 
TNF-α, IL-1, IL-1B, and IL-1A. Dashed lines represent indirect interactions, whereas 
continuous lines represent direct interactions. Abbreviations and numbers under the 
continuous or dashed line represents the relevant publications associated with the 
pathway. The green coded shapes represent reduced expression and the red coded 
shapes represent increased expression.  
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Figure 4-9 Microarray analysis of differentially expressed genes in WT and KO renal tissue 
(± 2% NaCl). 
Venn diagrams illustrating gene expression profiles in kidney tissue of WT and KO mice (± 
2% NaCl). The number of probes (genes) significantly differentially expressed for each 
strain and NaCl conditions are shown. The intersect displays genes in common between 
the strains. (A) Displays all genes identified, whereas (B) displays only genes associated 
with Na+ transport. Normalisation using Illumina/differential expression analysis 
(determined FDR cut off of p<0.05)/ explored connections using IPA. 
 
 
 
Table 4-2 Differentially expressed sodium transport genes. 
 
Conical pathway analysis of genes implicated in the microarray revealed 3 genes directly 
involved in Na+ to be differentially expressed in the salt loaded KO mice. SLC12a1 was 
down regulated whereas SLC38ac and PPARG were upregulated.  
  
WT.S vs. WT.NS WT.S vs. WT.NS
KO.S vs. KO.NS KO.S vs. KO.NS
A. B.
Illumina ID  Symbol  False Discovery Rate 
(FDR<0.05)  
Fold Change  
 
ILMN_3048630  
 
Slc12a1  
 
0.04  
 
-1.4  
 
ILMN_2750089  
 
Slc38a3  
 
0.04  
 
 1.4  
 
ILMN_1221060 
 
PPARG 
 
0.04  
 
 1.4  
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4.5 Discussion 
To investigate the role of UMOD in BP regulation, this chapter examined 
hemodynamic parameters, sodium excretion, and renal function under 
conditions of normal sodium and high sodium (2% NaCl) intake in WT and KO 
mice. There are clear blood pressure differences between the strains, in that 
the KO mice display a lower baseline SBP and are insensitive to salt induced 
changes in BP. Results here are the first to provide novel functional evidence 
that UMOD is involved in blood pressure regulation through altered sodium 
excretion. The results reported here are a major discovery confirming the role of 
UMOD in blood pressure regulation. 
 
The BP findings in this chapter were confirmed by two independent methods; 
tail cuff plethysmography and radiotelemetry. The methodological approaches 
chosen here are in concordance with previous reports demonstrating that SBP 
pressure values monitored with, indirect tail cuff plethysmography and direct 
intra-arterial pressure recordings are similar, providing that potential artefacts 
caused by stress are not included in data collection (Bunag, 1983, Ikeda et al., 
1991). Reports have suggested that errors in data collection maybe encountered 
with tail cuff plethysmography due to restraining and pre warming the animals 
causing stress artefact resulting in BP variability. This is apparent during the 
training week where the KO mice demonstrate increased SBP compared to the 
WT mice, consequently demonstrating the importance of this training period. 
However, beyond the training week tail cuff plethysmography demonstrated 
reduced error and defined BP differences between WT and KO mice (± 2% NaCl). 
Radiotelemetry is the most reliable method of BP pressure measurements in 
rodents, although it comes with increased costs and the surgical procedure is 
technically challenging. Here radiotelemetry confirmed the BP phenotypes (± 2% 
NaCl) demonstrated with tail cuff plethysmography, showing the KO mice have 
lower baseline SBP which is not increased upon salt loading, whereas the WT 
mice had significantly increased BP when salt loaded for six weeks with 2% NaCl. 
A recovery period post surgical procedure is necessary before data collection can 
occur with radiotelemetry as animals recover from surgery over a period of time; 
up to 7 days is optimally required for the animal to recover completely from 
surgery and before BP recordings, activity, and heart rate will to return to 
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normal (Meneton et al., 2000). BP values taken within this time display artefact 
and should not be included in any statistical analysis. Radiotelemetry results in 
this study display this pattern, with blood pressure values between the strains 
not separating until approximately day 8 post surgery, consequently data 
collected in the first week post surgery was not used in the analysis to 
demonstrate BP levels in KO or WT mice.  
 
Chronic renal function curves can be used to predict the long-term level at 
which SBP will be regulated for any given level of salt intake (Guyton, 1987). 
The chronic renal function curves in this chapter demonstrate progressively 
increasing levels of SBP, DBP, and MAP with increased sodium excretion in the 
WT mice. Usually when sodium intake vs. sodium output are in balance, blood 
pressure is maintained and renal function curves remaining to the “left” which is 
the case for KO mice here. Multiple studies in animals have shown that chronic 
renal function curve are shifted to the “right” in every type of hypertension 
studied thus far; hypertension in spontaneously hypertensive rats (Bianchi et al., 
1974), hypertension caused by aldosterone infusion (Lohmeier et al., 1980), 
hypertension caused by angiotensin II infusion (Declue et al., 1978) and 
hypertension caused by volume loading (Guyton, 1991). Therefore, the 
significantly lower BP phenotypes in KO mice can be explained by a leftward 
shift in the chronic renal function curves depicting the effect of urinary Na+ 
output on arterial pressure in the absence of UMOD. 
 
The KO mice in this study revealed increased fluid intake and urine output when 
salt loaded, suggesting the lower arterial pressure observed in KO mice may be 
explained in terms of increased Na+ loss. Urinary Na+ excretion was significantly 
increased in both mouse strains upon salt loading, but to a greater degree in the 
KO mice. The premise that KO mice do indeed have lower arterial pressure due 
to Na+ loss is further supported by lower lean body mass in this strain when salt 
loaded, as augmented natriuresis is normally accompanied by reduced 
extracellular fluid volume and blood volume which, in turn, leads to lower body 
weight. Therefore, on a high-salt diet, the KO animals retained less Na+ 
compared to the WT strain. Taste preference studies have shown that C57BL/6 
mice have a strong aversion to sodium addition in drinking water at any 
concentration, whereas 129 s/v mice prefer salty water to pure tap water 
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(Beauchamp and Fisher, 1993), as the mice used here were of 129 s/v 
background it could be thought the effect of taste preference may be a factor 
causing the increased fluid intake and hence urine output in the KO mice. 
However, this is not the case as both strains are on the background of 129 s/v, 
and only the KO mice display increased fluid intake with 2% NaCl conditions. As a 
result the increased micturition with natriuresis in salt loaded KO mice reflects 
the inability of these mice to reabsorb Na+ driving the lower BP phenotype in the 
absence of UMOD. 
 
One limitation of this study is that the reported fluid intake did not compare 
with urine output under normal sodium conditions. The urine volumes reported 
in our study are well within the typical ranges reported for male adult mice of 
approximately 20-30g i.e. 0.5 – 2.5ml/24 hours so evaporation during collection 
was not an issue (Stechman et al., 2010), on the contrary fluid volumes were 
more than the normal reported daily averages for these mouse strains. 
Bachmann et al utilised the same mice strains and reported that drinking is on 
average 134 µl / g BW in the WT mice and 157 µl / g BW in the KO mice, results 
here show almost two fold these volumes (Bachmann et al., 2005, Beauchamp 
and Fisher, 1993). These reports do support the present results in that there is a 
trend towards an increased fluid intake in the KO mice, but they did not 
consider salt loading in these strains. One explanation for the over estimation of 
fluid intake is that water bottles used in metabolic cages studies have a 
tendency to leak, as water volumes were measured every 24 hours some residual 
water may have been lost. To overcome this, bottles should have been weighed 
rather than volume measured and the water that leaks in to the troughs should 
be accounted for. Future studies should consider this method alongside a 
gelatine diet to ensure all mice receive exactly 2% NaCl in the diet for the 
duration of the study. Since the potential imbalances between fluid in and urine 
out may have confounded the finding of increased natriuresis in the KO mice, 
hence urinary Na+ excretion was corrected to creatinine levels.  
 
Steady state electrolyte handling has been investigated previously in the KO 
mice and demonstrated no differences compared to the WT strain. These 
findings are consistent with results here; WT and KO mice displayed no 
differences in Na+ excretion under normal salt conditions (Bachmann et al., 
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2005). Although previous studies have not examined the effects of salt loading in 
these mouse strains, and this chapter is the first to demonstrate that under high 
salt conditions the KO mice have altered Na+ handling. A defect in renal function 
related to renal damage does not appear to contribute to this effect as no 
differences in renal mass index or renal structures were observed between the 
strains. However, diffuse oedema with cellular and interstitial swelling was 
observed in the KO mice before and during salt loading suggesting increased 
inflammation that could impact Na+ reabsorption. The KO mice show lower CrCl 
under normal salt conditions, consistent with previous reports (Starremans et 
al., 2003) and higher CrCl when salt loaded compared to WT mice. This increase 
in CrCl suggests that KO mice have a greater capacity to excrete Na+ thereby 
maintaining body homeostasis despite increased Na+ intake. The present study 
did not investigate urinary excretion levels of magnesium (Mg+) and/or calcium 
(Ca2+), and to date these parameters have not been fully investigated in UMOD 
WT and KO mice. There have been previous studies investigating urinary levels 
of Mg+ and Ca2+ in mice following high and low Mg+ diets and found UMOD to be 
involved in Mg+ handling (de Baaij et al., 2013). This group reported that a high 
Mg+ diet resulted in high urinary Mg+ and Ca2+ levels, with no associated change 
in urinary Na+, K+, and Cl- concentrations. UMOD gene expression levels were 
significantly reduced during times of high Mg+ apparently due to increased 
urinary flow rate, proposing that after cleavage of UMOD into the pro-urine, 
UMOD forms gel like structures that prevent the movement of positively charged 
ions and uptake of cations such as Mg+ and Ca2+ (Vyletal et al., 2010). Additional 
reports have demonstrated that urinary Ca2+ loss in mutant UMOD mouse models 
exceeds the urinary sodium loss (Wolf et al., 2013). The dissociation of 
hypercalciuria from urinary sodium excretion in mutant UMOD mice suggests that 
UMOD may have a role in regulating transcellular Ca2+ reabsorption in the 
nephron. These urinary parameters, alongside Mg+ and Ca+ transporters should 
be investigated in the WT and KO mouse models in future studies.  
 
The lower baseline CrCl in KO mice reported here is in contrast to previous 
human GWAS studies which showed alleles associated with low UMOD excretion 
are associated with high eGFR (Padmanabhan et al., 2012, Kottgen et al., 2009). 
As KO mice displayed high CrCl only in relation to high salt intake, it is possible 
that the associations found in the GWAS were confounded by high dietary salt 
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intake in the population cohorts used. As previously reported, the minor G allele 
of rs13333226 (allele frequency 0.18 in Europeans) was associated with a lower 
risk of hypertension, lower urinary UMOD excretion and increased proximal 
tubular sodium reabsorption (Padmanabhan et al., 2010). These findings 
illustrated that the lower urinary UMOD excretion associated with the G allele 
was present only on low salt diets, and that this association was lost when the 
sodium intake was high. In the human study, the observation of increased 
proximal tubular sodium reabsorption was observed in studies where salt intake 
was not strictly controlled, so it is difficult to ascertain whether this is a 
consequence of increased GFR, or a compensatory reaction to a primary 
decrease in distal reabsorption (Padmanabhan et al., 2010). To elucidate this 
further implicated functional pathways driving Na+ loss in the KO mice were 
investigated via a systems approach. 
 
Metabolite analysis between WT and KO mice revealed that UMOD attenuated 
expression of metabolites linked with apoptosis, oxidative stress, 
atherosclerosis, and diabetes. Sphingomyelin, heme, phosphatidylethanolamine, 
and phosphatidylcholine were all reduced in the presence of UMOD and these 
four metabolites were shown by IPA analysis to be linked to UMOD via effects on 
TNF-α, IL-1, IL-1A, or IL-B. Sphingomyelin is associated with lipid rafts involved 
with oxidative stress and apoptosis. Lipid rafts can accumulate proteins involved 
in the cascade of apoptosis (Green, 2000). Heme was also down regulated in WT 
mice suggesting in the presence of UMOD there are lower levels of cytotoxic free 
radicals reducing risk of programmed cell death caused by pro-inflammatory 
cytokines in the kidney (Pamplona et al., 2007). Phosphatidylethanolamine and 
phosphatidylcholine are metabolites associated with atherosclerosis and 
diabetes caused by oxidative stress (Eitsuka et al., 2012, Wang et al., 2011b) 
and were also found to be down regulated in the WT mice by actions of UMOD 
via regulation of pro-inflammatory cytokines. The only metabolite upregulated 
in WT mice was 5-hydroxyindole-3-acetic acid which is linked with increasing 
endothelial nitric oxide synthase availability (McDuffie et al., 2000) however, 
vascular tone experiments were not performed in the current study and should 
be considered for future studies. 
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The strong association identified here between UMOD and metabolites regulated 
via TNF-α and IL-1 further supports the concept that UMOD is an 
immunoregulatory molecule in the kidney. As introduced in section 1.10.1.5 
UMOD exerts its immunosuppressive affects by binding with high affinity to TNF-
α and IL-1 (Sabharanjak et al., 2002, Kirkham et al., 2005). This gives rise to the 
hypothesis that available UMOD at the apical membrane may play a role in 
modulating cell surface events, linked with Na+ reabsorption. In vivo reports 
from Shahid and colleagues reported that TNF-α infusion in mice resulted in 
reduced renal blood flow and reduced GFR, along with increases in excretion of 
Na+ (Shahid et al., 2008b). This suggests TNF-α induces renal vasoconstriction via 
enhancing activity of O2
- which reduces the availability of nitric oxide. These 
reports coincide with metabolomics results discussed above. The natriuretic 
response described by Shahid et al of TNF-α is related to its direct effects on 
tubular sodium reabsorption. Ferreri et al demonstrated TNF-α inhibits ion 
fluxes, particularly Na+ reabsorption and water movement at the TAL, thus in 
the absence of UMOD ion transport in the TAL may be modulated by TNF-α 
release or accumulation which infiltrates the kidney (Escalante et al., 1994). 
Furthermore, in damaged kidneys TNF-α accumulates in the interstitium and once 
there promotes inflammatory cell recruitment and activation via engagement with 
Toll like receptor 4, scavenger receptors, and cell surface lectins (El-Achkar et al., 
2008). All of the above could lead to the reported consequence of increased 
interstitial swelling and cellular odema in the papillary regions of the kidney in 
KO mice.  
 
To dissect the salt effect in KO mice further and in addition to metabolomic 
profiling, microarray technology was utilised. Microarray analysis identified 
three genes specifically linked with Na+ transport that were differentially 
expressed in the salt loaded KO mice. Sodium dependent amino acid/proton anti 
porter (SLC38a3) and Peroxisome proliferator activated receptor gamma (PPARγ) 
expression were increased whereas, NKCC2 (SLC12a1) expression was decreased. 
SLC38a3 is not a TAL specific Na+ transporter and to date there are limited 
implicated roles of this gene in hypertension. PPARγ is primarily involved in fatty 
acid storage and glucose metabolism, and is well documented to be linked with 
diabetes and related cardiovascular morbidities (Mollsten and Torffvit, 2010). 
UMOD has also been connected to diabetes with sufferers displaying altered 
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urinary UMOD excretion, low nitric oxide synthase levels, increased mean 
arterial pressure, and low metabolic control (Mollsten and Torffvit, 2010). The 
UMOD variant rs13333226 on the minor G allele was associated with lower risk of 
nephropathy in patients with diabetes after correction for BP and kidney 
function (Ahluwalia et al., 2011). The excretion rate of UMOD has been shown to 
be directly correlated with distal tubular reabsorption in patients with chronic 
diabetic nephropathy, suggesting that Na+ may affect UMOD secretion (Torffvit 
et al., 1998). Therefore, increased PPARγ levels in salt loaded KO mice may be a 
consequence of increased Na+ excretion. Recently PPARγ has been associated 
with sodium and water homeostasis related to cardiovascular disease (Wang et 
al., 2008).  
 
The collecting ducts express PPARγ suggesting that ligands for this receptor 
modulate sodium and water homeostasis via ion transport regulation. ENaC is 
also expressed in this segment of the nephron and clinical data has already well 
established that stimulation of ENaC activity leads to an increase in Na+ and 
water reabsorption, resulting in elevated BP. Previous in vivo studies in PPARγ 
null mice have shown these mice gain weight, display volume expansion, and 
consequently demonstrate raised BP (Zhang et al., 2005, Guan et al., 2005). In 
vitro studies in primary cells cultures derived from the collecting duct of these 
mice displayed increased ENaC activity (Nofziger and Blazer-Yost, 2009). Thus, 
there is a consensus that loss of PPARγ increases BP potentially via increased Na+ 
reabsorption. This would postulate that increased PPARγ expression in the salt 
loaded KO mice may be a compensatory mechanism in the aim to regulate BP 
and Na+ reabsorption in the absence of UMOD, however, further investigation is 
needed.  
 
More interestingly the Na+-K+-2Cl- cotransporter (NKCC2) expression levels were 
reduced in the KO salt loaded mice according to microarray analysis. NKCC2, is 
selectively expressed in the TAL where it transports the vast majority of NaCl 
and is said to be modulated by co-localised UMOD (Mutig et al., 2011a). In 
humans inactivating mutations of the NKCC2 gene (SLC12A1) cause a significant 
reduction in BP, with severe natriuresis developing a severe salt wasting 
phenotype (Bartter syndrome) (Garcia et al., 1999, Acuna et al., 2010). In 
contrast to genetic inactivation of NKCC2, enhanced activities of NKCC2 have 
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been linked to salt sensitive hypertension (Ares et al., 2011). Indicating the 
important role NKCC2 plays in blood pressure regulation. Recent studies have 
implicated UMOD expression at the apical membrane in the TAL is responsible 
for modulating NKCC2 specific sodium reabsorption (Mutig et al., 2011b). As a 
result, the absence of UMOD may cause deficits in Na+ reabsorption inhibiting 
NKCC2 expression and activity. Renal pro-inflammatory cytokines are 
documented as reducing ion transport. TNF-α is produced by the TAL and acts in 
an autocrine manner to down regulate NKCC2 expression (Battula et al., 2011), 
lowering NaCl reabsorption at this site (Bachmann et al., 2005, Sherblom et al., 
1988, Mutig et al., 2011b, Hao et al., 2011). Collectively suggesting the absence 
of UMOD may increase TNF-α levels at the TAL, reducing Na+ reabsorption and 
providing a potential link between the intracellular and extracellular roles of 
UMOD in blood pressure control.  
 
In summary this results chapter has provided novel findings that UMOD KO mice 
have lower blood pressure than the WT counterparts, and do not display 
increases in BP when salt challenged. The KO mice display increased diuresis 
with substantial natriuresis, confirmed by a leftward shift in the chronic renal 
function curves. Urinary electrolyte analysis corrected to creatinine levels 
revealed augmented sodium loss in the KO mice during a high salt diet. 
Histological examination illustrated cellular swelling and papillary oedema in the 
KO mice before and after salt loading which may be triggered by the pro-
inflammatory cytokines TNF-α and IL-1 according to metabolomic analysis. These 
inflammatory signals may affect Na+ homeostasis at the TAL in the KO mice by 
reducing NKCC2 expression. All of the findings from this chapter suggest UMOD 
has a fundamental role in regulating Na+ reabsorption and extracellular volume 
homeostasis regulating BP. 
 
To assess potential mechanisms altering BP in the KO mice the next results 
chapter examines functionally the role UMOD plays in BP regulation by mediating 
the effects of TNF-α and NKCC2 on sodium homeostasis.  
 
 
 
5 The role of UMOD in sodium regulation at the 
Thick Ascending Limb of the Loop of Henle. 
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5.1 Introduction 
The thick ascending limb of the loop of Henle (TAL) is pivotal in the regulation of 
extracellular fluid volume and blood pressure control via sodium homeostasis. 
The reabsorption of NaCl at the TAL accounts for 25% of total renal salt 
retrieval, and it generates the energy for the urinary concentrating mechanism. 
NaCl uptake across the apical membrane of TAL cells is mediated to at least 80% 
by a co-transport process in which the influx of Na+ drives the uptake of Cl- and 
K+. To achieve net salt absorption, apical electroneutral co-transport of Na+, K+, 
and Cl- via NKCC2 is complemented by recycling of K+ via ROMK, efflux of Cl- via 
basolateral Cl- channels (CLC- Kb/Barttin), coupled transport of Na+ and H+ via 
NHE3 transporters, basolateral extrusion of Na+ by Na+ /K+ ATPase, and the final 
adjustment to urine concentration, K+ homeostasis, acid base balance with Na+ 
reabsorption is accomplished by ENaC.  
 
The results from the KO mice in the previous chapter suggest a possible link 
between UMOD and ion transport in the TAL. In the absence of UMOD there is 
augmented sodium excretion in the KO mice, suggested to be a consequence of 
reduced expression of the sodium transporter NKCC2. This modulated Na+ 
reabsorption by reduced NKCC2 leads to exaggerated natriuresis and lower 
arterial pressure in the KO mice and is consistent with findings in humans where 
salt wasting phenotypes and hypotension are characteristics of Bartter’s 
syndrome (Pressler et al., 2006, Simon et al., 1996a, Vargas-Poussou et al., 
1998). Ion channels, pumps, and transporters found along the nephron 
accomplish the fundamental functions of the kidney in regulating Na+ 
homeostasis and blood pressure phenotypes. In times of altered activity, blood 
pressure, ECF volume, and sodium reabsorption can be impaired and in contrast 
to hypertension, leads to hypotension and salt wasting phenotypes as seen thus 
far in the KO mice.  
 
Since the reabsorptive capacity of Na+ in downstream portions of the nephron is 
limited, it is likely that inhibition or modulation of NKCC2 expression is largely 
responsible for marked natriuresis and micturition with consequent reductions in 
arterial pressure. Three NKCC2 variants (A, B, and F) are derived by differential 
splicing of exon 4 of the SLC12A1 gene. These isoforms differ in their distribution 
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along the nephron and account for 20%, 10% and 70%, for A, B, and F 
respectively, of the total NKCC2 transcript abundance in mice (Castrop and 
Schnermann, 2008). Ferreri et al have previously reported that TNF-α is an 
endogenous inhibitor of NKCC2A in the TAL (Battula et al., 2011). In further 
support of this finding this group also demonstrate NKCC2A mRNA expression 
levels were selectively elevated accompanied by increased NKCC2 activity in 
TNF-/- mice with no differences in NKCC2B, and F expression levels between WT 
mice and TNF-α -/- mice (Battula et al., 2011). TNF-α administration has proven 
to be a potent inhibitor to sodium reabsorption at the TAL causing exaggerated 
natriuretic responses and blood pressure lowering effects (Evans et al., 1989, 
Nakatsuji et al., 1990). Interestingly, it has been reported that UMOD facilitates 
the co-transport of NKCC2 to the apical membrane of TAL cells (Mutig et al., 
2011b) and that UMOD exerts its immunosuppressive effects by binding with high 
affinity to TNF-α (Wu et al., 2008). This data suggests that in the absence of 
UMOD or altered available UMOD at the apical surface of TAL cells will result in 
enhanced levels of TNF-α production; in turn reducing NKCC2 activity and Na+ 
reabsorption.  
Given the hypothesis that altered UMOD expression regulates arterial pressure 
by controlling Na+ reabsorption, this chapter investigated levels of the pro-
inflammatory cytokine TNF-α levels in WT and KO mice (± 2% NaCl) and the 
subsequent effects on renal Na+ handling transporters. In vitro assays were 
utilised to further test the potential mechanistic role of UMOD related Na+ 
transport.  
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5.2 Aims 
• To investigate levels of mRNA abundance of the main renal Na+ channel 
transporters in whole kidney tissue and outer medulla tissue from WT and 
KO mice following six weeks ± salt loading with 2% NaCl. 
• To investigate levels of protein expression of the main renal Na+ channel 
transporters in whole kidney tissue and outer medulla tissue from WT and 
KO mice following six weeks ± salt loading with 2% NaCl. 
• To investigate the potential mechanistic role of UMOD to regulate Na+ 
levels at the TAL.  
• To utilise immunohistochemistry to investigate localisation of UMOD in WT 
and KO mouse kidney tissue following six weeks ± 2% NaCl. 
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5.3 Method 
5.3.1 Ion transporter and cytokine expression analysis 
RNA was extracted and prepared from WT and KO mouse whole kidney and outer 
medulla tissue (±2% NaCl) as described in section 2.3.8. The following Na+ 
transporters and TNF-α were assessed; UMOD, NKCC2, ENaC, ROMK, Na+/K+ -
ATPase-α, Na+/K+ -ATPase-β, and NHe3 using Taqman® gene expression assays 
described in section 2.4.1. Table 5-1 details the assays used in this chapter.  
Table 5-1 Taqman® assays used to determine expression levels of Ion transporters. 
Expression of UMOD, TNF-α, NKCC2, ROMK, ENaC, Na+/K+ - ATPase (α and β), and 
NHe3 was assessed at the mRNA level in WT and KO mouse kidney and outer medulla  
tissue (± 2% NaCl).  
QPCR was used to determine accumulation of mRNA for NKCC2 isoforms (A, B, 
and F) as per section 3.3.7.7. The primer specific pairs for murine NKCC2A, B, 
and F are as listed below:  
 Forward Primer Reverse Primer 
NKCC2A 5’ GGTAACCTCTATCACTGGGT 3’ 5’GTCATTGGTTGGATCCACCA 3’ 
NKCC2B 5’GCCGTGACAGTGACAGCCAT 3’ 5’ GGATCCACCATCATTGAATCG 3’ 
NKCC2F 5’ GTCATCATCATTGGCCTG 3’ 5’ GAATCCCACCACATACATAG 3’ 
Following mRNA expression analysis, the protein levels of the ion transporters 
and TNF-α were quantified in either: whole kidney tissue, outer medulla tissue, 
or TAL cell cultures. Protein samples were extracted, prepared, and blotted as 
per section 2.7 then probed using Abcam® primary and secondary antibodies 
(Abcam®, Cambridge, UK (Table 5-2)) with the exception of UMOD which was 
probed using AbD SeroTec primary and secondary antibodies (Sheep anti-human 
Tamm Horsfall Protein, (primary polyclonal antibody)) and STAR88P (secondary 
HRP Donkey anti-sheep polyclonal antibody), AbD SeroTec, Bio-Rad Laboratories 
Inc, Puchheim, Germany. The secondary antibodies used for Abcam® specific 
Transporter 
 
Gene name Taqman® assay Reference sequence Exon boundry 
UMOD Uromodulin Mm00447649_m1 Nm_0094704 2-3 
TNF-α TNF-α Mm00443260_g1 Nm_0.13693.2 3-4 
NKCC2 SLC12A1 Mm01275821_m1 Nm_001079690.1 19-20 
ROMK KCNJ1 Mm01173990_m1 Nm_001168354.1 1-2 
ENaC SCNN1 Mm00803380_m1 Nm_011324.2 2-3 
Na
+
 /K
+
 -ATPase α ATP1A1 Mm00523255_M1 Nm_144900.2 10-11 
Na
+
 /K
+
 -ATPase β ATP1B1 Mm00437612_m1 Nm_009721.5 2-3 
NaHe3 SLC9A3 Mm01352473_m1 Nm_001081060.1 14-15 
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primary antibodies were rabbit anti-mouse (polyclonal HRP, ab6709) and Mouse 
anti-rabbit (polyclonal HRP, ab6728), Abcam®, Cambridge, UK). All Abcam® 
antibodies were used at a concentration of 1 µg/ml in TBST with 1% milk and 
blocked with 5% milk. AbD SeroTec antibodies were used at 1:500 dilutions in 
TBST with 1% BSA and blocked with 5% BSA. All blots were stripped (2.8.5) and 
reprobed with GAPdh (ab8245) mouse monoclonal primary anti body from 
Abcam® Cambridge, UK.  
Table 5-2 Abcam® primary antibodies used to detect levels of renal Na+ transporters and 
TNF-α. 
 
5.3.2 Enzyme Linked ImmunoSorbent Assay (ELISA) 
TNF-α levels were measured in urine from KO and WT mice (±2% NaCl) by 
enzyme linked immunosorbent assay (ELISA), using a commercially available 
mouse TNF-α ELISA kit (BD Sciences, Oxford, UK) following the manufacturer’s 
instructions. Section 2.15 in the general methods section outlines the procedure. 
Urine was collected from WT and KO mice as per section 2.11.1. 
 
5.3.3 Isolation of outer medullary thick ascending limb of the loop 
of Henle cells 
5.3.3.1 Cell Isolation procedure 
Male WT mice of 5-7 weeks old were used for TAL cell isolation. Isolation of 
mTAL cells was performed as previously described (Eng et al., 2007). Mice were 
anesthetised with isofluorane and the kidneys were perfused with sterile 0.9% 
saline solution via retrograde perfusion of the aorta. Once the kidneys were 
excised they were cut along the corticopapillary axis, to expose the medulla. 
The inner strip of the outer medulla was then dissected out and minced with a 
sterile blade in 0.1% (w/v) collagenase solution (collagen type IV collagenase 
prepared in Hanks Balanced Saline) (Sigma Aldrich, Poole, UK and Gibco®, 
Transporter Gene name Abcam®antibody Host 
species 
Clonality Molecular 
weight  
TNF-α TNF-α ab52B3 Mouse Monoclonal 52 
NKCC2 SLC12A1 ab95302 Rabbit Polyclonal 111 
ROMK KCNJ1 ab85479 Rabbit Monoclonal 45 
Na
+
 /K
+
 -ATPase ATP1A1 ab7671 Mouse Polyclonal 112 
eNac SCNN1 ab65710 Rabbit Polyclonal 76 
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Paisley, UK) that was gassed with 95% oxygen. The pulp was then incubated for 
ten minutes at 37oC. The cell suspension was sedimented on ice and mixed with 
Hanks Balanced Saline (HBSS) containing 2% (w/v) BSA, and the crude suspension 
of tubles was collected. The remaining undigested tissue was collagenase 
treated a further three times. The combined supernatants were spun at a low 
speed (1000 RPM) for ten minutes, and resuspended in HBSS. The resuspension 
was passed over a 52µm nylon mesh membrane (Fisher Scientific, Loughborough, 
UK). The filtered solution was discarded and the tubules collected on the mesh 
were washed with HBSS and centrifuged for 5 minutes at a low speed (500 RPM). 
The supernatant was aspirated and the cells were resuspended with Clonetics™ 
REGM™ growth media supplemented with the growth factor BulletKit™ (CC-
3190): hEGF, 0.5 ml; hydrocortisone, 0.5 ml; epinephrine, 0.5 ml; insulin, 0.5 
ml; triiodothyronine 0.5 ml; transferrin, 0.5 ml; GA- 1000, 0.5 ml; FBS, 2.5 ml. 
The tubule suspension was then aliquoted onto a four wells of a six well plate 
containing individual cell culture inserts (BD Biosciences, Oxford, UK), to insure 
polarisation. The cells were grown to approximately 70% confluence prior to any 
experiment, with fresh media changes every 48 hours.  
 
5.3.3.2 UMOD knockdown 
Mouse TAL cells were cultured from WT mice only as cells from KO mice did not 
culture beyond 30 % confluence. As a representation WT TAL cells were treated 
±siRNA to knock down UMOD. Upon confluence, mouse TAL cells underwent 
transient siRNAoligo-mediated UMOD gene silencing over a 4 hour period. 
Constituents of the transfection reaction per well are as follows: 500 µl 
Optimem®, 10 nM siRNA (UMOD siRNA, CyTM3 negative control, or GAPDH 
(Ambion, Manchester, UK)), and Lipofectamine®2000 at a 3:1 ratio 
(Lipofectamine®2000: siRNA). The transfection mix was added to the insert 
containing the cells and the well under the insert on each plate. Reactions were 
performed in triplicate and each experiment was repeated 3 times. Following 
the 4 hour silencing period normal growth media replaced the transfection mix 
on cell cultures for 4 hours with incubation at 37oC, followed by overnight 
quiescing with RPMI 1640 media (Gibco, Manchester, UK). The optimum 
conditions for transient delivery of UMOD siRNA into TAL cells was assessed using 
siRNA that targeted GAPDH and CyTM3, as positive and negative controls 
respectively. Each siRNA was transfected separately into TAL cell cultures as 
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described above at the following concentrations: 5 nM, 10 nM, 15 nM, 20 nM, 30 
nM, 50 nM, and 100 nM. RNA was isolated as per section 2.3.8 and GAPDH and 
UMOD measured by qRT-PCR (2.4) with Applied biosystems Taqman® assay 
probes (NM_0094804, and NM_008084.2; UMOD and GAPDH respectively). Protein 
levels of UMOD were assessed (2.7) using antibodies summarised in Table 5-2. 
 
5.3.3.3 TNF-α stimulation 
Following siRNAoligo-mediated UMOD gene silencing, RPMI 1640 media was 
removed and cell cultures were treated ± with TNF-α (5 nM) (Peprotech New 
Jersey, USA) for a six hour period in fresh RPMI 1640 media.  
 
5.3.3.4 Cell culture conditions 
The knock down of UMOD in WT TAL cells and incubations with TNF-α gave rise 
to the following cell culture conditions; scrambled control (WT cells treated with 
10 nM negative control siRNA), scrambled control + TNF-α (WT TAL cells treated 
with 10 nM negative control siRNA + TNF-α (5 nM)), siRNA treated cells (WT TAL 
cells treated with UMOD siRNA (10 nM)), and siRNA treated cells + TNF-α (WT 
TAL cells treated with 10 nM  UMOD siRNA + TNF-α (5 nM)).  
5.3.3.5 Immunocytochemistry 
For immunocytochemistry cells seeded directly onto two chamber tissue culture 
treated glass slides (BD Biosciences Oxford, UK). The cells cultures were washed 
several times with PBS, fixed with freshly prepared 4% paraformaldehyde in PBS 
for 1 hour, and rinsed several times with fresh PBS. Cells were permeabilized 
with 0.1% Triton X-100 (v/v) in PBS for 1 hour at room temperature. Primary 
(Sheep anti-human Tamm Horsfall Protein, primary polyclonal antibody, Ab Sero 
Tec, Puchheim, Germany) and secondary antibodies (Donkey anti sheep 
conjugated with Alexa Fluor 488, Invitrogen, Paisley, UK) were diluted with PBS 
containing 0.1% FBS. Antibodies were diluted at a 1:1000. Primary antibodies 
were incubated overnight at 4oC, whilst secondary antibodies were incubated at 
room temperature (protected from light). After each sequence with either a 
primary or secondary antibody, the slides were washed five times with a high-
salt solution containing 1% BSA and 2.3% NaCl in PBS (w/v), followed by a single 
wash with PBS. Cells were stained with 1 µg/ml 4,6-diamidino-2-phenylindole 
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(DAPI) (Sigma Aldrich, Poole, UK) for 5 minutes followed by a single wash with 
PBS. The glass slides were mounted with cover slips and fixed with DPX (Sigma 
Aldrich, Poole, UK). Slides were examined using a Nikon Microphot FXA 
microscope equipped for epifluorescence illumination. Nuclear and cytoplasmic 
fluorescence was measured by laser scanning cytometry (LSC) using UV and 488 
nm wavelength argon ion lasers to excite the fluorescence of DAPI and Alexa 
Fluor 488. Nuclear colouring was based on blue fluorescence for DAPI and green 
for Alexa Fluor 488.  The integrated value of green fluorescence represented 
UMOD immunofluorescence.   
   
5.3.4 Immunohistochemistry 
Kidney sections from WT and KO mice following 6 weeks ± 2% NaCl were 
analysed for expression of Na+ transporters. A detailed outline of the procedure 
can be found in section 2.12.5. Table 5-3 summarises the primary antibodies and 
dilutions/concentrations used. All antibodies were diluted in 1 % BSA (w/v) in 
PBS. 
Table 5-3 Summary of antibodies, dilutions, and length of incubations used for 
Immunohistochemistry. 
 
  
Antibody/Protein Dilution/Incubation time Source/Product number 
UMOD 1:1000 / Overnight Santa Cruz / sc-20631 
NKCC2 1:500 / Overnight Abcam / ab60301 
TNF-α 1:1000 / 2 hours Abcam / ab1793 
Na
+
/K
+
 ATPase  1:500 / 2 hours Abcam / ab7671 
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5.4 Results 
5.4.1 Renal Na+ channel mRNA expression analysis  
Analysis by qRT-PCR on RNA isolated from whole kidney and outer medulla 
revealed an increased UMOD expression in WT mice upon salt loading (1.00 ± 0.1 
vs. 1.62 ± 0.2 and 1.00 ± 0.2 vs. 3.15 ± 2.4; relative expression in whole kidney 
and outer medulla, WT normal NaCl vs. WT +2% NaCl, *p=0.04, **p<0.001), 
whereas no expression was detected in renal tissue from KO mice (± 2% NaCl) 
(Figure 5-1 A and B). Relative expression of NKCC2 in whole kidney was not 
different between the strains (±2% NaCl) (1.00 ± 0.6, 1.42 ± 0.1, 1.33 ± 0.3, and 
1.14 ± 0.1; WT normal NaCl, WT +2% NaCl, KO normal NaCl, and KO +2% NaCl 
respectively, p=0.8) (Figure 5-1 C). Whereas, KO mice following 2% NaCl 
treatment resulted in a significantly reduced NKCC2 expression in the outer 
medulla tissue (0.41 ± 0.2 vs. 1.00 ± 0.1, 1.42 ± 0.2, and 1.38 ± 0.1; KO +2% NaCl 
vs. WT normal NaCl, WT +2% NaCl, and KO normal salt, **p=0.003) (Figure 5-1 
D). 
Relative expression levels of NKCC2 isoforms (A, B, and F) were assessed in outer 
medulla tissue from WT and KO mice (±2% NaCl) (Figure 5-2). NKCC2A was 
significantly increased in WT mice upon salt loading (1.00 ± 0.2 vs. 1.73 ± 0.2; 
WT normal salt vs. WT +2% NaCl,*p<0.05). Salt loading KO mice (+2% NaCl) 
resulted in lower NKCC2A expression compared to all groups (0.37 ± 0.1 vs. 1.00 
± 0.2 (‡p<0.001), 1.73 ± 0.2 (#p=0.001), and 0.60 ± 0.2 (*p<0.05); KO +2% NaCl 
vs. WT normal NaCl, WT +2% NaCl, and KO normal NaCl respectively)) (Figure 5-
2 A). NKCC2F was significantly increased in KO +2% NaCl vs. WT normal NaCl only 
(1.74 ± 0.2 vs.1.00 ± 0.2, KO +2% NaCl vs. WT normal NaCl, *p<0.05) (Figure 5-2 
B). NKCC2B mRNA expression levels demonstrated an approximate 4.5 fold 
increase in WT mice upon salt loading with 2% NaCl (1.00 ± 0.2 vs. 4.85 ± 0.1; 
WT normal NaCl vs. WT + 2% NaCl, ***p<0.0001). KO mice under normal NaCl 
conditions revealed attenuated expression of NKCC2B compared to the WT mice 
under normal NaCl conditions (1.00 ± 0.2 vs. 2.15 ± 0.2; WT normal NaCl vs. KO 
normal NaCl, **p=0.002). KO mice +2% NaCl had significantly reduced NKCC2B 
relative expression compared to the KO normal NaCl group and WT salt loaded 
mice (2% NaCl) (1.03 ± 0.2 vs. 2.15 ± 0.2, and 4.85 ± 0.1; KO +2% NaCl vs. KO 
normal NaCl and WT +2% NaCl, ***p<0.0001) Figure 5-2 C).   
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Salt loading the WT mice with 2% NaCl resulted in an increased ENaC expression 
in whole kidney tissue (1.00 ± 0.06 vs. 1.70 ± 0.07; WT normal NaCl vs. WT +2% 
NaCl, *p<0.05). In the KO mice, under normal NaCl conditions, ENac expression 
was at similar levels to that of the salt loaded WT mice and was significantly 
increased compared to the non salt loaded WT mice (1.00 ± 0.06 vs. 1.85 ± 0.1; 
WT mice vs. KO mice (normal NaCl),*p<0.05). Salt loaded KO mice demonstrated 
a significant reduction in ENac expression in whole kidney tissue compared to all 
other groups (***p<0.0001) (Figure 5-3 A). Outer medulla tissue from KO mice 
(+2% NaCl) demonstrated reduced ENac expression compared to the non salt 
loaded KO mice (normal NaCl) (1.93 ± 0.05 vs. 1.01 ± 0.2, KO mice vs. KO mice 
+2% NaCl, **p=0.001) (Figure 5-3 B). Under normal NaCl conditions, levels of Na+ 
/K+ ATPase α in whole kidney tissue was increased in KO mice compared to the 
WT mice (2.30 ± 0.1 vs.1.00 ± 0.2, KO vs. WT, ‡p=0.0003). KO mice +2% NaCl had 
significantly increased expression levels of Na+ /K+ ATPase α compared to all 
groups (***p<0.0001) (Figure 5-3 C). WT mice +2% NaCl had elevated expression 
of Na+ /K+ ATPase α in outer medulla tissue compared to all groups 
(***p<0.0001). Salt loaded KO mice had significantly reduced Na+ /K+ ATPase α 
expression compared to non salt loaded KO mice (*p<0.05) (Figure 5-3 D). Na+ 
/K+ ATPase β levels in whole kidney tissue was not different between the groups 
(p=0.24) (Figure 5-3 E). Whereas KO mice +2% NaCl had reduced expression 
levels of Na+ /K+ ATPase β in outer medulla tissue compared to all other groups 
(*p<0.05) (Figure 5-3 F). Relative expression levels of NHe3 were not altered in 
whole kidney tissue between the groups (p=0.26) (Figure 5-3 G). KO mice under 
normal NaCl conditions had significantly increased NHe3 expression in outer 
medulla tissue compared to all groups (***p<0.0001), which was attenuated upon 
2% NaCl loading (**p<0.001) (Figure 5-3 H). ROMK was undetected by qRT-PCR in 
whole kidney tissue from WT or KO mice (± 2% NaCl). Outer medulla levels of 
ROMK were reduced in KO mice upon salt loading compared with all groups 
(*p<0.05) (Figure 5-3 I).  
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Figure 5-1 qRT-PCR analysis of UMOD and NKCC2 in WT and KO mice (± 2% NaCl) from 
whole kidney (A and C) and outer medulla tissue (B and D).  
RNA was extracted from snap frozen whole kidney and outer medulla tissue of male WT 
and KO mice (±2% NaCl). UMOD and NKCC2 mRNA abundance was by qRT-PCR using 
gene specific probes. UMOD mRNA abundance was is elevated in WT mice upon salt 
loading with 2% NaCl in both (A) whole kidney and (B) outer medulla tissue. (C) Relative 
expression of NKCC2 was not different between the strains or altered by salt loading. (D) 
In the absence of UMOD and the addition of 2% NaCl resulted in a significant reduction in 
NKCC2 expression. Data are shown as Mean RQ ± SEM (Cycle threshold values were 
normalised to β-actin mRNA and expressed relative to the WT mice under normal NaCl 
conditions), n=5 per group, *p=0.04, **p=0.001. Analysed by One way ANOVA followed 
by Tukey’s post Hoc multiple comparison  test.  
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Figure 5-2 qRT-PCR analysis of the three major NKCC2 isoforms; A, F, and B in WT and KO 
mice (± 2% NaCl) from outer medulla tissue. 
RNA was extracted from snap frozen outer medulla tissue of WT and KO mice (±2% 
NaCl). NKCC2 A, B, and F mRNA abundance was assessed in outer medulla tissue by 
QPCR using gene specific primers. Salt loading with 2% NaCl resulted in significantly 
increased (A) NKCC2A and (C) NKCC2B expression in WT mice. In the absence of 
UMOD there was a significantly reduced (A) NKCC2A and (C) NKCC2B expression in KO 
mice, which was further attenuated upon NaCl loading. (B) NKCC2F was not changed in 
WT mice ± 2% NaCl, whereas KO mice had increased expression when salt loaded. Data 
are shown as Mean RQ ± SEM (Cycle threshold values were normalised to β-actin mRNA 
and expressed relative to the WT mice under normal NaCl conditions) n=5 per 
group,*p<0.05 (KO normal salt vs. KO salt loaded), **p<0.002 (KO normal salt vs. WT salt 
loaded), ***p<0.0001 (WT normal salt vs. WT salt loaded and KO salt loaded vs. KO 
normal salt and WT salt loaded), ‡ p<0.001 (KO salt loaded vs. WT normal salt), and 
#p<0.0001 (KO salt loaded vs. WT salt loaded). Analysed by One way ANOVA followed 
by Tukey’s post Hoc multiple comparison test.  
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Figure 5-3 qRT-PCR analysis of TAL Na+ channels from whole kidney (A, C, E, and G) and 
outer medulla tissue (B, D, F, H, and I) in WT and KO mice (± 2% NaCl).  
RNA was extracted from snap frozen whole kidney and outer medulla tissue of WT and 
KO mice (±2% NaCl). The TAL transporter mRNA abundance was assessed by qRT-PCR 
using gene specific probes. (A) WT mice displayed increased ENac expression in whole 
kidney when salt loaded (2% NaCl). KO mice under normal NaCl conditions had 
increased expression to comparable levels as salt loaded WT mice, which was attenuated 
with 2% NaCl stimulation. (B) In outer medulla tissue the KO mice +2% NaCl had reduced 
ENac expression. (C) Na+ /K+ ATPase α mRNA abundance in whole kidney was 
increased in KO mice under normal and 2% NaCl conditions. (D) However, was reduced 
in KO mice when assessed in outer medulla tissue upon salt loading. WT mice upon salt 
loading displayed increased expression of Na+ /K+ ATPase α. (E) Na+ /K+ ATPase β was 
not different between the strains or conditions in whole kidney tissue. (F) The KO mice 
+2% NaCl revealed reduced levels of Na+ /K+ ATPase β in the outer medulla tissue. (G) 
NHe3 was not altered between the strains ± 2% NaCl in whole kidney tissue. (H) However 
in outer medulla tissue salt loading increased expression in WT mice but reduced levels in 
KO mice. (I) ROMK was only detected in outer medulla tissue revealing reductions in 
mRNA abundance in KO salt loaded mice. Data are shown as Mean RQ ± SEM (Cycle 
threshold values were normalised to β-actin mRNA and expressed relative to the WT mice 
under normal NaCl conditions) n=5 per group,*p<0.05, **p<0.001, ‡ p=0.003, 
***p<0.0001. Analysed by One way ANOVA followed by Tukey’s post Hoc multiple 
comparison test.  
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5.4.2 Renal Na+ channel protein expression analysis 
Following mRNA expression analysis protein analysis was utilised to assess Na+ 
/K+ ATPase, NKCC2, ENaC, and ROMK from whole kidney tissue in WT and KO 
mice to reveal no difference between the strains under normal NaCl or 2% NaCl 
conditions (Figure 5-4). Representative immunoblots are shown in (Figure 5-4 
A). Protein expression was determined by densitometry in n=2 for salt loaded 
animals and n=3 for normal NaCl treated animals; statistical analysis was not 
performed (Figure 5-4 B-E).   
 
5.4.3 Interactions between UMOD, TNF-α and NKCC2 in the TAL.  
Under normal NaCl conditions, urinary TNF-α levels were significantly greater in 
KO mice compared to WT (4.61 ± 0.09 pg/24h vs. 34.95 ± 0.05 pg/24h; WT vs. 
KO mice, n=5 per group, **p<0.001). Salt intake over a 6 week period increased 
the levels of urinary TNF-α in both WT and KO mice (4.61 ± 0.09 pg/24h vs. 
29.97 ± 0.01 pg/24h and 34.95 ± 0.05 pg/24h vs. 163.13 ± 0.01 pg/24h; WT 
normal NaCl vs. WT +2% NaCl and KO normal NaCl vs. KO +2% NaCl respectively, 
n=5 per group, **p<0.001 and ***p<0.0001). This increase was approximately 5-
fold in the KO mice upon salt loading (***p<0.0001) (Figure 5-5 A). 
QRT-PCR on RNA isolated from kidney outer medulla showed an increase in the 
abundance of TNF-α in both WT and KO animals on salt-loading, reaching 
statistical significance in KO mice (1.39 ± 0.2 vs. 2.51 ± 0.5; KO normal NaCl vs. 
KO +2% NaCl, n=5 per group,*p=0.01) (Figure 5-5 B). The mRNA abundance of 
the NKCC2A was measured in mouse TAL cells ± TNF-α stimulation, ± UMOD 
siRNA. In the presence of UMOD, stimulation with TNF-α decreased relative 
NKCC2A mRNA levels (1.00 ± 0.03 vs. 0.51 ± 0.08; WT cells vs. cells + TNF-α 
stimulation, **p<0.001, n=3). UMOD knockdown caused an even greater 
reduction in NKCC2A transcript levels (1.00 ± 0.03 vs. 0.26 ± 0.2, WT cells vs. 
cells + UMOD siRNA treatment, ***p<0.0001, n=3) that could not be further 
lowered by the addition of exogenous TNF-α (Figure 5-5 C). In mTAL cells, 
stimulation with TNF-α was found to increase the relative levels of UMOD mRNA 
by approximately 3.5-fold (***p<0.0001, n=3) (Figure 5-5 D). 
Immunocytochemistry confirms the knockdown of UMOD in WT mTAL cells 
(Figure 5-5 E). Suggesting TNF-α can reduce the levels of NKCC2A mRNA in 
primary mTAL cells, and that this effect is enhanced in the absence of UMOD. 
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Stimulation with TNF-α was found to increase the relative levels of UMOD mRNA, 
creating a negative feedback loop in which the TNF-α induced reduction in 
NKCC2A gene expression is switched off through increasing the production of 
cell-surface UMOD. Ultimately, suggesting that UMOD acts as a negative 
regulator of TNF-α production by the TAL to maintain NaCl homeostasis. 
 
 
Protein expression levels of the Na+ transporters were assessed in outer medulla 
tissue from WT and KO mice ± 2% NaCl (Figure 5-6), representative immunoblots 
are shown in Figure 5-6 A. The addition of 2% NaCl increased UMOD expression 
in outer medulla tissue of WT mice by approximately 1.34 fold compared to the 
WT normal NaCl animals (54.63 ± 1.9 % intensity vs. 40.67 ± 1.9 % intensity, n=5 
per group, **p<0.001) (Figure 5-6 B). Expression levels of NKKC2 were increased 
in WT salt loaded mice compared to WT mice under normal NaCl conditions 
although did not reach statistical significance (58.29 ± 0.8 % intensity vs. 52.36 ± 
2.1 % intensity, n=5 per group, *p<0.01). Salt loading the KO mice resulted in 
reduced NKCC2 expression compared to the normal NaCl treated KO animals 
(41.39 ± 4.1 % intensity vs. 28.99 ± 1.5 % intensity, n=5 per group, #p<0.05) 
(Figure 5-6 C). There was an attenuated NKCC2 expression in salt loaded KO 
mice in comparison to salt loaded WT mice (28.99 ± 1.5 % intensity, n=5 per 
group, **p<0.01) (Figure 5-6 C). Levels of TNF-α were significantly increased in 
both mouse strains following salt loading with 2% NaCl (18.25 ± 1.1 % intensity 
vs. 34.23 ± 7.1 % intensity; WT normal NaCl vs. WT + 2% NaCl and 10.09 ± 1.8 % 
intensity vs. 54.08 ± 1.9 % intensity; KO normal NaCl vs. KO + 2% NaCl, n=5 per 
group, *p<0.01, **p<0.001) (Figure 5-6 D).  
 
Protein levels of UMOD, TNF-α, and NKCC2 were determined in TAL cells in 
which UMOD was silenced (Figure 5-7).  Representative immunoblots are shown 
in Figure 5-7 A. UMOD protein levels were successfully knocked down in WT 
mouse TAL cells by addition of UMOD siRNA (10 nM) (86.02 ± 1.0 % intensity vs. 
5.28 ± 1.1 % intensity and 126.26 ± 1.8% intensity vs. 5.11 ± 3.7 % intensity; 
scrambled control treated cells vs. scramble + TNF-α treated cells, UMOD siRNA 
treated cells vs. UMOD siRNA treated cells + TNF-α respectively,  ‡** p<0.001, 
n=3). Incubation of TAL cells for 6 hours with TNF-a (5 nM) increased the relative 
protein levels of UMOD by approximately 1.46 fold than cells treated with 
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scrambled siRNA only (n=3, **p<0.001) but not in cells in which UMOD mRNA was 
silenced with UMOD siRNA (Figure 5-7 B). Total NKCC2 protein expression was 
increased in scramble control treated cells when incubated with TNF-α by 
approximately 1.4 fold compared to scramble control treated cells (n=3, 
**p<0.001). NKKC2 protein levels were reduced when UMOD expression was 
knocked down by siRNA (55.10 ± 2.1 % intensity vs. 96.14 ± 0.8 % intensity, n=3, 
**p<0.001). In the absence of UMOD and stimulation with TNF-α further reduced 
NKCC2 protein expression (21.09 ± 3.2 % intensity vs. 55.10 ± 2.1% intensity, n=3, 
**p<0.001) which was significantly lower compared to all other conditions (# 
p<0.001) (Figure 5-7 C). TNF-α protein levels were assessed in cells treated ± 
UMOD siRNA only. TNF-α expression was increased in TAL cells that had UMOD 
knocked down by siRNA compared to scramble control treated cells (93.34 ± 1.7 
% intensity vs. 87.73 ± 0.8 % intensity; UMOD siRNA treated cells vs. scramble 
treated cells, n=3, *p=0.03) (Figure 5-7 D).  
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Figure 5-4 Western blot analysis of Na+  transport channels in WT and KO mice (±2% NaCl) from whole kidney tissue.  
Protein lysates from snap frozen whole kidney tissue from male WT and KO mice (±2%NaCl) was prepared, quantified, electrophoreses, blotted, and probed for the 
main TAL Na+  transporters.  (A) Representative Immunoblots. Densitometry showed no difference in protein expression levels of (B) Na+ /K+ ATPase, (C) NKCC2, (D) 
ENac, or (E) ROMK between the WT and KO mice (±2% NaCl). GAPDH demonstrates equivalent sample loading and expression levels are displayed as % intensity 
normalised to GAPDH (Mean ± SEM). All data sets were measured by densitometry using the global background subtraction method
A.
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Figure 5-5 Investigation into the relationship between UMOD and TNF-α. 
Urine samples collected from male WT and KO mice following 6 weeks ±2% NaCl were 
assessed for levels of TNF-α by ELISA. (A) KO mice have significantly increased urinary 
TNF-α levels under salt loading conditions (+2% NaCl) compared to all groups, 
***p<0.0001. WT mice also have significantly increased urinary TNF-α levels following salt 
loading, **p<0.001. All data expressed as Mean ± SEM, n=5 per group and analysed by 
One way ANOVA followed by Tukey’s post hoc test. RNA was extracted from outer 
medulla tissue of WT and KO mice (±2% NaCl). TNF-α mRNA abundance was assessed 
by qRT-PCR using gene specific probes. (B) qRT-PCR showed an increase in the 
abundance of TNF-α gene in both WT and KO mice on salt-loading, reaching statistical 
significance in KO mice (*p=0.01), n=3 per group, data shown as Mean RQ ± SEM, 
analysed via student T-test. TAL cells from male WT mice were extracted and cultured for 
6 days. Cells were then treated ±10nM UMOD siRNA for 4 hours, followed by ±5 nM TNF-
α for 6 hours. NKCC2 A, and TNF-α mRNA abundance were assessed by qRT-PCR using 
gene specific probes. (C) In the presence of UMOD, stimulation with TNF-α decreased 
relative NKCC2A mRNA levels (**p<0.001, n=3). UMOD knockdown caused a greater 
reduction in NKCC2A transcript levels (***p<0.0001, n=3) that could not be further lowered 
by the addition of exogenous TNF-α. Data are expressed as Mean RQ ± SEM, n=3 per 
group and analysed by One way ANOVA followed by Tukey’s post hoc test. (D) 
Simulation of mTAL cells with 5 nM TNF-α caused an increase in the relative levels of 
UMOD mRNA by approximately 3.5-fold (***p<0.0001, n=3) data shown as Mean RQ ± 
SEM, analysed via student’s T-test. (E) Immunocytochemistry confirms the knock down of 
UMOD in TAL cells (representative images are shown).  
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Figure 5-6 Western blot analysis of UMOD, NKCC2, and TNF-α from outer medulla tissue of 
WT and KO mice (± 2% NaCl). 
Protein lysates from snap frozen outer medulla tissue from male WT and KO mice 
(±2%NaCl) was prepared, quantified, electrophoreses, blotted, and probed for UMOD, 
NKCC2, and TNF-α. (A) Representative Immunoblots. (B) Salt loading significantly 
increase protein expression levels of UMOD in outer medulla tissue of WT mice (n=5 per 
group, **p<0.001). (C) NKCC2 protein levels were attenuated in KO mice upon salt 
loading (KO normal vs. KO +2%NaCl, n=5 per group, #p<0.05 and WT mice +2%NaCl vs. 
KO mice +2%NaCl, n=5 per group, **p<0.01). (D) TNF-α levels were increased in both 
mouse strains upon salt loading (n=5 per group, *p<0.05, **p<0.001). GAPDh 
demonstrates equivalent sample loading and expression levels are displayed as % 
intensity normalised to GAPDH (Mean ± SEM). All data sets were measured by 
densitometry using the global background subtraction method for UMOD, NKCC2, and 
GAPDH however the local background subtraction method was used for measuring TNF-α 
as the background varied across the blot. Data sets were analysed by One way ANOVA 
followed by Tukey’s post Hoc test. 
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Figure 5-7 Western blot analysis of UMOD, NKCC2, and TNF-α from TAL cells ± UMOD 
siRNA.  
Protein lysates from TAL cells from male WT (± UMOD siRNA (10nM) and TNF-α (5nM)) 
were  prepared, quantified, electrophoreses, blotted, and probed for UMOD, NKCC2, and 
TNF-α (A) Representative Immunoblots. (B) The knock down of UMOD was successful in 
WT mouse TAL cells using siRNA (10 nM) by transient transfection and was not altered 
with the addition of TNF-α stimulation (5 nM) (‡ p<0.001). WT cells (scrambled control 
siRNA (10 nM treated)) treated with TNF-α resulted in significantly increased UMOD 
expression levels (**p<0.001). (C) Total NKCC2 protein levels were increased in TNF-α 
stimulated WT cells (**p<0.001). In the absence of UMOD total NKCC2 protein expression 
levels were reduced (p<0.001), which was further attenuated upon TNF-α stimulation 
compared to all other conditions (#p<0.001). (D) TNF-α protein levels are increased in 
cells treated with siRNA to knock down UMOD compared to the WT cells treated with 
scrambled control siRNA (*p=0.03). GAPDH demonstrates equivalent sample loading and 
expression levels are displayed as % intensity normalised to GAPDH (Mean ± SEM). All 
data sets were measured by densitometry using the global background subtraction 
method. Cell experiments were represent Mean ± SEM, n=3 independent replicates. Data 
analysed by One way ANOVA followed by Tukey’s post hoc test.  
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5.4.4 Immunohistochemistry  
Immunohistochemistry for UMOD showed strong staining in the WT mice in the 
outer medulla specifically at the TAL. Weak tubular staining was apparent in the 
KO mice with distribution in the outer medulla. On a cellular level UMOD 
staining was positive in the WT mice and accentuated in the apical region. In 
contrast, cells in knockout animals only showed positivity in the basolateral and 
middle cellular regions. Salt-loading increased the intensity of UMOD staining in 
the WT animals but did not affect the staining pattern in the KO strain (Figure 
5-8).  
 
NKCC2 staining clearly demonstrates localisation at the apical membrane of the 
TAL within the inner stripe of the outer medulla in both strains. KO mice 
illustrate weaker staining intensity than the WT mice under normal NaCl 
conditions. An increase of NKCC2 stain intensity can be appreciated at the apical 
membrane of kidney section of salt loaded (2% NaCl) WT mice. In contrast, KO 
mice +2% NaCl display dramatic reductions in staining intensity (Figure 5-9).  
 
WT and KO mouse kidney sections stained for TNF-α demonstrates increased 
staining is found highly expressed in the interstitium between the nephron 
segments. At 20x magnification it can be seen that TNF-α staining is more 
concentrated in the KO mice under basal conditions. Both mouse strains upon 
salt loading displayed increase signal intensity, however abundance is more 
apparent in the KO salt loaded mice (Figure 5-10).  
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Figure 5-8 Immunohistochemical staining for UMOD in kidney sections of WT and KO mice 
(± 2% NaCl). 
Paraffin embedded kidney tissue from WT and KO mice (
3µm thick and stained to investigate the localisation of UMOD.
UMOD in WT (± 2% NaCl) revealed
medulla. The cellular distribution is different between strains
mice. Staining is much weaker in KO mice and only seen in the basolateral
and middle regions of the cells
kidney sections (scale
position of the apical and basolateral membranes. 
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Figure 5-9 Immunohistochemical staining for NKCC2 in kidney section of WT and KO mice 
(± 2% NaCl). 
Paraffin embedded kidney tissue from WT and KO mice (±2% NaCl) were sectioned at 
3µm thick and stained to investigate the localisation of NKCC2. Immunohistochemistry for 
NKCC2 demonstrates staining is localised to the apical membrane at the TAL in both 
mouse strains under normal NaCl conditions, however weaker staining is apparent in the 
KO mice. Shown are 20x and 40x magnification fields of representative kidney sections 
(scale bars represent 100µm).Staining was not quantified. Black arrows indicate the 
position of the apical membrane.  
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Figure 5-10 Immunohistochemical staining for TNF-α in kidney section of WT and KO mice 
(± 2% NaCl). 
Paraffin embedded kidney tissue from WT and KO mice (±2% NaCl) were sectioned at 
3µm thick and stained to investigate the localisation of TNF-α. The distribution of the TNF-
α stain can be seen in the interstitium between the nephron segments. Staining patterns 
are similar between the strains with more intensity in the KO. Staining is more prevalent in 
both strains upon salt loading, with KO mice displaying increased staining compared to 
that of the salt loaded WT mice. Shown are 20x magnification fields of representative 
kidney sections (scale bar represents 100µm). Staining was not quantified. Black arrows 
indicate the region of the interstitium, apical and basolateral membranes.  
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5.5 Discussion 
Experimental work in this chapter explored differential expression analysis of 
the major Na+ handling transporters in the kidney of WT and KO mice before and 
after 6 weeks of salt loading, to determine the role of UMOD in sodium 
homeostasis and blood pressure regulation. Results have demonstrated that 
UMOD plays a direct role in sodium handling by mediating levels of TNF-α at the 
TAL, maintaining control of Na+ reabsorption via modulation of NKCC2 providing 
evidence of a novel functional pathway of BP regulation by UMOD that impacts 
renal sodium/volume homeostasis. 
 
Normally, the kidney synthesises large quantities of UMOD and urinary excretion 
is used as an indicator for renal tubular function (Torffvit et al., 1998). A 
positive correlation between urinary UMOD and dietary salt intake demonstrates 
that in subjects with high salt sensitivity, there is a greater excretion of UMOD 
than in the urine of low salt intake (Torffvit et al., 2004). This implies that 
reduced synthesis of the protein may cause or reflect renal dysfunction. Indeed, 
urinary UMOD reductions have been implicated in pathological conditions such as 
acute tubular necrosis, diabetic nephropathy, hyperprostaglandin E syndrome 
triggered by inflammatory cytokines, and active lupus nephritis (Bernard et al., 
1987, McLaughlin et al., 1993, Schroter et al., 1993, Tsai et al., 2000). In 
addition, urinary UMOD excretion is said to be reduced in patients with UMOD 
mutations responsible for the 3 autosomal dominant tubulo-interstitial 
nephropathies; medullary cystic kidney disease type 2, familial juvenile 
hyperuricemic nephropathy, and glomerulocystic kidney disease which are 
postulated to cause misfolding and impair trafficking of UMOD inhibiting its 
actions at the apical membrane (Williams et al., 2009). However, there is a lack 
of reports in the literature examining renal tissue samples to explore the roles of 
UMOD expression and physiological function in these conditions. Therefore, in 
the clinic urinary UMOD seems to be an accessible marker to assess renal disease 
although still does not explain functional roles of the gene.  
 
Accordingly, a lower UMOD excretion (either genetically or acquired) is 
associated with less sodium reabsorption implicating the role of UMOD in sodium 
homeostasis. To test this hypothesis the effects of salt loading may elucidate its 
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function further. Ying et al studied dietary salt effects on renal UMOD 
expression in rats and reported that salt loading increased mRNA expression 
levels, additionally furosemide treatment alongside 8% NaCl loading further 
augmented UMOD expression along with increased luminal NaCl (Ying and 
Sanders, 1998). These findings suggest that high salt intake may directly 
promote self aggregation of UMOD at the apical surface, forming a highly 
negatively charged, hydrophobic, gel like barrier in an attempt to regulate NaCl 
uptake at the TAL, thus maintaining electrolyte flux. These findings are 
consistent with the results in this chapter; relative UMOD mRNA levels 
demonstrated a significant increase when measured in whole kidney from WT 
mice upon salt loading. The augmented expression was further enhanced by 
approximately 2 fold when assessed in outer medulla tissue, suggesting a dilution 
effect when assessing whole kidney as UMOD is exclusive to the TAL. Alongside 
the reported increased UMOD mRNA abundance in the outer medulla tissue from 
WT mice, there was also an increased expression of total NKCC2 with 2% NaCl in 
this strain.  
 
Previous immunolocalisation experiments revealed that NKCC2 is expressed at 
the apical cell surface and also in subapical vesicles, where intracellular 
trafficking regulates NKCC2 membrane expression. Vasopressin has been shown 
to shuttle the subapical vesicles of NKCC2 to the apical surface, leading to 
enhanced activity and expression levels (Gimenez and Forbush, 2003). The 
transporter undergoes constitutive exocytosis at the TAL (Caceres et al., 2009) 
suggesting NKCC2 trafficking is a continuous dynamic process rather than a 
triggered event. Ares et al studied endocytosis and recycling of NKCC2 in the 
absence of stimuli and reported that NKCC2 undergoes retrieval from the plasma 
membrane at a rate that closely matches the reported exocytosis insertion (Ares 
et al., 2011). These reports suggest that under basal conditions and in the 
absence of stimuli dynamic trafficking of NKCC2 occurs. NKCC2 demonstrates co-
localisation with UMOD and NaCl reabsorption in the TAL has been reported to 
be impaired in the absence of UMOD (Mutig et al., 2011b). These findings may 
explain the reduced BP and NKCC2 expression in the KO mice and the opposing 
effects demonstrated in the WT mice where NKCC2 expression and BP were 
increased upon salt loading.  
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In contrast to salt losing syndromes, enhanced NKCC2 activity leads to 
hypertension caused by augmented NaCl reabsorption and volume expansion. In 
2004, Sonalker et al illustrated that spontaneously hypertensive rats (SHR) had 4 
fold higher expression levels of total NKCC2 (Sonalker et al., 2004). This group 
later measured membrane bound and total NKCC2 in the outer medulla in these 
rats by subcellular fractionation and found no difference in the surface to 
intracellular ratio of NKCC2 (Sonalker et al., 2007). Yet, progression from 
normotension to hypertension (5 – 8 weeks of age) in SHR was accompanied by a 
two fold increase in the surface to intracellular ratio of NKCC2 (Gimenez and 
Forbush, 2003). Additionally, in Dahl salt sensitive rats, NKCC2 dependent TAL 
transport, phosphorylation, and cell surface NKCC2 were enhanced upon salt 
loading with increased BP (Haque et al., 2011). Indicating that during salt stimuli 
in WT mice, increased UMOD expression may modulate NKCC2 trafficking beyond 
essential requirements altering Na+ uptake, ECF volume, and increasing arterial 
pressure, suggesting, that net sodium balance requires synchronised actions 
between UMOD and apical Na+ transporters.  
 
In further support of this concept, and consistent with previous studies 
(Bachmann et al., 2005), the KO mice in our study displayed significantly 
reduced mRNA expression levels of total NKCC2 in the outer medulla region. 
When salt loaded the KO mice display further reductions in NKCC2 mRNA 
abundance, suggesting that high salt intake blunts NKCC2 trafficking in the 
absence of UMOD. This is consistent with findings in rat studies on high salt diets 
where total NKCC2 expression was augmented however, NKCC2 dependent TAL 
transport and cell surface NKCC2 were significantly reduced, indicating 
increased intracellular levels of NKCC2 were responsible for the augmented 
expression levels of total NKCC2 (Haque et al., 2011). This decreased NKCC2 
trafficking to the apical membrane may contribute to the increased sodium 
excretion in the KO mice. Interestingly, KO mice under normal NaCl conditions 
showed total NKCC2 expression was increased to a similar level as that reported 
in the salt loaded WT mice. This is consistent with studies from Bachmann et al 
who found increased total NKCC2 expression in UMOD KO mice under normal salt 
conditions, with a disproportionate accumulation of NKCC2 in the subapical 
vesicle enriched compartment of the TAL (Mutig et al., 2011b). This 
accumulation may reflect an altered turnover, possibly via impaired degradation 
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of NKCC2 or simply an increase intracellular accumulation in the absence of 
UMOD.  
 
The exact mechanisms of interaction between UMOD and NKCC2 are not clear. 
GPI anchored proteins have functions in trafficking membrane proteins by 
mechanisms of lipid rafts, which provide sorting signals to intracellular 
membrane compartments (Welker et al., 2008, Paladino et al., 2008). Suggesting 
the co-localisation of UMOD and NKCC2, may share lipid raft localisation as 
activation of NKCC2 is dependent on the presence of lipid rafts (Wilson et al., 
2004). GPI anchored UMOD could, therefore, affect the function of these rafts 
providing scaffolds to promote interaction with NKCC2 (Rinehart et al., 2005, 
Delpire and Gagnon, 2008). These possible interactions may serve to explain the 
failure of NKCC2 activation or localisation at the apical membrane in the 
absence of UMOD. Implying two considerations that need attention from future 
studies; is the absence of UMOD “switching off” NKCC2 a compensatory 
mechanism to protect against salt induced essential hypertension, or does UMOD 
protect against salt wasting syndromes and hypotension? To elucidate this 
further, compartmentalisation studies, phosphorylation studies, and kinetic 
properties of UMOD in relation to NKCC2 should be studied in TAL cells ± salt 
stimulation.  
 
In order to investigate this relationship further in the present chapter, the splice 
variants of NKCC2 were examined in outer medulla tissue from WT and KO mice 
(±2% NaCl). The three NKCC2 isoforms (NKCC2A, NKCC2B, and NKCC2F) differ in 
their localisation along the TAL, and their ion transport characteristics. NKCC2A 
is located in the medullary and cortical TAL and exhibits immediate affinity for 
Cl- and accounts for 20% of total NKCC2 abundance. The B isoform shows highest 
affinity for Cl- and is primarily located in the macula densa cells and cortical 
region and represents 10% of transcript abundance. NKCC2F has the lowest 
affinity for ion transport, however, is mainly located in the medullary TAL, this 
transcript accounts for 70% of total abundance. The relative distribution of these 
isoforms and affinity for ion transport matches the luminal concentration of NaCl 
along the TAL. Mice lacking NKCC2A revealed lower urine osmolality and 
decreased Cl- reabsorption with enhanced expression of NKCC2B indicating 
compensation (Payne et al., 1995). Results here show WT mice under salt 
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loading conditions display increased expression of NKCC2A in the outer medulla 
representing increased NaCl reabsorption. Whereas KO mice display lower 
expression which was further attenuated under salt loading, consistent with 
previous studies reporting reduced NKCC2A expression and NaCl reabsorption in 
the presence of increased levels of TNF-α at the TAL (Battula et al., 2011). The 
previous study described that the increased NKCC2A expression at the TAL was 
not accompanied by changes in either NKCC2B or F expression. However, results 
here demonstrate similar trends expression levels of NKCC2A with NKCC2B in 
that WT mice displayed increased mRNA abundance during salt loading and KO 
mice had reduced abundance even more so under salt conditions. Schiessl et al 
reported that during times of high salt diet in mice there are significant 
increases in NKCC2A and NKCC2B mRNA expression levels (Schiessl et al., 2013), 
suggesting here, the adaptive capacity of the TAL to cope with its reabsorptive 
needs are altered depending on UMOD expression levels at the TAL. NKCC2F was 
unchanged in WT mice ± 2% NaCl but increased in KO mice upon salt loading; 
even though this isoform is the most abundant at the TAL it has the least affinity 
for Cl- but as NKCC2A and B were downregulated in KO mice the increased 
NKCC2F maybe a compensatory mechanism in these mice in an attempt to 
stabilise ion flux.  
It has been demonstrated recently in rabbit TAL cells transfected with UMOD 
that there was marked reduction in Cl- concentrations reflecting functional 
activation of NKCC2. This implies that in the presence of UMOD low Cl- 
concentrations may mirror enhanced transport of NaCl triggered by higher 
NKCC2 phosphorylation. Total NKCC2 expression is reduced in salt loaded KO 
mice suggesting the transporter is inactivated or intracellular. Increases of 
NKCC2F expression in KO mice as a result of salt loading may have been a 
potential compensatory mechanism to regulate sodium uptake in the TAL, 
however was not efficient enough to do so as the activation of NKCC2 seems to 
be a chloride sensing mechanism that is not apparent in the KO mice. The results 
suggest insufficient function of NKCC2 with lower sensitivity of the isoforms to 
changes in intracellular chloride concentrations in UMOD KO mice.  
 
The sequence of signals and interactions between UMOD and molecular 
mechanisms that contribute to the dynamics of TAL function still remain elusive. 
Studies exploring how tubular luminal flow participates in regulation of complex 
Chapter 5  221 
 
signals at this region of the nephron may provide information that helps define 
the relationship between UMOD and mechanisms of TAL NaCl homeostasis. The 
UMOD KO mice studied here display increased micturition and natriuresis 
potentially via the inactivation of NKCC2, however, other Na+ transporters may 
be involved. Evidence suggests that increased luminal flow of urine, and 
increased Na+ excretion may be facilitated by reduced ENaC activity during high 
salt intake to maintain arterial pressure (Pochynyuk et al., 2010). Studies in 
mice have shown that if fractional activity of ENaC is closer to zero, capacity to 
excrete sodium and urine rises. Conversely, as fractional ENaC activity 
approaches equilibrium, sodium excretion capacity falls. In a corresponding 
fashion, arterial pressure is expected to be normal in the first instance and 
elevate in the latter, particularly in the presence of a high sodium diet. These 
findings support the current results as WT mice display increased ENaC 
expression upon salt loading when examined in whole kidney and outer medulla 
tissue, suggesting increased NaCl uptake, volume expansion, and explaining 
increased BP. Whereas, the opposite effects were demonstrated in the salt 
loaded KO mice. The TAL encompasses a variety of receptors that enable it to 
respond to diverse stimuli, purinergic receptors are expressed along the TAL and 
studies by Cabral et al have shown activation of these receptors is achieved by 
increased release of ATP and contribute essentially to renal function (Unwin et 
al., 2003). For example in time of high luminal flow and NaCl concentrations, 
ATP release is increased to activate the P2 purinergic receptors to inactivate Na+ 
transport at the TAL (Silva and Garvin, 2009). In P2 receptor knockout mice, 
ENaC expression and activity was reduced and the animals retain their ability to 
respond to sodium intake as arterial pressure was not altered (Stockand et al., 
2010, Mironova et al., 2011). Therefore the reduced expression of ENaC in KO 
mice in response to dietary sodium here maybe a compensatory pressure 
natriuresis response to regulate BP.  
 
An increase in the luminal perfusion rate in mouse proximal tubules to increase 
Na+ and HCO3- reabsorption is associated with direct stimulation of the apical 
Na+ /H+ exchanger 3 (NHE3) (Du et al., 2006). Increased luminal flow causes drag 
force on the brush border microvilli initiating mechanotransduction in the 
proximal tubule causing the principle cells and the intercalated cells in the 
collecting duct to respond via central apical transporters. Numerous reports 
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have described elevated NHE3 mRNA expression before the onset of 
hypertension in hereditary strains of hypertensive rats (reviewed in (Girardi and 
Di Sole, 2012)). LaPointe et al examined NHE3 function in the renal brush border 
membrane vesicles of SHR and WKY (Wistar-Kyoto) rats before and during the 
onset of hypertension, reporting that NHE3 activity was increased in renal 
proximal tubules in SHR before onset of hypertension and remained high with 
elevated blood pressure (LaPointe et al., 2002). Opposite to increased activity 
and expression levels of NHE3 found during hypertension, NHE3 KO mice display 
chronic volume depletion and hypotension (Schultheis et al., 1998). In the 
current study, NHE3 was not different between WT and KO mice either before or 
after salt loading suggesting either the expression analysis is masked by a 
dilution effect in the whole kidney or UMOD has no strong relationship with this 
transporter. However, the KO mice did display increased NHE3 expression in 
outer medulla tissue which is difficult to interpret as the bulk of the proximal 
tubule (convoluted tubule S1 and S2) is in the cortex region of the kidney with 
the straight segment (S3) only descending into the medulla region as far as the 
mid line between the inner and outer medullary strip. The increased expression 
in KO mice during normal salt may be a mechanism to regulate tubuloglomerular 
feedback in times of altered luminal NaCl concentrations, involving the macula 
densa to reduce renal resistance and increase GFR in an attempt to increase 
NaCl reabsorption (Komlosi et al., 2005). This hypothesis is further supported by 
reduced expressed NHE3 in outer medulla tissue from KO salt loaded mice, 
suggesting reduced NaCl reabsorption.  
 
Approximately two thirds of sodium transport along the nephron occurs by active 
transport. Na+ K+/ATPase at the basolateral membrane of tubular cells is critical 
in primary active transport across the membrane. Expression is low in the 
macula densa and thick descending limb of the loop of Henle and minimally 
expressed at the TAL (Komlosi et al., 2009). Na+ K+/ATPase is composed of α, β, 
and γ subunits where studies have demonstrated the α subunit participates in 
the natriuretic response to salt load (Loreaux et al., 2008). Suppression of Na+ 
K+/ATPase activity markedly increases intracellular sodium (O'Brien et al., 
1994). Studies have shown that rodents fed high salt diets display reduced levels 
of Na+ K+/ATPase in the renal tissues (MacGregor et al., 1981) and pigs 
administered deoxycorticosterone plus 1% NaCl in the drinking water develop 
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reduced natriuresis increasing Na+ K+/ATPase inactivity by 30 fold and resulting 
in augmented arterial pressure (Hamlyn, 1989).  In whole kidney tissue only the 
KO mice displayed increased Na+ K+/ATPase α expression (± 2% NaCl) suggesting 
increased natriuresis, hence lower ECF volume and lower BP, however, 
conflicting results were reported in outer medulla tissue where expression levels 
were reduced. WT mice display increased Na+ K+/ATPase α expression in outer 
medulla tissue, which would imply increased natriuresis to regulate fluid 
volume. However, chronic renal function curves assessed natriuresis in these 
mice demonstrating enhanced fractional sodium in salt loaded KO mice and not 
the WT mice upon salt loading. Na+ K+/ATPase β revealed no changes in 
expression pattern between WT and KO mice when assessed in whole kidney 
tissue, conversely KO mice displayed significant reductions in expression in outer 
medulla tissue when salt loaded with similar levels to the α subunit. These 
results demonstrate the importance of activity assays to asses and determine the 
role UMOD has on these transporters in the co-ordination of Na+ transport. Even 
though the mechanisms have not been elucidated the results here do show clear 
difference between the strains in that UMOD does seem to facilitate tubule Na+ 
reabsorption but during times of salt induced increases in BP may potentially 
drive excess NaCl reabsorption. The increased diuresis and natriuresis found in 
the salt loaded KO mice shows a link between increased luminal flow and altered 
Na+ uptake in the absence of UMOD.  
 
Axial flow regulates potassium transport along the nephron facilitating water 
impermeability at the TAL to maintain high medullary interstitial osmolality for 
conservation of the renal countercurrent exchange system to produce 
concentrated or dilute urine. The ATP sensitive potassium channel (ROMK) 
resides in the apical membrane in the TAL and processes NaCl reabsorption via 
the recycling of K+ ions into the tubular lumen. It forms a functional unit with 
NKCC2, the rate limiting transporter. Disrupted ROMK function at the TAL limits 
NaCl reabsorption resulting in the salt wasting phenotypes observed in Bartter’s 
syndrome. The KO mice in this study displayed significantly reduced ROMK 
expression in the outer medulla tissue under salt loading conditions, confirming 
a potential role of UMOD in regulating NaCl transport. Renigunta, et al identified 
UMOD as a ROMK interacting protein, regulating ROMK function by increasing its 
expression at the cell surface of the TAL apical membrane (Renigunta et al., 
Chapter 5  224 
 
2011). Furthermore, this group observed a decrease in ROMK immunoreactivity 
in the plasma membrane enriched fractions of UMOD KO mice kidney compared 
to WT counterparts. They demonstrated that UMOD ablation results in large 
accumulation of ROMK in the sub apical vesicles resulting in delayed or 
decreased surface expression leading to salt wasting in the following fashion: 
fluid enters the TAL at high concentrations of Na+ and Cl- with low 
concentrations of K+. Therefore, the stochiometric flux of Na+ and K+ into the 
cell via the co-transporter (NKCC2) would rapidly deplete K+ levels in the luminal 
fluid, preventing efficient reabsorption of Na+ and Cl-. This stimulation is 
normally avoided by the recycling of K+ entering the cell back into the lumen. 
Thus, the absence of K+ recycling results in markedly impaired NaCl 
reabsorption. Studies in 2010 by Fang et al demonstrated that resistive 
hypertension results from inhibited ROMK channel function and expression 
providing evidence into the role of the channel in blood pressure maintenance 
and further supporting the role of UMOD in Na+ and BP control (Fang et al., 
2010).  
 
Collectively, the expression studies described here alongside previous reports 
illustrate that UMOD functionally mediates NaCl transport at the TAL. The down 
regulation of NKCC2 and ROMK in the outer medulla tissue of salt loaded KO 
mice is of great interest. These channels are co-expressed with UMOD at the 
apical membrane and are well documented to be linked with salt wasting in 
times of altered function, suggesting that the reduced arterial pressure and 
increased natriuresis in the UMOD KO mice is driven by altered regulation of 
these channels. Additionally, it is documented that Na+ reabsorption at the TAL 
is adversely affected by increased cytokine production (Ferreri et al., 1997). 
UMOD has been described as having immunosuppressive effects by binding with 
high affinity to TNF-α, thereby inhibiting inflammation (Wu et al., 2008).  
 
The KO mice in this study display increased levels of urinary TNF-α, which is 
further increased upon salt loading. This data is consistent with a recent study 
reporting that salt loading increased TNF-α production by the kidney (Ferreri et 
al., 2012), and more specifically the TAL (Hao et al., 2011), an effect that is 
greatly accentuated in UMOD KO mice. Furthermore, salt loaded KO mice here 
display significantly increased mRNA levels of TNF-α in outer medulla tissue. The 
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elevated levels of TNF-α observed in KO mice suggests that cell-surface UMOD in 
the WT mice sequesters TNF-α, limiting the amount of cytokine that is 
generated. In TAL cells, Na+ uptake, across the apical cell membrane, is 
primarily mediated by NKCC2. Results here, show that TNF-α can reduce the 
levels of NKCC2A mRNA in primary mTAL cells, and that this effect is enhanced 
in the absence of UMOD. Ferreri and colleagues previously reported similar 
results showing that TNF-α is an endogenous inhibitor of the NKCC2A isoform, 
(Battula et al., 2011). The effect on NKCC2A mimics the effects of Bartter’s 
syndrome in humans which replicates the effect of thiazide diuretics, is 
associated with low BP, and patients self-select a high salt diet as an adaptive 
mechanism to maintain their BP. 
In mTAL cells, stimulation with TNF-α was found to increase the relative levels 
of UMOD mRNA, creating a negative feedback loop in which the TNF-α induced 
reduction in NKCC2A gene expression is switched off through increasing the 
production of cell-surface UMOD. Ultimately, suggesting that UMOD acts as a 
negative regulator of TNF-α production by the TAL to maintain NaCl 
homeostasis. Protein expression analysis from outer medulla tissue of KO mice 
+2% NaCl and WT cells ± siRNA to knock down UMOD expression, revealed 
consistent trends of increased TNF-α expression along with reduced NKCC2 
expression. Transient transfection of siRNA against UMOD was used to mimic the 
effects of the UMOD KO mouse TAL cells. This finding is not unique to this study, 
previous studies using KO rodent models have also experienced unsuccessful 
culture of TAL cells (Battula et al., 2012). The TAL cells extracted from KO mice 
did not culture beyond 30% confluence, therefore as a substitute WT mouse TAL 
cells were utilised. Results confirm that UMOD plays a critical role in BP 
regulation by mediating the effects of TNF-α on NKCC2 to maintain sodium 
homeostasis. UMOD KO mice on high salt have a mild Bartter’s phenotype, with 
reduced BP and reduced Na+ reabsorption compared to WT mice. However, 
protein analysis did detect UMOD expression in the KO mice tissue but at 
approximately 54 kDa which does not represent a physiologically active protein. 
Immunohistochemistry also displayed weak but, not absent staining in thick 
ascending limb in the knockout animals possibly due to the primary antibody 
being polyclonal raised against amino acids 291-425 corresponding to exons 4-6 
and the KO only covered exons 1-4. Weak staining for uromodulin in the basal 
and middle cellular regions in the knockout mice indicates that the shortened 
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protein is produced, but is not processed and transported to the apical cell 
surface. WT mice display increased intensity of staining at the apical membrane 
upon salt loading which is consistent with expression studies. In the absence of 
UMOD, NKCC2 staining is substantially weaker than the WT mice under normal 
NaCl conditions. Clear intense apical staining of NKCC2 was found in the WT 
mice upon salt loading consistent with expression studies, whereas salt loading 
reduces NKCC2 staining in the salt loaded KO mice. TNF-α was revealed to be 
increased in both strains upon salt loading although KO mice have increased 
interstitial staining. Future immunohistochemistry examination should be 
quantified and double immunocytochemistry should be utilised to examine co-
localisation of UMOD and TNF-α.  
 
Collectively, these data suggest that increased renal production of TNF-α may 
facilitate reduced Na+ reabsorption along the TAL, thereby increasing the 
sensitivity of the pressure natriuretic mechanism. The cardiovascular 
characterisation in the last chapter illustrated that blood pressure differences in 
UMOD KO mice were driven by altered Na+ reabsorption at the TAL causing 
increased pressure naturesis. Metabolomic and microarray investigation revealed 
UMOD regulates TNF-α and NaCl transport via NKCC2. The work outlined in this 
chapter has shown that UMOD may play a direct role in blood pressure regulation 
by modulating the effect of TNF-α on NKCC2A providing evidence of a novel 
functional pathway of BP regulation through UMOD and renal sodium/volume 
homeostasis. To confirm these findings translational studies in human kidney 
samples from normotensive and hypertensive subjects is assessed in the next 
chapter. 
  
   
 
6 Gene expression analysis in the Silesian Renal 
Tissue Bank collection (a pilot study) 
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6.1 Introduction 
The findings that the minor G allele of rs13333226; in the cis-acting region of the 
UMOD gene was associated with lower risk of hypertension, independent of renal 
function (Padmanabhan et al., 2010), along with UMODs exclusive synthesis and 
expression at the TAL suggests a putative functional role of UMOD in blood 
pressure regulation via mechanisms on sodium homeostasis.  This hypothesis is 
supported by findings from the previous chapters demonstrating variants in LD 
with the index SNP (rs13333226) alter UMOD promoter activity in a genotype 
dependent manner and that absent UMOD results in reduced blood pressure 
phenotypes, increased natriuresis, and altered expression of renal sodium 
transporters. To date there are lacking studies of functional follow up of rare 
variants implicated from GWAS in human essential hypertension. Analysis of 
association between index SNPs and measures of gene expression at the 
transcriptional and translational level in relevant tissues is one way to verify 
whether implicated variants are functionally important. Although relatively 
straightforward in concept the relationship between implicated SNP(s) with 
mRNA abundance always requires availability of relevant human tissue. This 
chapter examines whether genotype of the index SNP rs13333226 influences 
UMOD expression in a small cohort of human renal tissue and if so does this 
impact expression of other sodium transporters. Human kidney tissue samples 
from a cohort of normotensive and hypertensive subjects were utilised as part of 
a small pilot study to examine the translational findings from the UMOD KO mice 
to confirm the role of UMOD in BP regulation and sodium homeostasis. Access to 
the human kidney samples in this chapter was kindly facilitated by Dr Maciej 
Tomaszewski, at the University of Leicester.   
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6.2 Aims 
• To genotype a human cohort for SNP rs13333226. 
• To investigate genotype dependent gene expression levels of UMOD, 
NKCC2, TNF-α, and NHE3 in human kidney tissue from normotensive and 
hypertensive subjects following findings from the UMOD KO rodent model.   
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6.3 Methods 
6.3.1 Subjects 
6.3.1.1 Silesian Renal Tissue bank (SRTB)   
The Silesian Renal Tissue Bank (SRTB) is a collection of human renal tissue from 
hypertensive and normotensive subjects that was gathered to investigate renal 
expression of candidate genes in human cardiovascular disease. The SRTB is an 
on-going recruitment of individuals electing for unilateral nephrectompy due to 
non-invasive renal cancer. These individuals were classified as hypertensive or 
normotensive based on criteria used in the SHS study (Tomaszewski et al., 
2007a). Tissue samples (approximately 1 cm3) were collected from the healthy 
(unaffected by cancer) pole of the kidney and appropriately preserved 
immediately after surgery in RNAlater (Ambion, Texas, USA) for further analysis.  
6.3.1.2 The Silesian Hypertension Study (SHS) 
The SHS is a cohort of 207 Polish families with essential hypertension from the 
Silesian region of Southern Poland (Tomaszewski et al., 2007b). All hypertensive 
index patients were identified and recruited with available members of their 
families (parents and/or siblings). Out of the 207 families, 629 subjects with 
clustering of essential hypertension were recruited following phenotyping using 
standardised questionnaires, physical examinations, basic anthropometry 
measurements, and fasting blood biochemistry analysis. Blood pressure was 
measured in triplicate and in accordance with current guidelines (Whitworth, 
2003) using a mercury sphygmomanometer. Subjects were considered 
hypertensive if their BP readings on 3 different occasions were > 140/90 mm Hg 
(as SBP/DBP) and/or on enrolment they were taking antihypertensive treatment. 
6.3.1.3 Western Poland Kidney Project (WPKP) 
The Western Poland Kidney Project (WPKP) is an on-going study collecting 
human renal tissue from patients electing unilateral nephrectompy due to non-
invasive renal cancer. A detailed medical history and anthropometric 
measurements were recorded alongside BP measurements (using an automatic 
digital BP monitor after 10 minutes of rest, using a cuff size adjusted to the arm 
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circumference). Hypertension was defined as SBP and/or DBP >140/90 mmHg on 
3 separate occasions and/or remaining on antihypertensive treatment. Renal 
tissue samples were taken from the unaffected pole of the kidney immediately 
after surgery and placed in RNAlater (Ambion), before being preserved at -80’C. 
 
All patients were recruited in Silesia Poland and all were of white European 
ancestry. Averages of three BP measurements (after 10 minutes rest) were 
recorded. Each patient was classified as hypertensive or normotensive in 
accordance with the guidelines set out by the international society of 
hypertension (Whitworth, 2003). 
 
6.3.1.4 Bioethical approval 
Written, informed consent was obtained from all subjects, in accordance with 
the Declaration of Helsinki (WMA Declaration of Helsinki - Ethical Principles for 
Medical Research Involving Human Subjects).  All studies had approval from 
relevant institutional ethical committees. 
 
6.3.2 RNA extraction, cDNA synthesis, and quantitative Real Time 
PCR  
RNA was extracted, validated, and DNAse treated, as per sections 2.2.4 to 2.2.6 
in the general methods chapter. The concentration of the samples was 
quantified as per section 2.2.7 and qRT-PCR was performed using Taqman® assay 
systems according to section 2.3.1. Table 6-1 details the Taqman® assays used in 
this chapter. In this chapter β-microglobulin was used as the house keeper 
control gene (assay number Hs_04233590.91, reference sequence NR_036523.1, 
and exon boundary 1-1) (Life Technilogies, Paisley, UK).  
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Table 6-1 Taqman® assays used to determine expression levels of UMOD, TNF-α, NKCC2, 
and NHE3 
 
 
6.3.3 Genotyping 
Genotyping was performed as per section 3.3.2.  
6.3.4 Statistical analysis  
In this chapter, studies using qRT-PCR Taqman® assays were analysed as per 
section 2.3.2 in the general methods chapter. Genotyping assays of the Silesian 
and WPKP cohorts were assessed on the basis of Weinberg equilibrium (HWE) 
using Pearson x2 test available in SIB-PAIR software (Tomaszewski et al., 2007a). 
A non conservative cut off value of p<0.01 was used as a threshold of the HWE 
test. SNPs with HWE x2 statistics corresponding to the probability value of <0.01 
were excluded from the association analysis.  For statistical comparisons in data 
sets with more than two groups, analysis of variance (ANOVA) was applied, 
followed by the Tukey’s post hoc test, comparing all samples groups against a 
designated control group or for comparisons between the groups. 
  
Transporter 
 
Gene name Taqman® assay Reference sequence Exon boundry 
UMOD Uromodulin Hs00358451_m1 NM_001008389.1 5-6 
TNF-α TNF-α Hs9999073_m1 NM_000594.2 1-2 
NKCC2 SLC12A1 Hs00165731_m1 NM_000338.2 13-14 
NaHe3 SLC9A3 Hs000903842_m1 NM_004174.2 11-12 
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6.4 Results 
6.4.1 Demographics 
This study was blinded to which subjects were from which independent Silesian 
cohort, therefore, hypertensive status was the only variable used to distinguish 
between subjects in the entire cohort in this chapter. Two subject groups have 
been used; Normotensive and Hypertensive subjects. The clinical demographics 
are outlined in Tables 6-2 and 6-3. Gender of each group is outlined in Table 6-
4.There was no significant difference between Age (p=0.48), BMI (p=0.32), SBP 
(p>0.05), and DBP (p>0.05) between normotensive and hypertensive subjects.  
6.4.2 Genotype of subjects 
The distribution of rs13333226 in subjects genotyped in this chapter was in 
concordance with HWE (65 subjects were of AG genotype, 41 being of AA 
genotype, and 31 being of GG genotype) p=0.86 in x2 test.  Five samples of the 
cohort were undetermined (Figure 6-1).  
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Table 6-2 General clinical characteristics of Normotensive subjects from the SHS, SRTB, 
and WPKP cohorts 
 
Table 6-3 General clinical characteristics of Hypertensive subjects from the SHS, SRTB, and 
WPKP cohorts 
 
 
Table 6-4 Gender of Normotensive and Hypertensive subjects 
 
 
 
Variable Mean Std. Dev. Min Max n 
Age (years) 56.3 11.1 20 75 49 
BMI (kgm2) 25.6 4.1 17.9 37.7 49 
SBP (mmHg) 125.2 7.4 108.3 140 49 
DBP (mmHg) 78.2 6.5 60 90 49 
 
Variable Mean Std. Dev. Min Max n 
Age (years) 63.8 9.1 43 87 99 
BMI (kgm2) 28.9 4.1 20.4 42.3 99 
SBP (mmHg) 143.4 12.3 116.6 173 99 
DBP (mmHg) 86.8 7.3 70 103 99 
 
Sex Normotensive Hypertensive  
Male 22 38  
Female 27 61  
    
Total 49 99  
 
Chapter 6  235 
 
 
Figure 6-1 Genome cluster plot for rs13333226   
Each data point represents an individual subject that was genotyped for rs1333226.The 
results showed; Green dots are of AG genotype (n=65), blue dots are of AA genotype 
(n=41), and red dots are of GG genotype (n=31). Black crosses represent undetermined 
samples (n=5). Genotypes were in accordance of HWE (p=0.86).  
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6.4.3 Association between rs13333226 polymorphism, gene 
expression analysis, and hypertension status 
In this study rs13333226 was marginally significantly associated with UMOD 
expression and hypertension status (p=0.05), however, when adjusted for centre 
there was a significant association (p=0.02) (Table 6-5).  UMOD expression was 
significantly increased in hypertensive subjects when of AA genotype 
(***p<0.0001) as was NKCC2 (**p<0.001) and NHE3 (**p<0.001) (Figure 6-3 A). 
There was no difference in TNF-α expression levels in subjects of AA genotype 
(p=0.43) (Figure 6-3 A). Gene expression levels were not different between 
Hypertensive and Normotensive subjects when of AG genotype for SNP 
rs13333226 of UMOD (p=0.68), TNF-α (p=0.60), NKCC2 (p=0.31), and NHE3 
(p=0.26) (Figure 6-3 B). When rs13333226 was of GG genotype, there was no 
difference in UMOD (p=0.69), TNF-α (p=0.79), NKCC2 (p=0.34), and NHE3 relative 
expression levels (p=0.99) between Hypertensive and Normotensive subjects 
(Figure 6-3 C).  
 
 
 
 
 
 
 
 
 
 
Chapter 6  237 
 
 
Table 6-5 Association of rs13333226 and hypertension status 
Regression analysis reveals SNP rs13333226 was not significantly associated with 
UMOD expression or hypertension in the current cohort (p=0.05). However, when 
adjusted for centre (place tissues were collected, each place has a centre identification 
number) there was a significant association (p=0.02).  
 
 
 
 
Variable 
 
Coefficient St dev    t P(<) 95% Conf.     Interval 
rs13333226     -0.65  0.34 -1.94 0.05 -1.33               0.17 
Centre 3      2.65  1.14 -0.91 0.02   0.37              4.93     
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Figure 6-2 Association between Gene expression and rs13333226 vs. hypertension status  
(A) UMOD, NKCC2, and NHE3 mRNA abundance was increased in Hypertensive 
subjects when of AA genotype for rs13333226 (**p<0.001, ***p<0.0001, n=41 in total). (B) 
Subjects of AG genotype for rs13333226 show no difference in gene expression levels 
between Hypertensive vs. Normotensive subjects, n=65 in total. (C) Hypertensive and 
Normotensive subjects of GG genotype for rs13333226 showed no differential gene 
expression levels, n= 31 in total. Data shown as Mean dct ± SEM. Mean dct derived from 
ct values of each gene minus ct value of the β-microglobulin house keeper control gene, 
where increasing dCt represents reduced expression. Analysed by One way ANOVA 
followed by Tukey’s post Hoc multiple comparison test.  
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6.5 Discussion 
Results in this chapter outline the ongoing follow up of the GWAS signal from 
rs13333226 to elucidate further the functional roles of UMOD in blood pressure 
regulation. This study is the first to investigate UMOD expression levels along 
with other sodium transporters in human renal samples from normotensive and 
hypertensive individuals. The initial discovery of a significant association 
between hypertension and rs13333226 genotype by Padmanabhan and colleagues 
was not replicated in the present study (Padmanabhan et al., 2010) but did 
reach borderline statistical significance (p=0.05). Association only reached 
statistical significance when adjusted for centre that samples were collected, 
however the number of normotensive vs. hypertensive subjects within each 
centre was not divulged in the present study therefore it is difficult to stratify 
causality in this instance. Nevertheless, results here demonstrate that UMOD, 
NKCC2, and NHE3 expression levels are altered in the absence of the minor G 
allele of rs13333226. Following segregation by genotype for rs13333226 and 
hypertensive status, gene expression analysis revealed that hypertensive 
subjects of AA genotype demonstrated increased expression levels of UMOD, 
NKCC2, and NHE3. All of which have been implicated in the progression and/or 
duration of hypertension by means of increased NaCl reabsorption and volume 
expansion (extensively reviewed in (Ares et al., 2011, Girardi and Di Sole, 2012). 
The relationship between UMOD, and NKCC2 expression levels are consistent 
with findings in the previous results chapters. The evidence suggesting that 
altered UMOD expression leads to increased TNF-α mRNA abundance, inhibiting 
NKCC2 expression at the TAL was not confirmed in the present study. TNF-α was 
not differentially expressed between normotensive and hypertensive individuals 
of any genotype for rs13333226.  
 
Blood pressure was not significantly different between the groups presumably 
due to adequate treatment interventions to lower BP in the hypertensive 
subjects.  Pharmacological intervention was unknown in the present study but is 
a variable used to control sodium transport along the nephron. Diuretics are 
used as a common treatment to produce natriuresis and diuresis by acting upon 
Na+ transporters. Loop diuretics are the most potent class of diuretic 
therapeutics (Sahay et al., 2007), however, there are limited studies 
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documenting the direct effects of loop diuretics on UMOD. Early studies in the 
80’s demonstrated that the diuretic action and binding of furosemide and 
bumetanide did not act via UMOD (Brunisholz et al., 1987) however; conflicting 
studies report that UMOD binds with furosemide at concentrations close to those 
required for inhibition of electrolyte transport in vivo (Greven, 1983). 
Furthermore, the same study reported that the sodium concentration necessary 
for stimulation of active transport in the TAL is also necessary for binding of 
furosemide to UMOD (Greven, 1983). This hypothesis needs further study but 
may suggest counter regulatory effects of UMOD expression on sodium 
homeostasis. Interestingly, as gene expression levels were not dissimilar 
between normotensive and hypertensive individuals when of AG or GG genotype 
for rs13333226 support the hypothesis that the G allele is associated with lower 
risk of hypertension by means of altered UMOD expression at the TAL impacting 
sodium homeostasis. This finding should be confirmed by being repeated in a 
larger cohort and of differing sub-group populations. 
 
Genotyping assays show that allele frequencies of contrasting genotype for 
rs13333226 were more frequent than the initial GWAS study. The present study 
demonstrates that approximately 47.4 % of the tested cohorts were of AG 
genotype for rs13333226, with 29.9 % being of AA genotype, and the remaining 
22.6 % being of GG genotype which equates to a MAF of approximately 44%. This 
is substantially higher than expected when the MAF in the original GWAS study 
was only 18 %. However, in support, the population distributions seem highly 
variable, even between like groups, with sub European population between 11 % 
and 25 %, and global populations between 2 % and 36% (outlined in Figure 6-4) 
(Abecasis et al., 2010). It would have been informative to distinguish which of 
the 22.6 % of GG genotype individuals which were hypertensive. This may then 
substantiate gene expression results. The augmented allele frequency from this 
cohort vs. the original GWAS suggests other variables may be causing enrichment 
of this SNP. Thus, there are considerations that must be taken into account: the 
individuals in the cohort were of a selected population suffering renal cancer; 
the sample size is not sufficient for accurate assessment of allele frequency; or 
simply rs13333226 maybe associated more with cancer phenotypes.  
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Figure 6-3  Allele frequency of rs13333226 in global populations 
Image reproduced from (www.1000genomes.org). ALL represents all assessed 
populations, AFR = African, AMR = American, ASN = Asian, and EUR = European 
populations. ASW = African American populations from South West USA, LWK = Luhya 
Webuye, Kenya, and YRI = Yoruba Inbadan, Nigeria. CEU = Utah residents with Northern 
and Western ancestry, FIN = Finland, GBR = Great Britain, IBS = Iberian populations in 
Spain, and TSI = Tuscany in Italy.  
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To date, there are insufficient biological follow up studies translating GWAS 
findings into disease mechanisms. Findings must be investigated functionally to 
validated causality of identified variants and genes for complex traits of 
essential hypertension.  Here we have assessed the functional effects of 
rs13333226 genotype on UMOD expression levels in human renal tissues during 
hypertension. Demonstrating the G allele of rs13333226 may alter UMOD 
expression at the TAL to regulate sodium homeostasis via mechanisms on other 
sodium transporters; NKCC2 and NHE3. Although cause and effect are still 
undetermined, principally, these findings indicate that UMOD variants play a 
role in blood pressure regulation via altered sodium homeostasis. Future work 
should focus on functional mechanisms of sodium transport in a genotype 
dependent manner. Such studies are urgently needed, not only to identify 
variants that may contribute to the complex traits of disease, but perhaps even 
more importantly, to identify those that mediate differential gene expression 
resulting from environmental influences. 
 
   
  
7 General Discussion 
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The first successful GWAS for hypertension using an extreme case-control design 
in which a discovery sample of 1,621 hypertension cases and 1,699 
hypercontrols, representing the top 2% and bottom 20% of the BP distribution 
was conducted (Padmanabhan et al., 2010). Combined with follow-up validation 
analyses in 19,845 cases and 16,541 controls, a locus upstream of the UMOD 
gene was identified and linked with sodium homeostasis. The ultimate goals of 
GWAS analysis are to improve patient risk prediction, diagnosis, prevention, and 
finally to develop treatments that improve quality of life and survival. The 
reported association between hypertension status and rs13333226 will contribute 
little without understanding the functional impact of UMOD on BP and sodium 
homeostasis. These findings prompted the present thesis to investigate the 
mechanisms of altered UMOD expression in blood pressure regulation and the 
development of essential hypertension.  
 
The post GWAS reported analysis here is the first of its kind to include 
approaches for subsequent functional biological investigation in vitro, in vivo, 
and translational studies in human tissue to explore the role of UMOD variants in 
hypertension and sodium homeostasis. We have identified a SNP, rs4997081, in 
LD with rs13333226 that altered promoter activity and may be a causal variant 
altering transcriptional activity of UMOD. Furthermore, binding of rs4997081 to 
TFAP2A in a genotype (sequence) dependent manner leads to transcriptional 
changes of UMOD which were associated with altered sodium reabsorption. 
Cardiovascular characterisation studies revealed significantly lower SBP in the 
UMOD KO mouse which was not sensitive to change by salt loading. Chronic renal 
function curves demonstrate that the reduced SBP is attained by increased 
natriuresis via augmented GFR. Expression analysis studied in outer medulla 
tissue implicated down regulation of the major NaCl transporters in the absence 
of UMOD which were further reduced upon salt loading conditions. In contrast to 
these findings, WT mice displayed the opposite results with increasing SBP (± 2% 
NaCl). In particular NKCC2, ROMK, and NHE3 expression levels were reduced in 
UMOD KO mice and more so under salt loading potentially influenced by 
increased levels of TNF-α at the TAL. These results suggested decreased NaCl 
reabsorption leading to the reported reduced BP phenotype in the KO mice as 
UMOD acts as a negative regulator of TNF-α production by the TAL to maintain 
NaCl homeostasis. In human tissue we confirmed that in times of altered UMOD 
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expression there are changes in NKCC2 and NHE3 mRNA expression levels but not 
TNF-α. Interestingly we have demonstrated that UMOD, NKCC2, and NHE3 
expression levels are altered in a genotype dependant manner, suggesting the 
minor G allele of rs13333226 appears to be associated with altered sodium 
homeostasis.  
  
Genetic variants collectively identified so far explain only a small fraction of BP 
variance (< 3%) and often lack replication across studies (Bowden et al., 2010). 
Phenotypic heterogeneity (Charchar et al., 2008), genetic heterogeneity, 
differences in allele frequencies or LD patterns (Harrap, 2009), epistasis (Deng, 
2007), and gene-environment interactions, may explain the poor replication of 
implicated genetic variants across studies. The major breakthrough with GWAS 
has been the identification of robust signals for common diseases and traits and 
novel pathways of disease. Despite this success, these studies of blood pressure 
phenotypes have shown that many common variants exert very modest effects, 
for example the 29 loci identified so far equates to only approximately 0.9 % of 
the phenotypic variance for systolic and diastolic blood pressure (Ehret et al., 
2011). Several explanations for the missing heritability have been proposed, for 
example on the basis of quantitative genetic variation, causal polymorphisms 
may be rare (Pritchard, 2001) and in novel pathways. These low frequency, rare 
variants have larger effects than common variants (Abecasis et al., 2010). 
However, they have not been fully interrogated for association with BP. 
Therefore, it is of interest to test whether rare variants, at gene loci contribute 
to essential hypertension in the general population. Although, the ability of 
GWAS to detect rare BP influencing variants is hindered by the burden of 
multiple testing and some studies are simply underpowered to detect the effect 
sizes that loci exert on blood pressure. The modest findings from individual 
GWAS for blood pressure quantitative traits led to the progression of large meta-
analyses of GWAS. Since 2009 a number of large-scale meta-analyses of GWAS 
for blood pressure in individuals of European ancestry have identified loci 
affecting systolic, diastolic, pulse, and mean arterial blood pressure (Newton-
Cheh et al., 2009, Levy et al., 2009, Wain et al., 2011).  
An important limitation to GWAS is that index SNPs become known as “tag” SNPs 
and do not offer direct information on the causal variant. To translate these 
signals to biological function they need to be followed up to evaluate functional 
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impact. GWAS is based on the principle that a causal variant is located on a 
haplotype, and therefore a marker allele in LD with the implicated causal 
variant should show an association with a trait of interest. Observations from 
sequencing studies of individual loci and large-scale SNP data reveal that alleles 
of nearby SNPs tend to have stronger correlation with each other across 
individuals (Nickerson et al., 1998, Daly et al., 2001, Gabriel et al., 2002). That 
is, they are in strong LD and form limited numbers of haplotypes. These LD SNPs 
represent a range of complex trait genetic architectures to follow up 
functionally in the aim to discover polymorphic genes/loci that influence 
quantitative traits and susceptibility to essential hypertension.  
In the present study a 2 Kb region of interest, based on LD around the index SNP 
was identified to likely harbour the causal variant(s) (Iwai et al., 2006, Zhu et 
al., 2002). Using promoter activity assays this study was successful in verifying in 
vitro that the minor G allele of rs13333226 identified from the original GWAS 
was associated with altered transcriptional activity. Furthermore, with site 
directed mutagenesis we identified a potential causal variant (rs4497081) in LD 
with rs13333226 that altered promoter activity suggesting that rs13333226 was 
not a functional variant. It is not an unusual finding that the index SNP is not an 
implicated functional SNP as GWAS of disease typically result in the 
identification of genomic susceptibility loci, in which several SNPs showing 
strong inter-marker LD are equally associated with disease traits (Wang et al., 
2011a). Focusing on the tag SNPs only, without systematically capturing the 
underlying causal variants within a ‘tagged’ linkage block, limits the functional 
associations that can be drawn from GWAS. By incorporating the correlation 
between SNPs in LD a stronger and more consistent association with complex 
disease traits is expected.  
 
SNPs identified by GWAS often do not map within genes, but upstream in 
promoter regions therefore, complicating the interpretation of the findings 
(Hindorff et al., 2009). To narrow the list of plausible causal variants, 
bioinformatics approaches are often used to prioritise SNPs based on their 
potential functionality. These tools apply evaluation on for example; potential 
transcription factor binding sites to specific DNA sequences. Our computational 
analysis reported one differential transcription factor binding sites associated 
with rs4997081 on the G allele; TFAP2A. One way to investigate the 
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transcriptional regulation of identified variants is to study the effects of 
differential transcription factor binding effects on gene expression. These types 
of analysis add strength and robustness to detected associations with complex 
disease. In the current study we utilised ChIP to assess whether binding of the TF 
specifically at the DNA sequence of the G allele causes altered transcriptional 
activity of UMOD. ChIP investigation in this thesis validated the binding of 
TFAP2A to the G allele while suggesting lower affinity of binding to the C allele. 
Interestingly, when this binding was silenced it reduced promoter activity of the 
contrasting C allele. This evidence suggests that the repressive activity of 
TFAP2A causes indirect effects on promoter activity on the contrasting C allele. 
TFAP2A activity has been shown to modulate a wide range of interacting 
proteins (Hilger-Eversheim et al., 2000) thus, it is conceivable that differential 
binding to variants in the promoter region may account for altered expression of 
UMOD and contribute to functional effects of transcription; however, the exact 
mechanism remains to be elucidated. Network analysis was performed with IPA 
to investigate this hypothesis and demonstrated TFAP2A signals downstream to 
TNF-α (Gee et al., 1999, Nyormoi et al., 2001). As increased levels of TNF-α at the 
TAL have been shown to cause increased natriuresis (Escalante et al., 1994) it 
could be speculated that the minor G allele binds with TFAP2A to regulate levels 
of the pro-inflammatory cytokine to maintain normal sodium homeostasis. This is 
in keeping with the initial GWAS findings reported that the minor G allele of 
rs13333226 was associated with lower risk of hypertension and higher glomerular 
filtration rate (Padmanabhan et al., 2010). This hypothesis needs further work as 
at this stage it is not conclusive, investigation into urinary sodium excretion 
levels and TFAP2A expression analysis in these individuals of GG genotype may 
provide additional information. Importantly, the functional reports here have 
identified a causal variant (rs4997081) to follow up. Taken together, these 
studies with the original GWAS findings implicate UMOD variants in BP pressure 
control potentially via sodium homeostasis.  
 
To examine the biological roles of UMOD in BP control and sodium homeostasis 
we performed a number of in vivo and in vitro experiments. We are the first to 
demonstrate with cardiovascular characterisation studies in the UMOD knockout 
mice that UMOD is directly linked with BP. The absence of UMOD resulted in 
significantly lower blood pressure phenotypes that were not altered upon salt 
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loading. We have shown using chronic renal function curves novel evidence that 
differences in arterial pressure are a direct result of enhanced natriuresis and 
reduced sodium reabsorption in these mice. Extensive ex vivo analysis in this 
thesis has suggested the reduced sodium reabsorption in the absence of UMOD 
may be caused by increased pro-inflammatory cytokines at the TAL. UMOD is 
said to exert its immunosuppressive affects by binding with high affinity to TNF-
α and IL-1 (Sabharanjak et al., 2002, Kirkham et al., 2005). This gives rise to the 
hypothesis that available UMOD at the apical membrane may play a role in 
modulating cell surface events, linked with Na+ reabsorption. 
 
Ferreri et al demonstrated TNF-α inhibits ion fluxes in the kidney, particularly 
Na+ reabsorption and water movement at the TAL, thus in the absence of UMOD 
ion transport in the TAL may be modulated by TNF-α release or accumulation 
which infiltrates the kidney (Escalante et al., 1994). This prompted the 
histological examination in renal tissue from WT and KO mice (± 2% NaCl). 
Results revealed the KO mice display enhanced staining for TNF-α and exhibit 
cellular swelling and oedema in the papillary regions of the kidney under both 
normal and high salt conditions. These findings are similar to a study performed 
by El-Achkar et al who reported increased acute kidney injury in UMOD KO mice 
caused by increased inflammation in the S3 segment of the kidney. The injured 
S3 segments were infiltrated with neutrophils and over expression of 
macrophage inflammatory protein-2 (MIP-2) (El-Achkar et al., 2011). Metabolic 
analysis from whole kidney homogenates revealed that KO mice have increased 
levels of metabolites associated with signalling pathways of the pro-
inflammatory cytokines TNF-α and IL-1, further supporting the histological 
findings. Additionally, salt loading the KO mice augmented levels of urinary TNF-
α and mRNA expression levels in outer medulla tissue. This data is consistent 
with a recent study reporting that salt loading increased TNF-α production by 
the kidney (Ferreri et al., 2012), and more specifically the TAL (Hao et al., 
2011). TNF-α administration has proven to be a potent inhibitor to sodium 
reabsorption at the TAL causing exaggerated natriuretic responses and blood 
pressure lowering effects (Evans et al., 1989, Nakatsuji et al., 1990) which is 
consistent with novel results from cardiovascular and renal function studies in 
this thesis. Interestingly, the Na+-K+-2Cl- cotransporter (NKCC2) expression levels 
were reduced in the KO salt loaded mice according to microarray analysis.  
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NKCC2 is selectively expressed in the TAL where it transports the vast majority 
of NaCl and is said to be modulated by co-localised UMOD (Mutig et al., 2011a). 
In humans inactivating mutations of the NKCC2 gene (SLC12A1) cause a 
significant reduction in BP, with severe natriuresis developing a severe salt 
wasting phenotype (Bartter syndrome) (Garcia et al., 1999, Acuna et al., 2010). 
Re-sequencing of three salt-handling genes (SLC12A3 (NCC), SLC12A1 (NKCC2), 
and KCNJ1 (ROMK)) in a cohort of over 5000 subjects of the Framingham Heart 
study showed the large influence rare variants have on BP (Ji et al., 2008). The 
authors documented 30 mutations in these 3 genes that were inferred to have 
functional consequences. Carriers of any of the rare variants in the three salt-
handling genes (with minor allele frequency ≤ 1 %) had mean reductions of 6.3 
mmHg in SBP and 3.4 mm Hg in DBP, compared with the entire cohort. Mutation 
carriers had mean SBP values 6.6 mm Hg less than their non carrier siblings. 
These are large effects when compared with those of common variants, for 
which the effect size is usually 1 mm Hg or less (Ji et al., 2008). Authors 
conclusively demonstrated that these variants were associated with lower BP 
(approximately 6-10 mmHg) and were protective against increased risk for 
hypertension, emphasising the contribution of sodium handling in blood pressure 
regulation in the general populations.  
In contrast to genetic inactivation of NKCC2, enhanced activities of NKCC2 have 
been linked to salt sensitive hypertension  (Ares et al., 2011) consistent with 
findings here in WT mice. This Indicates the important role NKCC2 plays in blood 
pressure regulation via sodium homeostasis and ECF volume control. The 
literature has documented that UMOD modulates NKCC2 at the apical membrane 
to facilitate NaCl reabsorption (Mutig et al., 2011b). Whilst, TNF-α produced by 
the TAL acts in an autocrine manner to down regulate NKCC2 expression (Battula 
et al., 2011), lowering NaCl reabsorption at this site (Bachmann et al., 2005, 
Sherblom et al., 1988, Mutig et al., 2011b, Hao et al., 2011). These findings 
combined with promoter assay analysis where TNF-α signalling was implicated 
with altered UMOD expression, prompted the study of expression analysis in vivo 
and in vitro of the nephron sodium transporters to examine potential 
mechanisms that reduced BP and increased natriuresis in UMOD KO mice. 
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A number of the sodium transporters along the nephron were down regulated in 
the outer medulla tissue in the absence of UMOD before and after salt loading. 
Of particular interest, NKCC2A and ROMK mRNA levels in outer medulla tissue 
were significantly increased in WT mice upon salt loading which would imply 
augmented NaCl reabsorption and enhanced volume expansion leading to 
increased BP reported in these mice. Conversely, KO mice display lower 
expression which was further attenuated under salt loading, consistent with 
previous studies reporting reduced NKCC2A expression and NaCl reabsorption in 
the presence of increased levels of TNF-α at the TAL (Battula et al., 2011). The 
down regulation of NKCC2 and ROMK in the outer medulla tissue of salt loaded 
KO mice is of great interest. These channels are co-expressed with UMOD at the 
apical membrane and are well documented to be linked with salt wasting in 
times of altered function (Ares et al., 2011, Renigunta et al., 2011), suggesting 
that the reduced arterial pressure and increased natriuresis in the UMOD KO 
mice is driven by altered regulation of these channels. Collectively, the 
expression studies described here alongside previous reports illustrate that 
UMOD functionally mediates NaCl transport at the TAL. The elevated levels of 
TNF-α observed in KO mice suggests that normally cell-surface UMOD acts to 
sequester TNF-α, limiting the amount of cytokine that is generated.  
 
This hypothesis was confirmed using in vitro assays where we demonstrated 
stimulation with TNF-α increased the relative levels of UMOD mRNA, creating a 
negative feedback loop in which the TNF-α induced reduction in NKCC2A gene 
expression is switched off through increasing the production of cell-surface 
UMOD. Ultimately, this suggests that UMOD acts as a negative regulator of TNF-α 
production by the TAL to maintain NaCl homeostasis. These data sets suggest 
that increased renal production of TNF-α may facilitate reduced Na+ 
reabsorption along the TAL, thereby increasing the sensitivity of the pressure 
natriuretic mechanism. We have demonstrated with the use of promoter activity 
assays, in vitro, and in vivo assays that UMOD appear to play a functional role in 
blood pressure regulation by modulating the effect of TNF-α at the TAL to 
maintain NKCC2A expression. We have provided evidence of a novel functional 
pathway of BP regulation through UMOD and renal sodium/volume homeostasis.  
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To investigate this hypothesis the next phase of work was to investigate these 
findings in human translational studies and to follow up the original GWAS signal 
of rs13333226. The initial discovery that rs13333226 was significant association 
with hypertension was not statistically significant in the present study, however 
the p value was 0.05 which shows a trend towards significance which may if 
repeated with larger numbers transpire to replicate the original reports and will 
be important to follow up in a larger cohort. This result is particularly 
interesting as there are no studies to date in complex disease that have followed 
up GWAS signals in human tissue.   
 
We did confirm that UMOD expression was altered in a genotype dependent 
manner. In the presence of the minor G allele there was no difference in UMOD 
expression between normotensive and hypertensive subjects. Moreover, levels of 
mRNA abundance of NKCC2 and NHE3 were not differentially expressed 
suggesting sodium reabsorption is maintained confirming our studies that UMOD 
regulates sodium homeostasis. This supports the finding from the GWAS that the 
minor G allele is associated with lower risk of hypertension and coincides with 
lower transcriptional activity reported in the promoter activity assays. To 
further characterise the interdependencies of UMOD and NKCC2 levels and 
describe potential causal and effect future work should investigate whether 
knock down of NKCC2 has an effect on UMOD expression. Therefore, if NKCC2 
levels are modulated by therapeutic targets would this impact UMOD levels also? 
The cause and effect hypothesis needs further study but could suggest that 
UMOD signalling is upstream of NKCC2.  
 
In support of findings illustrating that levels of UMOD regulate NKCC2 expression 
to maintain NaCl reabsorption, we reported that hypertensive subjects of AA 
genotype for rs13333226 did reveal increased mRNA expression levels of UMOD, 
NKCC2, and NHE3. These findings implicate increased NaCl reabsorption 
consistent with well documented evidence of these transporters in hypertension. 
The link between UMOD, NKCC2, and TNF-α however was not replicated, there 
was no difference in TNF-α expression between normotensive and hypertensive 
individuals of contrasting genotype for rs13333226. Pharmacological treatment 
for hypertension and cancer was not known in the present study, which may 
contribute to altered gene expression levels of TNF-α (Balkwill, 2009). 
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Furthermore, following findings from the first results chapter it would have been 
interesting to have measured TFAP2A expression in this cohort, which may have 
provided further information on the relationships between UMOD expression and 
TNF-α in a genotype dependent manner. In addition cohorts should be genotyped 
for the functional SNP rs4997081. Nevertheless, a major consideration is that 
alternative pathways may be altering NKCC2, sodium reabsorption, and BP in 
times of altered UMOD expression.  
 
Many studies have investigated the regulation of NaCl reabsorption at the TAL 
and have suggested many pathways that enhance the pathophysiological 
understanding that could be implicated in the study of UMOD. Data from these 
studies indicate the cascade of events leading to reduced NKCC2 expression 
involves control of autocoids, hormones, and metabolites as outlined in Figure 
7-1.  
In brief, Ares et al reported cyclic guanosine monophosphate (cGMP) inhibits 
NaCl reabsorption by decreasing translocation of NKCC2 at the apical surface of 
the TAL (Ares et al., 2008). The effects mediated by cGMP stimulate 
prostaglandin E2 (PGE2). The diverse biological actions of PGE2 are mediated by 
activation of receptor subtypes; one of which is expressed in the TAL, 
prostaglandin E receptor 3 (EP3) (Vio et al., 2012). This receptor is a well 
characterised G protein coupled receptor that signals mainly via inhibitory G 
(GI), diminishing adenylate activity and lowering intracellular cyclic adenosine 
monophosphate (cAMP) levels (Sugimoto and Narumiya, 2007). Cyclooxygenase-2 
(COX2) is a rate limiting enzyme that catalyses the conversion of arachidonic 
acid to prostanoids, and is expressed in the TAL. It’s well established that COX-2 
increases the synthesis of PGE2. Ferreri et al were the first to demonstrate that 
PGE2 participates in a negative feedback loop in the TAL via activation of EP3 
receptors. They demonstrated that the EP3 signalling increases COX-2 along the 
TAL (Vio et al., 2012) leading to reduced NKCC2 translocation to the apical 
membrane. TNF-α production at the TAL also increases COX-2 expression at the 
TAL leading to the signalling cascade of events already described above (Wang et 
al., 2002, Ferreri et al., 1999). Systematic studies from these groups have shown 
that TNF-a mediated induction of COX-2 leads to the decrease in NKCC2 activity. 
The best studied hormone in the TAL is vasopressin (AVP), which enhances 
NKCC2 activity via augmented intracellular cAMP (Molony et al., 1987). cAMP 
Chapter 7  253 
 
stimulates protein trafficking by activating protein kinase A (PKA) (Caceres et 
al., 2009) which binds cAMP in response to AVP stimulation (Gapstur et al., 1988) 
Caceres et al reported that cAMP stimulates the rate of NKCC2 exocytosis via 
PKA and this trafficking step mediates the increase in steady state surface 
NKCC2 in the TAL (Caceres et al., 2009). To date we have not assessed 
downstream signalling events beyond TNF-α will but consider these in future 
studies.  
 
Figure 7-1 Proposed cascade of signalling events contributing to reduced NaCl 
reabsorption in the absence of UMOD. 
 
As we did not perform sodium transport or uptake assays in the present study, 
our future work will use sodium green and/or rubidium assays initially, to asses 
sodium transport in the presence or absence of UMOD. From here we will start 
to investigate the serine protease that cleaves UMOD and the role this plays in 
sodium transport. Some potential experiments to determine the roles in sodium 
regulation are as follows; 1- investigate cell adhesion properties between 
monomeric and polymeric forms of UMOD primary TAL cells, and 2 - determine 
the relative amounts of polymeric and monomeric forms of UMOD in healthy 
individuals by UMOD promoter SNP genotype. These objectives can be 
investigated by means of firstly purifying UMOD from urine by salt precipitation 
(Worcester et al., 1988) in healthy individuals, followed by genotyping for 
rs13333226 and rs4997081. Precipitated UMOD can then be electrophoresised on 
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native polyacrylamide gel to estimate proportions of monomer and polymeric 
UMOD. Cell adhesion assays can be utilised using monomeric and polymeric 
UMOD protein with a combination of cell lines (e.g. MDCK, Hek293, mIMCD and 
principal cells of the collecting duct) and primary cells TAL cells where UMOD 
adhesion will be measured by ELISA. Once cell adhesion has been established 
these cellular assays can be used to identify inhibitors that block cell adhesion 
to particular cells. Immunoprecipitation and mass spectrometry can be utilised 
to identify binding partners of UMOD which may then be tested in cell specific 
adhesion assays. These analyses will also allow determination of evidence for 
interactions between ZP domains within UMOD and other proteins containing ZP 
binding domains. In order to identify the serine protease that cleaves UMOD 
from the epithelial surface of the TAL a number of protease inhibitors would 
have to be tested in cells stably expressing UMOD. The media could then be 
tested for levels of UMOD before and after “cleavage”. To date there have been 
few studies investigating relevant proteases, however Fukuoka, et al in 2001 
have provided essential information that urinary UMOD is generated by a 
proteolytic cleavage between F548 and S549, 66 amino acids upstream of a 
possible GPI-anchor attachment site. These considerations will benefit future 
studies greatly.  
 
Collectively, results from this thesis and currently known information on UMOD 
variants suggest emerging novel pathways of UMOD for BP regulation and 
hypertension (Figure 7-2). Common variants in the UMOD gene have been 
associated with the risk of CKD, eGFR and hypertension (Kottgen et al., 2010, 
Padmanabhan et al., 2010, Gudbjartsson et al., 2010). Two SNPs (the T allele 
rs12917707 and the C allele of rs4293393) within the promoter region of the 
UMOD gene are associated with higher eGFR, decreased risk of CKD and a lower 
level of urinary UMOD excretion. The minor G allele of rs13333226 (in LD with 
rs12917707 and rs4293393) is associated with a lower risk of hypertension, 
reduced urinary UMOD excretion, and increased estimated eGFR in a large GWAS 
of BP extremes. In line with rs13333226 G allele (low UMOD expression), data 
from KO mice in this thesis, is associated with lower fractional excretion of 
sodium during conditions of liberal sodium intake, and lower fractional excretion 
of endogenous lithium, pointing to increased sodium reabsorption at the TAL. 
Data from this thesis combined with reports from Trudu et al, provide further 
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evidence for the critical role played by UMOD in sodium balance and 
hypertension (Trudu et al., 2013). Our UMOD KO mice had significantly lower SBP 
than the WT mice, they were resistant to salt induced changes of blood pressure 
and they demonstrated a shift to the left of the pressure-natriuresis curve, 
Trudu et al in contrast showed that UMOD over-expression caused a dose 
dependent increase in UMOD expression and excretion associated with an 
increase in blood pressure, together with reduced natriuresis. This is further 
supported by evidence from our UMOD KO mice where gene expression studies 
reported NKCC2 expression was significantly reduced before and after salt 
loading. Interestingly, TNF-α is also produced by the TAL and acts in an 
autocrine manner to down regulate NKCC2 expression, providing a potential link 
between the intracellular and extracellular roles of UMOD in blood pressure 
control. NKCC2 co-localises with UMOD and cultured TAL cells with low 
endogenous UMOD levels displayed low base-line NKCC2 expression, which was 
further reduced upon stimulation with TNF-α indicating UMOD plays a permissive 
role in the modulation of NKCC2-dependent TAL salt reabsorptive function.  
 
The macula densa expresses NKCC2 but not UMOD. Luminal chloride sensed by 
the macula densa via NKCC2 enables modulation of GFR through 
tubuloglomerular feedback (Briggs and Schnermann, 1987). Detection of 
elevated luminal chloride levels triggers the release of signalling molecules from 
the macula densa, causing constriction of the afferent arteriole and a drop in 
GFR (Briggs and Schnermann, 1987). Two interesting observations may shed 
some insight into the complex intra and extracellular role of UMOD in salt 
balance. If NKCC2 activity modulated by intra-cellular UMOD is the cause of BP 
variation, then in UMOD KO mice or humans carrying the low UMOD genetic 
variant, low BP should be associated with an activation of the renin angiotensin 
system, but evidence for this is lacking. Furthermore, in humans and salt loaded 
UMOD KO mice, GFR is increased with reduced UMOD, which is unexpected. This 
is because the increased sodium chloride in the luminal fluid should lead to the 
macula densa reducing GFR through tubuloglomerular feedback. This raises the 
possibility that extracellular luminal UMOD may interact with NKCC2 in the 
macula densa to interfere with tubuloglomerular feedback. Whilst these 
observations are preliminary, if validated it enlarges the scope of targeting 
UMOD both intracellularly and within the tubular lumen.  
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Additionally, mutations in the UMOD gene cause MCKD and FJHN that are 
autosomal dominant diseases characterised by tubulointerstitial nephritis and 
hyperuricemia. About 58 UMOD mutations have been reported so far and most of 
them occur in exons 3 and 4 encoding for the N-terminal half of the protein, and 
3 mutations in exon 5 affecting residues in the ZP domain (Rampoldi et al., 
2011, Vyletal et al., 2010, Scolari et al., 2004). The identified mutations in 
UMOD cause protein misfolding, which leads to its aberrant intracellular 
trafficking, retention in ER, altered formation of supramolecular domains on the 
apical plasma membrane of TAL cells, abnormal UMOD expression in the kidney 
and decreased urinary UMOD excretion. The decrease in UMOD excretion reflects 
massive intracellular accumulation of UMOD in tubular cells, leading to 
tubulointerstitial injury probably facilitated by ER stress, and lead to progressive 
renal damage.  
GWAS discovery followed by functional validation has resulted in a re-focussing 
of interest in UMOD and its role in BP regulation. These early functional data 
while promising highlights the importance of further work that needs to be 
prioritised to elucidate the underpinning molecular mechanisms of UMOD. Some 
of the crucial questions that need to be investigated include the role of UMOD in 
maintaining water impermeability in TAL; the effect of UMOD on NKCC2, macula 
densa, tubuloglomerular feedback, distal sodium transporters, renin-angiotensin-
aldosterone system, and whether immune mechanisms play a role in BP 
regulation by UMOD. More importantly, further insight into these questions will 
enable development of a therapeutic application, either novel drug or 
repurposing an existing drug, for targeted treatment. This is crucial, because 
despite major advances in cardiovascular health, hypertension remains the risk 
factor contributing most to the overall burden of disease globally and there is a 
paucity of novel anti-hypertensive drugs in clinical trials or pharmaceutical 
development pipeline.  
 
This body of work is the first of its kind to perform biological follow up from a 
GWAS in essential hypertension. We have demonstrated direct links between 
UMOD and sodium reabsorption in every results chapter. Our findings of altered 
UMOD expression in human tissue of GG genotype for SNP rs13333226 
functionally support the findings from the original GWAS. Furthermore, absent 
UMOD in KO mice supports findings that decreased urinary uromodulin excretion, 
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and higher glomerular filtration rate was associated with the G allele 
(Padmanabhan et al., 2010) as these mice displayed increased natriuresis, 
increased GFR, resulting in reduced BP that was not affected by salt loading. In 
the absence of UMOD there was altered expression of many sodium transporters 
along the nephron, most interestingly NKCC2 which was reproduced in 
translational in human studies. Collectively our data demonstrates that UMOD 
plays important regulatory roles in sodium homeostasis, fluid volume control, 
and blood pressure regulation. 
 
 
Figure 7-2 The effect of UMOD variation on blood pressure regulation and sodium 
homeostasis. 
CEU: European ancestry; CD: Collecting Duct; DCT: Distal Convoluted Tubule; JPT: 
Japanese ancestry; LD: Linkage Disequilibrium; MD: Macula Densa; PCT: Proximal 
Convoluted Tubule; TAL: Thick Ascending Limb of Loop of Henle; UAKD: Uromodulin 
Associated Kidney Disease; YRI: African ancestry. 
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While genome wide association studies have been very successful in identifying 
replicated and valid signals for complex traits, the major weakness of GWAS has 
been that these replicated signals are not causative and in many cases not 
clearly associated with genes of common disease. The true value of GWAS so far 
has been in the identification of novel pathways and our study exemplifies this. 
We have extended the GWAS discovery of rs13333226 in humans, using a UMOD 
KO mouse model, identifying a novel pathway linking uromodulin, sodium 
homeostasis and hypertension. Further work needs to be prioritised to elucidate 
the underpinning molecular mechanisms, so that this novel pathway can be 
translated into new drugs for hypertension. 
 
   
  
8 Appendix 
Table A1 Differentially expressed genes (n=67) discovered via microarray analysis between WT vs. WT salt loaded mice. 
 
Symbol 
 
Illumina 
 
 
 
False Discovery 
Rate (q-value) 
 
 
Fold 
Change 
 
Intensity/RPKM/FPKM 
 
 
 
Entrez Gene ID for mouse 
 
ACOX3 ILMN_2949844 0.031   1.30 1033.81  80911 
ACVR2B ILMN_1230145 0.009   1.44   275.74  11481 
AHDC1 ILMN_2689187 0.020  -1.39   294.88  230793 
ALAS2 ILMN_2675874 0.006  -1.57   194.73  11656 
ANGPTL4 ILMN_2759365 0.007   1.51   172.56  57875 
AOC3 ILMN_2625920 0.018   1.30    59.79  11754 
APOH ILMN_1243128 0.022  -1.30   106.27  11818 
AQP2 ILMN_2794276 0.008   1.57   348.74  11827 
AQP3 ILMN_2991272 0.007   1.47   603.08  11828 
ARNTL ILMN_2707510 0.009  -1.40     70.75 11865 
BBS2 ILMN_1253752 0.043  -1.34   155.89 67378 
BCL6 ILMN_1230353 0.0  -4.97 1249.47 12053 
BTC ILMN_2734097 0.009   1.50    82.42 12223 
C1orf51 ILMN_3102736 0.009   1.60    34.53 229599 
C4B  ILMN_3049559 0.037   1.36    45.12 625018 
C9orf24 ILMN_2617920 0.033  -1.42    34.59 73721 
CALR ILMN_2861176 0.043  -1.35 1229.26 12317 
Car15 ILMN_2871660 0.009   1.46   346.05 80733 
CCND1 ILMN_2601471 0.035   1.36 1832.80 12443 
CISH ILMN_2718330 0.0   2.74   164.42 12700 
CYP2A6  ILMN_2734598 0.0134   1.34 3402.38 13086 
DBP ILMN_2616226 8.3916E-4   1.59 1557.94 13170 
Defb42 ILMN_2876755 0.0165   1.45    47.80 619548 
EAPP ILMN_1258998 0.0227  -1.33    40.90 66266 
FMO5 ILMN_2620233 7.2727E-4  -1.65    72.59 14263 
FTCD ILMN_1216722 0.002  1.51   224.03 14317 
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GADD45A ILMN_2947568 0.007 -1.59   360.38 13197 
Gm2016  ILMN_3073818 0.016  1.27   107.25 100039129 
GPR112 ILMN_2856383 0.019  1.38    90.25 236798 
GSDMC ILMN_3115255 0.041  1.33    32.28 83492 
GTPBP4 ILMN_1216072 0.035  1.31   491.58 69237 
HBA1/HBA2 ILMN_1212702 0.006 -1.62 11591.92 110257 
HSD3B1 ILMN_1241116 0.012 -1.40    85.96 15493 
ID1 ILMN_2672190 0.016 -1.48   216.01 15901 
ID4 ILMN_2678714 0.024 -1.35   132.29 15904 
IDI1 ILMN_2590923 0.001 -1.63   154.19 319554 
IER5L ILMN_2961005 0.005 -1.45   173.21 72500 
IFI27L2 ILMN_2762944 0.006  1.48   162.98 76933 
IGFBP3 ILMN_2727503 0.007 -1.27   364.17 16009 
IL34 ILMN_2753761 0.020 -1.35    77.08 76527 
KIAA1279 ILMN_1255236 0.027 -1.41   180.54 72320 
LCN2 ILMN_2712075 7.272E-4  1.80    22.16 16819 
LEO1 ILMN_2903351 0.0370 -1.34   86.19 235497 
LPAR2 ILMN_2773817 0.035  1.40    18.34 53978 
LY6E ILMN_2984828 0.006 -1.45   616.56 17069 
LYPLAL1 ILMN_1254112 0.001  1.52   131.48 226791 
MGLL ILMN_2857957 0.007  1.47   291.22 23945 
MID1  ILMN_3159435 0.008 -1.51    83.75 17318 
MSMO1 ILMN_2823778 0.041 -1.35   573.30 66234 
NR1H4 ILMN_2727013 0.013  1.41 1359.45 20186 
NT5E ILMN_2636285 0.003 -1.49   474.17 23959 
PCSK9 ILMN_2756023 0.007 -1.56    99.12 100102 
PIGR ILMN_1225605 0.007  1.38   783.28 18703 
PPAP2A ILMN_1222991 0.022 -1.33   123.16 19012 
PROZ ILMN_2736621 0.040  1.32    59.92 66901 
RBP7 ILMN_2733708 0.021  1.34    29.52 63954 
SERPINA3 ILMN_1246800 0.013  1.35    26.54 20716 
SESN2 ILMN_2948945 0.022 -1.31   104.40 230784 
SLC14A2 ILMN_3128363 0.010  1.35    34.62 27411 
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SLC25A44 ILMN_2734283 0.047  1.34   301.45 229517 
SLC5A6 ILMN_1225056 0.024  1.33   327.53 330064 
SP5 ILMN_2641201 0.033 -1.32   529.86 64406 
STIP1 ILMN_2603953 0.035 -1.31   820.69 20867 
TNFAIP2 ILMN_2841289 0.043 -1.39   175.28 21928 
TRIB2 ILMN_2432550 0.021  1.47   397.64 217410 
UNG ILMN_3133352 0.040  1.32    33.51 22256 
UPP2 ILMN_2462988 0.007  1.45    65.58 76654 
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Table A2 Differentially expressed genes (n=210) discovered via microarray analysis between KO vs. KO salt loaded mice. 
 
Symbol 
 
 
 
Illumina 
 
 
 
False Discovery Rate 
(q-value) 
 
 
Fold Change 
 
 
 
Intensity/RPKM/FPKM 
 
 
 
Entrez Gene ID for Mouse 
 
 
AADAT ILMN_2594302 0.036 -1.48  922.80 23923 
Acnat1 ILMN_2858121 0.009 -1.65  133.74 230161 
ACOT4 ILMN_2622613 0.034 -1.33  627.48 171282 
ACSL5 ILMN_2892222 0.026  1.37  669.63 433256 
ACSM2A ILMN_2662329 0.002 -1.55 1772.15 233799 
ACSM3 ILMN_3111685 0.003 -1.80 4137.37 20216 
ACTB ILMN_2846865 0.003  1.58  730.70 11461 
AGPAT2 ILMN_1215901 0.006  1.59  208.04 67512 
AHCTF1 ILMN_2717696 0.018 -1.49  371.22 226747 
Akr1c14 ILMN_2921215 0.031 -1.55  276.15 105387 
ANG ILMN_2875251 0.022  1.51  107.58 11727 
APOA2 ILMN_1247156 1.818E-4  1.75   21.62 11807 
APOC1 ILMN_2599794 0.003  1.65   66.37 11812 
APRT ILMN_2630946 0.032  1.35 810.15 11821 
AQR ILMN_2676056 0.045 -1.40   60.68 11834 
ARL3 ILMN_1238801 0.035 -1.43 110.04 56350 
ASB9 ILMN_2682835 0.034  1.43 290.63 69299 
ATG3  ILMN_2651781 0.033 -1.37 415.40 67841 
ATXN1 ILMN_1254409 0.038  1.44 286.59 20238 
BCAR3 ILMN_2676615 0.038 -1.46   52.08 29815 
BCAT1 ILMN_3131478 0.023  1.51 414.96 12035 
BCKDHB ILMN_2660803 0.017 -1.46 335.503 12040 
C10orf10 ILMN_2894211 0.001  2.02   78.32 213393 
C1qtnf3 ILMN_2760318 0.008 -1.79 432.18 81799 
C20orf3 ILMN_2799667 0.032  1.34 996.41 71881 
C5orf45 ILMN_1247302 0.002  1.56 185.50 68067 
C8A ILMN_1213805 0.044 -1.43 229.59 230558 
CCRN4L ILMN_2591440 0.032 -1.53   92.60 12457 
CD1D ILMN_2734212 0.043  1.33   28.61 12479 
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Cd55 ILMN_1248714 0.030 -1.41 82.24 13136 
CDC14B ILMN_2874816 0.029  1.36 178.18 218294 
CDKN2C ILMN_1228366 0.038  1.32 123.91 12580 
CHCHD7 ILMN_1240104 0.032 -1.48 1118.33 66433 
CHMP5 ILMN_2670352 0.021 -1.63 275.36 76959 
CIB2 ILMN_2744587 0.035  1.36 49.70 56506 
CIRBP ILMN_2761594 0.008  1.52 118.06 12696 
CLSTN3 ILMN_2827217 0.013  1.50 9.08 232370 
Cml3 ILMN_2735046 0.006 -1.57 1472.99 100043497 
COL4A4 ILMN_2983387 0.031 -1.47 658.71 12829 
COX6C ILMN_2589039 0.012 -1.54 7900.78 621837 
COX7A2 ILMN_2733698 0.044 -1.38 712.90 12866 
CRELD2 ILMN_2983948 0.012 -1.63 398.48 76737 
CRLS1 ILMN_1231132 0.036 -1.40 507.31 66586 
CTAGE5 ILMN_2645138 0.040 -1.44 90.41 217615 
CTDSPL ILMN_2632489 0.024  1.38 415.93 69274 
CTGF ILMN_2909150 0.019 -1.60 1164.44 14219 
CYB5A  ILMN_2966632 0.040 -1.28 4517.07 109672 
CYFIP2 ILMN_2670713 0.045 -1.38 363.09 76884 
CYP24A1 ILMN_2639900 0.0 -3.03 1429.40 13081 
CYP2F1 ILMN_2702903 0.003  1.55 33.22 13107 
Cyp4a14 ILMN_2691680 8.754E-4  1.76 38.98 13119 
CYP4A22 ILMN_1254109 0.029 -1.40 6266.68 13118 
Cyp4a31 ILMN_2960044 0.002  1.64 316.21 666168 
DAZAP1 ILMN_2860674 0.034 -1.41 166.14 70248 
DDC ILMN_2628647 0.002  1.57 429.18 13195 
DGKG ILMN_1237518 0.007  1.48 81.62 110197 
DHRS7 ILMN_1213456 0.032  1.35 320.84 66375 
DLD ILMN_2703657 0.034 -1.39 810.37 13382 
DPYD ILMN_2605329 0.029 -1.38 155.85 99586 
EGR1 ILMN_2662926 7.509E-4  1.49 229.31 13653 
EHHADH ILMN_2706120 0.016 -1.55 1295.49 74147 
EIF4G2 ILMN_2625167 0.047 -1.33 192.79 13690 
ELOVL6 ILMN_2614752 0.003  1.57 233.93 170439 
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ETHE1 ILMN_2621074 0.001  1.59 736.19 66071 
FAAH ILMN_2766930 0.004  1.55 204.13 14073 
FAM69A ILMN_2842802 0.004  1.56 108.80 67266 
FBXO21 ILMN_1244991 0.009  1.42 429.77 231670 
FGA ILMN_2624363 0.012  1.48 194.69 14161 
G0S2 ILMN_1257299 0.029  1.38 311.93 14373 
GABARAPL1 ILMN_1236958 0.044  1.32 2692.17 57436 
GCLC ILMN_2608016 0.008 -1.68 211.13 14629 
GHR ILMN_3138922 0.041 -1.37 1799.29 14600 
Gm13342 ILMN_3163159 3.3492E-4 -2.32 475.19 100041703 
Gm4956 ILMN_2911009 0.002 -1.74 211.48 241041 
GPD1 ILMN_2808811 0.038  1.36 356.89 14555 
GPD2 ILMN_1247257 0.035  1.35 720.51 14571 
GPIHBP1 ILMN_1217969 0.048  1.34 36.08 68453 
GSTA5 ILMN_1248849 0.001  1.71 894.93 100042314 
GZF1 ILMN_3007959 0.007 -1.66 271.69 74533 
HBP1 ILMN_3020240 0.034  1.36 927.63 73389 
HEXB ILMN_2829330 0.008 -1.60 2238.59 15212 
HIATL1 ILMN_2796878 0.045 -1.47 45.83 66631 
HIST1H1C ILMN_2855315 0.017  1.48 2213.01 50708 
HIST1H2BJ ILMN_2677231 0.011 -1.52 67.05 68024 
HK2 ILMN_1239397 0.004  1.816 36.42 15277 
HMGCS2 ILMN_1216322 2.673E-4  1.85 101.01 15360 
HNRNPA2B1 ILMN_2771074 0.029 -1.47 172.42 53379 
HOXD4 ILMN_1219807 0.031 -1.35 205.27 15436 
HPRT1 ILMN_2767487 0.036 -1.39 145.58 15452 
HRSP12 ILMN_1251300 0.008 -1.67 748.65 15473 
HSD11B1 ILMN_3115917 0.001 -1.89 2581.42 15483 
HSD17B11 ILMN_2642985 8.264E-5 -2.13 1406.90 114664 
HSPE1 ILMN_2960308 0.001 -1.68 1484.44 15528 
ID2 ILMN_1228557 0.009 -1.56 1962.45 15902 
IFI27 ILMN_3125606 0.004  1.48 1020.93 52668 
IFRD2 ILMN_2736762 0.009 -1.52 320.93 15983 
IGFBP1  ILMN_1230739 0.031  1.35 9.64 16006 
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ITGA3 ILMN_2616164 0.035 -1.44 207.78 16400 
ITM2B ILMN_2782082 0.035 -1.36 5389.19 16432 
KIF1B ILMN_1239729 0.011 -1.58 665.34 16561 
KTI12 ILMN_2599412 0.040 -1.39 195.68 100087 
KYNU ILMN_1214750 0.00  1.53 76.44 70789 
LGALS3BP ILMN_1258526 0.029  1.36 240.90 19039 
LIPA ILMN_2649291 0.035 -1.37 1062.91 16889 
Lipo1  ILMN_2793739 0.032 -1.43 600.52 381236 
LPGAT1 ILMN_2720479 0.016 -1.42 147.75 226856 
LRRC19 ILMN_1238743 0.016 -1.43 116.53 100061 
LSM5  ILMN_2971946 0.038 -1.47 320.93 66373 
MAL ILMN_1248947 0.027 -1.48 956.60 17153 
MAP2K1 ILMN_2714534 0.020 -1.56 102.38 26395 
MAT2A ILMN_2593368 0.028 -1.44 999.79 232087 
MEMO1  ILMN_2903379 0.030 -1.41 125.60 76890 
MGST1 ILMN_2940195 0.018  1.43 487.54 56615 
MLEC ILMN_1222602 0.044 -1.43 433.14 109154 
MRPS10 ILMN_2841840 0.038  1.39 151.47 64657 
MTMR12 ILMN_2755215 0.037 -1.44 632.10 268783 
MXI1 ILMN_2765741 0.042 -1.46 253.45 17859 
MYL1 ILMN_2878542 0.042  1.37 10.11 17901 
NAA15 ILMN_2848090 0.032 -1.42 177.88 74838 
NAMPT ILMN_2821850 0.002 -1.84 425.40 59027 
NDN ILMN_2622374 0.036  1.33 61.22 17984 
NDRG1 ILMN_2646166 0.034  1.43 5554.00 17988 
NDUFA5 ILMN_2691460 0.012 -1.55 644.94 68202 
NDUFB4 ILMN_1227012 0.004 -1.78 426.18 100041273 
NEU1 ILMN_2708906 0.029  1.36 4034.14 18010 
NFIB ILMN_2726585 0.044 -1.34 693.41 18028 
NINL ILMN_2677065 0.046  1.32 143.73 78177 
NPHS2 ILMN_2717146 0.001  1.65 261.694 170484 
NPM3 ILMN_3093150 0.003 -1.78 104.24 18150 
Npm3-ps1 ILMN_2965417 0.031 -1.45 1030.85 108176 
NR1D1 ILMN_2749669 4.329E-4  1.87 32.00 217166 
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NSDHL ILMN_2594521 0.021  1.45 159.74 18194 
NT5C2 ILMN_2630939 0.033 -1.40 109.64 76952 
OAT ILMN_2933112 0.030  1.32 2024.68 18242 
ORM1 ILMN_1226935 0.006  1.43 16.96 18405 
PAH ILMN_2731024 0.00 -1.55 3569.18 18478 
PCCB ILMN_2622761 0.00 -1.61 1063.34 66904 
PER2 ILMN_2987863 2.277E-4 -2.11  608.11 18627 
PGPEP1 ILMN_2846255 0.038  1.37  572.33 66522 
PGRMC1 ILMN_2623216 0.0183 -1.44  749.39 53328 
PITX2 ILMN_3118071 0.033 -1.44  269.27 18741 
PKHD1 ILMN_1223914 0.046 -1.37 116.25 241035 
PMPCB ILMN_2640122 0.021 -1.46 911.17 73078 
PPARG ILMN_1221060 0.031  1.40   26.31 19016 
PPP1R3C ILMN_2667091 0.030  1.38   39.68 53412 
PPP6R3 ILMN_1235583 0.034 -1.41  142.22 52036 
PRLR ILMN_2617005 0.002  1.76   47.03 19116 
PRPF40A ILMN_2642806 0.029 -1.46  143.40 56194 
PRPSAP2 ILMN_2629446 0.025 -1.57  140.26 212627 
PSMD12 ILMN_1216211 0.027 -1.57  187.46 66997 
PSMD6 ILMN_1241910 0.032 -1.46  136.54 66413 
PTEN ILMN_2594450 0.002 -1.59  111.36 19211 
PTPRB ILMN_2591731 0.021 -1.45  376.41 19263 
PYGL ILMN_2615015 7.575E-4  1.61  118.64 110095 
RAB11FIP5 ILMN_1216781 0.015  1.39  726.18 52055 
RGL1 ILMN_2717176 0.029 -1.41 1042.43 19731 
RHOB ILMN_1215212 0.048 -1.45  379.75 11852 
RORC ILMN_2760272 0.007 -1.73  166.12 19885 
RPL22L1 ILMN_2678755 0.031 -1.45   96.21 68028 
RPS3 ILMN_2637639 0.016 -1.50 1350.70 27050 
SCIN ILMN_1259174 0.029  1.43  553.15 20259 
SCOC ILMN_1216231 0.013 -1.59  373.71 56367 
SDHD ILMN_1239143 0.019 -1.59 1067.94 66925 
SEL1L ILMN_3137920 0.008 -1.69  235.69 20338 
SEMA4A ILMN_1215120 0.011  1.42 1226.18 20351 
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SEPP1 ILMN_1247553 3.341E-4 -1.82 2763.69 20363 
SERPINA1 ILMN_2659680 0.031  1.44  292.95 20703 
SERPINB6 ILMN_1250279 0.031  1.37  280.42 20719 
SH3TC2 ILMN_1240728 0.016  1.41  434.42 225608 
SLC12A1 ILMN_3048630 0.041 -1.31  120.61 20495 
SLC16A14 ILMN_1217704 0.016 -1.51   34.45 71781 
SLC16A6 ILMN_3152241 0.038 -1.42   54.74 104681 
SLC29A3 ILMN_2961091 0.005  1.46  465.38 71279 
SLC30A1 ILMN_1224883 0.032 -1.40  235.54 22782 
SLC38A2 ILMN_2955671 0.004 -1.88  307.28 67760 
SLC38A3 ILMN_2750089 0.037  1.41   82.45 76257 
SLC6A19 ILMN_3161159 0.020  1.46 1358.15 74338 
Slc7a12 ILMN_2633726 8.7546E-4  1.80   38.44 140918 
SLCO1A2 ILMN_1258323 0.020 -1.50   81.39 28250 
SLCO3A1 ILMN_1235635 0.001 -1.72  244.47 108116 
SLIRP ILMN_1239860 0.028 -1.53  736.27 380773 
SMEK2 ILMN_2683138 0.004 -1.65  426.79 104570 
SNX1 ILMN_2605465 0.038 -1.47  422.32 56440 
SNX7 ILMN_2760244 0.044 -1.40  689.30 76561 
SOCS2 ILMN_2628178 0.003 -1.69  458.40 216233 
SPAST ILMN_1224658 0.036 -1.35  202.46 50850 
SQRDL ILMN_1247947 0.037 -1.47  344.92 59010 
SS18 ILMN_1233813 0.012 -1.61  258.08 268996 
STX3 ILMN_3162879 0.045  1.33  314.66 20908 
TF ILMN_2485323 0.017  1.57   64.60 22041 
THBD ILMN_1249767 0.028 -1.55  125.87 21824 
TIMM8A ILMN_2896552 0.037 -1.43 1127.97 30058 
TKT ILMN_2607880 0.004  1.58 1191.85 21881 
TMEM184C ILMN_1248892 0.038 -1.45   75.32 234463 
TMEM86A ILMN_2645662 0.016  1.52  478.98 67893 
TPRKB ILMN_2811240 0.027  1.47  136.19 69786 
TRPS1 ILMN_2466527 0.010 -1.57  420.58 83925 
TSC22D3 ILMN_3150811 0.010 -1.62 1091.63 14605 
TSPAN3 ILMN_1251499 0.034 -1.39   58.84 56434 
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TTC39C ILMN_1250576 0.034816653934301 -1.33  280.64 72747 
TXN  ILMN_3009572 8.76623376623377E-4 -1.87 1184.60 22166 
TXNRD1 ILMN_2484465 0.0391042780748663 -1.26   67.36 50493 
UCHL3 ILMN_2970879 0.030417439703154 -1.43  293.99 50933 
USMG5 ILMN_1219002 0.0048951048951049 -1.71  285.82 66477 
USP33 ILMN_3129526 0.0380808080808081 -1.47  680.96 170822 
VBP1 ILMN_1243095 0.0253997809419496 -1.47  268.58 22327 
YWHAZ ILMN_2510612 0.00238383838383838 -1.65  118.45 22631 
ZBTB38 ILMN_1250618 0.0297416267942584 -1.33   84.93 245007 
ZFYVE16 ILMN_1244584 0.029007371007371 -1.48 193.82 218441 
ZKSCAN3 ILMN_2491526 0.0117554858934169 -1.60 182.93 72739 
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